Serious & Notifiable Infections — MCQs

Q: A 62-year-old man with diabetes presents with a foot ulcer and fever. X-ray shows bone destruction. Blood cultures grow Staphylococcus aureus. What is the recommended antibiotic duration?

8-12 weeks. ***8-12 weeks***- This prolonged duration is typically recommended for **diabetic foot osteomyelitis (DFO)**, especially when complicated by **Staphylococcus aureus bacteremia** and radiographic evidence of **bone destruction**.- The extended treatment ensures adequate eradication of bacteria from the poorly vascularized bone, which is crucial in diabetic patients prone to **recurrence**.*2 weeks*- This duration is vastly insufficient for established **osteomyelitis**, which requires prolonged therapy due to poor antibiotic penetration into bone and the potential for **biofilm** formation.- A 2-week course is generally reserved for uncomplicated **soft tissue infections** or **cellulitis**, not for deep bone infections with systemic involvement.*4 weeks*- While sometimes used for acute, uncomplicated osteomyelitis without extensive bone involvement, **4 weeks** is typically inadequate for severe cases like **DFO** with **bacteremia** and significant **bone destruction**.- In such complex scenarios, a shorter course significantly increases the risk of **treatment failure** and **relapse**.*6 weeks*- **6 weeks** is considered the standard minimum duration for acute, uncomplicated osteomyelitis, particularly after successful **surgical debridement** of infected bone.- However, for complicated DFO with **S. aureus bacteremia** and significant bone destruction, a longer course, often up to 12 weeks, is frequently necessary, especially if debridement is limited.*6 months*- This exceptionally long duration is generally reserved for very specific, highly refractory infections, such as **tuberculosis osteomyelitis**, or for chronic suppressive therapy in certain **prosthetic joint infections**.- It is typically excessive for **Staphylococcus aureus** DFO when managed with appropriate initial therapy and a standard prolonged course (8-12 weeks).

Q: A 26-year-old man presents with acute onset severe headache, fever, and neck stiffness. This shows lymphocytic pleocytosis with normal glucose. HSV PCR is positive. What is the most appropriate treatment?

IV aciclovir. ***IV aciclovir***- The positive **HSV PCR** confirms Herpes Simplex Virus encephalitis/meningitis, which requires immediate high-dose IV **aciclovir** to prevent severe neurological damage or death.- Aciclovir inhibits viral **DNA synthesis** and is the specific, life-saving antiviral treatment for HSV **meningoencephalitis**.*IV ceftriaxone*- **Ceftriaxone** is a broad-spectrum antibiotic used to cover common causes of **bacterial meningitis** (*S. pneumoniae*, *N. meningitidis*).- It is ineffective against a viral infection confirmed by a positive **HSV PCR**.*IV ampicillin*- **Ampicillin** is typically added to empiric bacterial regimens to cover **Listeria monocytogenes**, particularly in immunocompromised or older patients.- It provides no specific or therapeutic benefit against **Herpes Simplex Virus**.*Supportive care only*- HSV encephalitis is a medical emergency with high mortality and morbidity; definitive antiviral therapy is mandatory, not just **supportive care**.- While supportive care (e.g., fever management) is necessary, it cannot eradicate the highly destructive **HSV viral load** in the central nervous system.*IV immunoglobulin*- **IV immunoglobulin (IVIg)** is generally used for autoimmune, inflammatory conditions (like Guillain-Barré) or certain immunodeficiencies.- It has no proven role in the primary treatment or eradication of acute **HSV CNS infection**.

Q: A 22-year-old student presents with fever, headache, and a petechial rash on her legs. CSF shows: protein 2.1 g/L, glucose 1.8 mmol/L (serum 5.2), WCC 850 (90% neutrophils). What is the most likely organism?

Neisseria meningitidis. ***Neisseria meningitidis***- The classic presentation of fever, headache, and a **petechial rash** (indicating **meningococcemia**) in a young adult is highly characteristic of *Neisseria meningitidis* infection.- The CSF profilehigh protein, **low glucose** (low CSF/serum ratio), and **high white cell count** with **predominantly neutrophils** (90%)-is consistent with acute bacterial meningitis caused by this organism.*Streptococcus pneumoniae*- While *Streptococcus pneumoniae* is a common cause of bacterial meningitis with a similar CSF profile (high protein, low glucose, neutrophilic pleocytosis), it is less typically associated with a fulminant **petechial rash**.- This organism often affects extremes of age (very young or elderly) or individuals with specific risk factors such as **pneumonia**, **otitis media**, or **CSF leaks**.*Haemophilus influenzae*- *Haemophilus influenzae* type b (HiB) was a major cause of meningitis in **unvaccinated children** before widespread vaccination, making it less common in immunocompetent young adults.- Although it can cause bacterial meningitis with similar CSF findings, the striking **petechial rash** and patient's age make *Neisseria meningitidis* a more likely diagnosis.*Listeria monocytogenes*- *Listeria monocytogenes* typically causes meningitis in specific vulnerable populations, including **neonates**, the **elderly**, pregnant women, or the **immunosuppressed**.- Given the patient is a healthy 22-year-old student, *Listeria* is a less probable cause compared to *Neisseria meningitidis*.*Enterovirus*- **Enteroviruses** cause **aseptic (viral) meningitis**, which is characterized by a different CSF profile than seen here.- Viral meningitis typically presents with **normal CSF glucose**, normal or mildly elevated protein, and a **lymphocytic pleocytosis** (lymphocyte predominance), which contradicts the 90% neutrophil count in this case.

Q: A 37-year-old man presents with acute onset severe headache, fever, and neck stiffness. Lumbar puncture shows lymphocytic pleocytosis with normal glucose. HSV PCR is positive. What is the most appropriate treatment?

IV aciclovir. ***IV aciclovir*** - The clinical presentation (acute severe headache, fever, neck stiffness) and cerebrospinal fluid (CSF) findings (**lymphocytic pleocytosis**, **normal glucose**) are highly suggestive of **viral meningoencephalitis**. - A positive **HSV PCR** in the CSF confirms **Herpes Simplex Virus (HSV) encephalitis**, a severe and potentially fatal condition that necessitates immediate high-dose intravenous **aciclovir**. *IV ceftriaxone* - Ceftriaxone is an antibiotic primarily used for **bacterial meningitis**, which typically presents with **neutrophilic pleocytosis** and **low CSF glucose**. - It is ineffective against **viral infections** like HSV, making it an inappropriate treatment for confirmed HSV encephalitis. *IV ampicillin* - Ampicillin is another antibiotic used to treat specific forms of **bacterial meningitis**, particularly covering *Listeria monocytogenes*. - It does not have antiviral activity and therefore is not an effective treatment for **HSV encephalitis**. *Supportive care only* - **HSV encephalitis** carries a high risk of mortality and significant neurological sequelae if left untreated with specific antiviral agents. - Relying solely on supportive care is insufficient and would be detrimental in a confirmed case of HSV encephalitis. *IV immunoglobulin* - Intravenous immunoglobulin (IVIG) is typically used in the management of certain **immunodeficiency syndromes** or **autoimmune disorders**. - It has no established role or efficacy in the **acute treatment** of viral encephalitis, including that caused by HSV.

Q: A 65-year-old man with diabetes presents with a non-healing foot ulcer for 3 months. X-ray shows osteolytic changes in the underlying bone. MRI confirms osteomyelitis. What is the most appropriate treatment duration for antibiotics?

12 weeks total therapy. ***12 weeks total therapy***- The treatment duration for confirmed **diabetic foot osteomyelitis (DFO)** without amputation or with residual infected bone often requires 10–12 weeks or 3 months of total antibiotic therapy (IV and/or oral) to achieve cure and prevent relapse.- Prolonged treatment is crucial because of the **poor vascular supply** in diabetic feet and the low penetration of antibiotics into the avascular, infected bone. *2 weeks IV*- This duration is insufficient for bone infection, as antibiotics require extended time to reach therapeutic concentrations within the **avascular, necrotic bone**.- **Acute uncomplicated cellulitis** or soft tissue infection might be treated in 2 weeks, but not osteomyelitis. *4 weeks IV*- A 4-week course might be considered sufficient only if the infected bone has been completely removed during **surgical debridement** (e.g., partial foot amputation), which is not guaranteed by the prompt.- This duration drastically increases the risk of **relapse** in confirmed, non-surgically cleared osteomyelitis. *6 weeks IV*- This is the standard duration for **vertebral osteomyelitis** or chronic osteomyelitis where adequate surgical debridement was achieved, often substituting for the total 12-week regimen.- However, for conservative management of **DFO**, guidelines often recommend a total of 10–12 weeks (IV and oral) to maximize bone penetration. *4-6 weeks IV followed by 2-6 weeks oral*- While this combination (totaling 6–12 weeks) is a common strategy, it is less definitive than the 12-week option and can be interpreted as potentially insufficient depending on the chosen duration (e.g., 6 weeks total is too short).- The **IDSA guidelines** often suggest at least 6 weeks following resection of infected bone, but up to 12 weeks is recommended if bone cannot be fully resected or infection is severe.

Q: A 37-year-old man presents with acute onset severe headache, fever, and neck stiffness. Lumbar puncture shows lymphocytic pleocytosis with normal glucose. HSV PCR is positive. What is the most appropriate treatment?

IV aciclovir. ***IV aciclovir*** - The clinical presentation (headache, fever, neck stiffness) combined with **lymphocytic pleocytosis** and **normal glucose** in CSF is highly suggestive of **viral meningoencephalitis**.- The definitive diagnosis of **HSV encephalitis** is confirmed by a **positive HSV PCR** in the CSF, making intravenous aciclovir the essential and life-saving antiviral treatment.*IV ceftriaxone*- **IV ceftriaxone** is a broad-spectrum antibiotic primarily used to treat **bacterial meningitis**, which typically presents with **neutrophilic pleocytosis** and **low CSF glucose**.- It has no efficacy against **viral infections** like HSV and would be inappropriate as a sole treatment given the positive HSV PCR.*IV ampicillin*- **IV ampicillin** is an antibiotic used for bacterial meningitis, particularly effective against **Listeria monocytogenes** and **Streptococcus agalactiae**, but the CSF findings and positive HSV PCR point away from bacterial etiology.- Similar to ceftriaxone, ampicillin is ineffective against **viral pathogens** and would not treat HSV encephalitis.*Supportive care only*- Given the severity and potentially devastating neurological sequelae of **HSV encephalitis**, supportive care alone is completely insufficient and would lead to significant morbidity and mortality.- **HSV encephalitis** requires urgent and specific antiviral therapy to prevent irreversible brain damage.*IV immunoglobulin*- **IV immunoglobulin (IVIG)** is typically used in conditions involving immune dysfunction, such as certain autoimmune diseases or severe infections in immunocompromised patients, but it is not a primary treatment for **acute viral encephalitis**.- While IVIG might have some immunomodulatory effects, it lacks direct antiviral activity against **HSV** and would not address the underlying viral replication causing the encephalitis.

Q: A 58-year-old woman with diabetes presents with severe foot pain and a deep ulcer exposing bone. X-ray shows osteolytic changes. What is the most likely complication?

Osteomyelitis. ***Osteomyelitis***- The combination of a **deep ulcer exposing bone** and radiologic evidence of **osteolytic changes** strongly indicates infection and destruction of the bone itself.- In patients with **diabetes**, foot ulcers often progress rapidly from soft tissue infection to bone infection due to underlying neuropathy and vascular disease.*Cellulitis*- Cellulitis is a superficial soft tissue infection characterized by erythema, swelling, and warmth, typically without **ulceration exposing bone**.- It affects the dermal and subcutaneous layers and does not cause **osteolytic changes** on X-ray.*Charcot arthropathy*- Charcot foot involves **neuropathic joint destruction** and deformity (e.g., *rocker-bottom* foot), but typically presents with little pain and diffuse bony fragmentation, rather than a localized deep, infected ulcer causing severe pain and lytic changes.- Although common in diabetes, pure Charcot arthropathy is usually sterile; the presence of a deep, draining ulcer points strongly to a progressive infection.*Peripheral arterial disease*- While PAD often contributes to ulcer formation (ischemic ulcers), these ulcers are typically **dry**, **punched-out**, and associated with diminished or absent pedal pulses.- PAD causes ischemia, but the identification of a deep ulcer exposing bone and active **osteolytic changes** points primarily toward a severe, established bone infection.*Deep vein thrombosis*- DVT involves clotting in a deep vein, presenting primarily with **unilateral swelling**, pain, and warmth in the leg (often calf or thigh).- It does not cause localized deep foot ulcers or underlying **osteolytic changes** in the bone.

Q: A 19-year-old student presents with fever, headache, and a non-blanching purpuric rash on his legs. Lumbar puncture shows: WCC 2000/μL (95% neutrophils), protein 3.2 g/L, glucose 1.0 mmol/L. Gram stain shows gram-negative diplococci. What is the most appropriate treatment?

IV ceftriaxone. ***IV ceftriaxone***- This third-generation cephalosporin is the **first-line treatment** for suspected bacterial meningitis due to its excellent penetration into the **cerebrospinal fluid (CSF)** and broad coverage of common pathogens like *Neisseria meningitidis*.- The clinical presentation (fever, purpura) and CSF findings (Gram-negative diplococci) confirm **meningococcal meningitis**, necessitating immediate, high-dose parenteral antibiotics.*IV benzylpenicillin*- While IV penicillin is effective against penicillin-sensitive *N. meningitidis*, **penicillin resistance** has been reported, making **ceftriaxone** the preferred initial empirical therapy until antimicrobial susceptibilities are known.- It may be used as targeted monotherapy if the organism is confirmed sensitive, but it is not the universally recommended initial empirical agent for severe disease.*IV vancomycin*- Vancomycin is primarily used to cover **multi-drug resistant *Streptococcus pneumoniae*** or **MRSA**, and is typically unnecessary as monotherapy for a Gram-negative infection like *N. meningitidis*.- Although often included in very broad empirical coverage, it would be insufficient alone and is usually added only if co-infection with resistant Gram-positive organisms is highly suspected.*IV ampicillin*- Ampicillin is primarily added to empirical meningitis regimens to cover **Listeria monocytogenes**, which typically causes disease in neonates, the elderly, or those who are **T-cell immunocompromised**.- It is not indicated as the primary treatment agent for meningococcal disease in an otherwise healthy young adult.*Oral ciprofloxacin*- **Oral ciprofloxacin** is used strictly for **chemoprophylaxis** of close contacts exposed to *N. meningitidis*, such as household members or roommates.- It is ineffective and inappropriate for the treatment of established, life-threatening invasive meningococcal disease, which requires high-dose intravenous therapy.

A 35-year-old man with HIV infection (CD4 count 80 cells/mm³, viral load 125,000 copies/mL, not on antiretroviral therapy) presents with a 4-week history of headache, fever, and confusion. CT head shows basal meningeal enhancement and multiple small nodules. Lumbar puncture shows: opening pressure 32 cmH2O, CSF white cells 45/mm³ (80% lymphocytes), protein 1.2 g/L, glucose 1.9 mmol/L (serum glucose 5.4 mmol/L). India ink stain is positive. Cryptococcal antigen is positive in both CSF and serum at titres of 1:2048 and 1:1024 respectively. He is started on liposomal amphotericin B and flucytosine. Which one of the following additional interventions has been shown to improve survival in this patient?

Serious & Notifiable Infections UK Medical PG Practice Questions and MCQs

Question 1: A 62-year-old man with diabetes presents with a foot ulcer and fever. X-ray shows bone destruction. Blood cultures grow Staphylococcus aureus. What is the recommended antibiotic duration?

A. 2 weeks
B. 4 weeks
C. 6 weeks
D. 8-12 weeks (Correct Answer)
E. 6 months

Explanation: ***8-12 weeks***- This prolonged duration is typically recommended for **diabetic foot osteomyelitis (DFO)**, especially when complicated by **Staphylococcus aureus bacteremia** and radiographic evidence of **bone destruction**.- The extended treatment ensures adequate eradication of bacteria from the poorly vascularized bone, which is crucial in diabetic patients prone to **recurrence**.*2 weeks*- This duration is vastly insufficient for established **osteomyelitis**, which requires prolonged therapy due to poor antibiotic penetration into bone and the potential for **biofilm** formation.- A 2-week course is generally reserved for uncomplicated **soft tissue infections** or **cellulitis**, not for deep bone infections with systemic involvement.*4 weeks*- While sometimes used for acute, uncomplicated osteomyelitis without extensive bone involvement, **4 weeks** is typically inadequate for severe cases like **DFO** with **bacteremia** and significant **bone destruction**.- In such complex scenarios, a shorter course significantly increases the risk of **treatment failure** and **relapse**.*6 weeks*- **6 weeks** is considered the standard minimum duration for acute, uncomplicated osteomyelitis, particularly after successful **surgical debridement** of infected bone.- However, for complicated DFO with **S. aureus bacteremia** and significant bone destruction, a longer course, often up to 12 weeks, is frequently necessary, especially if debridement is limited.*6 months*- This exceptionally long duration is generally reserved for very specific, highly refractory infections, such as **tuberculosis osteomyelitis**, or for chronic suppressive therapy in certain **prosthetic joint infections**.- It is typically excessive for **Staphylococcus aureus** DFO when managed with appropriate initial therapy and a standard prolonged course (8-12 weeks).

Question 2: A 26-year-old man presents with acute onset severe headache, fever, and neck stiffness. This shows lymphocytic pleocytosis with normal glucose. HSV PCR is positive. What is the most appropriate treatment?

A. IV aciclovir (Correct Answer)
B. IV ceftriaxone
C. IV ampicillin
D. Supportive care only
E. IV immunoglobulin

Explanation: ***IV aciclovir***- The positive **HSV PCR** confirms Herpes Simplex Virus encephalitis/meningitis, which requires immediate high-dose IV **aciclovir** to prevent severe neurological damage or death.- Aciclovir inhibits viral **DNA synthesis** and is the specific, life-saving antiviral treatment for HSV **meningoencephalitis**.*IV ceftriaxone*- **Ceftriaxone** is a broad-spectrum antibiotic used to cover common causes of **bacterial meningitis** (*S. pneumoniae*, *N. meningitidis*).- It is ineffective against a viral infection confirmed by a positive **HSV PCR**.*IV ampicillin*- **Ampicillin** is typically added to empiric bacterial regimens to cover **Listeria monocytogenes**, particularly in immunocompromised or older patients.- It provides no specific or therapeutic benefit against **Herpes Simplex Virus**.*Supportive care only*- HSV encephalitis is a medical emergency with high mortality and morbidity; definitive antiviral therapy is mandatory, not just **supportive care**.- While supportive care (e.g., fever management) is necessary, it cannot eradicate the highly destructive **HSV viral load** in the central nervous system.*IV immunoglobulin*- **IV immunoglobulin (IVIg)** is generally used for autoimmune, inflammatory conditions (like Guillain-Barré) or certain immunodeficiencies.- It has no proven role in the primary treatment or eradication of acute **HSV CNS infection**.

Question 3: A 22-year-old student presents with fever, headache, and a petechial rash on her legs. CSF shows: protein 2.1 g/L, glucose 1.8 mmol/L (serum 5.2), WCC 850 (90% neutrophils). What is the most likely organism?

A. Streptococcus pneumoniae
B. Neisseria meningitidis (Correct Answer)
C. Haemophilus influenzae
D. Listeria monocytogenes
E. Enterovirus

Explanation: ***Neisseria meningitidis***- The classic presentation of fever, headache, and a **petechial rash** (indicating **meningococcemia**) in a young adult is highly characteristic of *Neisseria meningitidis* infection.- The CSF profilehigh protein, **low glucose** (low CSF/serum ratio), and **high white cell count** with **predominantly neutrophils** (90%)-is consistent with acute bacterial meningitis caused by this organism.*Streptococcus pneumoniae*- While *Streptococcus pneumoniae* is a common cause of bacterial meningitis with a similar CSF profile (high protein, low glucose, neutrophilic pleocytosis), it is less typically associated with a fulminant **petechial rash**.- This organism often affects extremes of age (very young or elderly) or individuals with specific risk factors such as **pneumonia**, **otitis media**, or **CSF leaks**.*Haemophilus influenzae*- *Haemophilus influenzae* type b (HiB) was a major cause of meningitis in **unvaccinated children** before widespread vaccination, making it less common in immunocompetent young adults.- Although it can cause bacterial meningitis with similar CSF findings, the striking **petechial rash** and patient's age make *Neisseria meningitidis* a more likely diagnosis.*Listeria monocytogenes*- *Listeria monocytogenes* typically causes meningitis in specific vulnerable populations, including **neonates**, the **elderly**, pregnant women, or the **immunosuppressed**.- Given the patient is a healthy 22-year-old student, *Listeria* is a less probable cause compared to *Neisseria meningitidis*.*Enterovirus*- **Enteroviruses** cause **aseptic (viral) meningitis**, which is characterized by a different CSF profile than seen here.- Viral meningitis typically presents with **normal CSF glucose**, normal or mildly elevated protein, and a **lymphocytic pleocytosis** (lymphocyte predominance), which contradicts the 90% neutrophil count in this case.

Question 4: A 37-year-old man presents with acute onset severe headache, fever, and neck stiffness. Lumbar puncture shows lymphocytic pleocytosis with normal glucose. HSV PCR is positive. What is the most appropriate treatment?

A. IV aciclovir (Correct Answer)
B. IV ceftriaxone
C. IV ampicillin
D. Supportive care only
E. IV immunoglobulin

Explanation: ***IV aciclovir*** - The clinical presentation (acute severe headache, fever, neck stiffness) and cerebrospinal fluid (CSF) findings (**lymphocytic pleocytosis**, **normal glucose**) are highly suggestive of **viral meningoencephalitis**. - A positive **HSV PCR** in the CSF confirms **Herpes Simplex Virus (HSV) encephalitis**, a severe and potentially fatal condition that necessitates immediate high-dose intravenous **aciclovir**. *IV ceftriaxone* - Ceftriaxone is an antibiotic primarily used for **bacterial meningitis**, which typically presents with **neutrophilic pleocytosis** and **low CSF glucose**. - It is ineffective against **viral infections** like HSV, making it an inappropriate treatment for confirmed HSV encephalitis. *IV ampicillin* - Ampicillin is another antibiotic used to treat specific forms of **bacterial meningitis**, particularly covering *Listeria monocytogenes*. - It does not have antiviral activity and therefore is not an effective treatment for **HSV encephalitis**. *Supportive care only* - **HSV encephalitis** carries a high risk of mortality and significant neurological sequelae if left untreated with specific antiviral agents. - Relying solely on supportive care is insufficient and would be detrimental in a confirmed case of HSV encephalitis. *IV immunoglobulin* - Intravenous immunoglobulin (IVIG) is typically used in the management of certain **immunodeficiency syndromes** or **autoimmune disorders**. - It has no established role or efficacy in the **acute treatment** of viral encephalitis, including that caused by HSV.

Question 5: A 65-year-old man with diabetes presents with a non-healing foot ulcer for 3 months. X-ray shows osteolytic changes in the underlying bone. MRI confirms osteomyelitis. What is the most appropriate treatment duration for antibiotics?

A. 2 weeks IV
B. 4 weeks IV
C. 6 weeks IV
D. 4-6 weeks IV followed by 2-6 weeks oral
E. 12 weeks total therapy (Correct Answer)

Explanation: ***12 weeks total therapy***- Management of **diabetic foot osteomyelitis (DFO)** often requires **prolonged antibiotic therapy**, typically ranging from **6 to 12 weeks**, especially given the chronicity (3 months non-healing ulcer) and confirmed osteolytic changes.- For **DFO** where surgical debridement is incomplete or non-surgical management is chosen, a **12-week course** maximizes cure rates and prevents recurrence.*2 weeks IV*- This duration is generally too short for established **osteomyelitis**, particularly in a patient with **diabetes** and a **chronic foot ulcer**, which suggests a complex infection.- Such a short course is more appropriate for uncomplicated **soft tissue infections** or as a very brief initial therapy before transitioning to oral in specific, less severe cases, not for confirmed bone infection.*4 weeks IV*- While 4 weeks of IV antibiotics might be considered in some cases of osteomyelitis *after* complete and aggressive surgical resection of all infected bone (e.g., amputation), it is usually insufficient for severe **diabetic foot osteomyelitis** if significant infected bone remains.- This duration is not standard for definitive treatment of **DFO** when managed primarily with antibiotics or limited debridement, as the risk of relapse is high.*6 weeks IV*- A **6-week course** of IV or highly bioavailable oral antibiotics is the standard minimum for most non-diabetic cases of osteomyelitis after successful debridement.- For **diabetic foot osteomyelitis (DFO)**, 6 weeks is the typical minimum *if* extensive surgical debridement or amputation has been performed; however, for extensive or chronic cases without complete debridement, a longer course is often warranted.*4-6 weeks IV followed by 2-6 weeks oral*- This option suggests a total treatment duration of 6 to 12 weeks (4+2=6 to 6+6=12 weeks), which aligns with the overall recommended duration for **DFO**.- However, it emphasizes a prolonged initial IV course, whereas current guidelines often allow for an earlier transition to high-bioavailability *oral* antibiotics, potentially making the "12 weeks total therapy" a more encompassing and accurate statement for this complex scenario without specifying strict IV/oral proportions initially.

Question 6: A 65-year-old man with diabetes presents with a non-healing foot ulcer for 3 months. X-ray shows osteolytic changes in the underlying bone. MRI confirms osteomyelitis. What is the most appropriate treatment duration for antibiotics?

A. 2 weeks IV
B. 4 weeks IV
C. 6 weeks IV
D. 4-6 weeks IV followed by 2-6 weeks oral
E. 12 weeks total therapy (Correct Answer)

Explanation: ***12 weeks total therapy***- The treatment duration for confirmed **diabetic foot osteomyelitis (DFO)** without amputation or with residual infected bone often requires 10–12 weeks or 3 months of total antibiotic therapy (IV and/or oral) to achieve cure and prevent relapse.- Prolonged treatment is crucial because of the **poor vascular supply** in diabetic feet and the low penetration of antibiotics into the avascular, infected bone. *2 weeks IV*- This duration is insufficient for bone infection, as antibiotics require extended time to reach therapeutic concentrations within the **avascular, necrotic bone**.- **Acute uncomplicated cellulitis** or soft tissue infection might be treated in 2 weeks, but not osteomyelitis. *4 weeks IV*- A 4-week course might be considered sufficient only if the infected bone has been completely removed during **surgical debridement** (e.g., partial foot amputation), which is not guaranteed by the prompt.- This duration drastically increases the risk of **relapse** in confirmed, non-surgically cleared osteomyelitis. *6 weeks IV*- This is the standard duration for **vertebral osteomyelitis** or chronic osteomyelitis where adequate surgical debridement was achieved, often substituting for the total 12-week regimen.- However, for conservative management of **DFO**, guidelines often recommend a total of 10–12 weeks (IV and oral) to maximize bone penetration. *4-6 weeks IV followed by 2-6 weeks oral*- While this combination (totaling 6–12 weeks) is a common strategy, it is less definitive than the 12-week option and can be interpreted as potentially insufficient depending on the chosen duration (e.g., 6 weeks total is too short).- The **IDSA guidelines** often suggest at least 6 weeks following resection of infected bone, but up to 12 weeks is recommended if bone cannot be fully resected or infection is severe.

Question 7: A 37-year-old man presents with acute onset severe headache, fever, and neck stiffness. Lumbar puncture shows lymphocytic pleocytosis with normal glucose. HSV PCR is positive. What is the most appropriate treatment?

A. IV aciclovir (Correct Answer)
B. IV ceftriaxone
C. IV ampicillin
D. Supportive care only
E. IV immunoglobulin

Explanation: ***IV aciclovir*** - The clinical presentation (headache, fever, neck stiffness) combined with **lymphocytic pleocytosis** and **normal glucose** in CSF is highly suggestive of **viral meningoencephalitis**.- The definitive diagnosis of **HSV encephalitis** is confirmed by a **positive HSV PCR** in the CSF, making intravenous aciclovir the essential and life-saving antiviral treatment.*IV ceftriaxone*- **IV ceftriaxone** is a broad-spectrum antibiotic primarily used to treat **bacterial meningitis**, which typically presents with **neutrophilic pleocytosis** and **low CSF glucose**.- It has no efficacy against **viral infections** like HSV and would be inappropriate as a sole treatment given the positive HSV PCR.*IV ampicillin*- **IV ampicillin** is an antibiotic used for bacterial meningitis, particularly effective against **Listeria monocytogenes** and **Streptococcus agalactiae**, but the CSF findings and positive HSV PCR point away from bacterial etiology.- Similar to ceftriaxone, ampicillin is ineffective against **viral pathogens** and would not treat HSV encephalitis.*Supportive care only*- Given the severity and potentially devastating neurological sequelae of **HSV encephalitis**, supportive care alone is completely insufficient and would lead to significant morbidity and mortality.- **HSV encephalitis** requires urgent and specific antiviral therapy to prevent irreversible brain damage.*IV immunoglobulin*- **IV immunoglobulin (IVIG)** is typically used in conditions involving immune dysfunction, such as certain autoimmune diseases or severe infections in immunocompromised patients, but it is not a primary treatment for **acute viral encephalitis**.- While IVIG might have some immunomodulatory effects, it lacks direct antiviral activity against **HSV** and would not address the underlying viral replication causing the encephalitis.

Question 8: A 58-year-old woman with diabetes presents with severe foot pain and a deep ulcer exposing bone. X-ray shows osteolytic changes. What is the most likely complication?

A. Cellulitis
B. Osteomyelitis (Correct Answer)
C. Charcot arthropathy
D. Peripheral arterial disease
E. Deep vein thrombosis

Explanation: ***Osteomyelitis***- The combination of a **deep ulcer exposing bone** and radiologic evidence of **osteolytic changes** strongly indicates infection and destruction of the bone itself.- In patients with **diabetes**, foot ulcers often progress rapidly from soft tissue infection to bone infection due to underlying neuropathy and vascular disease.*Cellulitis*- Cellulitis is a superficial soft tissue infection characterized by erythema, swelling, and warmth, typically without **ulceration exposing bone**.- It affects the dermal and subcutaneous layers and does not cause **osteolytic changes** on X-ray.*Charcot arthropathy*- Charcot foot involves **neuropathic joint destruction** and deformity (e.g., *rocker-bottom* foot), but typically presents with little pain and diffuse bony fragmentation, rather than a localized deep, infected ulcer causing severe pain and lytic changes.- Although common in diabetes, pure Charcot arthropathy is usually sterile; the presence of a deep, draining ulcer points strongly to a progressive infection.*Peripheral arterial disease*- While PAD often contributes to ulcer formation (ischemic ulcers), these ulcers are typically **dry**, **punched-out**, and associated with diminished or absent pedal pulses.- PAD causes ischemia, but the identification of a deep ulcer exposing bone and active **osteolytic changes** points primarily toward a severe, established bone infection.*Deep vein thrombosis*- DVT involves clotting in a deep vein, presenting primarily with **unilateral swelling**, pain, and warmth in the leg (often calf or thigh).- It does not cause localized deep foot ulcers or underlying **osteolytic changes** in the bone.

Question 9: A 19-year-old student presents with fever, headache, and a non-blanching purpuric rash on his legs. Lumbar puncture shows: WCC 2000/μL (95% neutrophils), protein 3.2 g/L, glucose 1.0 mmol/L. Gram stain shows gram-negative diplococci. What is the most appropriate treatment?

A. IV benzylpenicillin
B. IV ceftriaxone (Correct Answer)
C. IV vancomycin
D. IV ampicillin
E. Oral ciprofloxacin

Explanation: ***IV ceftriaxone***- This third-generation cephalosporin is the **first-line treatment** for suspected bacterial meningitis due to its excellent penetration into the **cerebrospinal fluid (CSF)** and broad coverage of common pathogens like *Neisseria meningitidis*.- The clinical presentation (fever, purpura) and CSF findings (Gram-negative diplococci) confirm **meningococcal meningitis**, necessitating immediate, high-dose parenteral antibiotics.*IV benzylpenicillin*- While IV penicillin is effective against penicillin-sensitive *N. meningitidis*, **penicillin resistance** has been reported, making **ceftriaxone** the preferred initial empirical therapy until antimicrobial susceptibilities are known.- It may be used as targeted monotherapy if the organism is confirmed sensitive, but it is not the universally recommended initial empirical agent for severe disease.*IV vancomycin*- Vancomycin is primarily used to cover **multi-drug resistant *Streptococcus pneumoniae*** or **MRSA**, and is typically unnecessary as monotherapy for a Gram-negative infection like *N. meningitidis*.- Although often included in very broad empirical coverage, it would be insufficient alone and is usually added only if co-infection with resistant Gram-positive organisms is highly suspected.*IV ampicillin*- Ampicillin is primarily added to empirical meningitis regimens to cover **Listeria monocytogenes**, which typically causes disease in neonates, the elderly, or those who are **T-cell immunocompromised**.- It is not indicated as the primary treatment agent for meningococcal disease in an otherwise healthy young adult.*Oral ciprofloxacin*- **Oral ciprofloxacin** is used strictly for **chemoprophylaxis** of close contacts exposed to *N. meningitidis*, such as household members or roommates.- It is ineffective and inappropriate for the treatment of established, life-threatening invasive meningococcal disease, which requires high-dose intravenous therapy.

Question 10: A 35-year-old man with HIV infection (CD4 count 80 cells/mm³, viral load 125,000 copies/mL, not on antiretroviral therapy) presents with a 4-week history of headache, fever, and confusion. CT head shows basal meningeal enhancement and multiple small nodules. Lumbar puncture shows: opening pressure 32 cmH2O, CSF white cells 45/mm³ (80% lymphocytes), protein 1.2 g/L, glucose 1.9 mmol/L (serum glucose 5.4 mmol/L). India ink stain is positive. Cryptococcal antigen is positive in both CSF and serum at titres of 1:2048 and 1:1024 respectively. He is started on liposomal amphotericin B and flucytosine. Which one of the following additional interventions has been shown to improve survival in this patient?

A. Commencing antiretroviral therapy immediately alongside antifungal treatment
B. Adding adjunctive dexamethasone 0.4 mg/kg daily for 6 weeks
C. Performing daily therapeutic lumbar punctures until opening pressure normalizes (Correct Answer)
D. Adding adjunctive interferon-gamma to enhance immune response
E. Inserting a ventriculoperitoneal shunt to manage hydrocephalus

Explanation: ***Performing daily therapeutic lumbar punctures until opening pressure normalizes*** - Management of **elevated intracranial pressure** (opening pressure >25 cmH2O) is critical, as it is a major cause of mortality in **cryptococcal meningitis** associated with HIV. - Daily drainage of 20-30 mL of CSF is recommended to achieve an **opening pressure** of <20 cmH2O or a 50% reduction from baseline, which significantly **improves survival** and reduces neurological sequelae. *Commencing antiretroviral therapy immediately alongside antifungal treatment* - **Early initiation of ART** (within 2 weeks) in HIV-associated cryptococcal meningitis is associated with an increased risk of **Immune Reconstitution Inflammatory Syndrome (IRIS)** and higher mortality. - Current guidelines recommend deferring ART for **4 to 6 weeks** after the initiation of induction antifungal therapy to allow for partial clearance of the fungal load and reduce IRIS risk. *Adding adjunctive dexamethasone 0.4 mg/kg daily for 6 weeks* - Routine use of **corticosteroids** is contraindicated in cryptococcal meningitis as they have been shown to **increase mortality** and reduce fungal clearance rates in clinical trials. - Steroids also increase the risk of serious **adverse events** without providing any survival benefit in these patients. *Adding adjunctive interferon-gamma to enhance immune response* - While **interferon-gamma** may facilitate faster fungal clearance in some experimental settings, it has not been shown to provide a **survival benefit** in high-quality clinical trials for HIV-associated cryptococcal meningitis. - It is not currently recommended as part of the **standard induction therapy** for this condition. *Inserting a ventriculoperitoneal shunt to manage hydrocephalus* - **Ventriculoperitoneal (VP) shunts** are generally reserved for patients who fail to respond to repeated **therapeutic lumbar punctures** or develop persistent symptomatic hydrocephalus refractory to medical management. - Although useful for long-term pressure management, it is not the primary or first-line intervention for improving **acute survival** compared to serial lumbar punctures, which are less invasive and carry fewer immediate risks.

Question 11: A 48-year-old woman from Kazakhstan is diagnosed with pulmonary tuberculosis. Initial molecular testing (GeneXpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. Subsequent culture and phenotypic drug susceptibility testing confirms resistance to rifampicin and isoniazid, but the isolate is sensitive to pyrazinamide, ethambutol, fluoroquinolones, bedaquiline, and linezolid. She has a history of seizures controlled with carbamazepine and is otherwise well. Which one of the following represents the most significant drug interaction that needs to be considered when designing her MDR-TB treatment regimen?

A. Linezolid may reduce seizure threshold and interact with carbamazepine
B. Bedaquiline requires dose adjustment due to carbamazepine-induced enzyme induction
C. Moxifloxacin may prolong QT interval which is exacerbated by carbamazepine
D. Carbamazepine induces cytochrome P450 enzymes which will reduce levels of bedaquiline and fluoroquinolones (Correct Answer)
E. Clofazimine absorption is significantly reduced by carbamazepine

Explanation: ***Carbamazepine induces cytochrome P450 enzymes which will reduce levels of bedaquiline and fluoroquinolones*** - **Carbamazepine** is a potent **CYP3A4 inducer**, which significantly increases the metabolism of **Bedaquiline** and certain **fluoroquinolones** (e.g., moxifloxacin), leading to subtherapeutic drug levels. - This interaction can result in **treatment failure** and the development of further **drug resistance** in patients with **MDR-TB**, making it a critical consideration for regimen design. *Linezolid may reduce seizure threshold and interact with carbamazepine* - **Linezolid** is a weak **monoamine oxidase inhibitor (MAOI)**, primarily associated with **serotonin syndrome** in combination with other serotonergic drugs, not a direct significant reduction of the **seizure threshold** or interaction with carbamazepine's antiepileptic effect. - There is no significant metabolic interaction between Linezolid and **Carbamazepine** that would necessitate avoiding the drug for its impact on seizure control. *Bedaquiline requires dose adjustment due to carbamazepine-induced enzyme induction* - While **carbamazepine** does induce **bedaquiline** metabolism, simple **dose adjustment** is often insufficient and not recommended due to the potent and variable nature of enzyme induction. - Current guidelines typically recommend **avoiding co-administration** of strong CYP3A4 inducers with bedaquiline; if carbamazepine is essential, alternative non-inducing anti-epileptics like **levetiracetam** should be considered. *Moxifloxacin may prolong QT interval which is exacerbated by carbamazepine* - Both **Moxifloxacin** and **Bedaquiline** can prolong the **QT interval**, necessitating careful monitoring when used together; however, **Carbamazepine** itself does not significantly exacerbate QTc prolongation. - The primary concern with **Carbamazepine** in this context is its **enzymatic induction** effect, which reduces the levels of other drugs, rather than an additive electrophysiological effect on cardiac repolarization. *Clofazimine absorption is significantly reduced by carbamazepine* - **Clofazimine** absorption is primarily influenced by the presence of food, particularly **fatty meals**, and it is not significantly affected by **cytochrome P450 enzyme induction** by drugs like carbamazepine. - There is no documented significant pharmacokinetic interaction where **Carbamazepine** reduces **Clofazimine** serum levels to a clinically relevant extent.

Question 12: A 28-year-old previously healthy man is admitted with suspected bacterial meningitis. He is treated empirically with IV ceftriaxone 2 g twice daily and IV dexamethasone 10 mg four times daily. Lumbar puncture performed before antibiotics shows: CSF white cells 2,100/mm³ (90% neutrophils), protein 2.3 g/L, glucose 1.5 mmol/L (serum glucose 6.0 mmol/L). Blood and CSF cultures taken on admission subsequently grow Streptococcus pneumoniae fully sensitive to penicillin (penicillin MIC 0.06 mg/L). He improves clinically over 48 hours. Which one of the following represents the most appropriate modification to his antimicrobial therapy at this stage?

A. Continue ceftriaxone 2 g twice daily and stop dexamethasone
B. Switch to benzylpenicillin 2.4 g four-hourly and continue dexamethasone
C. Switch to amoxicillin 2 g four-hourly and continue dexamethasone
D. Switch to benzylpenicillin 2.4 g four-hourly and stop dexamethasone (Correct Answer)
E. Continue ceftriaxone 2 g twice daily and continue dexamethasone for the full 10-day course

Explanation: ***Switch to benzylpenicillin 2.4 g four-hourly and stop dexamethasone*** - Once **Streptococcus pneumoniae** is confirmed to be **fully penicillin-sensitive** (MIC ≤ 0.06 mg/L), treatment should be narrowed from ceftriaxone to **high-dose benzylpenicillin** as it is the drug of choice for sensitive strains in meningitis. - **Dexamethasone** should be stopped because its primary benefit in pneumococcal meningitis is typically achieved within **4 days** of administration, and continuing it beyond this duration, especially with clinical improvement, offers no additional benefit and carries risks of side effects. *Continue ceftriaxone 2 g twice daily and stop dexamethasone* - Continuing **ceftriaxone** is unnecessary and represents **overly broad antimicrobial coverage** when a narrow-spectrum, highly effective antibiotic like benzylpenicillin is available for a penicillin-sensitive pathogen. - While stopping dexamethasone is correct for the reasons mentioned above, failing to **de-escalate** the antibiotic therapy is not in line with good **antimicrobial stewardship** principles. *Switch to benzylpenicillin 2.4 g four-hourly and continue dexamethasone* - Although switching to **benzylpenicillin** is the correct choice for a penicillin-sensitive *Streptococcus pneumoniae* infection, continuing **dexamethasone** indefinitely or beyond the recommended duration (typically **4 days**) is not indicated. - The adjunctive benefit of dexamethasone is primarily during the initial inflammatory phase, and its continued use after clinical improvement and pathogen identification is generally not supported by evidence for routine cases. *Switch to amoxicillin 2 g four-hourly and continue dexamethasone* - **Intravenous benzylpenicillin (penicillin G)** is preferred over amoxicillin for treating bacterial meningitis due to its superior and more consistent **cerebrospinal fluid (CSF) penetration** at high doses, which is crucial for CNS infections. - Continuing **dexamethasone** in a patient improving clinically with a penicillin-sensitive organism is not appropriate; its use is typically limited to the initial 4-day course. *Continue ceftriaxone 2 g twice daily and continue dexamethasone for the full 10-day course* - Maintaining **broad-spectrum ceftriaxone** when the pathogen's **MIC confirms penicillin sensitivity** is inappropriate, contributing to the risk of **antibiotic resistance** and potential drug-related adverse effects. - A **10-day course of dexamethasone** for pneumococcal meningitis is not supported by current clinical guidelines, which recommend a maximum of **4 days** of adjunctive steroid therapy.

Question 13: A 56-year-old man with end-stage renal failure on haemodialysis three times per week is diagnosed with fully drug-sensitive pulmonary tuberculosis. He weighs 70 kg. His renal function shows: creatinine 680 micromol/L, eGFR <10 mL/min/1.73m². Which one of the following represents the most appropriate dosing regimen for the intensive phase of treatment?

A. Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 1.5 g three times per week post-dialysis, ethambutol 600 mg three times per week post-dialysis (Correct Answer)
B. Rifampicin 450 mg once daily, isoniazid 200 mg once daily, pyrazinamide 1 g once daily, ethambutol 800 mg three times per week post-dialysis
C. Rifampicin 600 mg three times per week post-dialysis, isoniazid 300 mg three times per week post-dialysis, pyrazinamide 25 mg/kg three times per week post-dialysis, ethambutol 15 mg/kg three times per week post-dialysis
D. Rifampicin 600 mg once daily, isoniazid 300 mg three times per week post-dialysis, pyrazinamide 25 mg/kg three times per week post-dialysis, ethambutol 15 mg/kg three times per week post-dialysis
E. Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 500 mg once daily, ethambutol 400 mg once daily

Explanation: ***Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 1.5 g three times per week post-dialysis, ethambutol 600 mg three times per week post-dialysis***- **Rifampicin** and **isoniazid** are primarily metabolized by the **liver**, so standard daily doses are maintained regardless of renal function or dialysis.- **Pyrazinamide** and **ethambutol** (or their metabolites) are **renally excreted** and cleared by dialysis; they must be given **thrice weekly after dialysis** to prevent toxic accumulation while maintaining efficacy.*Rifampicin 450 mg once daily, isoniazid 200 mg once daily, pyrazinamide 1 g once daily, ethambutol 800 mg three times per week post-dialysis*- The **rifampicin** and **isoniazid** doses are inappropriately low for a 70 kg patient, as their metabolism is independent of renal clearance.- Daily dosing of **pyrazinamide** is contraindicated in **ESRF** due to the high risk of **hyperuricemia** and **hepatotoxicity** from metabolite buildup.*Rifampicin 600 mg three times per week post-dialysis, isoniazid 300 mg three times per week post-dialysis, pyrazinamide 25 mg/kg three times per week post-dialysis, ethambutol 15 mg/kg three times per week post-dialysis*- **Rifampicin** and **isoniazid** should not be switched to intermittent dosing solely based on renal failure, as they require daily administration for optimal plasma levels and efficacy.- Reducing the frequency of these particular drugs increases the risk of **treatment failure** and the development of **drug resistance**.*Rifampicin 600 mg once daily, isoniazid 300 mg three times per week post-dialysis, pyrazinamide 25 mg/kg three times per week post-dialysis, ethambutol 15 mg/kg three times per week post-dialysis*- While the pyrazinamide and ethambutol adjustments are correct, **isoniazid** does not require a reduction in frequency for dialysis patients.- Standard **isoniazid** 300 mg daily dosing ensures adequate exposure, especially in **fast acetylators**, even with low **eGFR**.*Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 500 mg once daily, ethambutol 400 mg once daily*- Administering **ethambutol** daily in renal failure, even at low doses, significantly increases the risk of **optic neuritis** due to cumulative toxicity.- Daily dosing of **pyrazinamide** in ESRF leads to the accumulation of several toxic metabolites which cannot be managed safely by simple dose reduction; intermittent dosing is the standard of care.

Question 14: A 32-year-old woman presents with a 16-hour history of severe headache, fever, photophobia, and neck stiffness. She appears unwell but is alert and oriented. Vital signs: temperature 39.1°C, blood pressure 118/75 mmHg, heart rate 105 bpm. There are no focal neurological signs or papilloedema. CT head performed prior to lumbar puncture is normal. Lumbar puncture shows: opening pressure 26 cmH2O, CSF white cells 1,450/mm³ (88% neutrophils), protein 1.9 g/L, glucose 2.4 mmol/L (serum glucose 6.2 mmol/L). Gram stain shows Gram-positive cocci in chains. Which one of the following organisms is most likely responsible?

A. Streptococcus pneumoniae (Correct Answer)
B. Streptococcus agalactiae (Group B Streptococcus)
C. Enterococcus faecalis
D. Streptococcus pyogenes (Group A Streptococcus)
E. Viridans group streptococci

Explanation: ***Streptococcus pneumoniae*** - This organism is the **most common cause of community-acquired bacterial meningitis** in adults, fitting the patient's acute presentation with fever, headache, photophobia, and neck stiffness. - The CSF findings (high neutrophils, elevated protein, low glucose) are classic for **bacterial meningitis**, and while often described as diplococci, *S. pneumoniae* can appear as **Gram-positive cocci in chains** on Gram stain. *Streptococcus agalactiae (Group B Streptococcus)* - While a significant cause of meningitis, it primarily affects **neonates** and, less commonly, immunocompromised or elderly adults. - A healthy 32-year-old woman is not typically at high risk for GBS meningitis unless specific risk factors like **pregnancy** or severe underlying disease are present. *Enterococcus faecalis* - Meningitis due to *Enterococcus faecalis* is uncommon and usually associated with specific risk factors such as recent **neurosurgery**, head trauma, or **CSF shunts**. - It is a rare cause of primary community-acquired bacterial meningitis in an otherwise healthy individual, despite being a Gram-positive coccus. *Streptococcus pyogenes (Group A Streptococcus)* - *S. pyogenes* is a very rare cause of meningitis and typically occurs as a secondary complication of a primary infection such as **otitis media**, sinusitis, or mastoiditis. - The clinical picture in this case is a primary acute bacterial meningitis, making *S. pneumoniae* statistically much more likely. *Viridans group streptococci* - These organisms are generally low-virulence commensals of the oral cavity and are typically associated with meningitis only in specific settings, such as following **neurosurgery** or in patients with **infective endocarditis**. - They are not a common cause of acute, severe community-acquired meningitis in a healthy young adult, unlike *S. pneumoniae*.

Question 15: A 45-year-old man from Georgia (country in the Caucasus) presents with an 11-week history of cough, fever, and weight loss. Chest X-ray shows bilateral upper zone cavitation. Sputum smear is positive for acid-fast bacilli. Culture confirms Mycobacterium tuberculosis, and molecular testing shows resistance to rifampicin and isoniazid, but sensitivity to fluoroquinolones and second-line injectable agents. He has no other medical conditions and normal renal function. According to current WHO guidelines for multidrug-resistant tuberculosis (MDR-TB), which one of the following is the minimum recommended total treatment duration?

A. 9 months
B. 12 months
C. 15 months
D. 18 months (Correct Answer)
E. 24 months

Explanation: ***18 months*** - The WHO recommends a total treatment duration of **18 to 20 months** for patients with **multidrug-resistant TB (MDR-TB)** who are receiving longer all-oral regimens. - This duration is preferred in cases with **extensive pulmonary disease**, such as the bilateral cavitation seen in this patient, to ensure complete eradication and prevent relapse. *9 months* - While a **shorter 9-11 month regimen** exists for MDR-TB, it is typically reserved for patients without **extensive cavitation** or specific resistance patterns. - This patient's bilateral upper zone cavitation indicates a high bacterial load, often disqualifying them from the shorter treatment protocol under standard guidelines. *12 months* - A **12-month duration** is not a standard recommended minimum for conventional or established shorter **MDR-TB** treatment protocols. - Most standardized regimens for **rifampicin-resistant TB** are either shorter (9-11 months) or longer (18+ months). *15 months* - **15 months** is considered insufficient for the longer regimen, which requires at least **15-17 months** of treatment after **culture conversion**. - Using a shorter-than-recommended duration for MDR-TB significantly increases the risk of acquiring further resistance to **fluoroquinolones**. *24 months* - While treatment may be extended to **24 months** in cases of delayed culture conversion, **18 months** is the minimum recommended duration for the longer regimen. - **24 months** is generally the upper limit of the recommended range rather than the minimum standard for a patient with normal renal function and no prior treatment failure.

Question 16: A 9-month-old infant is brought to the emergency department with a 10-hour history of fever, poor feeding, and irritability. The infant was born at term with no complications but has not received any vaccinations due to parental choice. On examination, temperature is 39.2°C, heart rate 165 bpm, respiratory rate 45/min, blood pressure 75/50 mmHg. The infant is lethargic with a bulging anterior fontanelle. Capillary refill time is 3 seconds. Blood tests show: white cells 22.1 × 10⁹/L (neutrophils 18.5 × 10⁹/L), CRP 145 mg/L. Lumbar puncture shows: CSF white cells 4,800/mm³ (92% neutrophils), protein 3.2 g/L, glucose 0.8 mmol/L (serum glucose 4.5 mmol/L). Which one of the following organisms is most likely responsible?

A. Streptococcus pneumoniae (Correct Answer)
B. Neisseria meningitidis
C. Haemophilus influenzae type b
D. Group B Streptococcus
E. Listeria monocytogenes

Explanation: ***Streptococcus pneumoniae***- This is currently the most common cause of **bacterial meningitis** in children aged 2 months to 5 years, especially in **unvaccinated individuals**.- The CSF profile showing **neutrophilic pleocytosis**, high protein, and **severely low glucose** (ratio < 0.2) is classic for this aggressive pathogen.*Neisseria meningitidis*- While a very common cause of meningitis in this age group, it often presents with a characteristic **non-blanching purpuric rash**, which is not mentioned.- Although it causes similar CSF changes, **Streptococcus pneumoniae** remains slightly more prevalent in the specific pediatric context of non-immunization.*Haemophilus influenzae type b*- This was a leading cause in infants prior to the introduction of the **Hib vaccine**; however, it is less common than pneumococcus even in unvaccinated populations.- While technically possible in an unvaccinated child, **Streptococcus pneumoniae** is statistically more likely to cause severe meningitis in this age bracket today.*Group B Streptococcus*- This organism is a leading cause of neonatal meningitis but typically occurs in the **first 3 months** of life (early and late-onset disease).- It is a very unlikely cause for a **9-month-old** infant who has moved past the typical window for vertical transmission or maternal colonization risks.*Listeria monocytogenes*- This pathogen primarily affects **neonates** (under 1 month), the elderly, or those who are **immunocompromised**.- A healthy 9-month-old infant is not the typical demographic for *Listeria*, and the CSF profile usually shows a more mixed or **mononuclear** cell response.

Question 17: A 41-year-old man from Afghanistan with newly diagnosed drug-sensitive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. He has no other medical conditions and takes no regular medications. At his 4-week review, he is clinically improving but complains of painful, swollen joints in his feet. On examination, his first metatarsophalangeal joints are erythematous, warm, and exquisitely tender bilaterally. His serum uric acid level is 620 micromol/L (normal range 200-430 micromol/L). Which one of the following is the most appropriate management?

A. Continue all anti-tuberculous medications and start allopurinol 100 mg daily
B. Stop pyrazinamide and replace with levofloxacin 750 mg daily
C. Continue all anti-tuberculous medications and start colchicine 500 mcg twice daily (Correct Answer)
D. Stop ethambutol and continue with rifampicin, isoniazid, and pyrazinamide only
E. Continue all anti-tuberculous medications and start prednisolone 30 mg daily

Explanation: ***Continue all anti-tuberculous medications and start colchicine 500 mcg twice daily*** - The patient's symptoms (painful, swollen, erythematous, tender first MTP joints, elevated **serum uric acid**) are classic for **acute gout**, which is a known side effect of **pyrazinamide** due to inhibited renal uric acid excretion. - The most appropriate management is to treat the acute flare symptomatically with an anti-inflammatory agent like **colchicine** or NSAIDs, while continuing the critical **anti-tuberculous regimen** to ensure effective treatment of TB. *Continue all anti-tuberculous medications and start allopurinol 100 mg daily* - **Allopurinol** is a urate-lowering drug for chronic gout management and **prophylaxis**, but initiating it during an **acute gout attack** can worsen or prolong the flare. - It does not provide immediate relief from the **acute inflammation** and pain, which requires specific anti-inflammatory treatment. *Stop pyrazinamide and replace with levofloxacin 750 mg daily* - **Pyrazinamide** is an essential component of the **intensive phase** of drug-sensitive TB treatment, and its removal would significantly prolong the total duration of therapy. - Replacing it with a **fluoroquinolone** like levofloxacin is typically reserved for cases where first-line drugs are truly intolerable or in instances of drug resistance, not for manageable side effects like acute gout. *Stop ethambutol and continue with rifampicin, isoniazid, and pyrazinamide only* - **Ethambutol** is primarily associated with **optic neuritis** as a key adverse effect, not hyperuricemia or gouty arthritis. - Discontinuing ethambutol would not address the underlying cause of the patient's **acute gout flare**, which is attributed to pyrazinamide. *Continue all anti-tuberculous medications and start prednisolone 30 mg daily* - While **systemic corticosteroids** can effectively treat acute gout, they are generally considered a second-line option after **colchicine** or NSAIDs for localized flares. - Using high-dose **prednisolone** in a patient with active **pulmonary tuberculosis** requires careful consideration due to its potential **immunosuppressive effects**, which might compromise TB control.

Question 18: A 63-year-old woman with a history of breast cancer treated with mastectomy 5 years ago presents with a 6-week history of progressive confusion and personality change. Her husband reports she has become withdrawn and forgetful. On examination, temperature is 37.6°C, Glasgow Coma Scale is 14/15 (E4V4M6), and she has subtle left-sided weakness. CT head shows a ring-enhancing lesion in the right frontal lobe with surrounding oedema. Lumbar puncture shows: opening pressure 24 cmH2O, CSF white cells 180/mm³ (70% lymphocytes), protein 1.8 g/L, glucose 2.3 mmol/L (serum glucose 5.8 mmol/L). Gram stain and initial bacterial cultures are negative. Which one of the following is the most likely diagnosis?

A. Brain metastasis from breast cancer
B. Tuberculous meningitis with tuberculoma (Correct Answer)
C. Cerebral toxoplasmosis
D. Herpes simplex encephalitis
E. Cryptococcal meningitis

Explanation: ***Tuberculous meningitis with tuberculoma*** - The 6-week progressive course and classic CSF findings of **lymphocytic pleocytosis**, **elevated protein**, and **markedly low glucose** (CSF/serum glucose ratio <0.5) are highly indicative of tuberculous meningitis. - The presence of a **ring-enhancing lesion** with surrounding edema on CT head, alongside these CSF findings, is characteristic of a cerebral tuberculoma, a common manifestation of CNS tuberculosis. *Brain metastasis from breast cancer* - While the patient has a history of breast cancer and ring-enhancing lesions can be metastases, this diagnosis does not explain the significant **inflammatory CSF profile** with high white cell count and protein. - Metastases typically do not cause **meningeal inflammation** leading to a marked lymphocytic pleocytosis and low CSF glucose unless there is extensive leptomeningeal carcinomatosis, which has a distinct clinical presentation. *Cerebral toxoplasmosis* - This condition is almost exclusively seen in **severely immunocompromised** individuals, particularly those with HIV/AIDS and low CD4 counts, which is not indicated here. - Toxoplasmosis typically presents with **multiple ring-enhancing lesions**, often in the basal ganglia, whereas this patient has a single lesion and a CSF profile more consistent with tuberculosis. *Herpes simplex encephalitis* - This encephalitis typically presents with an **acute onset** (days, not weeks) and has a predilection for the **temporal lobes**, often causing focal seizures, aphasia, or personality changes. - While CSF shows lymphocytic pleocytosis and elevated protein, **CSF glucose is usually normal**, unlike the very low glucose observed in this patient. *Cryptococcal meningitis* - This fungal meningitis primarily affects **immunocompromised hosts** (e.g., HIV/AIDS, organ transplant recipients), which is not the case for this patient. - While it can cause CSF changes similar to TB (lymphocytic pleocytosis, low glucose, high protein), a **solitary large ring-enhancing lesion** is less typical, and diagnosis often requires India ink stain or cryptococcal antigen testing.

Question 19: According to current UK Public Health England guidance on tuberculosis contact tracing, which one of the following scenarios requires chemoprophylaxis for latent tuberculosis infection to be offered to exposed contacts, regardless of the Mantoux test or interferon-gamma release assay (IGRA) result?

A. A 35-year-old immunocompetent adult exposed to smear-negative, culture-positive pulmonary TB
B. A 4-year-old child exposed to smear-positive pulmonary TB in the household (Correct Answer)
C. A 28-year-old healthcare worker exposed to a patient with cavitating pulmonary TB for 2 hours without appropriate PPE
D. A 45-year-old man with type 2 diabetes exposed to smear-positive pulmonary TB for 8 hours in a poorly ventilated room
E. A 32-year-old HIV-positive patient (CD4 350 cells/mm³) exposed to drug-resistant TB for 3 hours

Explanation: ***A 4-year-old child exposed to smear-positive pulmonary TB in the household***- Children **under 5 years of age** who are household contacts of **smear-positive pulmonary TB** must receive chemoprophylaxis regardless of initial test results due to high risk of rapid progression.- This approach covers the **window period** where initial Mantoux or IGRA may be negative despite recent infection, preventing severe outcomes like **TB meningitis**.*A 35-year-old immunocompetent adult exposed to smear-negative, culture-positive pulmonary TB*- For **immunocompetent adults**, chemoprophylaxis for **latent TB** is only indicated if the Mantoux test or IGRA is positive.- Smear-negative cases are considered **less infectious** than smear-positive cases, reducing the immediate urgency for empiric treatment in healthy adults.*A 28-year-old healthcare worker exposed to a patient with cavitating pulmonary TB for 2 hours without appropriate PPE*- Guidance for healthcare workers requires **screening with IGRA or Mantoux** following a significant exposure before initiating treatment.- **Chemoprophylaxis** is only offered if evidence of latent infection is found during the follow-up testing at 6-12 weeks.*A 45-year-old man with type 2 diabetes exposed to smear-positive pulmonary TB for 8 hours in a poorly ventilated room*- While diabetes is a risk factor, **immunocompetent adults** still require a positive screening test result to justify starting chemoprophylaxis.- Routine practice involves performing a **Mantoux or IGRA** first and treating only if these indicate latent tuberculosis.*A 32-year-old HIV-positive patient (CD4 350 cells/mm³) exposed to drug-resistant TB for 3 hours*- Empiric chemoprophylaxis for HIV-positive contacts is generally reserved for those with **CD4 counts <200 cells/mm³** or other significant immunosuppression.- With a **CD4 count of 350**, this patient would typically undergo standard IGRA/Mantoux testing rather than receiving immediate prophylaxis regardless of result.

Question 20: A 52-year-old man with newly diagnosed smear-positive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. He has a history of schizophrenia and is taking clozapine 400 mg daily, which has achieved good symptom control. Three weeks after starting TB treatment, his community psychiatric nurse contacts you reporting that he has developed auditory hallucinations and persecutory delusions. His clozapine level is 180 mcg/L (therapeutic range 350-600 mcg/L). Which one of the following best explains this presentation?

A. Isoniazid has directly neurotoxic effects causing psychosis
B. Rifampicin has induced hepatic enzymes, reducing clozapine levels (Correct Answer)
C. Ethambutol has crossed the blood-brain barrier and caused CNS toxicity
D. Pyrazinamide has competed with clozapine for protein binding sites
E. The patient has developed tuberculous meningitis with neuropsychiatric manifestations

Explanation: ***Rifampicin has induced hepatic enzymes, reducing clozapine levels*** - **Rifampicin** is a potent inducer of the **cytochrome P450 system** (specifically CYP1A2 and CYP3A4), which are the primary enzymes responsible for metabolizing **clozapine**. - This induction increases **clozapine clearance**, resulting in the subtherapeutic level of **180 mcg/L** and the subsequent relapse of psychotic symptoms like **hallucinations and delusions**. *Isoniazid has directly neurotoxic effects causing psychosis* - While **isoniazid** can cause peripheral neuropathy or rare neuropsychiatric side effects, it typically does so through **pyridoxine (Vitamin B6) deficiency**. - This mechanism does not account for the laboratory finding of **low clozapine levels**, which is the primary driver of this patient's relapse. *Ethambutol has crossed the blood-brain barrier and caused CNS toxicity* - **Ethambutol** is primarily known for **optic neuritis** (painless blurred vision and red-green color blindness) rather than global CNS toxicity or psychosis. - It does not significantly alter the **metabolic pathways** or serum concentrations of antipsychotic medications like clozapine. *Pyrazinamide has competed with clozapine for protein binding sites* - Displacement from **protein binding sites** would theoretically increase the free (active) fraction of a drug, potentially leading to **toxicity**, not the low levels seen here. - **Pyrazinamide** does not have a clinically significant interaction with clozapine regarding **protein binding** or hepatic enzyme modulation. *The patient has developed tuberculous meningitis with neuropsychiatric manifestations* - **Tuberculous meningitis** typically presents with systemic symptoms like **fever**, headache, neck stiffness, and cranial nerve palsies. - While it can causes altered mental status, it would not cause a specific **decrease in clozapine serum concentration** to subtherapeutic levels.

Question 21: A 5-year-old boy who recently emigrated from Pakistan presents with a 5-week history of progressive lethargy, low-grade fever, and behavioural changes. His parents report he has become increasingly irritable and has difficulty walking. On examination, temperature is 37.8°C, he has neck stiffness and bilateral sixth nerve palsies. CT head shows basal meningeal enhancement and hydrocephalus. Lumbar puncture shows: opening pressure 35 cmH2O, CSF white cells 250/mm³ (80% lymphocytes), protein 3.2 g/L, glucose 1.8 mmol/L (serum glucose 5.4 mmol/L). Ziehl-Neelsen stain of CSF is negative. What is the most appropriate initial antimicrobial regimen?

A. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 10 months (Correct Answer)
B. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months
C. Rifampicin, isoniazid, pyrazinamide, and moxifloxacin for 2 months, then rifampicin and isoniazid for 10 months
D. Rifampicin, isoniazid, and pyrazinamide for 2 months, then rifampicin and isoniazid for 10 months
E. Rifampicin, isoniazid, ethambutol, and levofloxacin for 2 months, then rifampicin and isoniazid for 4 months

Explanation: ***Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 10 months***- The clinical presentation, including **basal meningeal enhancement**, **hydrocephalus**, **cranial nerve palsies**, and characteristic **CSF findings** (lymphocytic pleocytosis, high protein, low glucose), is highly suggestive of **Tuberculous Meningitis (TBM)**.- TBM requires a prolonged treatment course of **12 months** (2 months intensive 4-drug phase followed by 10 months continuation phase) due to the severity and difficulty of drug penetration into the **central nervous system**.*Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months*- This 6-month regimen is typically used for **pulmonary tuberculosis** and is inadequate for the treatment of **Tuberculous Meningitis**.- Shorter treatment durations in TBM are associated with increased risk of **relapse** and poorer neurological outcomes.*Rifampicin, isoniazid, pyrazinamide, and moxifloxacin for 2 months, then rifampicin and isoniazid for 10 months*- **Moxifloxacin** is a fluoroquinolone generally reserved for **multidrug-resistant TB** or when first-line drugs are contraindicated, not as a standard first-line agent.- **Ethambutol** is the preferred fourth drug in the initial intensive phase for drug-sensitive TBM due to its effectiveness and favorable side effect profile.*Rifampicin, isoniazid, and pyrazinamide for 2 months, then rifampicin and isoniazid for 10 months*- A **four-drug regimen** is essential in the initial intensive phase of TBM to ensure adequate empiric coverage and prevent the development of **drug resistance**.- Omitting the fourth drug (like ethambutol or streptomycin) can lead to treatment failure, especially if there is underlying **isoniazid resistance**.*Rifampicin, isoniazid, ethambutol, and levofloxacin for 2 months, then rifampicin and isoniazid for 4 months*- This regimen incorrectly omits **pyrazinamide**, which is a crucial first-line drug with excellent **CSF penetration** and sterilizing activity against *M. tuberculosis*.- The total duration of 6 months is also insufficient for treating **Tuberculous Meningitis**, which requires a longer course.

Question 22: A 27-year-old woman presents with a 10-hour history of severe headache, photophobia, and vomiting. On examination, temperature is 38.9°C, blood pressure 105/68 mmHg, heart rate 118 bpm. She has marked neck stiffness and a positive Kernig's sign. A non-blanching purpuric rash is noted on her lower limbs. Lumbar puncture shows: opening pressure 28 cmH2O, CSF white cells 3,200/mm³ (95% neutrophils), protein 2.8 g/L, glucose 1.2 mmol/L (serum glucose 6.1 mmol/L). Gram stain shows Gram-negative diplococci. Which one of the following should be administered immediately after blood cultures are obtained?

A. IV ceftriaxone 2 g and IV dexamethasone 10 mg (Correct Answer)
B. IV benzylpenicillin 2.4 g and IV dexamethasone 10 mg
C. IV ceftriaxone 2 g and IV aciclovir 10 mg/kg
D. IV benzylpenicillin 2.4 g alone
E. IV cefotaxime 2 g and IV vancomycin 1 g

Explanation: ***IV ceftriaxone 2 g and IV dexamethasone 10 mg*** - Third-generation cephalosporins like **ceftriaxone** are the first-line empirical treatment for bacterial meningitis due to their excellent **CSF penetration** and coverage against **Neisseria meningitidis** (Gram-negative diplococci). - **Dexamethasone** should be administered with or just before the first dose of antibiotics to reduce the **inflammatory response** and decrease the risk of neurological sequelae such as **hearing loss**. *IV benzylpenicillin 2.4 g and IV dexamethasone 10 mg* - While effective against meningococci, **benzylpenicillin** is no longer the empirical choice in the hospital setting due to potential **penicillin resistance** in Streptococcus pneumoniae. - High-dose intravenous penicillin is generally reserved for the **pre-hospital setting** when a purpuric rash is seen and transfer to a hospital is delayed. *IV ceftriaxone 2 g and IV aciclovir 10 mg/kg* - **Aciclovir** is used for viral causes like **Herpes Simplex Encephalitis**, but the CSF findings (high neutrophils, low glucose, high protein) clearly indicate a **bacterial etiology**. - Failure to provide **dexamethasone** in a patient with suspected bacterial meningitis misses an opportunity to reduce potential long-term **morbidity**. *IV benzylpenicillin 2.4 g alone* - Administering penicillin alone does not cover the possibility of other bacteria and fails to address the **septic inflammatory response** managed by steroids. - The absence of **dexamethasone** is contrary to current clinical guidelines which emphasize the prevention of **cerebral edema** and vasculitis. *IV cefotaxime 2 g and IV vancomycin 1 g* - This combination is typically used when **resistant pneumococci** are suspected or in regions with high penicillin resistance; however, the Gram stain specifically points to **meningococcus**. - **Ceftriaxone** 2g twice daily is the standard UK and international recommendation for adult suspected bacterial meningitis; adding **vancomycin** is not routinely required for Gram-negative diplococci.

Question 23: A 34-year-old man from Romania with newly diagnosed smear-positive pulmonary tuberculosis is started on standard four-drug therapy. He has no significant past medical history. After 3 days of treatment, he develops a red, itchy maculopapular rash over his trunk and limbs, with no mucosal involvement or systemic features. His vital signs are normal. Which one of the following is the most appropriate initial management?

A. Continue all anti-tuberculous drugs and add oral antihistamines
B. Stop all anti-tuberculous drugs and rechallenge with each drug individually after the rash resolves (Correct Answer)
C. Continue rifampicin, isoniazid, and ethambutol; stop pyrazinamide
D. Stop all anti-tuberculous drugs and start corticosteroids
E. Continue all anti-tuberculous drugs and add oral corticosteroids

Explanation: ***Stop all anti-tuberculous drugs and rechallenge with each drug individually after the rash resolves***- For a widespread **maculopapular rash** occurring after starting TB therapy, global guidelines recommend stopping all drugs to prevent potential progression to **severe cutaneous adverse reactions (SCARs)** like SJS/TEN.- Once the rash clears, drugs are reintroduced one by one (starting with the least likely culprit, such as **Ethambutol**, then **Isoniazid**, then **Rifampicin**) to identify the specific offending agent.*Continue all anti-tuberculous drugs and add oral antihistamines*- Continuing therapy in the presence of a generalized rash is dangerous as it may lead to **exfoliative dermatitis** or life-threatening hypersensitivity.- **Antihistamines** only mask symptomatic itching and do not address the underlying drug-induced immune response.*Continue rifampicin, isoniazid, and ethambutol; stop pyrazinamide*- Although **Pyrazinamide** is a frequent cause of rash, any of the four drugs could be the culprit, and clinical judgment cannot definitively rule others out without a **structured rechallenge**.- Continuing the other three drugs risks worsening the reaction if the culprit was actually **Isoniazid** or **Rifampicin**.*Stop all anti-tuberculous drugs and start corticosteroids*- **Systemic corticosteroids** are generally reserved for severe reactions with systemic features (DRESS) or mucosal involvement, which this patient lacks.- Stopping the medications should be the first step; routine use of steroids can interfere with the diagnosis of the drug reaction and carries its own side-effect profile.*Continue all anti-tuberculous drugs and add oral corticosteroids*- This approach is incorrect as it risks severe **immunosuppression** in a TB patient and potentially hides a worsening **hypersensitivity reaction**.- Effective management of drug-induced allergy requires the removal of the **offending antigen** rather than attempting to suppress the immune response while the antigen is still present.

Question 24: What is the primary pathophysiological mechanism by which Mycobacterium tuberculosis causes caseous necrosis in infected tissues?

A. Direct cytotoxic effect of mycobacterial cord factor on host cell membranes
B. Hypersensitivity reaction mediated by CD4+ T lymphocytes and macrophage activation (Correct Answer)
C. Ischaemic necrosis secondary to mycobacterial-induced vasculitis and thrombosis
D. Secretion of bacterial exotoxins that directly destroy host tissue architecture
E. Complement-mediated cytolysis of infected cells through antibody-dependent mechanisms

Explanation: ***Hypersensitivity reaction mediated by CD4+ T lymphocytes and macrophage activation*** - Caseous necrosis is the result of a **Type IV delayed-type hypersensitivity** reaction where **CD4+ Th1 cells** activate macrophages via **Interferon-gamma**. - This intense immune-mediated response leads to the formation of **granulomas** and the characteristic cheese-like tissue destruction intended to contain the pathogen. *Direct cytotoxic effect of mycobacterial cord factor on host cell membranes* - **Cord factor** (trehalose dimycolate) is a virulence factor responsible for the **serpentine growth** of M. tuberculosis and inhibits leukocyte migration. - While it contributes to pathogenicity and granuloma maintenance, it does not possess a **direct cytotoxic** mechanism that causes the necrosis itself. *Ischaemic necrosis secondary to mycobacterial-induced vasculitis and thrombosis* - Though **vasculitis** can occur as a complication (especially in **CNS tuberculosis**), it is not the standard mechanism for caseous necrosis. - Caseation is defined by **immune-mediated** cell death rather than a primary lack of blood supply or **microvascular thrombosis**. *Secretion of bacterial exotoxins that directly destroy host tissue architecture* - Unlike organisms like Clostridium, *Mycobacterium tuberculosis* does not secrete significant **lethal exotoxins**. - Pathogenicity is primarily due to its ability to survive within **alveolar macrophages** and provoke a host immune response. *Complement-mediated cytolysis of infected cells through antibody-dependent mechanisms* - Tuberculosis defense relies almost entirely on **cell-mediated immunity** rather than humoral (antibody) pathways. - **Complement-mediated lysis** is not a feature of TB pathogenesis, as the bacteria are specialized **intracellular pathogens** that evade such extracellular defenses.

Question 25: A 25-year-old man presents to the emergency department with a 14-hour history of severe headache, fever, and photophobia. He is drowsy with a Glasgow Coma Scale of 13/15. Purpuric lesions are visible on his legs. Blood tests show: WBC 19.5 × 10⁹/L, neutrophils 16.8 × 10⁹/L, CRP 245 mg/L, prothrombin time 18 seconds, APTT 42 seconds, fibrinogen 1.2 g/L, platelets 78 × 10⁹/L. He is started on immediate management. His younger sister (aged 18) who lives with him attends the hospital worried about her risk. Which one of the following is the most appropriate chemoprophylaxis for the sister?

A. Ciprofloxacin 500 mg single oral dose (Correct Answer)
B. Rifampicin 600 mg twice daily for 2 days
C. Ceftriaxone 250 mg intramuscular single dose
D. Benzylpenicillin 1.2 g intramuscular single dose
E. Azithromycin 500 mg once daily for 5 days

Explanation: ***Ciprofloxacin 500 mg single oral dose*** - This is the **first-line** recommended **chemoprophylaxis** for close contacts of individuals with invasive **meningococcal disease** in adults and older children. - Its **single oral dose** makes it convenient, ensuring good compliance, and it effectively eradicates **nasopharyngeal carriage** of *Neisseria meningitidis*. *Rifampicin 600 mg twice daily for 2 days* - While effective for **meningococcal chemoprophylaxis**, it requires **multiple doses** over two days (four doses total), which is less convenient than single-dose options. - It can cause **orange discoloration** of body fluids and has significant **drug interactions** due to its potent CYP450 enzyme induction. *Ceftriaxone 250 mg intramuscular single dose* - This is an effective option for **meningococcal prophylaxis**, particularly recommended for **pregnant women** or those who cannot tolerate oral medications. - However, for a healthy, orally compliant 18-year-old, an **intramuscular injection** is generally less preferred than a single oral dose. *Benzylpenicillin 1.2 g intramuscular single dose* - **Benzylpenicillin** is used for the **treatment** of suspected **meningococcal disease** (especially in pre-hospital settings) due to its bactericidal activity. - It is **not effective** as chemoprophylaxis because it does not reliably eliminate **nasopharyngeal carriage** of *Neisseria meningitidis*, which is the goal of prophylaxis. *Azithromycin 500 mg once daily for 5 days* - **Azithromycin** is generally **not recommended** as a first-line agent for **meningococcal chemoprophylaxis** according to most national guidelines. - Its role is primarily in prophylaxis for other respiratory infections, such as **pertussis**, or for treating atypical bacterial infections.

Question 26: Which one of the following clinical scenarios requires contact tracing and chemoprophylaxis for tuberculosis according to current UK guidelines?

A. A 45-year-old man with smear-negative, culture-positive pulmonary TB who has been on treatment for 3 weeks
B. A 38-year-old woman with tuberculous lymphadenitis without pulmonary involvement
C. A 52-year-old man with laryngeal tuberculosis who has completed 2 weeks of appropriate therapy (Correct Answer)
D. A 61-year-old woman with pleural tuberculosis and negative sputum samples
E. A 29-year-old man with spinal tuberculosis without respiratory symptoms

Explanation: ***A 52-year-old man with laryngeal tuberculosis who has completed 2 weeks of appropriate therapy*** - **Laryngeal tuberculosis** is highly infectious due to aerosolization of bacilli during coughing and speaking, necessitating stringent public health measures. - Current **UK guidelines** mandate contact tracing and potential chemoprophylaxis for close contacts of patients with laryngeal TB, regardless of the duration of treatment, due to the high risk of transmission. *A 45-year-old man with smear-negative, culture-positive pulmonary TB who has been on treatment for 3 weeks* - While **culture-positive**, the patient being **smear-negative** significantly reduces the immediate risk of transmission compared to smear-positive cases. - After **three weeks of effective treatment**, individuals with pulmonary TB are generally considered non-infectious, reducing the urgency for new contact tracing or chemoprophylaxis unless clinical circumstances suggest otherwise. *A 38-year-old woman with tuberculous lymphadenitis without pulmonary involvement* - **Tuberculous lymphadenitis** is an extrapulmonary form of TB that does not involve the respiratory tract, making it non-contagious. - There is no risk of airborne transmission, so **contact tracing** and **chemoprophylaxis** are not indicated for isolated nodal disease. *A 61-year-old woman with pleural tuberculosis and negative sputum samples* - **Pleural tuberculosis** is a non-infectious form of extrapulmonary TB as the bacteria are confined to the pleural space. - The absence of **positive sputum samples** confirms no respiratory shedding of bacilli, thus precluding the need for contact tracing. *A 29-year-old man with spinal tuberculosis without respiratory symptoms* - **Spinal tuberculosis** (Pott's disease) is a form of extrapulmonary TB that does not involve the lungs or airways. - Without any **respiratory symptoms** or evidence of pulmonary involvement, there is no risk of airborne transmission to contacts.

Question 27: A 34-year-old woman presents with a 6-week history of headache and personality change. Her husband reports she has become increasingly forgetful and confused. She has no significant past medical history and takes no regular medications. On examination, she is afebrile, has mild photophobia, and demonstrates cognitive impairment with difficulty with short-term memory. Lumbar puncture shows: opening pressure 26 cmH₂O, CSF protein 1.8 g/L, glucose 1.6 mmol/L (plasma glucose 5.4 mmol/L), white cells 180/mm³ (95% lymphocytes). MRI brain shows meningeal enhancement predominantly at the base of the skull. What is the single most important investigation to guide immediate management?

A. CSF Ziehl-Neelsen stain and TB culture
B. HIV antibody and p24 antigen testing (Correct Answer)
C. CSF cryptococcal antigen lateral flow assay
D. CSF viral PCR including herpes simplex and varicella zoster
E. Serum and CSF angiotensin-converting enzyme levels

Explanation: ***HIV antibody and p24 antigen testing*** - The profound CSF abnormalities (elevated pressure and protein, very low glucose, lymphocytic pleocytosis) and **basal meningeal enhancement** strongly suggest **subacute meningitis**, likely due to **tuberculosis** or **fungal infection**. - Knowing the patient's **HIV status** is paramount as it fundamentally alters the likelihood of opportunistic infections (e.g., **cryptococcal meningitis** is much more common in HIV) and dictates immediate empirical treatment strategies. *CSF Ziehl-Neelsen stain and TB culture* - While **tuberculous meningitis** is a high suspicion, the **Ziehl-Neelsen stain** has very low sensitivity in CSF, often failing to detect acid-fast bacilli. - **TB culture** is definitive but takes weeks for results, making it unsuitable for guiding **immediate management** in this critically ill patient. *CSF cryptococcal antigen lateral flow assay* - This is a rapid and highly sensitive test for **Cryptococcus**, a potential cause of meningitis, especially in immunocompromised patients. - However, determining the patient's **immunosuppression status** (e.g., HIV) is a more fundamental and immediate step to assess overall risk and guide the interpretation and urgency of further investigations and treatment. *CSF viral PCR including herpes simplex and varicella zoster* - **Viral meningitis/encephalitis** typically presents acutely, not over 6 weeks, and usually does not cause the profound **hypoglycorrhachia** (low CSF glucose) observed in this patient. - **Basal meningeal enhancement** and severe cognitive impairment are not typical features of **HSV** or **VZV** encephalitis, which often present with more focal neurological signs. *Serum and CSF angiotensin-converting enzyme levels* - These tests are used to investigate **neurosarcoidosis**, which can cause chronic meningitis and basal enhancement, but it is a diagnosis of exclusion and less common than infectious causes. - **ACE levels** have poor sensitivity and specificity for **neurosarcoidosis** and would not be the most important immediate investigation given the highly suggestive infectious picture.

Question 28: A 56-year-old man with end-stage renal failure on peritoneal dialysis is diagnosed with pulmonary tuberculosis. Sputum culture confirms Mycobacterium tuberculosis fully sensitive to first-line agents. His current medications include alfacalcidol, calcium carbonate, and erythropoietin. Which one of the following represents the most appropriate dosing regimen for his anti-tuberculosis therapy?

A. Standard daily doses of rifampicin, isoniazid, pyrazinamide, and ethambutol with no adjustment required
B. Standard doses of rifampicin and isoniazid daily, with pyrazinamide and ethambutol given three times weekly
C. Reduce all four first-line drugs to half the standard dose given daily due to reduced clearance
D. Standard daily doses of rifampicin, isoniazid, and pyrazinamide, avoid ethambutol due to risk of optic neuropathy
E. Standard doses of rifampicin and isoniazid daily, pyrazinamide 25-35 mg/kg three times weekly, and avoid ethambutol (Correct Answer)

Explanation: ***Standard doses of rifampicin and isoniazid daily, pyrazinamide 25-35 mg/kg three times weekly, and avoid ethambutol*** - **Rifampicin** and **isoniazid** are predominantly metabolized by the **liver**, allowing for standard daily dosing in patients with **end-stage renal failure** without significant accumulation. - **Pyrazinamide** metabolites are renally cleared, requiring a reduced frequency (e.g., **three times weekly**) to prevent toxicity, while **ethambutol** is generally avoided due to the high risk of **irreversible optic neuropathy** in renal impairment. *Standard daily doses of rifampicin, isoniazid, pyrazinamide, and ethambutol with no adjustment required* - This regimen is inappropriate as **pyrazinamide** and **ethambutol** are substantially cleared by the kidneys, leading to toxic accumulation and severe adverse effects in **ESRF**. - Ignoring dose adjustments for renally excreted drugs in dialysis patients significantly increases the risk of side effects such as **hyperuricemia** (from pyrazinamide) and **vision loss** (from ethambutol). *Standard doses of rifampicin and isoniazid daily, with pyrazinamide and ethambutol given three times weekly* - While **pyrazinamide** often requires reduced frequency (three times weekly) in renal failure, **ethambutol** is typically **avoided** entirely in this population due to its narrow therapeutic index and the high risk of **optic toxicity**. - Using **ethambutol** in ESRD necessitates rigorous monitoring for **visual changes**, which is often impractical and carries a significant risk compared to its benefits. *Reduce all four first-line drugs to half the standard dose given daily due to reduced clearance* - Reducing the daily dose of **rifampicin** and **isoniazid** is incorrect as their metabolism is primarily **hepatic**, potentially leading to **subtherapeutic levels** and **treatment failure**. - For renally cleared drugs like pyrazinamide, adjusting the **frequency** rather than simply reducing the daily dose is generally preferred to maintain adequate drug exposure while preventing accumulation. *Standard daily doses of rifampicin, isoniazid, and pyrazinamide, avoid ethambutol due to risk of optic neuropathy* - Although avoiding **ethambutol** is correct in ESRD, this option incorrectly suggests giving **pyrazinamide daily**. - **Pyrazinamide** requires **frequency adjustment** in renal failure to prevent accumulation of its renally excreted metabolites, which can cause severe **hepatotoxicity** and **gout**.

Question 29: A 3-year-old girl presents with a 6-hour history of fever, irritability, and reduced consciousness. Examination reveals temperature 39.4°C, Glasgow Coma Scale 11/15, and a non-blanching purpuric rash on her trunk and limbs. Her capillary refill time is 4 seconds. Blood pressure is 75/40 mmHg and heart rate 165 bpm. She received three doses of the meningococcal B vaccine and the ACWY vaccine as per the UK immunisation schedule. Which one of the following is the most likely causative organism?

A. Neisseria meningitidis serogroup B (Correct Answer)
B. Neisseria meningitidis serogroup W
C. Streptococcus pneumoniae
D. Haemophilus influenzae type b
E. Neisseria meningitidis serogroup Y

Explanation: ***Neisseria meningitidis serogroup B*** - **Meningococcal B** remains the most common cause of invasive meningococcal disease in the UK, even in vaccinated children, due to **vaccine failure** or strains not covered by the **Bexsero** vaccine. - The classic triad of **fever**, **non-blanching purpuric rash**, and rapid progression to **septic shock** (hypotension and prolonged capillary refill) is pathognomonic for meningococcal septicaemia. *Neisseria meningitidis serogroup W* - While serogroup W has increased in incidence, the **MenACWY vaccine** administered in the UK schedule provides robust protection, making it less likely than serogroup B. - It often presents with atypical symptoms like **gastrointestinal distress** or severe **epiglottitis**, though it can cause standard septicaemia. *Streptococcus pneumoniae* - **Streptococcus pneumoniae** is a common cause of meningitis and sepsis but is less frequently associated with a rapidly spreading **purpuric rash**. - Most children are protected by the **pneumococcal conjugate vaccine (PCV)** included in the routine immunisation schedule. *Haemophilus influenzae type b* - **Hib** infections have become extremely rare in the UK since the introduction of the **Hib vaccine**, which is highly effective. - Clinical presentation usually involves **meningitis**, **epiglottitis**, or **pneumonia** rather than the specific purpuric rash seen in meningococcal disease. *Neisseria meningitidis serogroup Y* - Serogroup Y is covered by the **MenACWY vaccine** given to adolescents, but even indirect protection and routine schedules make it a less common cause than serogroup B in young children. - It typically accounts for a smaller percentage of invasive disease cases compared to the **meningococcal B** strain.

Question 30: A 51-year-old man with type 2 diabetes mellitus is being treated for smear-positive pulmonary tuberculosis with rifampicin, isoniazid, pyrazinamide, and ethambutol. He takes metformin 1 g twice daily for diabetes. At his 4-week review, his HbA1c has increased from 58 mmol/mol to 76 mmol/mol despite good adherence to metformin. His fasting glucose is consistently 11-13 mmol/L. What is the most likely explanation for his deteriorating glycaemic control?

A. Pyrazinamide-induced pancreatic beta cell dysfunction reducing insulin secretion
B. Rifampicin-induced hepatic enzyme induction increasing metformin metabolism (Correct Answer)
C. Isoniazid-induced peripheral insulin resistance through neuropathic mechanisms
D. Direct diabetogenic effect of the Mycobacterium tuberculosis infection
E. Ethambutol interference with glucose transporter function in pancreatic cells

Explanation: ***Rifampicin-induced hepatic enzyme induction increasing metformin metabolism*** - **Rifampicin** is a potent inducer of **cytochrome P450 enzymes** (e.g., CYP2C9, CYP3A4) and drug transporters like **organic cation transporters (OCTs)**, which are critical for **metformin** uptake into hepatocytes and subsequent metabolism/elimination. - This induction accelerates the **metabolism and clearance** of metformin, leading to reduced systemic concentrations and therefore decreased therapeutic effect, worsening glycaemic control. *Pyrazinamide-induced pancreatic beta cell dysfunction reducing insulin secretion* - **Pyrazinamide** is primarily associated with **hyperuricaemia** and hepatotoxicity, not direct damage to pancreatic **beta cells** or reduced insulin secretion. - While some antitubercular drugs can cause glucose intolerance, pyrazinamide is not a leading cause of **significant beta cell dysfunction** as described. *Isoniazid-induced peripheral insulin resistance through neuropathic mechanisms* - **Isoniazid** is well-known for causing **peripheral neuropathy** due to **pyridoxine (Vitamin B6)** depletion, which is not directly linked to inducing peripheral insulin resistance. - Its mechanism of action and side effect profile do not include causing **insulin resistance** or affecting glucose metabolism through neuropathic pathways. *Direct diabetogenic effect of the Mycobacterium tuberculosis infection* - While chronic infections like **tuberculosis** can cause **stress-induced hyperglycemia** due to inflammatory mediators and cortisol release, this usually improves with effective treatment. - The observed increase in **HbA1c** despite 4 weeks of treatment, when the infection should be improving, strongly suggests a **drug-related interaction** rather than the infection itself. *Ethambutol interference with glucose transporter function in pancreatic cells* - **Ethambutol** is primarily associated with **optic neuritis** and visual disturbances, as well as hyperuricemia, but not with direct interference with **glucose transporter function**. - There is no established clinical evidence to support a mechanism where ethambutol affects **GLUT transporters** in pancreatic cells or other tissues to impair glucose regulation.

Question 31: A 29-year-old woman with no significant past medical history presents with a 12-hour history of severe headache, photophobia, and vomiting. She is febrile at 38.9°C with marked neck stiffness. Blood tests show: WBC 18.2 × 10⁹/L, CRP 156 mg/L, platelets 145 × 10⁹/L. CT head is normal. Lumbar puncture is performed: opening pressure 32 cmH₂O, CSF appears turbid. While awaiting CSF analysis results, she is started on appropriate empirical antibiotic therapy. Which one of the following factors would most strongly indicate a need to extend her antibiotic treatment duration beyond the standard course?

A. CSF opening pressure of 32 cmH₂O at initial lumbar puncture
B. Persistence of fever for 5 days after starting appropriate antibiotic therapy (Correct Answer)
C. CSF white cell count of 5,000 cells/mm³ at initial presentation
D. Development of seizure activity on day 2 of admission
E. Isolation of penicillin-resistant Streptococcus pneumoniae from CSF culture

Explanation: ***Persistence of fever for 5 days after starting appropriate antibiotic therapy*** - **Persistent fever** beyond 5-7 days after initiating appropriate antibiotic therapy for bacterial meningitis is a significant indicator of treatment failure or the development of complications such as **brain abscess**, **subdural empyema**, or **ventriculitis**. - This clinical sign necessitates further evaluation (e.g., repeat imaging or lumbar puncture) and almost always warrants an **extension of antibiotic duration** to ensure complete eradication of the infection and resolution of complications. *CSF opening pressure of 32 cmH₂O at initial lumbar puncture* - An elevated **CSF opening pressure** (normal range typically below 20-25 cmH₂O) is a common finding in bacterial meningitis, indicating **intracranial hypertension** due to inflammation and edema. - While it reflects the severity of the initial insult, it is not a direct factor that dictates the *length* of antibiotic treatment; instead, it guides supportive measures to reduce intracranial pressure. *CSF white cell count of 5,000 cells/mm³ at initial presentation* - A **CSF white cell count** of 5,000 cells/mm³ is extremely high and characteristic of severe bacterial meningitis, indicating a robust inflammatory response within the central nervous system. - Although it points to a severe infection, the *initial* CSF cell count alone does not determine the *total duration* of antibiotic therapy, which is primarily guided by the identified pathogen, its sensitivities, and the patient's clinical response. *Development of seizure activity on day 2 of admission* - **Seizures** are a relatively common acute complication of bacterial meningitis, often occurring early in the course due to cerebral inflammation, edema, or vasculitis. - While they signify neurological involvement and require **anticonvulsant management**, their occurrence early in the admission does not automatically necessitate an extension of the antibiotic course, unless they are linked to ongoing, uncontrolled infection or evolving focal complications. *Isolation of penicillin-resistant Streptococcus pneumoniae from CSF culture* - The isolation of **penicillin-resistant Streptococcus pneumoniae** requires modification of the initial empirical antibiotic regimen (e.g., adding **vancomycin** to a third-generation cephalosporin like **ceftriaxone**) to ensure effective coverage based on susceptibility. - However, once an effective and appropriate antibiotic regimen is established, the mere fact of initial resistance does not, by itself, require extending the *duration* of treatment beyond the standard recommended course (e.g., 10-14 days for pneumococcal meningitis), provided the patient demonstrates a good clinical response.

Question 32: A 4-year-old boy who recently emigrated from Pakistan presents with a 4-week history of lethargy, low-grade fever, and behavioural changes. His mother reports he has been increasingly drowsy over the past week. Examination reveals temperature 37.8°C, Glasgow Coma Scale 13/15, and subtle right-sided weakness. Lumbar puncture shows: opening pressure 24 cmH₂O, CSF protein 3.2 g/L, glucose 1.4 mmol/L (plasma glucose 5.6 mmol/L), white cells 280/mm³ (85% lymphocytes). CT head shows basal meningeal enhancement and hydrocephalus. Which one of the following is the most appropriate initial management?

A. Start rifampicin, isoniazid, pyrazinamide, ethambutol, and high-dose dexamethasone (Correct Answer)
B. Commence ceftriaxone, vancomycin, and aciclovir pending CSF culture results
C. Arrange urgent neurosurgical insertion of ventriculoperitoneal shunt before starting treatment
D. Start rifampicin, isoniazid, pyrazinamide, and ethambutol only, avoiding steroids due to immunosuppression risk
E. Perform CSF TB PCR and defer treatment until molecular confirmation obtained

Explanation: ***Start rifampicin, isoniazid, pyrazinamide, ethambutol, and high-dose dexamethasone***- The clinical presentation of subacute fever, **lymphocytic pleocytosis**, very high protein, very low glucose, and **basal meningeal enhancement** with **hydrocephalus** in a child from an endemic area is classic for **Tuberculous Meningitis (TBM)**.- Inclusion of **adjunctive corticosteroids** (dexamethasone) is mandatory as it significantly reduces **mortality** and neurological morbidity by decreasing intracranial inflammation.*Commence ceftriaxone, vancomycin, and aciclovir pending CSF culture results*- This regimen targets acute **bacterial and viral meningitis**, which typically present with a more rapid onset and **neutrophilic pleocytosis** (for bacterial).- It fails to address **Mycobacterium tuberculosis**, which is the primary suspicion given the **emigration history** and characteristic subacute course and CSF profile.*Arrange urgent neurosurgical insertion of ventriculoperitoneal shunt before starting treatment*- While **hydrocephalus** may eventually require surgical intervention, medical management of the underlying infection and inflammation must be initiated **immediately**.- Surgical shunting does not treat the primary cause of TBM and should not **delay** life-saving anti-tuberculous chemotherapy, which may itself reduce hydrocephalus.*Start rifampicin, isoniazid, pyrazinamide, and ethambutol only, avoiding steroids due to immunosuppression risk*- Avoiding steroids is incorrect in the context of TBM; they are a **grade A recommendation** to minimize **vasculitis**, cerebral edema, and subsequent neurological damage.- The benefits of reducing **intracranial pressure** and neurological deficits far outweigh the risks of temporary immunosuppression in this severe condition.*Perform CSF TB PCR and defer treatment until molecular confirmation obtained*- **Tuberculous meningitis** is a medical emergency; any delay in treatment is associated with rapid **neurological decline** and death.- While **PCR/GeneXpert** is helpful, sensitivity can be low, and treatment should be started based on **clinical suspicion** and CSF findings alone without waiting for confirmation.

Question 33: A 47-year-old man from Georgia is diagnosed with pulmonary tuberculosis. Molecular testing shows rifampicin resistance. He is started on an appropriate modified regimen. After 4 months of treatment, he reports orange discoloration of his contact lenses. Which one of the following medications in his current regimen is most likely responsible for this adverse effect?

A. Levofloxacin
B. Linezolid
C. Bedaquiline
D. Clofazimine (Correct Answer)
E. Cycloserine

Explanation: ***Clofazimine*** - **Clofazimine** is a core component of the modified regimen for **rifampicin-resistant tuberculosis** and is notorious for causing **orange-brown to reddish-black discoloration** of skin and body fluids. - This drug accumulates in tissues and is excreted in **tears**, which can lead to the permanent staining of **contact lenses** and other body secretions. *Levofloxacin* - This **fluoroquinolone** is commonly used in drug-resistant TB but is primarily associated with **tendonitis**, tendon rupture, and **QT prolongation**. - It does not cause pigmentary changes or discoloration of body fluids or medical devices. *Linezolid* - **Linezolid** is an oxazolidinone used for resistant TB, known for causing **myelosuppression** (anemia, thrombocytopenia) and **peripheral neuropathy**. - It may cause a reversible **black hairy tongue**, but it does not cause orange staining of contact lenses or tears. *Bedaquiline* - **Bedaquiline** inhibits mycobacterial ATP synthase and is a key drug for MDR-TB, but its main safety concerns are **hepatotoxicity** and **QTc interval prolongation**. - Unlike the riminophenazine dye derivatives, it does not possess pigment-staining properties that affect **contact lenses**. *Cycloserine* - This second-line agent is frequently associated with **neuropsychiatric adverse effects**, including seizures, psychosis, and **depression**. - It lacks any metabolic pathways or chemical properties that would result in the **discoloration** of body fluids or secretions.

Question 34: According to current UK public health guidelines, which one of the following scenarios requires notification of suspected meningococcal disease to the local Health Protection Team before laboratory confirmation?

A. A 45-year-old man with confirmed Neisseria meningitidis isolated from CSF
B. A 22-year-old woman with purpuric rash and suspected meningococcal septicaemia in the emergency department (Correct Answer)
C. A 35-year-old man with Neisseria meningitidis identified on blood culture after 48 hours
D. A 19-year-old student with viral meningitis confirmed by PCR testing
E. A 28-year-old woman with confirmed Streptococcus pneumoniae meningitis

Explanation: ***A 22-year-old woman with purpuric rash and suspected meningococcal septicaemia in the emergency department*** - Public health guidelines require **notification on clinical suspicion** of meningococcal disease to ensure rapid chemoprophylaxis for close contacts. - A **non-blanching purpuric rash** is a hallmark clinical sign that warrants immediate action before waiting for formal laboratory results. *A 45-year-old man with confirmed Neisseria meningitidis isolated from CSF* - While notification is required, the prompt asks which must be reported based on **suspicion before laboratory confirmation**. - Reporting at the point of **isolate identification** is too late for optimal public health intervention for high-risk contacts. *A 35-year-old man with Neisseria meningitidis identified on blood culture after 48 hours* - Notification should have occurred much earlier; waiting for **48-hour blood cultures** delays essential preventive measures for the community. - Statutory notification is mandated for **suspected cases**, not just laboratory-confirmed ones, to mitigate the risk of clusters. *A 19-year-old student with viral meningitis confirmed by PCR testing* - **Viral meningitis** is generally not a notifiable condition under standard UK public health regulations. - PCR confirmation of a virus does not trigger the same **emergency public health response** required for bacterial meningococcal disease. *A 28-year-old woman with confirmed Streptococcus pneumoniae meningitis* - **Streptococcus pneumoniae** causes serious illness but does not typically require immediate notification for contact tracing or prophylaxis. - Unlike *N. meningitidis*, it does not usually result in **outbreaks** requiring urgent intervention by the Health Protection Team.

Question 35: A 58-year-old man with recently diagnosed pulmonary tuberculosis has completed 2 months of rifampicin, isoniazid, pyrazinamide, and ethambutol. His sputum culture at diagnosis grew Mycobacterium tuberculosis fully sensitive to all first-line agents. Repeat sputum samples at 2 months remain culture positive. He has been fully adherent to treatment, confirmed by directly observed therapy. His liver and renal function are normal. What is the most appropriate next step in his management?

A. Continue rifampicin and isoniazid for standard 4-month continuation phase (Correct Answer)
B. Extend the intensive phase by adding pyrazinamide and ethambutol for another month
C. Send sputum for repeat drug susceptibility testing and continue current regimen
D. Switch to second-line therapy with fluoroquinolone and injectable agent
E. Add a fluoroquinolone to rifampicin and isoniazid for the continuation phase

Explanation: ***Continue rifampicin and isoniazid for standard 4-month continuation phase*** - In a patient with confirmed **drug-sensitive TB** who is adherent to **Directly Observed Therapy (DOT)**, a positive culture at 2 months does not equate to treatment failure. This occurs in approximately 15% of patients. - The standard management is to proceed to the **continuation phase** with rifampicin and isoniazid for 4 months, as most patients will achieve culture negativity by month 3. *Extend the intensive phase by adding pyrazinamide and ethambutol for another month* - Extending the **intensive phase** beyond 2 months is not routinely recommended by current guidelines for pansensitive TB, as it does not significantly improve outcomes and increases pill burden and potential side effects. - The primary goal of the intensive phase is rapid bacterial killing and prevention of resistance, which should be achieved within the standard 2 months for sensitive strains. *Send sputum for repeat drug susceptibility testing and continue current regimen* - **Repeat drug susceptibility testing (DST)** is typically indicated if cultures remain positive at 3 months or later, or if there is a suspicion of non-adherence or initial drug resistance. - Given initial full sensitivity and confirmed **adherence** via DOT, immediate repeat DST at 2 months is premature and not the standard next step. *Switch to second-line therapy with fluoroquinolone and injectable agent* - Switching to **second-line drugs** is unwarranted here because there is no evidence of **Multidrug-Resistant TB (MDR-TB)** or extensive drug resistance. - Second-line agents are associated with higher toxicity, lower efficacy, and a longer duration of treatment, making their use inappropriate for a fully sensitive strain. *Add a fluoroquinolone to rifampicin and isoniazid for the continuation phase* - Adding a single drug like a **fluoroquinolone** to the standard continuation phase is not recommended and can promote the development of **acquired drug resistance**. - The standard 2HREZ/4HR regimen is a highly effective and **validated protocol** for treating pansensitive Mycobacterium tuberculosis.

Question 36: A 35-year-old woman from the Philippines with newly diagnosed smear-positive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 3 weeks of treatment, she develops painful red nodules on her shins and ankle swelling. Examination reveals bilateral tender erythematous nodules on the anterior shins and periarticular swelling of both ankles. Her observations are: temperature 37.2°C, blood pressure 118/76 mmHg, heart rate 78 bpm. Which one of the following is the most appropriate management?

A. Stop all anti-tuberculosis medications and perform drug rechallenge sequentially
B. Continue current treatment and provide symptomatic relief with NSAIDs (Correct Answer)
C. Replace pyrazinamide with moxifloxacin and continue other medications
D. Add prednisolone 40 mg daily and continue current anti-tuberculosis therapy
E. Stop ethambutol immediately and replace with a second-line agent

Explanation: ***Continue current treatment and provide symptomatic relief with NSAIDs*** - The patient is experiencing **erythema nodosum**, a delayed hypersensitivity reaction to **tuberculous antigens** released during effective treatment, often considered a form of **Immune Reconstitution Inflammatory Syndrome (IRIS)**. - These nodules and periarticular swelling are **self-limiting** and do not represent drug toxicity; therefore, the full RIPE regimen should be continued while managing pain with **NSAIDs**. *Stop all anti-tuberculosis medications and perform drug rechallenge sequentially* - Stopping medications is reserved for **severe cutaneous adverse reactions (SCAR)** or **drug-induced hepatitis**, not for immunological reactions like erythema nodosum. - Erythema nodosum is a reaction to the **bacillus**, not a hypersensitivity to the specific anti-tuberculous drugs themselves. *Replace pyrazinamide with moxifloxacin and continue other medications* - **Pyrazinamide** is commonly associated with hyperuricemia and gouty arthritis, but it does not cause the tender, red shin nodules classic of **erythema nodosum**. - Replacing a first-line agent without evidence of **drug-induced liver injury** or intolerable toxicity compromises the efficacy of the intensive phase of treatment. *Add prednisolone 40 mg daily and continue current anti-tuberculosis therapy* - **Corticosteroids** are typically reserved for severe IRIS involving closed spaces (e.g., **CNS TB**) or life-threatening systemic inflammation. - Erythema nodosum is generally mild and manageable with **simple analgesics**, making high-dose steroids unnecessary and potentially immunosuppressive. *Stop ethambutol immediately and replace with a second-line agent* - **Ethambutol** is primarily associated with **optic neuritis**; it is not the causative agent for pretibial nodules or ankle swelling. - Routine cessation and replacement with less effective **second-line agents** increase the risk of developing drug-resistant tuberculosis.

Question 37: A 42-year-old man with HIV infection (CD4 count 150 cells/mm³) presents with a 2-week history of headache and fever. Lumbar puncture shows: opening pressure 28 cmH₂O, CSF protein 1.2 g/L, glucose 1.8 mmol/L (plasma glucose 5.2 mmol/L), white cells 120/mm³ (90% lymphocytes). India ink staining is positive. He is started on appropriate antifungal therapy. Which one of the following is the most important additional intervention to improve his outcome?

A. Commence adjunctive dexamethasone 0.4 mg/kg daily
B. Perform therapeutic lumbar puncture to reduce CSF opening pressure (Correct Answer)
C. Start empirical anti-tuberculosis therapy pending TB culture results
D. Insert external ventricular drain for continuous CSF drainage
E. Administer mannitol 20% infusion to reduce intracranial pressure

Explanation: ***Perform therapeutic lumbar puncture to reduce CSF opening pressure*** - Raised **intracranial pressure (ICP)**, indicated by an opening pressure of 28 cmH₂O, is the most important modifiable risk factor for mortality in **cryptococcal meningitis**. - **Serial therapeutic lumbar punctures** are essential to reduce CSF pressure, relieve symptoms, and improve outcomes by draining excess CSF, aiming for a pressure <20 cmH₂O or a 50% reduction. *Commence adjunctive dexamethasone 0.4 mg/kg daily* - Unlike in bacterial meningitis, **adjunctive corticosteroids** like dexamethasone are generally not recommended and may be harmful in **cryptococcal meningitis**, potentially increasing mortality and delaying fungal clearance. - Studies have not shown a benefit with steroid use in cryptococcal meningitis and it can exacerbate immunosuppression in HIV patients. *Start empirical anti-tuberculosis therapy pending TB culture results* - The **India ink stain** definitively confirmed **Cryptococcus neoformans**, making empirical anti-tuberculosis therapy unnecessary at this stage. - While TB meningitis is a differential in HIV, the specific diagnostic finding of **Cryptococcus** rules out the need for empirical TB treatment. *Insert external ventricular drain for continuous CSF drainage* - An **external ventricular drain (EVD)** is typically a salvage procedure for refractory raised ICP or **hydrocephalus** that doesn't respond to serial lumbar punctures. - It is a more invasive procedure and not the first-line management for elevated ICP in cryptococcal meningitis. *Administer mannitol 20% infusion to reduce intracranial pressure* - **Mannitol** provides only transient reduction in ICP by drawing water out of brain tissue and is primarily used for acute cerebral edema or herniation, not for chronic elevated ICP due to impaired CSF reabsorption in cryptococcal meningitis. - It does not address the underlying pathophysiology of **cryptococcal meningitis**-associated ICP and its effects are short-lived.

Question 38: A 56-year-old man with end-stage renal failure on haemodialysis is diagnosed with smear-positive pulmonary tuberculosis. Drug susceptibility testing confirms fully sensitive Mycobacterium tuberculosis. Baseline blood tests show: creatinine 680 µmol/L, eGFR <15 mL/min/1.73m². Which anti-tuberculosis drug requires the most significant dose adjustment in this patient?

A. Rifampicin - reduce dose by 50% due to reduced renal clearance
B. Isoniazid - give three times weekly after haemodialysis sessions only
C. Pyrazinamide - reduce dose and extend dosing interval due to renal excretion
D. Ethambutol - reduce dose and extend dosing interval due to renal excretion (Correct Answer)
E. None - all first-line drugs can be given at standard doses in renal failure

Explanation: ***Ethambutol - reduce dose and extend dosing interval due to renal excretion*** - **Ethambutol** is primarily eliminated via the **kidneys** (approximately 80%), and its accumulation in renal failure significantly increases the risk of dose-related **optic neuropathy**. - In patients with an **eGFR <30 mL/min** or those on **haemodialysis**, the frequency is typically reduced to **three times weekly** to prevent irreversible visual loss. *Rifampicin - reduce dose by 50% due to reduced renal clearance* - **Rifampicin** is primarily metabolized by the **liver** and excreted into the bile, making it safe to use at standard doses in renal failure. - No dose adjustment is required because its **renal clearance** is a negligible component of its total elimination. *Isoniazid - give three times weekly after haemodialysis sessions only* - **Isoniazid** undergoes **hepatic acetylation**, so it does not require significant dose reduction in renal impairment, though pyridoxine is added to prevent **neurotoxicity**. - While it can be removed by dialysis, it is typically administered **daily**, though timing it after dialysis sessions is preferred to avoid premature drug removal. *Pyrazinamide - reduce dose and extend dosing interval due to renal excretion* - Although **Pyrazinamide** metabolites are renally cleared, current guidelines often prioritize keeping the dose standard while extending the **interval** rather than reducing the dose itself. - While it does require adjustment (typically to **three times weekly**), **Ethambutol** is considered the most critical drug to adjust due to the higher specificity of its **toxic profile** (vision loss) to renal clearance. *None - all first-line drugs can be given at standard doses in renal failure* - This is incorrect because several first-line agents, specifically **Ethambutol** and **Pyrazinamide**, are known to accumulate to toxic levels in **end-stage renal disease**. - Failure to adjust doses in **haemodialysis** patients leads to severe adverse effects, including **retrobulbar neuritis** and hyperuricaemia.

Question 39: A 24-year-old woman presents with an 18-hour history of severe headache, photophobia, and fever. Examination reveals neck stiffness and Kernig's sign is positive. Lumbar puncture shows: opening pressure 18 cmH2O, clear CSF, white cells 380/mm³ (85% lymphocytes), protein 0.9 g/L, glucose 3.2 mmol/L (plasma glucose 5.5 mmol/L). CSF Gram stain and bacterial culture are negative. PCR for enteroviruses is positive. What is the most appropriate management?

A. Intravenous aciclovir 10 mg/kg three times daily for 14 days
B. Intravenous ceftriaxone and aciclovir until HSV PCR excluded
C. Supportive care with analgesia and hydration only (Correct Answer)
D. Intravenous pleconaril if available through compassionate use
E. Intravenous immunoglobulin and supportive care

Explanation: ***Supportive care with analgesia and hydration only***- This patient has confirmed **enteroviral meningitis**, evidenced by lymphocytic pleocytosis, normal glucose, negative bacterial tests, and positive enterovirus PCR, which is typically a **self-limiting** condition in immunocompetent adults.- Management focuses on **symptomatic relief**, including adequate fluid intake and **analgesia** for headache and fever, as specific antiviral therapy is generally not required.*Intravenous aciclovir 10 mg/kg three times daily for 14 days*- **Aciclovir** is an antiviral specifically active against **Herpes Simplex Virus (HSV)** and Varicella-Zoster Virus, but it has **no efficacy** against **enteroviruses**.- This regimen is typically reserved for **HSV encephalitis**, which presents with more severe symptoms like **altered mental status** or focal neurological signs, not just meningitis.*Intravenous ceftriaxone and aciclovir until HSV PCR excluded*- While empirical broad-spectrum treatment is often initiated for suspected meningitis, the diagnostic workup here has **excluded bacterial meningitis** and confirmed **enteroviral etiology**.- Continuing unnecessary **antibiotics** (ceftriaxone) and **antivirals** (aciclovir) once the cause is identified contributes to **antimicrobial resistance** and potential side effects.*Intravenous pleconaril if available through compassionate use*- **Pleconaril** is an antiviral with activity against some enteroviruses, but it is **not routinely approved** or recommended for the treatment of typical enteroviral meningitis.- Its use is generally restricted to **severe, life-threatening enteroviral infections** or in specific high-risk populations, and it is usually only available through **compassionate use** protocols.*Intravenous immunoglobulin and supportive care*- **Intravenous immunoglobulin (IVIG)** is generally **not indicated** for the treatment of viral meningitis in **immunocompetent adults**.- IVIG may be considered for severe enteroviral infections in specific populations such as **neonates** or **immunocompromised** patients, which does not apply to this case.

Question 40: A 35-year-old homeless man with alcohol dependency and untreated pulmonary tuberculosis presents to the emergency department with haemoptysis of approximately 400 mL of bright red blood over 2 hours. He is tachycardic (heart rate 125/min) and hypotensive (blood pressure 90/55 mmHg). Chest X-ray shows a cavity in the right upper lobe. What is the most appropriate immediate intervention?

A. Arrange immediate bronchial artery embolisation
B. Position patient with right side down (bleeding side down) (Correct Answer)
C. Administer tranexamic acid and arrange urgent thoracic surgery
D. Intubate with a double-lumen endotracheal tube to isolate the lungs
E. Perform emergency rigid bronchoscopy for direct haemostasis

Explanation: ***Position patient with right side down (bleeding side down)*** - In cases of **massive haemoptysis**, the immediate priority is to prevent **asphyxiation** by ensuring blood does not flood the non-bleeding lung. - Positioning the patient with the **affected side down** (the right side, as indicated by the cavitation on CXR) prevents aspiration into the healthy lung and may provide a slight **gravity-assisted tamponade** effect. *Arrange immediate bronchial artery embolisation* - **Bronchial artery embolisation (BAE)** is the gold standard for definitive management of massive haemoptysis in stable or stabilized patients. - However, it is not the *immediate* bedside intervention required before the patient is safe for transport to the **radiology suite**. *Administer tranexamic acid and arrange urgent thoracic surgery* - **Tranexamic acid** may have a role in reducing the volume of bleeding but cannot replace the urgent mechanical stabilization needed for airway protection. - **Thoracic surgery** is generally a second-line or salvage treatment if BAE fails, due to the high mortality associated with emergency lung resection in unstable patients. *Intubate with a double-lumen endotracheal tube to isolate the lungs* - While **lung isolation** is a key goal, a **double-lumen tube (DLT)** is technically difficult to insert, especially in an emergency with high volumes of blood obstructing the view. - Standard initial management prioritizes positioning and large-bore **single-lumen intubation** if necessary, as placing a DLT requires specialized anesthesia skill and often a bronchoscope. *Perform emergency rigid bronchoscopy for direct haemostasis* - **Rigid bronchoscopy** is highly effective for clearing clots and providing mechanical tamponade, but it requires general anesthesia and specialized equipment. - It is a procedural intervention that follows the immediate stabilization steps of **positioning** and fluid resuscitation.

Question 41: A 43-year-old man from Uzbekistan presents with an 11-week history of fever, cough, and weight loss. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Sputum is smear-positive for acid-fast bacilli. Xpert MTB/RIF detects Mycobacterium tuberculosis with rifampicin resistance. He is started on an MDR-TB regimen including bedaquiline, linezolid, levofloxacin, cycloserine, and clofazimine. What baseline investigation is most critical to perform before continuing bedaquiline therapy?

A. 12-lead electrocardiogram to assess QTc interval (Correct Answer)
B. Echocardiogram to assess left ventricular function
C. 24-hour Holter monitor to detect arrhythmias
D. Exercise tolerance test to assess cardiovascular fitness
E. Cardiac MRI to assess for myocardial involvement

Explanation: ***12-lead electrocardiogram to assess QTc interval*** - **Bedaquiline**, along with **clofazimine** and **levofloxacin**, is known to cause **QTc interval prolongation**, which increases the risk of life-threatening **torsades de pointes**. - A baseline **12-lead ECG** is mandatory to ensure the QTc is within safe limits (typically <450ms in men) before initiation and for ongoing monitoring at specific intervals. *Echocardiogram to assess left ventricular function* - While useful for evaluating anatomical heart disease, this test does not provide information regarding the **cardiac electrical conduction** system affected by the medication. - Bedaquiline does not typically cause **heart failure** or structural dysfunction that would necessitate a baseline echocardiogram. *24-hour Holter monitor to detect arrhythmias* - A **Holter monitor** is generally used for detecting intermittent arrhythmias over a long period rather than characterizing the **QT interval** for drug safety screening. - A standard **12-lead ECG** is more practical, cost-effective, and sufficient for the standardized measurement of the **Fridericia-corrected QT (QTcF)**. *Exercise tolerance test to assess cardiovascular fitness* - There is no clinical indication that **exercise-induced ischemia** or fitness levels impact the safety profile of bedaquiline therapy. - This test does not provide a reliable measure of the **resting QTc interval**, which is the primary safety concern for this MDR-TB drug. *Cardiac MRI to assess for myocardial involvement* - **Cardiac MRI** is an advanced imaging modality used for detecting infiltrative diseases or **myocarditis**, which are not standard complications of bedaquiline. - It is not a recommended or necessary baseline screening tool for patients starting **MDR-TB** regimens.

Question 42: A 61-year-old man with a CSF shunt for previous subarachnoid haemorrhage presents with a 5-day history of headache, fever, and confusion. CT head shows no acute changes. Lumbar puncture reveals: opening pressure 22 cmH2O, white cells 450/mm³ (80% neutrophils), protein 1.8 g/L, glucose 2.1 mmol/L (plasma glucose 5.8 mmol/L). Gram stain shows Gram-positive cocci in clusters. What is the most appropriate antibiotic regimen?

A. Intravenous ceftriaxone and vancomycin
B. Intravenous vancomycin and rifampicin (Correct Answer)
C. Intravenous flucloxacillin and gentamicin
D. Intravenous meropenem and amikacin
E. Intravenous benzylpenicillin and chloramphenicol

Explanation: ***Intravenous vancomycin and rifampicin*** - The presence of **Gram-positive cocci in clusters** in a patient with a **CSF shunt** strongly indicates a staphylococcal infection, such as *Staphylococcus epidermidis* or *Staphylococcus aureus*. - **Vancomycin** is the treatment of choice to cover methicillin resistance, while **rifampicin** is added for its excellent CNS penetration and ability to penetrate **biofilms** on prosthetic devices. *Intravenous ceftriaxone and vancomycin* - While this is a standard regimen for **community-acquired meningitis**, ceftriaxone lacks sufficient activity against many **healthcare-associated staphylococci**. - This combination is more suited for coverage of *Streptococcus pneumoniae* and *Neisseria meningitidis*, which do not present as clusters on Gram stain. *Intravenous flucloxacillin and gentamicin* - **Flucloxacillin** is inappropriate here because a high percentage of shunt infections are caused by **methicillin-resistant** organisms (MRSA or MRSE). - **Gentamicin** has poor **cerebrospinal fluid (CSF) penetration** and is not the preferred agent for empirical shunt-related ventriculitis. *Intravenous meropenem and amikacin* - These agents provide broad **Gram-negative coverage**, which might be considered empirically if the Gram stain was negative or showed Gram-negative rods. - They do not provide optimal coverage for the **Gram-positive clusters** identified in this clinical scenario. *Intravenous benzylpenicillin and chloramphenicol* - **Benzylpenicillin** is narrow-spectrum and ineffective against the **beta-lactamase-producing** staphylococci commonly found in shunt infections. - This regimen is outdated for most modern healthcare-associated CNS infections where **resistant organisms** are highly prevalent.

Question 43: A 29-year-old woman at 8 weeks gestation presents with a 5-week history of productive cough, fever, and night sweats. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Three sputum samples are smear-positive for acid-fast bacilli. Xpert MTB/RIF confirms Mycobacterium tuberculosis with no rifampicin resistance detected. What is the most appropriate initial treatment regimen?

A. Rifampicin, isoniazid, and ethambutol for 2 months, then rifampicin and isoniazid for 7 months (Correct Answer)
B. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months
C. Delay treatment until after delivery to avoid teratogenic effects
D. Rifampicin and isoniazid only for 9 months
E. Levofloxacin, ethambutol, and ethionamide for 18 months

Explanation: ***Rifampicin, isoniazid, and ethambutol for 2 months, then rifampicin and isoniazid for 7 months*** - In pregnancy, **pyrazinamide** is often avoided in the initial phase (particularly in the first trimester) due to limited safety data; omitting it requires extending the total treatment duration from 6 to **9 months**. - This regimen is safe for the fetus while ensuring maternal cure, provided that **pyridoxine (vitamin B6)** is co-administered with isoniazid to prevent peripheral neuropathy. *Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months* - While the WHO supports the standard 6-month regimen, many national guidelines (like those in the UK/USA) recommend avoiding **pyrazinamide** in early pregnancy, making this shorter regimen less preferred in this context. - The absence of clear teratogenicity for pyrazinamide exists, but the **extended 9-month regimen** without it is the classical conservative approach to maximize safety. *Delay treatment until after delivery to avoid teratogenic effects* - Active tuberculosis poses a severe risk of **preterm labor**, low birth weight, and **congenital TB**, making immediate treatment mandatory. - The medications in the first-line regimen (RHE) are not considered **teratogenic**, whereas the risk of untreated smear-positive TB to both mother and fetus is life-threatening. *Rifampicin and isoniazid only for 9 months* - Treatment must begin with a third agent like **ethambutol** to prevent the development of drug resistance during the initial high-bacterial-load phase. - Using only two drugs in the intensive phase for **cavitary disease** and smear-positive results is insufficient and increases the risk of **treatment failure**. *Levofloxacin, ethambutol, and ethionamide for 18 months* - This is an **MDR-TB (Multidrug-resistant TB)** regimen, which is inappropriate here since the Xpert MTB/RIF confirmed no **rifampicin resistance**. - **Ethionamide** and fluoroquinolones are generally avoided in pregnancy unless absolutely necessary, and an 18-month duration is unnecessary for drug-sensitive organisms.

Question 44: A 52-year-old man completes 6 months of treatment for fully drug-sensitive pulmonary tuberculosis (rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months). He had good adherence and clinical response. His pre-treatment chest X-ray showed right upper lobe consolidation with cavitation. What is the most appropriate post-treatment monitoring strategy?

A. Repeat chest X-ray at completion, then clinical follow-up only if symptoms recur (Correct Answer)
B. Monthly sputum cultures for 6 months post-treatment
C. Repeat chest X-ray and sputum culture at treatment completion, then routine follow-up
D. CT chest at treatment completion to assess for residual disease
E. Mantoux test at 3 months post-treatment to assess treatment response

Explanation: ***Repeat chest X-ray at completion, then clinical follow-up only if symptoms recur*** - A **chest X-ray at the end of treatment** is recommended to serve as a **baseline** for future comparison if the patient develops respiratory symptoms later. - For patients with **fully drug-sensitive TB** and good adherence, routine follow-up or serial testing is not required; patients should be advised to seek care if **symptoms recur**. *Monthly sputum cultures for 6 months post-treatment* - Routine **microbiological monitoring** after treatment completion is unnecessary for patients who have successfully completed the standard regimen for **drug-sensitive TB**. - This intensive monitoring is typically reserved for **multidrug-resistant TB (MDR-TB)** or cases with poor initial clinical response. *Repeat chest X-ray and sputum culture at treatment completion, then routine follow-up* - While an end-of-treatment X-ray is useful, **routine sputum cultures** and scheduled long-term follow-up are not recommended by **national and international guidelines** for uncomplicated cases. - Treatment success is primarily determined by **clinical improvement** and completion of the prescribed therapeutic course, rather than repetitive post-treatment testing. *CT chest at treatment completion to assess for residual disease* - A **CT chest** is not a standard tool for routine monitoring of treatment response due to **radiation exposure** and cost. - Residual changes like **fibrosis or calcification** are common post-TB and do not indicate active disease or the need for further treatment. *Mantoux test at 3 months post-treatment to assess treatment response* - The **Mantoux test (TST)** or **IGRA** cannot be used to monitor treatment efficacy as they typically remain positive due to **immunological memory**. - These tests measure **delayed-type hypersensitivity** and cannot distinguish between latent infection, active disease, or successfully treated tuberculosis.

Question 45: A 33-year-old man presents with a 14-hour history of severe headache, fever, photophobia, and vomiting. He has a petechial rash on his legs. Blood pressure is 95/60 mmHg, heart rate 115/min, and he has a GCS of 13/15. Lumbar puncture is performed before antibiotics. CSF results show: turbid appearance, white cells 2800/mm³ (95% neutrophils), protein 3.2 g/L, glucose 1.1 mmol/L (plasma glucose 6.8 mmol/L). CSF Gram stain shows Gram-negative diplococci. What is the most important additional acute treatment alongside antibiotics?

A. Intravenous dexamethasone 10 mg six-hourly for 4 days
B. Intravenous aciclovir 10 mg/kg eight-hourly
C. Immediate fluid resuscitation with crystalloids to restore blood pressure (Correct Answer)
D. Mannitol infusion to reduce intracranial pressure
E. Fresh frozen plasma to correct coagulopathy

Explanation: ***Immediate fluid resuscitation with crystalloids to restore blood pressure*** - The patient exhibits classic signs of **septic shock** (hypotension, tachycardia, and altered GCS) secondary to confirmed **bacterial meningitis** with meningococcemia, making immediate hemodynamic stabilization paramount. - Prompt **volume expansion** with crystalloids is essential to improve organ perfusion, reverse shock, and significantly reduce mortality in this critical condition. *Intravenous dexamethasone 10 mg six-hourly for 4 days* - While **dexamethasone** is an adjunct therapy for bacterial meningitis to reduce inflammatory complications, especially in **pneumococcal meningitis**, its benefit in meningococcal meningitis is less clear and it is secondary to life-saving resuscitation. - Prioritizing corticosteroids over immediate management of **circulatory collapse** would delay critical care for a patient in septic shock. *Intravenous aciclovir 10 mg/kg eight-hourly* - **Aciclovir** is a specific antiviral agent for conditions like **Herpes Simplex Encephalitis**, which presents with distinct CSF findings (lymphocytic pleocytosis, normal glucose, no bacterial growth). - The CSF results here (turbid, high neutrophils, very low glucose, **Gram-negative diplococci**) definitively point to a bacterial infection, making antiviral therapy inappropriate. *Mannitol infusion to reduce intracranial pressure* - **Mannitol** is used to reduce **intracranial pressure (ICP)** in cases of cerebral edema or impending herniation, which can be a complication of severe meningitis. - However, the most immediate life-threatening issue in this patient is **septic shock**; addressing hypotension and hypoperfusion takes precedence over managing ICP unless there are clear signs of acute herniation. *Fresh frozen plasma to correct coagulopathy* - **Fresh frozen plasma (FFP)** is used to correct **coagulopathy** or treat **disseminated intravascular coagulation (DIC)**, which can complicate severe sepsis. - While DIC can occur, the most immediate and critical intervention for a patient in **septic shock** with hypotension is fluid resuscitation to maintain vital organ perfusion, rather than FFP for potential coagulopathy.

Question 46: A 47-year-old man with newly diagnosed pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. He has a history of major depressive disorder and is currently stable on sertraline 100 mg daily. After 4 weeks of TB treatment, he reports worsening mood, poor sleep, and feelings of hopelessness. What is the most likely explanation for his deteriorating mental health?

A. Drug-induced hepatitis causing hepatic encephalopathy
B. Direct neurotoxic effect of isoniazid causing depression
C. Rifampicin-induced metabolism of sertraline reducing its effectiveness (Correct Answer)
D. Pyrazinamide-related hyperuricaemia affecting mood
E. Psychological reaction to the diagnosis of tuberculosis

Explanation: ***Rifampicin-induced metabolism of sertraline reducing its effectiveness*** - **Rifampicin** is a potent inducer of **cytochrome P450 enzymes**, particularly CYP3A4, which is responsible for the metabolism of **sertraline**. - This induction leads to significantly **reduced plasma concentrations** of sertraline, diminishing its therapeutic effect and causing a relapse of the patient's **depressive symptoms**. *Drug-induced hepatitis causing hepatic encephalopathy* - While rifampicin and isoniazid can cause **hepatitis**, hepatic encephalopathy typically presents with altered consciousness, confusion, and **asterixis**, not primarily a worsening of mood. - This condition is usually associated with significant liver dysfunction and would likely manifest with other signs of liver failure such as **jaundice** or severe derangements in liver function tests. *Direct neurotoxic effect of isoniazid causing depression* - **Isoniazid (INH)** neurotoxicity commonly presents as **peripheral neuropathy** due to pyridoxine (vitamin B6) deficiency, or, less frequently, **seizures** or **psychosis**. - Although psychiatric side effects are possible, INH is not a primary or common cause of isolated worsening of a previously stable major depressive disorder. *Pyrazinamide-related hyperuricaemia affecting mood* - **Pyrazinamide** is known to cause **hyperuricaemia** by inhibiting renal uric acid excretion, which can lead to **gout**. - There is no established clinical link or evidence suggesting that **elevated uric acid levels** directly cause an acute worsening of depressive symptoms. *Psychological reaction to the diagnosis of tuberculosis* - While a chronic illness diagnosis can certainly impact mental health, the patient was described as **stable on sertraline** prior to treatment, and symptoms began after starting the **enzyme-inducing** TB regimen. - The timing and nature of the mood deterioration strongly point to a **pharmacokinetic drug interaction** rather than a purely psychological reaction.

Question 47: A 6-month-old infant is brought to the emergency department with a 4-hour history of high fever (39.5°C), irritability, and a rapidly spreading purpuric rash. The child appears shocked with capillary refill time of 5 seconds, heart rate 180/min, and blood pressure 65/40 mmHg. Blood cultures are obtained. What is the most appropriate immediate antibiotic therapy?

A. Intravenous ceftriaxone 80 mg/kg as a single dose
B. Intravenous cefotaxime 50 mg/kg plus amoxicillin 50 mg/kg (Correct Answer)
C. Intramuscular benzylpenicillin 300 mg as a single dose
D. Intravenous vancomycin 15 mg/kg plus gentamicin 2.5 mg/kg
E. Intravenous meropenem 40 mg/kg as a single dose

Explanation: ***Intravenous cefotaxime 50 mg/kg plus amoxicillin 50 mg/kg*** - The clinical presentation of **high fever, irritability, rapidly spreading purpuric rash, and shock** is highly suggestive of **meningococcal septicaemia**, a life-threatening emergency requiring immediate broad-spectrum antibiotic coverage. - In infants up to 3-6 months, empirical therapy must include coverage for **Listeria monocytogenes** (with **amoxicillin** or ampicillin), as **third-generation cephalosporins** like cefotaxime lack activity against it, alongside coverage for *Neisseria meningitidis* and *Streptococcus pneumoniae*. *Intravenous ceftriaxone 80 mg/kg as a single dose* - While **ceftriaxone** is an excellent third-generation cephalosporin for suspected **meningococcal disease** and **pneumococcal infections**, it **lacks activity against *Listeria monocytogenes***, which is a crucial pathogen to cover in young infants with severe sepsis/meningitis. - Ceftriaxone is generally avoided in neonates due to risks of **biliary sludging** and displacement of bilirubin, though this risk lessens by 6 months, the lack of Listeria coverage remains a significant drawback. *Intramuscular benzylpenicillin 300 mg as a single dose* - **Intramuscular benzylpenicillin** is a critical **pre-hospital intervention** for suspected **meningococcal disease** when intravenous access is not immediately available or hospital transfer is delayed. - In an emergency department setting with a critically ill, shocked infant and established IV access, comprehensive **intravenous broad-spectrum therapy** is required, making single-dose IM penicillin insufficient. *Intravenous vancomycin 15 mg/kg plus gentamicin 2.5 mg/kg* - This combination is typically reserved for suspected **MRSA infections**, **healthcare-associated sepsis**, or in specific circumstances where highly resistant Gram-positive pathogens are a concern. - While **gentamicin** provides Gram-negative coverage, this regimen is not the first-line empirical choice for community-acquired bacterial meningitis/sepsis in infants, which is primarily driven by *N. meningitidis*, *S. pneumoniae*, and *L. monocytogenes*. *Intravenous meropenem 40 mg/kg as a single dose* - **Meropenem** is a **carbapenem**, a very broad-spectrum antibiotic reserved for severe **multi-drug resistant infections** or in cases where first-line cephalosporins have failed or resistance is proven. - It is not recommended as the initial **empirical therapy** for a previously healthy infant presenting with a typical community-acquired purpuric rash and shock, as simpler, more targeted regimens are preferred initially.

Question 48: A 41-year-old man from Moldova presents with an 8-week history of productive cough, fever, and weight loss. Chest X-ray shows bilateral upper lobe cavitation. Three sputum samples are smear-positive for acid-fast bacilli. Molecular testing (Xpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. What is the most appropriate next investigation to guide treatment?

A. Repeat Xpert MTB/RIF testing on a new sputum sample
B. Send sputum for full drug susceptibility testing including first and second-line drugs (Correct Answer)
C. Start standard four-drug therapy pending culture results
D. CT chest to assess extent of disease
E. HIV testing and CD4 count

Explanation: ***Send sputum for full drug susceptibility testing including first and second-line drugs*** - Rifampicin resistance detected by **Xpert MTB/RIF** is highly predictive of **multidrug-resistant tuberculosis (MDR-TB)**, as rifampicin resistance is strongly associated with isoniazid resistance. - Comprehensive **drug susceptibility testing (DST)** for first and second-line drugs is essential to design an effective treatment regimen that prevents further resistance and optimizes clinical outcomes. *Repeat Xpert MTB/RIF testing on a new sputum sample* - The **Xpert MTB/RIF** assay is highly specific for detecting rifampicin resistance; repeating it would delay the necessary comprehensive resistance profiling. - In patients from high-risk areas like **Moldova**, a positive result is considered reliable and should prompt immediate escalation to definitive **culture-based DST**. *Start standard four-drug therapy pending culture results* - Standard therapy (RIPE) is inappropriate because the organism is already known to be **rifampicin-resistant**, meaning the core of the regimen is ineffective. - Starting standard therapy in the presence of known resistance risks the development of further **amplified resistance** to the remaining active drugs like ethambutol or pyrazinamide. *CT chest to assess extent of disease* - While a **CT chest** may show the anatomical extent of disease or complications like cavitation, it provides no information about the drug sensitivity of the pathogen. - Management of tuberculosis is primarily driven by the **microbiological phenotype** and drug resistance patterns rather than radiographic severity. *HIV testing and CD4 count* - Although **HIV screening** is recommended for all TB patients, it is not the priority investigation for guiding the specific **anti-tuberculosis drug regimen**. - Identifying the full profile of drug resistance is the immediate clinical requirement to prevent treatment failure and community transmission of **MDR-TB**.

Question 49: A 38-year-old woman with systemic lupus erythematosus on hydroxychloroquine and prednisolone 15 mg daily presents with a 7-week history of headache, personality change, and intermittent low-grade fever. MRI brain shows basal meningeal enhancement. CSF analysis shows: opening pressure 28 cmH2O, protein 2.1 g/L, glucose 1.8 mmol/L (plasma glucose 5.2 mmol/L), white cells 180/mm³ (85% lymphocytes). India ink stain is positive. What is the most appropriate initial antifungal treatment regimen?

A. Amphotericin B liposomal and flucytosine for 2 weeks, then fluconazole (Correct Answer)
B. Fluconazole monotherapy at high dose (800 mg daily)
C. Voriconazole monotherapy for 6 weeks
D. Amphotericin B liposomal monotherapy for 4 weeks
E. Itraconazole and flucytosine combination therapy

Explanation: ***Amphotericin B liposomal and flucytosine for 2 weeks, then fluconazole*** - The patient's presentation with headache, personality change, basal meningeal enhancement, classic CSF findings (high protein, low glucose, lymphocytic pleocytosis), and a **positive India ink stain** confirms **Cryptococcal meningitis**. - The recommended initial treatment (induction phase) for severe cryptococcal meningitis, especially in immunocompromised patients, is a combination of **liposomal amphotericin B** and **flucytosine** for 2 weeks, followed by fluconazole for consolidation. *Fluconazole monotherapy at high dose (800 mg daily)* - **Fluconazole monotherapy** is less effective for the induction phase of cryptococcal meningitis and is associated with slower CSF sterilization and higher mortality compared to combination therapy. - It is typically used for the **consolidation phase** after initial induction or for milder cases without CNS involvement. *Voriconazole monotherapy for 6 weeks* - **Voriconazole** is primarily effective against *Aspergillus* and some *Candida* species, and is not a first-line antifungal agent for the treatment of **Cryptococcus neoformans** infections. - There is insufficient evidence to support its use as an initial induction therapy for cryptococcal meningitis over standard regimens. *Amphotericin B liposomal monotherapy for 4 weeks* - While **Amphotericin B** is a crucial component, monotherapy is inferior to its combination with **flucytosine**, which provides synergistic fungicidal activity and faster clearance of the organism from the CSF. - The addition of flucytosine allows for a shorter induction period (2 weeks) and reduces the overall exposure to amphotericin B, mitigating potential **nephrotoxicity**. *Itraconazole and flucytosine combination therapy* - **Itraconazole** exhibits poor penetration into the central nervous system (**CNS**), making it an unsuitable agent for treating cryptococcal meningitis. - While flucytosine is appropriate, itraconazole's poor CNS pharmacokinetics mean this combination would be ineffective for a meningeal infection.

Question 50: A 2-year-old child is brought to the emergency department with a 6-hour history of fever (39.2°C), drowsiness, and refusing to feed. On examination, she has a bulging fontanelle and a purpuric rash on her trunk and limbs. Blood cultures are taken and intravenous ceftriaxone is commenced immediately. Which statutory notification requirement applies in this case?

A. Notification must be made within 24 hours to the local Health Protection Team
B. Notification must be made immediately by telephone to the local Health Protection Team (Correct Answer)
C. Notification is only required after microbiological confirmation
D. Notification is only required for fatal cases
E. Notification is the responsibility of the microbiologist once cultures are positive

Explanation: ***Notification must be made immediately by telephone to the local Health Protection Team*** - The clinical presentation (fever, drowsiness, bulging fontanelle, purpuric rash) is highly suggestive of **meningococcal disease**, a **medical emergency** and a **notifiable disease**. - For such serious infections, **immediate telephone notification** to the **Health Protection Team** is crucial for prompt public health action, including rapid contact tracing and prophylaxis. *Notification must be made within 24 hours to the local Health Protection Team* - While many notifiable diseases have a 24-hour reporting window, **meningococcal disease** requires **immediate notification** due to its rapid progression and high infectivity. - The urgency is to allow for **rapid contact tracing** and **chemoprophylaxis** to prevent secondary cases and further transmission. *Notification is only required after microbiological confirmation* - **Statutory notification** for highly contagious and severe diseases like **meningococcal meningitis** is based on **clinical suspicion** to avoid delays in public health intervention. - Waiting for **laboratory confirmation** would significantly delay essential actions like **contact management** and risk further spread of the disease. *Notification is only required for fatal cases* - All suspected cases of **notifiable diseases**, irrespective of outcome, must be reported to enable comprehensive **disease surveillance** and **outbreak control**. - Reporting non-fatal cases is crucial for understanding disease epidemiology and **preventing further cases** in the community. *Notification is the responsibility of the microbiologist once cultures are positive* - The **attending medical practitioner** who first suspects a notifiable disease has the **primary legal responsibility** to notify. - While laboratories also notify upon positive results, the initial clinical suspicion and **immediate notification** by the clinician are paramount for timely public health action before lab results are available.

Question 51: A 55-year-old man with newly diagnosed smear-positive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 3 weeks of treatment, he develops painful swelling of his right great toe with erythema and tenderness. His serum uric acid level is elevated at 520 µmol/L. What is the most appropriate initial management step?

A. Discontinue pyrazinamide and substitute with levofloxacin
B. Continue all four drugs and start allopurinol
C. Continue all four drugs and start colchicine for symptom control (Correct Answer)
D. Reduce the dose of pyrazinamide by 50%
E. Continue all four drugs and start high-dose prednisolone

Explanation: ***Continue all four drugs and start colchicine for symptom control*** - **Pyrazinamide** is known to cause **hyperuricemia** and can precipitate acute **gouty arthritis** by inhibiting renal uric acid excretion. - It is critical to continue the full anti-tuberculosis regimen during the intensive phase to ensure efficacy, while managing the acute gout attack symptomatically with agents like **colchicine** or NSAIDs. *Discontinue pyrazinamide and substitute with levofloxacin* - **Pyrazinamide** is a cornerstone drug in the initial phase of TB treatment, crucial for sterilizing lesions and shortening treatment duration; it should only be discontinued if side effects are severe and uncontrollable. - Substituting with **levofloxacin** is generally reserved for cases of drug resistance or severe intolerance to first-line agents, which is not indicated here. *Continue all four drugs and start allopurinol* - **Allopurinol** is a urate-lowering therapy used for chronic management of hyperuricemia and prevention of future gout attacks, but it should not be initiated during an **acute gout attack** as it can prolong or worsen symptoms. - For pyrazinamide-induced hyperuricemia, symptomatic treatment of gout flares is usually sufficient without the need for chronic urate-lowering therapy unless flares are frequent and severe. *Reduce the dose of pyrazinamide by 50%* - Reducing the dose of **pyrazinamide** without proper clinical justification can lead to **sub-therapeutic drug levels**, increasing the risk of **treatment failure** and the development of drug resistance. - Maintaining appropriate drug concentrations is essential for effective **tuberculosis eradication**, especially during the intensive phase. *Continue all four drugs and start high-dose prednisolone* - While corticosteroids can be effective for acute gout, **high-dose prednisolone** is not typically the first-line choice when other options like **colchicine** or NSAIDs are available and appropriate. - High-dose corticosteroids carry the risk of **immunosuppression**, which needs careful consideration in a patient with active **pulmonary tuberculosis**.

Question 52: A 44-year-old woman is diagnosed with smear-positive pulmonary tuberculosis. Molecular testing (GeneXpert MTB/RIF) confirms Mycobacterium tuberculosis with rifampicin resistance detected. She is referred to the regional MDR-TB service. Further drug susceptibility testing shows: resistant to rifampicin and isoniazid, sensitive to pyrazinamide, ethambutol, fluoroquinolones, and aminoglycosides. What minimum number of effective drugs and treatment duration are recommended for her MDR-TB regimen according to current WHO guidelines?

A. At least 3 effective drugs for a total of 9 months
B. At least 4 effective drugs for a total of 9-12 months (Correct Answer)
C. At least 4 effective drugs for a total of 18-20 months
D. At least 5 effective drugs for a total of 18-24 months
E. At least 5 effective drugs for a total of 12-15 months

Explanation: ***At least 4 effective drugs for a total of 9-12 months*** - According to **WHO guidelines**, patients with **MDR-TB** (resistant to isoniazid and rifampicin) who have preserved **fluoroquinolone sensitivity** are candidates for the **all-oral shorter regimen**. - This regimen requires a minimum of **4 effective drugs** in the initial phase and typically lasts **9 to 12 months** total, improving patient compliance compared to longer traditional protocols. *At least 3 effective drugs for a total of 9 months* - A minimum of **3 drugs** is generally insufficient to maintain the necessary bactericidal and sterilizing power required for **drug-resistant tuberculosis**. - Standard shortest regimens (like BPaL) use 3 drugs but are reserved for specific populations; however, the broader **WHO shorter regimen** standard for eligible MDR-TB patients is at least **4 drugs**. *At least 4 effective drugs for a total of 18-20 months* - An 18–20 month duration refers to the **longer individualized regimen**, which is no longer the primary choice for patients eligible for shorter courses. - This longer duration is reserved for cases involving **fluoroquinolone resistance**, treatment failure, or extensive **extrapulmonary disease**, none of which are indicated here. *At least 5 effective drugs for a total of 18-24 months* - Using **5 effective drugs** for up to 24 months was the traditional approach for complicated or **Pre-XDR/XDR-TB** before the advent of newer oral agents. - Current guidelines prioritize **shorter durations** to reduce toxicity and improve **treatment completion rates** when susceptibility allows. *At least 5 effective drugs for a total of 12-15 months* - This specific drug count and duration combination does not align with the standardized **WHO-recommended** categories for MDR-TB management. - While individualized regimens vary, the target for shorter regimens is **9-12 months**, and the target for longer regimens is over **18 months**, making this option inconsistent with current guidelines.

Question 53: A 53-year-old man completes 9 months of treatment for drug-sensitive pulmonary tuberculosis (rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 7 months). His treatment was extended from 6 to 9 months because of cavitating disease on initial chest X-ray and positive sputum culture at 2 months. He is now asymptomatic. End-of-treatment chest X-ray shows residual fibrotic changes in the right upper lobe but no active disease. His most recent sputum samples (taken at 8 months) were smear and culture negative. What follow-up is most appropriate?

A. Routine clinic review at 3, 6, and 12 months with repeat chest X-rays and sputum samples
B. Discharge with written advice to seek medical attention if symptoms recur (Correct Answer)
C. Continue rifampicin and isoniazid for a further 3 months then review
D. Monthly clinic reviews for 6 months with clinical assessment only
E. Arrange CT thorax in 3 months to assess for occult disease

Explanation: ***Discharge with written advice to seek medical attention if symptoms recur*** - Patients who have completed a full course of treatment for **drug-sensitive TB** with clinical and **microbiological cure** (negative cultures) do not require routine long-term follow-up. - **NICE guidelines** recommend discharging patients with clear information about symptoms of **relapse** and how to re-access services if needed. *Routine clinic review at 3, 6, and 12 months with repeat chest X-rays and sputum samples* - Routine **radiological surveillance** and sputum testing are not cost-effective and have not been shown to improve outcomes in successfully treated patients. - This approach is typically reserved for complex cases such as **Multi-Drug Resistant (MDR) TB**, not drug-sensitive disease. *Continue rifampicin and isoniazid for a further 3 months then review* - The patient has already completed an extended **9-month regimen** necessitated by the initial **cavitation** and delayed culture conversion; further extension is unnecessary. - Prolonging treatment beyond evidenced standards increases the risk of **drug toxicity** without providing additional benefit against relapse. *Monthly clinic reviews for 6 months with clinical assessment only* - Routine clinical assessment is not required if the patient is **asymptomatic** and has confirmed **negative sputum cultures** at the end of treatment. - Resources are better prioritized toward ensuring **treatment adherence** in active cases rather than monitoring those already cured. *Arrange CT thorax in 3 months to assess for occult disease* - **CT imaging** is not indicated for monitoring post-treatment when the patient is asymptomatic and the **end-of-treatment X-ray** shows only expected fibrotic changes. - **Residual fibrosis** is a common sequela of healed pulmonary TB and does not represent active or occult infection.

Question 54: A 31-year-old man presents to the emergency department with a 10-hour history of severe headache, fever, neck stiffness, and photophobia. He appears acutely unwell. Blood pressure is 98/55 mmHg, heart rate 118 bpm, temperature 39.3°C, GCS 14/15. There is no rash. CT head is performed and shows no contraindication to lumbar puncture. Blood cultures are taken. What is the most appropriate next step in management?

A. Proceed immediately to lumbar puncture before administering antibiotics
B. Administer intravenous ceftriaxone then perform lumbar puncture within 1 hour
C. Administer intravenous ceftriaxone and dexamethasone then perform lumbar puncture within 1 hour (Correct Answer)
D. Administer intravenous ceftriaxone, arrange lumbar puncture when convenient within 6 hours
E. Administer intravenous ceftriaxone, aciclovir, and dexamethasone then perform lumbar puncture

Explanation: ***Administer intravenous ceftriaxone and dexamethasone then perform lumbar puncture within 1 hour*** - In suspected **bacterial meningitis**, empirical antibiotics like **ceftriaxone** should be administered immediately to prevent rapid deterioration, especially when the patient shows signs of **sepsis** (hypotension, tachycardia). - **Dexamethasone** should be given beforehand or with the first dose of antibiotics to reduce the risk of **neurological sequelae** and mortality, particularly in cases of pneumococcal meningitis. *Proceed immediately to lumbar puncture before administering antibiotics* - While obtaining a pre-antibiotic **CSF sample** is ideal for culture yield, treatment must never be delayed for a procedure in a clinically unstable or **acutely unwell** patient. - Delayed antibiotic administration in meningitis is directly correlated with increased **morbidity and mortality**. *Administer intravenous ceftriaxone then perform lumbar puncture within 1 hour* - This option is incorrect because it lacks the co-administration of **dexamethasone**, which is a vital component of initial therapy in adults. - Omitting **corticosteroids** in the initial management window can lead to increased inflammation-mediated damage during bacterial lysis. *Administer intravenous ceftriaxone, arrange lumbar puncture when convenient within 6 hours* - A delay of up to **6 hours** for a lumbar puncture is inappropriate; it should be performed as soon as safely possible, ideally within **1 hour** of arrival. - Prolonged delay after antibiotics significantly reduces the diagnostic sensitivity of **CSF cultures**, although PCR may remain positive. *Administer intravenous ceftriaxone, aciclovir, and dexamethasone then perform lumbar puncture* - **Aciclovir** is used for **viral encephalitis**, but this patient lacks the typical features such as focal neurological deficits, seizures, or significant behavioral changes. - The clinical presentation of sudden onset **fever, headache, and neck stiffness** points strongly toward bacterial rather than viral etiology.

Question 55: A 5-year-old girl presents with a 3-day history of fever, headache, and increasing drowsiness. On examination, temperature is 39.2°C, GCS 12/15 (E3 V4 M5), there is neck stiffness and a positive Kernig's sign. Lumbar puncture is performed: opening pressure 24 cm H₂O, white cells 850/mm³ (85% lymphocytes), protein 3.2 g/L, glucose 1.1 mmol/L (plasma glucose 5.6 mmol/L). Gram stain is negative. Ziehl-Neelsen stain is negative. She was born in the UK and has received all routine vaccinations including BCG at birth (her mother is from India). What is the most appropriate initial treatment regimen?

A. Intravenous ceftriaxone and dexamethasone
B. Rifampicin, isoniazid, pyrazinamide, ethionamide, and dexamethasone
C. Intravenous ceftriaxone, aciclovir, and dexamethasone pending further results
D. Rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone (Correct Answer)
E. Rifampicin, isoniazid, pyrazinamide, levofloxacin, and dexamethasone

Explanation: ***Rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone*** - The CSF profile showing **lymphocytic pleocytosis**, **markedly elevated protein** (3.2 g/L), and **low glucose** (CSF:plasma ratio <0.3) is highly characteristic of **tuberculous meningitis (TBM)**. - Initial treatment for TBM requires a four-drug antitubercular regimen plus **dexamethasone**, which is shown to significantly reduce mortality and neurological morbidity. *Intravenous ceftriaxone and dexamethasone* - This is the standard treatment for **acute bacterial meningitis**, which typically presents with a **neutrophilic** (not lymphocytic) pleocytosis. - While bacterial meningitis causes low glucose, the high protein and subacute presentation (GCS 12, 3-day history) point more towards the **subacute nature** of TB. *Rifampicin, isoniazid, pyrazinamide, ethionamide, and dexamethasone* - **Ethionamide** is sometimes used in younger children (<5 years) who cannot cooperate with visual acuity testing required for ethambutol. - However, for a 5-year-old child, **ethambutol** remains the standard fourth agent in the preferred first-line regimen for sensitive TB. *Intravenous ceftriaxone, aciclovir, and dexamethasone pending further results* - This regimen covers **bacterial meningitis** and **herpes simplex encephalitis**, but viral encephalitis usually presents with **normal CSF glucose**. - Given the epidemiological risk (maternal origin) and the classic **very low glucose and high protein**, anti-TB therapy must not be delayed. *Rifampicin, isoniazid, pyrazinamide, levofloxacin, and dexamethasone* - **Levofloxacin** or other fluoroquinolones are generally reserved for cases of **multidrug-resistant TB (MDR-TB)**. - There is no clinical or epidemiological evidence in this history to suggest a drug-resistant strain as the initial suspicion.

Question 56: A 38-year-old homeless man with alcohol dependency is diagnosed with smear-positive pulmonary tuberculosis. He has a history of poor treatment adherence for other medical conditions. Molecular testing shows fully sensitive Mycobacterium tuberculosis. He is started on standard four-drug therapy. What is the most appropriate strategy to optimize treatment completion in this patient?

A. Arrange daily directly observed therapy (DOT) for the entire 6-month treatment course (Correct Answer)
B. Arrange daily DOT for the intensive phase only (first 2 months)
C. Provide weekly dispensing with self-administration and intensive case management
D. Arrange admission to hospital for the first 2 months to ensure adherence
E. Use monthly injectable rifampicin and isoniazid preparations

Explanation: ***Arrange daily directly observed therapy (DOT) for the entire 6-month treatment course*** - In patients with high risk factors for non-adherence, such as **homelessness**, **alcohol dependency**, and a history of poor medical compliance, **Directly Observed Therapy (DOT)** is the gold standard to ensure treatment completion. - Supervising every dose for the **entire 6-month course** (not just the intensive phase) is crucial to prevent **treatment failure**, **relapse**, and the development of **drug resistance**. *Arrange daily DOT for the intensive phase only (first 2 months)* - Limiting DOT to only the **intensive phase** is insufficient for this patient, as his psychosocial risk factors persist throughout the entire treatment duration. - The risk of **acquired drug resistance** remains high during the continuation phase if doses are missed after the first 2 months. *Provide weekly dispensing with self-administration and intensive case management* - **Self-administration** is high-risk in patients with severe social instability; medication can be easily lost, stolen, or forgotten due to **alcohol use disorder**. - Case management is a useful adjunct, but it does not provide the **level of supervision** required to guarantee ingestion of anti-TB drugs in such high-risk scenarios. *Arrange admission to hospital for the first 2 months to ensure adherence* - Prolonged **hospitalization** solely for adherence is unnecessary and costly, as **community-based DOT** is effective and less restrictive for the patient. - Admission does not address the need for adherence during the subsequent **4-month continuation phase** once the patient returns to his unstable environment. *Use monthly injectable rifampicin and isoniazid preparations* - There are no standard **monthly injectable** versions of first-line anti-TB drugs; treatment requires **daily oral dosing** to maintain therapeutic levels. - Reliance on non-existent long-acting injectables would lead to **subtherapeutic levels** and treatment failure in an active smear-positive patient.

Question 57: A 25-year-old woman is investigated for persistent headache. She is found to have a CSF opening pressure of 28 cm H₂O. The CSF shows: white cells 8/mm³ (all lymphocytes), protein 0.65 g/L, glucose 2.9 mmol/L (plasma glucose 5.2 mmol/L). Gram stain, India ink stain, and routine bacterial culture are negative. She was born in Hong Kong and moved to the UK at age 5. She works as a teacher and is in good general health with no weight loss or fever. What investigation is most likely to establish the diagnosis?

A. CSF tuberculosis PCR (GeneXpert MTB/RIF)
B. CSF cytology for malignant cells
C. MRI brain with gadolinium contrast (Correct Answer)
D. Repeat lumbar puncture after 1 week for comparison
E. CSF adenosine deaminase (ADA) level

Explanation: ***MRI brain with gadolinium contrast*** - The patient presents with **elevated opening pressure**, mild lymphocytic pleocytosis, and elevated protein, requiring imaging to exclude **basal meningeal enhancement**, tuberculomas, or venous sinus thrombosis. - MRI is the most sensitive imaging modality to differentiate between **idiopathic intracranial hypertension (IIH)** and subacute infections like **tuberculous meningitis** in a high-risk patient. *CSF tuberculosis PCR (GeneXpert MTB/RIF)* - While specific, **GeneXpert** has a relatively low sensitivity in paucibacillary CSF samples and may yield a false negative in early or mild disease. - It is generally used as a confirmatory tool rather than the primary investigation to establish a diagnosis of intracranial pathology. *CSF cytology for malignant cells* - **Neoplastic meningitis** typically presents with more significant constitutional symptoms or more profound CSF abnormalities such as very low glucose. - Cytology is not the first-line investigation when imaging and basic CSF biochemistry have not yet narrowed the differential to malignancy. *Repeat lumbar puncture after 1 week for comparison* - Delaying diagnosis by waiting one week is inappropriate given the risk of **permanent visual loss** from high intracranial pressure or progression of infection. - Serial punctures are not diagnostic tools; imaging must be performed first to ensure there is no **obstructive hydrocephalus** or space-occupying lesion. *CSF adenosine deaminase (ADA) level* - **ADA levels** are helpful supportive markers for tuberculosis but lack the specificity to definitively establish a diagnosis on their own. - ADA results can be elevated in other conditions like **lymphoma** or neurosarcoidosis, making MRI more useful for visualizing the distribution of disease.

Question 58: A 58-year-old man with newly diagnosed sputum smear-positive pulmonary tuberculosis is started on rifampicin 600 mg daily, isoniazid 300 mg daily, pyrazinamide 2000 mg daily, and ethambutol 1200 mg daily. His baseline investigations show: ALT 38 U/L, bilirubin 14 µmol/L, creatinine 105 µmol/L, eGFR 68 mL/min/1.73m². He weighs 95 kg. Two weeks into treatment, repeat blood tests show: ALT 165 U/L, bilirubin 18 µmol/L. He is asymptomatic. What is the most appropriate management?

A. Continue current regimen and recheck liver function in 1 week (Correct Answer)
B. Stop all drugs until liver function normalizes, then rechallenge sequentially
C. Reduce doses of rifampicin and isoniazid by 50% and monitor closely
D. Discontinue pyrazinamide and continue other three drugs
E. Continue current regimen but add ursodeoxycholic acid

Explanation: ***Continue current regimen and recheck liver function in 1 week***- Guidelines recommend continuing TB treatment in **asymptomatic** patients if the **ALT is less than 5 times** the upper limit of normal (ULN).- This patient’s ALT (165 U/L) is approximately **4.3 times the ULN** (38 U/L), and since he is asymptomatic with a **normal bilirubin**, close monitoring is the standard of care.*Stop all drugs until liver function normalizes, then rechallenge sequentially*- Discontinuation of anti-TB drugs is typically indicated if the **ALT >3 times ULN with symptoms** (e.g., nausea, jaundice) or **ALT >5 times ULN** if asymptomatic.- Stopping treatment prematurely increases the risk of **drug resistance** and delays the clearance of **Mycobacterium tuberculosis** infection, which is crucial for public health.*Reduce doses of rifampicin and isoniazid by 50% and monitor closely*- **Sub-therapeutic dosing** is not recommended as it promotes the development of **multidrug-resistant TB (MDR-TB)**, compromising treatment efficacy.- Management of suspected drug-induced hepatotoxicity requires either maintaining the full dose with monitoring (as in this case) or **complete cessation** followed by a structured rechallenge.*Discontinue pyrazinamide and continue other three drugs*- Although **pyrazinamide** is known for its higher potential for hepatotoxicity, the regimen should not be modified unless the criteria for **drug-induced liver injury (DILI)** are strictly met.- Prematurely modifying the regimen without meeting established threshold criteria may compromise the **intensive phase** of treatment and lead to suboptimal clinical outcomes.*Continue current regimen but add ursodeoxycholic acid*- **Ursodeoxycholic acid** has no proven clinical role in preventing or treating **anti-tuberculosis drug-induced hepatotoxicity** and is not a standard adjunct in this setting.- The primary management strategy for raised transaminases, when not requiring cessation, is **biochemical monitoring** and careful clinical assessment for symptoms of hepatitis.

Question 59: A 12-year-old boy presents to the emergency department with an 8-hour history of fever, severe headache, and vomiting. On examination, temperature is 38.7°C, heart rate 125 bpm, blood pressure 95/60 mmHg, GCS 14/15. There is neck stiffness but no rash. A senior clinician performs lumbar puncture which shows: clear CSF, white cells 180/mm³ (65% lymphocytes, 35% neutrophils), protein 0.8 g/L, glucose 3.2 mmol/L (plasma glucose 5.8 mmol/L). Gram stain is negative. What is the most appropriate initial management?

A. Start intravenous ceftriaxone and admit for observation
B. Start intravenous aciclovir and supportive care
C. Discharge with safety-netting advice as viral meningitis is most likely
D. Start intravenous ceftriaxone and aciclovir pending further investigation (Correct Answer)
E. Repeat lumbar puncture in 12 hours to clarify diagnosis

Explanation: ***Start intravenous ceftriaxone and aciclovir pending further investigation***- The patient presents with **meningism** and an ambiguous CSF profile showing **lymphocytic pleocytosis**, making it difficult to definitively distinguish between bacterial and viral causes.- Empiric treatment with **ceftriaxone** (for bacterial meningitis) and **aciclovir** (for HSV encephalitis) is mandatory in an unwell patient with **GCS 14** until cultures and PCR results are available.*Start intravenous ceftriaxone and admit for observation*- While ceftriaxone covers common bacterial pathogens, it fails to address potential **HSV encephalitis**, which can also present with headache and slightly altered consciousness.- The CSF findings of **lymphocytic predominance** and **mildly elevated protein** are consistent with viral etiologies that require specific antiviral therapy.*Start intravenous aciclovir and supportive care*- This approach is dangerously narrow because it ignores the risk of **bacterial meningitis**, which can occasionally present with atypical CSF counts early in the disease course.- Failing to provide **empiric antibiotics** like ceftriaxone in a patient with fever and neck stiffness increases the risk of rapid neurological deterioration.*Discharge with safety-netting advice as viral meningitis is most likely*- Discharging an acutely unwell child with **altered GCS** and signs of systemic infection is clinically unsafe and violates standard management protocols.- Even if viral etiology is suspected, the patient requires **inpatient management** and monitoring to ensure clinical stability and rule out life-threatening alternatives.*Repeat lumbar puncture in 12 hours to clarify diagnosis*- Delaying treatment to repeat a procedure is inappropriate when the patient is already showing signs of **tachycardia and hypotension** (incipient shock).- Starting **life-saving therapy** takes absolute priority over obtaining perfectly clear diagnostic results in the setting of suspected meningitis.

Question 60: A 46-year-old woman from Pakistan with smear-positive pulmonary tuberculosis has been on treatment with rifampicin, isoniazid, pyrazinamide, and ethambutol for 3 weeks. She attends clinic complaining of numbness and tingling in both feet. She has no other medical history and takes no other medications. On examination, she has reduced sensation to light touch and pinprick in a glove-and-stocking distribution, and absent ankle reflexes. Which medication requires adjustment and what should be added to prevent progression?

A. Discontinue ethambutol and replace with levofloxacin
B. Reduce dose of isoniazid and add pyridoxine 10 mg daily
C. Reduce dose of ethambutol and add thiamine 100 mg daily
D. Continue same dose of all drugs and add pyridoxine 50 mg daily (Correct Answer)
E. Discontinue isoniazid and replace with levofloxacin

Explanation: ***Continue same dose of all drugs and add pyridoxine 50 mg daily***- The patient is experiencing **isoniazid-induced peripheral neuropathy**, which occurs because isoniazid increases the excretion of and interferes with the metabolism of **Vitamin B6 (pyridoxine)**.- For established neuropathy, the treatment is to add high-dose **pyridoxine (50–100 mg daily)** while maintaining the standard **isoniazid** dose to avoid compromising the efficacy of the tuberculosis regimen.*Reduce dose of isoniazid and add pyridoxine 10 mg daily*- Reducing the dose of **isoniazid** is not recommended as it is a primary bactericidal agent essential for successful tuberculosis treatment.- **Pyridoxine 10 mg** is a prophylactic dose used to prevent deficiency, but a higher therapeutic dose (at least 50 mg) is required once neuropathy symptoms have manifested.*Reduce dose of ethambutol and add thiamine 100 mg daily*- **Ethambutol** is primarily associated with **optic neuritis** (loss of visual acuity and red-green color blindness) rather than peripheral sensory neuropathy.- **Thiamine (Vitamin B1)** is used to treat Wernicke-Korsakoff syndrome and certain types of Beriberi, but it does not address the specific metabolic interference caused by isoniazid.*Discontinue ethambutol and replace with levofloxacin*- **Ethambutol** is not the causative agent for the patient's sensory numbness and absent ankle reflexes, so discontinuing it would not resolve the symptoms.- Replacing a first-line drug with **levofloxacin** is reserved for drug-resistant cases or severe drug toxicity and is not indicated for manageable side effects like neuropathy.*Discontinue isoniazid and replace with levofloxacin*- **Isoniazid** is a cornerstone of TB treatment, and discontinuation is unnecessary if the side effect can be managed with **pyridoxine supplementation**.- Replacing it with **levofloxacin** increases the risk of treatment failure and the development of drug resistance in a patient with a previously sensitive smear-positive infection.

Question 61: A 34-year-old man with HIV infection (CD4 count 55 cells/mm³) presents with a 4-week history of headache and fever. Lumbar puncture shows: opening pressure 32 cm H₂O, white cells 25/mm³ (90% lymphocytes), protein 0.9 g/L, glucose 2.1 mmol/L (plasma glucose 5.4 mmol/L). India ink stain is positive. He is started on intravenous liposomal amphotericin B and flucytosine. After 5 days of treatment, he develops acute deterioration with worsening headache, confusion, and reduced GCS. Repeat CT head shows no new findings. What is the most likely cause of his deterioration?

A. Amphotericin B-induced nephrotoxicity with uraemic encephalopathy
B. Inadequate antifungal penetration to CSF requiring intrathecal therapy
C. Paradoxical inflammatory deterioration due to immune reconstitution
D. Raised intracranial pressure requiring therapeutic lumbar puncture (Correct Answer)
E. Treatment failure requiring addition of voriconazole

Explanation: ***Raised intracranial pressure requiring therapeutic lumbar puncture*** - The patient has **cryptococcal meningitis** with an already elevated **opening pressure (32 cm H₂O)**; acute deterioration suggests it has worsened due to poor CSF resorption from **fungal capsular polysaccharides**. - Management of symptomatic raised ICP in these patients requires repeat **therapeutic lumbar punctures** to lower pressure by 50% or to <20 cm H₂O. *Amphotericin B-induced nephrotoxicity with uraemic encephalopathy* - While **Amphotericin B** is nephrotoxic, it typically causes **electrolyte disturbances** and gradual creatinine rise rather than acute coma without preceding systemic signs. - **Liposomal** formulations are specifically designed to reduce renal toxicity compared to conventional amphotericin. *Inadequate antifungal penetration to CSF requiring intrathecal therapy* - The combination of **amphotericin B and flucytosine** is the gold standard induction therapy and achieves very high levels in the **CNS**. - **Intrathecal therapy** is generally contraindicated and not a standard of care for cryptococcal meningitis due to risks of chemical arachnoiditis. *Paradoxical inflammatory deterioration due to immune reconstitution* - **Immune Reconstitution Inflammatory Syndrome (IRIS)** typically occurs after the initiation of **antiretroviral therapy (ART)**, which this patient has not yet started. - Clinical guidelines recommend delaying ART by 4-6 weeks to prevent life-threatening **cerebral edema** associated with paradoxical inflammation. *Treatment failure requiring addition of voriconazole* - **Voriconazole** is not indicated as a first-line agent or as an add-on during the initial 5 days of standard induction therapy. - Clinical deterioration at this stage is more often due to **mechanical complications** (ICP) rather than primary resistance to amphotericin.

Question 62: A 67-year-old woman with a history of mastoidectomy 20 years ago presents with a 2-day history of fever, severe headache, and confusion. On examination, temperature is 39.1°C, GCS 13/15, there is left-sided otorrhoea and neck stiffness. CT head shows no mass lesion or hydrocephalus. Lumbar puncture is performed: opening pressure 28 cm H₂O, white cells 2400/mm³ (88% neutrophils), protein 2.8 g/L, glucose 1.8 mmol/L (plasma glucose 6.2 mmol/L). Gram stain shows Gram-positive diplococci. What is the most appropriate initial antibiotic regimen?

A. Intravenous ceftriaxone
B. Intravenous ceftriaxone and vancomycin
C. Intravenous ceftriaxone, vancomycin, and amoxicillin
D. Intravenous ceftriaxone, vancomycin, and metronidazole (Correct Answer)
E. Intravenous meropenem and vancomycin

Explanation: ***Intravenous ceftriaxone, vancomycin, and metronidazole*** - The patient presents with **bacterial meningitis** secondary to **chronic otitis media** and a history of **mastoid surgery**, necessitating empirical coverage for **anaerobes** via **metronidazole**. - **Ceftriaxone** and **vancomycin** are essential for suspected **Streptococcus pneumoniae** (indicated by **Gram-positive diplococci**) and to address potential **penicillin resistance**. *Intravenous ceftriaxone* - This monotherapy is insufficient as it does not reliably cover **penicillin-resistant pneumococci**, which are a significant concern in bacterial meningitis, especially in an older patient. - It also completely lacks coverage for **anaerobic organisms**, which are highly probable given the **otogenic source** (otorrhoea, mastoidectomy history). *Intravenous ceftriaxone and vancomycin* - This is the standard empirical regimen for **community-acquired bacterial meningitis** to cover *S. pneumoniae* and *N. meningitidis*, including resistant strains. - However, it **lacks anaerobic coverage**, which is crucial given the clear evidence of an **otogenic source** (otorrhoea, history of mastoidectomy). *Intravenous ceftriaxone, vancomycin, and amoxicillin* - **Amoxicillin** is typically added for patients over 50 years to cover **Listeria monocytogenes**, but the Gram stain revealed **Gram-positive diplococci**, not the Gram-positive bacilli characteristic of Listeria. - This regimen still fails to provide adequate **anaerobic coverage** for a suspected **otogenic infection**, which is a critical omission in this case. *Intravenous meropenem and vancomycin* - While **meropenem** is a broad-spectrum carbapenem that covers Gram-positives, Gram-negatives, and anaerobes, the combination of **ceftriaxone, vancomycin, and metronidazole** is the more targeted and usually preferred empirical regimen for **otogenic meningitis**. - Using **carbapenems** as first-line therapy, when a more specific regimen is effective, can contribute to resistance and is often reserved for specific highly resistant pathogens or immunocompromised patients.

Question 63: A 41-year-old man from India presents with a 5-week history of productive cough, fever, and weight loss. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Three sputum samples are smear-positive for acid-fast bacilli. He is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. Culture subsequently grows Mycobacterium tuberculosis with the following sensitivities: sensitive to rifampicin and isoniazid, resistant to pyrazinamide and streptomycin. What is the most appropriate treatment duration?

A. Continue all four drugs for 2 months, then rifampicin and isoniazid for 4 months (total 6 months)
B. Continue rifampicin, isoniazid, and ethambutol for 2 months, then rifampicin and isoniazid for 7 months (total 9 months)
C. Continue rifampicin, isoniazid, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months (total 6 months) (Correct Answer)
D. Continue rifampicin, isoniazid, and ethambutol for 3 months, then rifampicin and isoniazid for 9 months (total 12 months)
E. Refer to specialist MDR-TB service for second-line drug regimen

Explanation: ***Continue rifampicin, isoniazid, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months (total 6 months)***- Isolated **pyrazinamide resistance** (and streptomycin resistance) with **sensitivity to rifampicin and isoniazid** allows for a standard 6-month treatment duration for pulmonary TB.- The intensive phase becomes 2 months of R-H-E (omitting Z), and the continuation phase remains 4 months of R-H, which is sufficient to achieve a **sterilizing effect** as the core drugs are fully active.*Continue all four drugs for 2 months, then rifampicin and isoniazid for 4 months (total 6 months)*- Continuing **pyrazinamide** after resistance is confirmed is inappropriate as it adds unnecessary **hepatotoxicity risk** and other adverse effects without therapeutic benefit.- Successful treatment requires the regimen to be modified based on **drug susceptibility testing (DST)** to include only effective drugs.*Continue rifampicin, isoniazid, and ethambutol for 2 months, then rifampicin and isoniazid for 7 months (total 9 months)*- Extending the continuation phase to 7 months (total 9 months) is typically reserved for specific situations like **cavitary disease** with positive sputum cultures at 2 months of treatment, or certain forms of extrapulmonary TB.- While the patient has cavitary disease, isolated **PZA resistance** alone does not automatically necessitate a 9-month regimen if the patient is sensitive to rifampicin and isoniazid and is responding to therapy.*Continue rifampicin, isoniazid, and ethambutol for 3 months, then rifampicin and isoniazid for 9 months (total 12 months)*- A 12-month regimen is unnecessarily long for standard **pulmonary TB**, even with PZA resistance, and is usually reserved for complex forms like **TB meningitis** or extensive bone and joint TB.- Such extended treatment increases the risk of **drug toxicity** and decreases **patient adherence** without additional efficacy in this scenario.*Refer to specialist MDR-TB service for second-line drug regimen*- **Multidrug-resistant TB (MDR-TB)** is defined as resistance to at least both **rifampicin and isoniazid**.- Since this patient's isolate is sensitive to both rifampicin and isoniazid, it does not meet the criteria for MDR-TB, and therefore, a referral for second-line, typically more toxic, drugs is not indicated.

Question 64: A 29-year-old woman presents with a 14-hour history of severe headache, fever, photophobia, and vomiting. On examination, she is drowsy with GCS 13/15, temperature 38.9°C, blood pressure 105/65 mmHg, heart rate 118 bpm. There is marked neck stiffness and a non-blanching purpuric rash on her lower limbs. Blood cultures are taken and she is given immediate empirical treatment. What is the minimum duration she should be considered infectious to close contacts requiring chemoprophylaxis?

A. Until 12 hours of appropriate antibiotic therapy
B. Until 24 hours of appropriate antibiotic therapy (Correct Answer)
C. Until 48 hours of appropriate antibiotic therapy
D. Until 72 hours of appropriate antibiotic therapy
E. Until completion of the full antibiotic course

Explanation: ***Until 24 hours of appropriate antibiotic therapy***- For cases of **meningococcal meningitis**, as suggested by the clinical presentation including the **non-blanching purpuric rash**, patients are considered infectious until they have received **24 hours** of effective systemic antibiotics.- This duration is critical as it ensures sufficient eradication of **Neisseria meningitidis** from the nasopharynx, significantly reducing the risk of transmission to close contacts, as per public health guidelines.*Until 12 hours of appropriate antibiotic therapy*- This timeframe is generally considered insufficient to reliably eliminate **Neisseria meningitidis** from the nasopharynx to a safe level, meaning the patient could still be contagious.- Relying on 12 hours would prematurely lift precautions and could potentially expose close contacts to the pathogen, negating the purpose of **chemoprophylaxis**.*Until 48 hours of appropriate antibiotic therapy*- While the patient continues treatment, they are typically no longer considered infectious to contacts well before the **48-hour** mark if effective antibiotics, such as **third-generation cephalosporins**, are being administered.- Extending infectious precautions to 48 hours would be an unnecessary prolongation beyond the evidence-based window for **meningococcal transmission**.*Until 72 hours of appropriate antibiotic therapy*- A 72-hour period is excessively long for defining the cessation of infectiousness in **meningococcal disease**, given the prompt response of the bacteria to appropriate antibiotic therapy.- This duration is usually more relevant for monitoring **clinical improvement** or awaiting full culture sensitivities, rather than determining the immediate **risk of transmission**.*Until completion of the full antibiotic course*- Patients become non-infectious much earlier in the course of treatment, as the goal for reducing transmission is the eradication of bacteria from the **respiratory tract**, not the complete resolution of the clinical infection.- Requiring isolation or precautions for the entire antibiotic course would be impractical and not supported by guidelines for **contact management** and **chemoprophylaxis**.

Question 65: A 52-year-old man with newly diagnosed smear-positive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 2 weeks of treatment, he develops painful, red, swollen joints affecting both ankles and the right wrist. Blood tests show: urate 580 µmol/L (reference range 200-430), creatinine 98 µmol/L. What is the most appropriate management of this complication?

A. Discontinue ethambutol and replace with levofloxacin
B. Discontinue pyrazinamide and continue with three-drug therapy (Correct Answer)
C. Add allopurinol and continue all four anti-tuberculosis drugs
D. Stop all anti-tuberculosis drugs and rechallenge sequentially
E. Add colchicine and continue all four anti-tuberculosis drugs

Explanation: ***Discontinue pyrazinamide and continue with three-drug therapy***- **Pyrazinamide** is well-known for inhibiting the renal secretion of **urates**, leading to **hyperuricemia** and potentially precipitating **acute gouty arthritis**.- When clinically significant gout occurs (painful, red, swollen joints), the standard management is to **discontinue pyrazinamide** and continue the intensive phase with the remaining three drugs, typically for an extended duration.*Discontinue ethambutol and replace with levofloxacin*- **Ethambutol** is primarily associated with **optic neuritis** (visual acuity and color vision loss), not hyperuricemia or joint pain.- Replacing it with a fluoroquinolone is unnecessary here because ethambutol is not the cause of the patient's **acute arthralgia**.*Add allopurinol and continue all four anti-tuberculosis drugs*- Adding **allopurinol** is generally ineffective because pyrazinamide-induced hyperuricemia is resistant to standard urate-lowering therapy due to **competitive inhibition** in the renal tubules.- It is clinically preferable to remove the offending agent rather than adding long-term medications to manage a **drug-induced side effect**.*Stop all anti-tuberculosis drugs and rechallenge sequentially*- Sequential **rechallenge** is reserved for severe **hypersensitivity reactions** (like DRESS or Stevens-Johnson) or severe **hepatotoxicity** where the causative agent is unclear.- In this case, the **biochemical evidence** (elevated urate) clearly identifies pyrazinamide as the culprit, making a full stop and rechallenge unnecessary.*Add colchicine and continue all four anti-tuberculosis drugs*- While **colchicine** or NSAIDs may provide temporary symptomatic relief for the pain, they do not address the underlying **metabolic disturbance** caused by the pyrazinamide.- Continuing the offending drug despite **clinical gout** increases the risk of recurrent attacks and potential **urate nephropathy**.

Question 66: In the UK, which one of the following baseline investigations is NOT routinely required before initiating standard first-line anti-tuberculosis therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol?

A. Liver function tests (ALT, AST, bilirubin)
B. Renal function (urea, creatinine, eGFR)
C. Visual acuity and colour vision assessment using Ishihara charts
D. Chest X-ray
E. Serum uric acid level (Correct Answer)

Explanation: ***Serum uric acid level*** - While **pyrazinamide** is known to cause **hyperuricaemia** and can potentially trigger gout, routine measurement of **serum uric acid** is not recommended as a baseline investigation in UK guidelines. - Uric acid levels are only typically monitored if the patient develops **clinical symptoms of gout** or has pre-existing risk factors during the course of treatment. *Liver function tests (ALT, AST, bilirubin)* - Baseline **liver function tests** are mandatory because **rifampicin**, **isoniazid**, and **pyrazinamide** are all potentially **hepatotoxic**. - Establishing a baseline is critical for monitoring the development of **drug-induced hepatitis** and managing treatment interruptions if enzymes rise significantly. *Renal function (urea, creatinine, eGFR)* - **Renal function** must be assessed because **ethambutol** is primarily cleared by the kidneys and requires **dose adjustment** in cases of impairment. - Maintaining correct dosing is vital as renal dysfunction increases the risk of **ethambutol-related optic neuritis** toxicity. *Visual acuity and colour vision assessment using Ishihara charts* - Formal documentation of **visual acuity** and **Ishihara colour vision** is mandatory before starting **ethambutol** to detect baseline deficits. - These baseline results are essential for identifying early **optic neuritis**, a known side effect that warrants immediate cessation of the drug. *Chest X-ray* - A **chest X-ray** is a fundamental baseline investigation used to document the **extent of disease** and identifying cavitary lesions. - It serves as the primary radiological reference to evaluate **treatment response** and resolution of infection over the 6-month therapy period.

Question 67: A 48-year-old man from Nepal who has been living in the UK for 6 months presents with a 12-week history of progressive lower back pain, night sweats, and weight loss. He reports difficulty walking due to pain. On examination, he has tenderness over the L2-L3 vertebrae and reduced power (4/5) in both lower limbs. MRI spine shows destruction of L2 and L3 vertebral bodies with a paravertebral abscess. What is the most appropriate next step in investigation to establish the diagnosis?

A. Sputum sample for acid-fast bacilli smear and culture
B. CT-guided biopsy of the vertebral lesion for histology and microbiological culture (Correct Answer)
C. Mantoux tuberculin skin test
D. Blood cultures for Mycobacterium tuberculosis
E. Serum inflammatory markers (ESR and CRP) and trial of anti-tuberculosis therapy

Explanation: ***CT-guided biopsy of the vertebral lesion for histology and microbiological culture***- A tissue diagnosis is essential to confirm **Pott's disease (spinal TB)** and rule out mimics like **malignancy** or **pyogenic osteomyelitis** before starting long-term treatment.- Biopsy allows for **histological examination** (caseating granulomas), **GeneXpert** testing, and **drug susceptibility testing**, which is vital given the risk of **MDR-TB**.*Sputum sample for acid-fast bacilli smear and culture*- This investigation assesses for **pulmonary TB**, which may not be present or active in cases of isolated **extrapulmonary spinal tuberculosis**.- A negative sputum result does not rule out the diagnosis, especially since the patient presents primarily with **spinal involvement** and neurological signs.*Mantoux tuberculin skin test*- The **Mantoux test** measures immune reactivity but cannot distinguish between **latent TB infection** and **active disease**.- It has limited diagnostic value in a patient from an **endemic region** (Nepal) who may have had prior **BCG vaccination** or exposure.*Blood cultures for Mycobacterium tuberculosis*- **M. tuberculosis** is rarely isolated from blood cultures unless the patient has **miliary TB** or is severely **immunocompromised** (e.g., HIV).- This method has a very **low diagnostic yield** for focal spinal infections compared to direct tissue sampling.*Serum inflammatory markers (ESR and CRP) and trial of anti-tuberculosis therapy*- While **ESR and CRP** are often elevated, they are **non-specific** and cannot confirm the underlying cause of vertebral destruction.- Starting **empirical therapy** without a tissue diagnosis is inappropriate due to the risk of **drug toxicity** and the failure to identify **resistant strains**.

Question 68: A 26-year-old man presents to the emergency department with an 8-hour history of severe headache, fever, vomiting, and photophobia. On examination, he has temperature 39.2°C, heart rate 118/min, blood pressure 105/68 mmHg, and a purpuric non-blanching rash on his trunk and legs. He is confused with GCS 13/15 (E3, V4, M6). Blood tests show: WBC 18.2 × 10⁹/L, CRP 156 mg/L, platelets 98 × 10⁹/L, APTT 42 seconds, fibrinogen 1.2 g/L. What is the most appropriate immediate management?

A. Perform lumbar puncture immediately to confirm the diagnosis before starting any treatment
B. Administer intravenous ceftriaxone 2 g immediately without delay, defer lumbar puncture (Correct Answer)
C. Arrange urgent CT head before lumbar puncture, then start antibiotics after CSF obtained
D. Administer intravenous aciclovir and await viral PCR results
E. Administer intravenous benzylpenicillin and perform lumbar puncture after 2 hours of antibiotics

Explanation: ***Administer intravenous ceftriaxone 2 g immediately without delay, defer lumbar puncture*** - The patient presents with a severe headache, fever, photophobia, confusion (GCS 13), and a **purpuric non-blanching rash**, strongly suggestive of **meningococcal sepsis** with meningitis, which is a life-threatening emergency requiring immediate broad-spectrum antibiotics. - **Lumbar puncture** is contraindicated due to signs of **raised intracranial pressure** (altered GCS) and a significant **coagulopathy** (low platelets, prolonged APTT, low fibrinogen), which increase the risk of brain herniation or spinal hematoma. *Perform lumbar puncture immediately to confirm the diagnosis before starting any treatment* - Delaying **antibiotic administration** for a diagnostic procedure like lumbar puncture significantly increases mortality in suspected **bacterial meningitis/sepsis**. - Performing an LP in a patient with altered mental status and **coagulopathy** carries a high risk of adverse events, including **brain herniation** and **spinal hematoma**. *Arrange urgent CT head before lumbar puncture, then start antibiotics after CSF obtained* - Obtaining a **CT head** and then a **lumbar puncture** would cause critical delays in administering **life-saving antibiotics**, which must be given immediately in suspected meningococcal disease. - While a CT scan may be indicated to rule out mass lesions before LP if no contraindications exist, it should never delay the prompt administration of **empiric antibiotics**. *Administer intravenous aciclovir and await viral PCR results* - **Aciclovir** is an antiviral agent used for conditions like **Herpes Simplex Encephalitis**, but the prominent **purpuric rash** and rapid progression to sepsis strongly indicate a **bacterial etiology**, such as *Neisseria meningitidis*. - Awaiting viral PCR results before initiating definitive treatment for suspected bacterial meningitis is inappropriate and could be fatal due to the rapid progression of the disease. *Administer intravenous benzylpenicillin and perform lumbar puncture after 2 hours of antibiotics* - While **benzylpenicillin** is effective against *Neisseria meningitidis*, **ceftriaxone** is generally preferred in the hospital setting for its broader coverage against other potential bacterial meningitis pathogens, such as *Streptococcus pneumoniae*. - The decision to perform a lumbar puncture should be based on the resolution of contraindications (e.g., improved GCS, corrected coagulopathy), not on a fixed time interval after starting antibiotics.

Question 69: A 44-year-old woman with rheumatoid arthritis managed with methotrexate and adalimumab has been diagnosed with latent tuberculosis infection based on a positive interferon-gamma release assay (IGRA) and normal chest X-ray. She is started on rifampicin and isoniazid for 3 months as preventive therapy. Her adalimumab was discontinued 4 weeks before starting TB treatment. When would it be most appropriate to restart her adalimumab therapy?

A. After completing 1 month of TB preventive therapy (Correct Answer)
B. Immediately, as concurrent treatment is safe
C. After 2 weeks of TB preventive therapy
D. After completing the full 3-month course of TB preventive therapy
E. After 6 months, regardless of completion of TB treatment

Explanation: ***After completing 1 month of TB preventive therapy*** - For patients with **latent tuberculosis infection (LTBI)**, current guidelines recommend starting **anti-TNF therapy** (like adalimumab) after at least **one month** of appropriate preventive treatment has been completed. - This duration ensures a sufficient reduction in the **mycobacterial load** and provides protection against the reactivation of TB once **immunosuppression** is reintroduced. *Immediately, as concurrent treatment is safe* - Starting biologics immediately increases the risk of **TB reactivation** before the preventive antibiotics have had time to work. - **TNF-alpha inhibitors** are potent immunosuppressants that can worsen an underlying latent infection into **disseminated disease** if not preceded by treatment. *After 2 weeks of TB preventive therapy* - Two weeks is considered an **insufficient duration** to achieve the clinical consensus for safety when reintroducing high-potency biologics. - Guidelines specifically advocate for the **4-week (1 month) threshold** to mitigate the risk of developing active tuberculosis. *After completing the full 3-month course of TB preventive therapy* - While this is safe, it is **unnecessarily restrictive** and delays the management of the patient's **rheumatoid arthritis**. - Delaying biological therapy for three months can lead to significant **joint damage** and disease flares that could have been avoided by restarting after the first month. *After 6 months, regardless of completion of TB treatment* - This timeframe is **arbitrary and inconsistent** with clinical standards for managing LTBI in patients on biologics. - Waiting six months would pose an extreme and unnecessary risk to the patient's **rheumatological health** without offering additional benefit over the standard 1-month rule.

Question 70: What is the primary immunological mechanism by which adjunctive dexamethasone therapy reduces mortality in adult patients with acute bacterial meningitis caused by Streptococcus pneumoniae?

A. Direct antimicrobial activity through disruption of bacterial cell wall synthesis
B. Reduction of inflammatory cytokine release and attenuation of subarachnoid space inflammatory response (Correct Answer)
C. Enhancement of antibiotic penetration across the blood-brain barrier through increased vascular permeability
D. Stimulation of neutrophil recruitment to improve bacterial clearance from cerebrospinal fluid
E. Blockade of bacterial adhesion molecules preventing further CNS invasion

Explanation: ***Reduction of inflammatory cytokine release and attenuation of subarachnoid space inflammatory response*** - Dexamethasone, a corticosteroid, primarily acts by **suppressing the exaggerated inflammatory response** in the subarachnoid space. - It reduces the production and release of **pro-inflammatory cytokines** (e.g., TNF-α, IL-1β) that are triggered by bacterial components and lysis, thereby attenuating cerebral edema and neuronal damage. *Direct antimicrobial activity through disruption of bacterial cell wall synthesis* - Dexamethasone is a **glucocorticoid** and possesses no direct **antimicrobial properties** or ability to disrupt bacterial cell walls. - **Antibiotics** are responsible for bacterial clearance, while dexamethasone modulates the host's inflammatory response. *Enhancement of antibiotic penetration across the blood-brain barrier through increased vascular permeability* - Dexamethasone actually works to **stabilize the blood-brain barrier** and reduce its permeability, thereby **decreasing** rather than increasing vascular permeability. - This can potentially decrease the penetration of some antibiotics, but its overall benefit in reducing inflammation outweighs this effect. *Stimulation of neutrophil recruitment to improve bacterial clearance from cerebrospinal fluid* - Corticosteroids like dexamethasone generally **reduce inflammation** by inhibiting the recruitment and activity of immune cells, including neutrophils. - The primary mechanism of bacterial clearance is through **antibiotic therapy**, not enhanced neutrophil activity due to corticosteroids. *Blockade of bacterial adhesion molecules preventing further CNS invasion* - Dexamethasone does not act by blocking **bacterial adhesion molecules** or directly preventing the invasion of the central nervous system. - Its role is centered on modulating the host's immune response to **already established infection** within the subarachnoid space.

Question 71: A 55-year-old man is diagnosed with smear-positive pulmonary tuberculosis. Molecular testing using GeneXpert MTB/RIF confirms Mycobacterium tuberculosis but shows rifampicin resistance. He is started on an appropriate MDR-TB regimen. His 8-year-old daughter, who lives with him and has had close daily contact for the past 3 months, is asymptomatic with a normal clinical examination. Her Mantoux test shows 12 mm induration. Chest X-ray is normal. What is the most appropriate management for the daughter?

A. Observe with clinical review in 3 months and repeat chest X-ray
B. BCG vaccination
C. Isoniazid monotherapy for 6 months
D. Rifampicin and isoniazid for 3 months
E. Specialist referral for individualized MDR-TB contact prophylaxis regimen (Correct Answer)

Explanation: ***Specialist referral for individualized MDR-TB contact prophylaxis regimen*** - The daughter has **Latent TB Infection (LTBI)**, indicated by a **positive Mantoux test (12mm induration)** in a high-risk contact (child living with an active TB case), with a **normal chest X-ray**. - Her father has **rifampicin-resistant pulmonary TB (MDR-TB)**, meaning standard LTBI prophylaxis (e.g., isoniazid monotherapy) is likely ineffective. Therefore, an **individualized regimen** based on the source case's drug susceptibility testing is crucial, necessitating **specialist consultation**. *Observe with clinical review in 3 months and repeat chest X-ray* - **Passive observation** is insufficient for a child, especially one exposed to **MDR-TB** and having a **positive Mantoux test**, due to their significantly higher risk of progression from LTBI to **active TB disease**. - Delaying effective prophylaxis increases the risk of developing severe forms of active TB, such as **TB meningitis** or **miliary TB**, which are more common and devastating in young children. *BCG vaccination* - **BCG vaccination** is primarily a prevention strategy for uninfected individuals, particularly infants in high-burden settings, and is **contraindicated** in someone with **latent TB infection** (positive Mantoux). - Administering BCG to an individual with a positive Mantoux test provides no additional benefit against existing infection and can cause unnecessary local reactions. *Isoniazid monotherapy for 6 months* - **Isoniazid monotherapy** is the standard for drug-susceptible LTBI, but the source patient has **MDR-TB**, which by definition includes resistance to at least **isoniazid** and **rifampicin**. - Administering **isoniazid alone** when the infecting strain is likely resistant would be ineffective, providing **no prophylactic benefit** and potentially fostering further drug resistance. *Rifampicin and isoniazid for 3 months* - This combined regimen is a common choice for drug-susceptible LTBI, but the father's TB is confirmed as **rifampicin-resistant** by molecular testing (GeneXpert). - Using drugs (specifically **rifampicin** and **isoniazid**) to which the source strain is resistant makes the prophylaxis **ineffective** and exposes the child to medication side effects without any protective benefit.

Question 72: A 38-year-old man from Romania presents with a 10-week history of headache, vomiting, and personality change. He is known to be HIV-positive but has not been taking antiretroviral therapy. His CD4 count is 55 cells/mm³. Lumbar puncture shows: opening pressure 26 cmH2O, glucose 2.1 mmol/L (serum 5.8 mmol/L), protein 2.4 g/L, white cells 180/mm³ (80% lymphocytes). India ink staining is positive. MRI brain shows multiple small enhancing lesions in the basal ganglia. What is the most appropriate initial antifungal therapy?

A. Intravenous amphotericin B and oral flucytosine for 2 weeks, followed by oral fluconazole (Correct Answer)
B. Oral fluconazole 400 mg daily for 8 weeks
C. Intravenous caspofungin 70 mg loading dose then 50 mg daily
D. Intravenous voriconazole 6 mg/kg twice daily for 2 doses, then 4 mg/kg twice daily
E. Oral itraconazole 200 mg twice daily

Explanation: ***Intravenous amphotericin B and oral flucytosine for 2 weeks, followed by oral fluconazole*** - The patient presents with **Cryptococcal meningitis**, confirmed by severe immunosuppression (**CD4 count 55 cells/mm³**), classic CSF findings (low glucose, high protein, lymphocytic pleocytosis), and a **positive India ink stain**.- The recommended **induction therapy** for cryptococcal meningitis in HIV-positive patients is a combination of **amphotericin B** and **flucytosine** for at least 2 weeks, followed by oral fluconazole for consolidation. *Oral fluconazole 400 mg daily for 8 weeks* - **Fluconazole monotherapy** is insufficient for the **initial induction phase** of cryptococcal meningitis, especially in severely immunocompromised patients.- Using fluconazole alone for induction leads to **slower CSF sterilization** and higher mortality rates compared to combination therapy.*Intravenous caspofungin 70 mg loading dose then 50 mg daily* - **Caspofungin**, an echinocandin, has **no significant clinical activity** against *Cryptococcus neoformans*. - Echinocandins primarily target fungal cell walls of *Candida* and *Aspergillus*, not *Cryptococcus*.*Intravenous voriconazole 6 mg/kg twice daily for 2 doses, then 4 mg/kg twice daily* - While **voriconazole** has some *in vitro* activity against *Cryptococcus*, it is **not a first-line therapy** for cryptococcal meningitis. - Its efficacy for this condition has not been shown to be superior to **amphotericin B-based regimens**, making it an alternative for refractory cases only.*Oral itraconazole 200 mg twice daily* - **Itraconazole** exhibits **poor central nervous system (CNS) penetration**, rendering it largely ineffective for treating cryptococcal meningitis. - It is not recommended for either the **induction** or **consolidation phases** of treatment due to its inferior efficacy and limited CSF levels.

Question 73: A 67-year-old man with a cochlear implant presents with a 12-hour history of fever, severe headache, and confusion. Lumbar puncture shows: opening pressure 32 cmH2O, white cells 2800/mm³ (95% neutrophils), protein 2.8 g/L, glucose 1.2 mmol/L (serum glucose 6.4 mmol/L). Gram stain shows Gram-positive diplococci. Blood cultures are pending. Which empirical antibiotic regimen should be started immediately?

A. Intravenous ceftriaxone 2 g twice daily
B. Intravenous ceftriaxone 2 g twice daily and vancomycin 15-20 mg/kg twice daily (Correct Answer)
C. Intravenous benzylpenicillin 2.4 g every 4 hours and gentamicin 5-7 mg/kg once daily
D. Intravenous meropenem 2 g three times daily
E. Intravenous ceftriaxone 2 g twice daily and metronidazole 500 mg three times daily

Explanation: ***Intravenous ceftriaxone 2 g twice daily and vancomycin 15-20 mg/kg twice daily*** - The patient's presentation with fever, headache, confusion, and classic CSF findings (elevated pressure, high neutrophils, high protein, low glucose) points to bacterial meningitis, likely caused by **Streptococcus pneumoniae** (Gram-positive diplococci). - The presence of a **cochlear implant** is a significant risk factor for infection with **penicillin-resistant** and **cephalosporin-resistant *S. pneumoniae***, necessitating the addition of **vancomycin** to ceftriaxone for adequate empirical coverage. *Intravenous ceftriaxone 2 g twice daily* - While **ceftriaxone** is a cornerstone for bacterial meningitis, its use as monotherapy is insufficient for empirical treatment in patients at high risk for resistant strains, such as those with **cochlear implants**. - Without **vancomycin**, there is a critical gap in coverage for highly drug-resistant **pneumococci**, which can lead to treatment failure and increased mortality. *Intravenous benzylpenicillin 2.4 g every 4 hours and gentamicin 5-7 mg/kg once daily* - **Benzylpenicillin** alone is inadequate as empirical therapy for meningitis in a patient with a **cochlear implant** due to the high prevalence of **penicillin-resistant *S. pneumoniae*** in this population. - **Gentamicin** provides poor penetration into the **cerebrospinal fluid (CSF)** and is not effective against Gram-positive organisms like *S. pneumoniae* in meningitis treatment. *Intravenous meropenem 2 g three times daily* - **Meropenem** is a broad-spectrum carbapenem with excellent CSF penetration, but it is typically reserved for meningitis caused by highly resistant Gram-negative bacteria or in cases of treatment failure. - For suspected pneumococcal meningitis with risk factors for resistance, the combination of **ceftriaxone and vancomycin** is the preferred empirical regimen due to its targeted coverage and stewardship principles. *Intravenous ceftriaxone 2 g twice daily and metronidazole 500 mg three times daily* - **Metronidazole** provides coverage against **anaerobic bacteria**, which are not typically the primary cause of meningitis presenting with Gram-positive diplococci unless there is an associated brain abscess or chronic ear infection. - This regimen lacks the crucial **vancomycin** component, leaving the patient vulnerable to potentially **drug-resistant *Streptococcus pneumoniae***, especially given the presence of a cochlear implant.

Question 74: According to UK Public Health notification requirements and clinical management protocols, which one of the following scenarios requires notification to the local Health Protection Team within the shortest timeframe?

A. A 45-year-old man with culture-confirmed pulmonary tuberculosis who completed 2 weeks of standard treatment
B. A 28-year-old woman with a positive interferon-gamma release assay (IGRA) and normal chest X-ray diagnosed with latent tuberculosis infection
C. A 19-year-old university student with suspected meningococcal meningitis presenting to the emergency department with fever, headache, and non-blanching purpuric rash (Correct Answer)
D. A 52-year-old man with confirmed Mycobacterium avium complex (MAC) pulmonary infection
E. A 34-year-old woman with confirmed viral meningitis secondary to enterovirus on CSF PCR

Explanation: ***A 19-year-old university student with suspected meningococcal meningitis presenting to the emergency department with fever, headache, and non-blanching purpuric rash*** - **Meningococcal disease** is a flagship notifiable condition because it carries significant risk for **rapid outbreaks**, high mortality, and requires **immediate public health action** (chemoprophylaxis for contacts). - Notification must occur **urgently** (usually by telephone) as soon as the diagnosis is suspected, even before **microbiological confirmation** or laboratory results are available. *A 45-year-old man with culture-confirmed pulmonary tuberculosis who completed 2 weeks of standard treatment* - While **active tuberculosis** is a notifiable disease in the UK, it generally requires notification within **3 days** rather than the immediate urgency of meningococcal cases. - Notification usually happens upon **diagnosis**; once the patient has completed two weeks of treatment, they are generally considered **non-infectious** to the public. *A 28-year-old woman with a positive interferon-gamma release assay (IGRA) and normal chest X-ray diagnosed with latent tuberculosis infection* - **Latent tuberculosis infection (LTBI)** is not included in the statutory list of notifiable diseases under UK Public Health regulations. - Notification is only required for **active disease** where there is a risk of transmission or a requirement for collective monitoring. *A 52-year-old man with confirmed Mycobacterium avium complex (MAC) pulmonary infection* - Unlike *M. tuberculosis*, **Mycobacterium avium complex (MAC)** consists of environmental organisms that are not transmitted **person-to-person**. - Because there is no **public health risk** of transmission, non-tuberculous mycobacteria infections are not classified as **notifiable diseases**. *A 34-year-old woman with confirmed viral meningitis secondary to enterovirus on CSF PCR* - **Viral meningitis** is typically not on the statutory list of notifiable diseases in the UK; the regulations specifically emphasize **bacterial meningitis** due to its severity. - While the pathogen (enterovirus) may be monitored via laboratory reporting, it does not trigger the same **immediate clinical notification** pathway as **Neisseria meningitidis**.

Question 75: A 35-year-old man with HIV infection (CD4 count 80 cells/mm³, not on antiretroviral therapy) is diagnosed with tuberculous meningitis. He is started on rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone. Five days after starting tuberculosis treatment, antiretroviral therapy (ART) is initiated with tenofovir, emtricitabine, and dolutegravir. Two weeks later, he develops worsening confusion, new onset right hemiparesis, and deteriorating Glasgow Coma Scale. Repeat CT head shows new enhancing lesions and increased oedema. What is the most likely explanation for his clinical deterioration?

A. Drug-resistant tuberculosis with treatment failure
B. Tuberculous meningitis-associated immune reconstitution inflammatory syndrome (IRIS) (Correct Answer)
C. Dexamethasone-induced hyperglycaemia causing cerebral oedema
D. Progressive multifocal leukoencephalopathy
E. Isoniazid-induced hepatic encephalopathy

Explanation: ***Tuberculous meningitis-associated immune reconstitution inflammatory syndrome (IRIS)*** - Paradoxical **TB-IRIS** occurs due to a restored immune response against mycobacterial antigens shortly after starting **ART**, especially in patients with a low **CD4 count** (<100 cells/mm³). - Clinical deterioration with **new enhancing lesions** and worsening cerebral oedema 2 weeks after ART initiation is classic for **CNS-IRIS**, often requiring high-dose **corticosteroids**. *Drug-resistant tuberculosis with treatment failure* - Clinical failure due to **drug resistance** typically presents as a gradual lack of improvement or slow decline rather than sudden **neurological deterioration** immediately following ART. - The timing of this patient's collapse specifically matches the **immune recovery** phase rather than the expected progression of resistant TB. *Dexamethasone-induced hyperglycaemia causing cerebral oedema* - While **dexamethasone** can cause significant **hyperglycaemia**, it does not typically result in focal **enhancing brain lesions** or focal deficits like hemiparesis. - Steroids are actually the primary treatment to **reduce cerebral oedema** in CNS TB; their use should theoretically prevent, not cause, these radiological changes. *Progressive multifocal leukoencephalopathy* - **PML** (caused by JC virus) usually presents as **non-enhancing**, white matter lesions without significant mass effect or widespread oedema. - It is a condition of **severe immunosuppression** rather than an inflammatory worsening triggered by the initiation of ART and TB treatment. *Isoniazid-induced hepatic encephalopathy* - **Isoniazid** toxicity would manifest with **elevated liver enzymes**, jaundice, and potentially asterixis, rather than **focal neurological deficits** and new brain lesions. - **Hepatic encephalopathy** causes global cerebral dysfunction and diffuse oedema on imaging, not localized **enhancing masses** or hemiparesis.

Question 76: A 42-year-old man from Kazakhstan presents with an 8-week history of cough, fever, and weight loss. Chest X-ray shows bilateral upper lobe cavitation. Sputum samples are sent for culture and molecular testing. GeneXpert MTB/RIF returns positive for Mycobacterium tuberculosis with rifampicin resistance detected. Culture subsequently confirms multidrug-resistant tuberculosis resistant to both rifampicin and isoniazid. Which regimen would be most appropriate for the initial intensive phase of treatment according to current WHO guidelines?

A. Rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin
B. Bedaquiline, linezolid, levofloxacin, cycloserine, and clofazimine (Correct Answer)
C. Amoxicillin-clavulanate, imipenem, linezolid, and moxifloxacin
D. Rifabutin, isoniazid, pyrazinamide, and levofloxacin
E. Ethambutol, pyrazinamide, streptomycin, kanamycin, and para-aminosalicylic acid

Explanation: ***Bedaquiline, linezolid, levofloxacin, cycloserine, and clofazimine*** - Multidrug-resistant Tuberculosis (**MDR-TB**) is defined as resistance to at least **isoniazid** and **rifampicin**, requiring a shift to WHO Group A and B oral agents. - Current guidelines prioritize **Bedaquiline**, **Linezolid**, and a **Fluoroquinolone** (e.g., levofloxacin) as the core components of an all-oral, longer regimen to improve outcomes and reduce toxicity. *Rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin* - This is the standard first-line therapy for **drug-susceptible TB**, which is ineffective here due to documented **rifampicin** and **isoniazid** resistance. - **Streptomycin** is no longer recommended as a primary agent due to high rates of resistance and significant **ototoxicity**. *Amoxicillin-clavulanate, imipenem, linezolid, and moxifloxacin* - While some of these drugs have activity, **amoxicillin-clavulanate** is not a recommended core anti-TB agent and has poor efficacy against *M. tuberculosis*. - **Imipenem** is typically reserved as a Group C (add-on) drug and requires intravenous administration, making it unsuitable for a standard initial MDR-TB oral regimen. *Rifabutin, isoniazid, pyrazinamide, and levofloxacin* - High-level **isoniazid** resistance usually renders the drug ineffective, and **rifabutin** typically exhibits complete **cross-resistance** in the presence of rifampicin resistance. - This regimen lacks a sufficient number of effective core agents (at least four) to achieve sterilization in MDR-TB. *Ethambutol, pyrazinamide, streptomycin, kanamycin, and para-aminosalicylic acid* - These agents represent older **injectable-based** therapeutic models that are no longer preferred due to high failure rates and severe **nephrotoxicity** or **hearing loss**. - Modern WHO guidelines have moved away from **Kanamycin** and **Streptomycin** in favor of more effective, less toxic **oral agents** like Bedaquiline.

Question 77: A 28-year-old woman at 32 weeks gestation is diagnosed with tuberculous meningitis. CSF analysis confirms the diagnosis and she requires urgent treatment. Regarding anti-tuberculosis therapy in this clinical scenario, which statement is most accurate?

A. Streptomycin should be included in the initial regimen as it crosses the placenta well and is safe in pregnancy
B. Pyrazinamide should be avoided throughout pregnancy due to teratogenic effects
C. Standard four-drug therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol can be used safely (Correct Answer)
D. Ethambutol should be avoided after the first trimester due to risk of kernicterus
E. Treatment should be delayed until after delivery to avoid fetal harm

Explanation: ***Standard four-drug therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol can be used safely***- **Rifampicin**, **Isoniazid**, and **Ethambutol** are first-line agents considered safe in pregnancy, with **Pyridoxine (B6)** supplementation required to prevent isoniazid-induced peripheral neuropathy.- Guidelines from the **WHO** and other major bodies recommend this regimen for **tuberculous meningitis** in pregnancy as the benefits of treating this life-threatening condition significantly outweigh potential risks.*Streptomycin should be included in the initial regimen as it crosses the placenta well and is safe in pregnancy*- **Streptomycin** and other aminoglycosides are strictly **contraindicated** in pregnancy because they are known to cause **ototoxicity** and permanent **eighth cranial nerve damage** in the fetus.- While it may cross the placenta, its safety profile makes it unsuitable for standard obstetric tuberculosis management.*Pyrazinamide should be avoided throughout pregnancy due to teratogenic effects*- **Pyrazinamide** has no documented **teratogenic effects** in humans, and its use is now standard in many international guidelines for severe TB manifestations.- The drug is considered safe enough to be included in the intensive phase, especially in **meningitis** cases where it provides excellent **CSF penetration**.*Ethambutol should be avoided after the first trimester due to risk of kernicterus*- **Ethambutol** is not associated with **kernicterus**; that risk is primarily linked to medications like **sulfonamides** which displace bilirubin from albumin.- The primary safety concern with **Ethambutol** is **optic neuritis**, which is monitored in the mother but is not a contraindication for fetal safety.*Treatment should be delayed until after delivery to avoid fetal harm*- **Tuberculous meningitis** is a medical emergency with high **maternal and fetal mortality** rates if left untreated.- Delaying therapy would lead to irreversible neurological damage or death for the mother and severe complications or loss of the pregnancy.

Question 78: A 52-year-old woman with newly diagnosed smear-positive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. She has been taking warfarin for atrial fibrillation for the past 3 years with stable INR values between 2.0-3.0. Two weeks after starting anti-tuberculosis treatment, her INR is found to be 1.2. What is the most appropriate management of her anticoagulation?

A. Increase warfarin dose and monitor INR closely (Correct Answer)
B. Switch warfarin to apixaban
C. Add aspirin 75 mg daily and continue current warfarin dose
D. Stop rifampicin and replace with levofloxacin
E. Continue current warfarin dose and recheck INR in 4 weeks

Explanation: ***Increase warfarin dose and monitor INR closely***- **Rifampicin** is a potent inducer of hepatic **cytochrome P450 enzymes**, primarily CYP2C9, which significantly accelerates the metabolism of warfarin, leading to a subtherapeutic **INR** of 1.2.- To maintain therapeutic anticoagulation and prevent **thromboembolic events** like stroke in atrial fibrillation, the **warfarin dose** must be substantially increased with frequent **INR monitoring** until a new stable dose is achieved.*Switch warfarin to apixaban*- **Rifampicin** also induces P-glycoprotein and CYP3A4, which are involved in the metabolism of **DOACs** like apixaban, potentially reducing their efficacy and making them unreliable.- Unlike warfarin, **DOACs** cannot be easily titrated or monitored with a laboratory test like INR, making dose adjustment in the presence of a potent inducer challenging and potentially unsafe.*Add aspirin 75 mg daily and continue current warfarin dose*- **Aspirin** is an antiplatelet agent and provides insufficient antithrombotic protection against stroke in **atrial fibrillation** compared to therapeutic anticoagulation with warfarin.- Adding aspirin increases the **risk of bleeding** without correcting the underlying subtherapeutic anticoagulation caused by the rifampicin-warfarin interaction.*Stop rifampicin and replace with levofloxacin*- **Rifampicin** is a cornerstone of first-line **tuberculosis treatment**; stopping it unnecessarily could lead to treatment failure and development of **drug-resistant TB**.- Management should focus on addressing the drug-drug interaction by adjusting the **warfarin dose**, rather than compromising the highly effective and essential anti-tuberculosis regimen.*Continue current warfarin dose and recheck INR in 4 weeks*- An **INR of 1.2** in a patient with **atrial fibrillation** indicates a dangerously subtherapeutic level, placing her at an immediate and high risk for **embolic stroke**.- Delaying dose adjustment for four weeks is unacceptable and unsafe given the established **enzyme induction** by rifampicin and the critical need for therapeutic anticoagulation.

Question 79: A 3-year-old boy presents with a 2-week history of fever, irritability, and decreased activity. His parents report he has been refusing to walk for the past 3 days. On examination, he has neck stiffness, photophobia, and right-sided focal weakness. Lumbar puncture shows: opening pressure 28 cmH2O, glucose 1.8 mmol/L (serum glucose 5.2 mmol/L), protein 3.2 g/L, white cells 450/mm³ (70% lymphocytes). CT head shows basal meningeal enhancement and hydrocephalus. The most likely organism responsible for this presentation is:

A. Mycobacterium tuberculosis (Correct Answer)
B. Neisseria meningitidis
C. Streptococcus pneumoniae
D. Haemophilus influenzae type b
E. Listeria monocytogenes

Explanation: ***Mycobacterium tuberculosis*** - The subacute presentation over 2 weeks, **lymphocytic pleocytosis**, markedly **elevated protein**, and **low glucose** in the CSF are classic hallmarks of tuberculous meningitis. - Key neuroimaging findings of **basal meningeal enhancement** and **hydrocephalus**, combined with focal neurological deficits from **vasculitis**, are highly specific for this diagnosis. *Neisseria meningitidis* - Typically presents acutely over hours to days with high fever, a **petechial or purpuric rash**, and rapid clinical deterioration. - CSF analysis in bacterial meningitis usually shows a **neutrophilic predominance** rather than the lymphocytic shift seen here. *Streptococcus pneumoniae* - This is the most common cause of bacterial meningitis in children but presents with an **acute onset** and significantly higher **white cell counts** with neutrophilia. - While it can cause complications, it does not typically produce the **basal exudates** or the prolonged 2-week prodrome characteristic of TB. *Haemophilus influenzae type b* - Incidence has significantly decreased due to **Hib vaccination**, and it usually presents as an **acute pyogenic meningitis**. - It lacks the characteristic **subacute progression** and specific **basal cistern involvement** seen in this patient's CT scan. *Listeria monocytogenes* - Usually affects **neonates**, the elderly, or **immunocompromised individuals**, making it an unlikely cause for a healthy 3-year-old. - While it can cause a subacute picture (rhombencephalitis), it does not typically present with the extensive **basal enhancement** and hydrocephalus seen in tuberculous meningitis.

Question 80: A 64-year-old man with chronic obstructive pulmonary disease presents with a 4-week history of productive cough and weight loss. Chest X-ray shows upper lobe cavitation. Sputum microscopy reveals acid-fast bacilli. He is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 2 weeks of treatment, he develops acute painful vision loss in his right eye with reduced visual acuity and red-green colour discrimination impairment. Which anti-tuberculosis medication is most likely responsible for his visual symptoms?

A. Ethambutol (Correct Answer)
B. Isoniazid
C. Pyrazinamide
D. Rifampicin
E. Streptomycin

Explanation: ***Ethambutol*** - This medication is classically associated with **optic neuritis**, leading to reduced **visual acuity**, central scotomas, and a characteristic loss of **red-green colour discrimination**. - The toxicity is typically **dose-dependent** and requires immediate discontinuation of the drug to prevent permanent visual impairment. *Isoniazid* - Primarily known for causing **peripheral neuropathy** due to competitive inhibition of **pyridoxine (vitamin B6)**. - It is also frequently associated with **hepatotoxicity** (elevated liver enzymes) rather than direct visual pathway damage. *Pyrazinamide* - The most common side effects are **hyperuricemia**, which can precipitate acute **gouty arthritis**, and hepatotoxicity. - It does not have any documented association with **optic nerve** damage or visual acuity changes. *Rifampicin* - Known for causing a benign **orange discoloration** of body fluids, including urine, sweat, and tears. - While it can be hepatotoxic and induce **cytochrome P450**, it does not cause acute painful **vision loss**. *Streptomycin* - This aminoglycoside is primarily associated with **ototoxicity**, leading to hearing loss or **vestibular dysfunction** (vertigo/tinnitus). - It is also known for **nephrotoxicity**, but it does not affect **color vision** or the optic nerve.

Question 81: A 35-year-old woman is diagnosed with drug-sensitive pulmonary tuberculosis and started on rifampicin 600 mg, isoniazid 300 mg, pyrazinamide 1500 mg, and ethambutol 900 mg daily. She is also taking combined oral contraceptive pills. After 6 weeks, she presents with an unplanned pregnancy confirmed at 8 weeks gestation. What is the most appropriate modification to her tuberculosis treatment regimen?

A. Stop ethambutol and pyrazinamide, continue rifampicin and isoniazid only
B. Stop all tuberculosis drugs until after delivery to avoid teratogenic effects
C. Continue current four-drug regimen unchanged and add pyridoxine supplementation (Correct Answer)
D. Replace rifampicin with moxifloxacin due to concerns about fetal safety
E. Continue rifampicin and isoniazid only, stop pyrazinamide and ethambutol

Explanation: ***Continue current four-drug regimen unchanged and add pyridoxine supplementation*** - First-line anti-tuberculosis drugs (**Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol**) are considered safe in pregnancy, and untreated tuberculosis poses a greater risk to the fetus than the medications. - **Pyridoxine (Vitamin B6)** must be added to prevent **isoniazid-induced peripheral neuropathy**, as the requirement for B6 is increased during pregnancy. *Stop ethambutol and pyrazinamide, continue rifampicin and isoniazid only* - Standard TB treatment requires an intensive phase of four drugs to prevent the development of **drug resistance** and ensure the sterilization of lesions. - Reducing the number of agents without clinical indication (like drug-induced hepatitis) increases the risk of **treatment failure** and persistent infection. *Stop all tuberculosis drugs until after delivery to avoid teratogenic effects* - Untreated pulmonary tuberculosis is associated with significantly increased rates of **spontaneous abortion**, low birth weight, and **congenital tuberculosis**. - First-line anti-TB medications are not classified as significantly **teratogenic**; therefore, the benefits of maternal treatment far outweigh the risks. *Replace rifampicin with moxifloxacin due to concerns about fetal safety* - **Fluoroquinolones** like moxifloxacin are generally avoided in pregnancy due to concerns regarding **fetal cartilage toxicity** observed in animal studies. - Rifampicin is a cornerstone of therapy and is safe for the fetus, though maternal use requires **Vitamin K** supplementation for the neonate at birth to prevent hemorrhagic disease. *Continue rifampicin and isoniazid only, stop pyrazinamide and ethambutol* - This approach is incorrect for the **intensive phase** of treatment (first 2 months), where all four drugs are necessary to kill rapidly dividing bacilli. - While pyrazinamide was historically avoided due to limited data, modern international guidelines (WHO) confirm it is **safe and effective** for use during pregnancy.

Question 82: According to UK guidelines, which of the following baseline investigations is mandatory before starting treatment for drug-sensitive pulmonary tuberculosis?

A. Visual acuity and colour vision testing using Ishihara charts (Correct Answer)
B. Audiometry to establish baseline hearing thresholds
C. Electrocardiogram to assess QTc interval
D. Chest CT scan to assess extent of parenchymal disease
E. Full blood count, renal function, and liver function tests

Explanation: ***Visual acuity and colour vision testing using Ishihara charts*** - Mandatory baseline testing is required because **ethambutol** can cause dose-related **optic neuritis**, which may lead to irreversible visual loss. - Establishing a baseline for **visual acuity** and **red-green color discrimination** allows for early detection and comparison if visual side effects occur during treatment. *Audiometry to establish baseline hearing thresholds* - Baseline hearing tests are essential when using **aminoglycosides** (like streptomycin or amikacin), which are **ototoxic**. - Audiometry is not a mandatory baseline investigation for the standard drug-sensitive regimen of **rifampicin, isoniazid, pyrazinamide, and ethambutol**. *Electrocardiogram to assess QTc interval* - ECG monitoring for **QTc prolongation** is necessary when using certain second-line MDR-TB drugs or **fluoroquinolones** (e.g., moxifloxacin). - Standard first-line pulmonary tuberculosis treatment does not typically mandate an ECG unless there is significant **electrolyte imbalance** or pre-existing cardiac risk. *Chest CT scan to assess extent of parenchymal disease* - A **chest X-ray** is the standard radiological investigation for diagnosis and monitoring; a **CT scan** is not routinely mandatory. - CT scans are generally reserved for clarifying diagnostic uncertainties or screening for complications like **bronchiectasis** or **cavitation** not seen on X-ray. *Full blood count, renal function, and liver function tests* - While these are recommended to monitor for **hepatotoxicity** (isoniazid, rifampicin, pyrazinamide) and manage drug dosing, the question asks for the specific mandatory test related to drug-specific toxicity unique to the first-line regimen's safety profile. - **Liver function tests (LFTs)** are crucial, but **visual assessment** is the unique mandatory sensory baseline required before the administration of **ethambutol**.

Question 83: A 18-year-old university student presents to the emergency department with a 12-hour history of headache, fever, vomiting, and photophobia. Examination reveals fever of 39.1°C, neck stiffness, and a non-blanching petechial rash on the lower limbs. Blood pressure is 95/58 mmHg, heart rate 118 bpm. What is the most appropriate timing for administration of corticosteroids in this patient?

A. Immediately, before or with the first dose of antibiotics
B. After lumbar puncture confirms bacterial meningitis
C. Only if CSF Gram stain shows Gram-positive organisms
D. Corticosteroids are contraindicated due to hypotension and possible septic shock (Correct Answer)
E. After 24 hours of antibiotics if clinical improvement is not seen

Explanation: ***Corticosteroids are contraindicated due to hypotension and possible septic shock*** - The patient presents with a **non-blanching petechial rash** and **hypotension** (95/58 mmHg), indicating **meningococcal septicaemia** and septic shock. - Clinical guidelines state that **dexamethasone** should be avoided in cases of suspected **meningococcal septicaemia** or when the patient is in **septic shock**, as it may worsen outcomes. *Immediately, before or with the first dose of antibiotics* - While this is the standard timing for **bacterial meningitis** to reduce neurological sequelae, it is withheld here due to signs of **circulatory collapse**. - Administering steroids during **septic shock** is generally not recommended in the initial management of suspected meningitis with a rash. *After lumbar puncture confirms bacterial meningitis* - Steroids should be given **before or with** the first dose of antibiotics; waiting for **lumbar puncture** results causes a delay that increases morbidity. - In this specific case, **meningococcal septicaemia** is already suspected clinically, making steroids inappropriate regardless of the LP results. *Only if CSF Gram stain shows Gram-positive organisms* - This approach targets **Streptococcus pneumoniae**, where steroids provide the most benefit, but the decision to start or withhold them is made **before** Gram stain results are available. - The priority in this patient is managing **sepsis** and **haemodynamic instability** rather than targeted steroid therapy for Gram-positive organisms. *After 24 hours of antibiotics if clinical improvement is not seen* - **Corticosteroids** do not provide the desired anti-inflammatory benefit if started more than **12 hours** after the first dose of antibiotics. - Delayed administration has no proven benefit in reducing the **neurological complications** of acute bacterial meningitis.

Question 84: A 44-year-old man with newly diagnosed smear-positive pulmonary tuberculosis is commenced on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 3 weeks of treatment, he develops painful, red, swollen joints affecting both knees and ankles. He also complains of burning pain in both feet. Blood tests show: uric acid 625 μmol/L, creatinine 110 μmol/L (baseline 98 μmol/L), ALT 45 U/L. Which anti-tuberculosis drug is most likely responsible for his joint symptoms?

A. Rifampicin
B. Isoniazid
C. Pyrazinamide (Correct Answer)
D. Ethambutol
E. The combination of rifampicin and isoniazid

Explanation: ***Pyrazinamide*** - **Pyrazinamide** inhibits the renal tubular secretion of **uric acid**, leading to **hyperuricaemia** and frequently causing arthralgia or acute **gouty arthritis**. - The patient's serum **uric acid level of 625 μmol/L** and involvement of large joints like the knees and ankles are classic manifestations of pyrazinamide-induced joint symptoms. *Rifampicin* - Key side effects include **orange-colored body fluids**, hepatitis, and a flu-like syndrome, but it is not directly linked to **hyperuricaemia**. - While it can cause general arthralgia, it does not typically present as acute, swollen joint **arthritis** like gout. *Isoniazid* - This drug is primarily associated with **peripheral neuropathy** (burning pain in the feet) due to **pyridoxine (Vitamin B6)** depletion, which this patient also displays. - It does not significantly affect **uric acid levels** or cause the red, swollen joints characteristic of inflammatory arthritis. *Ethambutol* - The most significant toxic effect of ethambutol is **optic neuritis**, necessitating regular visual acuity and color vision monitoring. - Although it may moderately increase serum urate, **Pyrazinamide** is much more potently associated with clinical **hyperuricaemic arthritis**. *The combination of rifampicin and isoniazid* - This combination is notorious for causing **drug-induced hepatitis**, evidenced by elevated **ALT** and bilirubin, rather than joint pathology. - Their combined effect does not explain the specific biochemical finding of **elevated uric acid** and the resulting acute arthritic symptoms.

Question 85: What is the primary mechanism by which BCG vaccination provides protection against tuberculosis?

A. Production of neutralizing antibodies against mycobacterial surface antigens
B. Direct killing of Mycobacterium tuberculosis by vaccine-derived antibodies
C. Stimulation of cell-mediated immunity through T-lymphocyte activation (Correct Answer)
D. Enhancement of complement-mediated lysis of mycobacteria
E. Induction of trained immunity in natural killer cells

Explanation: ***Stimulation of cell-mediated immunity through T-lymphocyte activation*** - BCG is a live attenuated vaccine that triggers a **Th1-mediated response**, activating **CD4+ and CD8+ T-cells** to recognize mycobacterial antigens. - These activated T-cells produce **interferon-gamma (IFN-γ)**, which enhances the ability of **macrophages** to kill intracellular Mycobacterium tuberculosis. *Production of neutralizing antibodies against mycobacterial surface antigens* - Mycobacterium tuberculosis is an **intracellular pathogen**, primarily residing within cells where antibodies have limited access and effectiveness. - While **humoral immunity** (antibodies) is induced by many vaccines, it does not provide primary or effective protection against tuberculosis. *Direct killing of Mycobacterium tuberculosis by vaccine-derived antibodies* - Protection against TB primarily relies on the **cellular arm** of the immune system, specifically T-cells and activated macrophages, rather than direct antibody-mediated killing. - Antibody-mediated killing is largely ineffective because the bacteria survive and replicate inside **phagosomes** of macrophages, protected from extracellular antibodies. *Enhancement of complement-mediated lysis of mycobacteria* - The **waxy cell wall (mycolic acids)** of mycobacteria provides significant resistance to complement-mediated lysis and other innate immune defenses. - **Complement activation** is not a primary or effective mechanism for the clearance or control of Mycobacterium tuberculosis infection. *Induction of trained immunity in natural killer cells* - While BCG is known to induce **trained immunity** via epigenetic reprogramming of innate cells, providing broader non-specific protection, this is a secondary effect. - The specific, primary mechanism of targeted protection against M. tuberculosis itself remains the activation of the **adaptive cell-mediated immune system**.

Question 86: A 51-year-old man presents with a 9-week history of low-grade fever, weight loss, and lower back pain. He has a history of intravenous drug use. MRI spine shows destruction of the L3-L4 vertebral bodies with paravertebral abscess formation and disc space involvement. Three blood cultures are negative. CT-guided biopsy of the paravertebral collection is planned. What is the most likely diagnosis?

A. Pyogenic vertebral osteomyelitis due to Staphylococcus aureus
B. Spinal tuberculosis (Pott's disease) (Correct Answer)
C. Brucella spondylitis
D. Fungal vertebral osteomyelitis
E. Metastatic spinal malignancy with pathological fracture

Explanation: ***Spinal tuberculosis (Pott's disease)*** - The chronic course over **9 weeks** with constitutional symptoms like **low-grade fever** and **weight loss**, combined with a history of **intravenous drug use**, strongly suggests an indolent infection such as **Mycobacterium tuberculosis**. - MRI findings of **L3-L4 vertebral body destruction**, **disc space involvement**, and a large **paravertebral abscess** (often referred to as a **cold abscess**) are classic features of spinal tuberculosis, especially when **blood cultures are negative**. *Pyogenic vertebral osteomyelitis due to Staphylococcus aureus* - Pyogenic osteomyelitis, particularly from **Staphylococcus aureus**, typically presents with a more **acute onset** (days to a few weeks) and often higher-grade fevers. - **Blood cultures** are positive in a majority of cases (50-70%) of pyogenic osteomyelitis, making three negative cultures less consistent with this diagnosis despite the IV drug use history. *Brucella spondylitis* - This diagnosis typically requires specific epidemiological risk factors, such as **occupational exposure** to livestock or consumption of **unpasteurized dairy products**, which are not mentioned in the patient's history. - While it can cause vertebral involvement, the extensive **paravertebral abscess formation** and prominent **disc space destruction** are more characteristic of **Pott's disease**. *Fungal vertebral osteomyelitis* - Fungal osteomyelitis is generally rare and usually affects patients who are **severely immunocompromised**, though IV drug use can be a risk factor for some fungal infections. - The overall clinical and radiological picture, including the significant **paravertebral cold abscess**, aligns more closely with **tuberculosis** than a fungal etiology. *Metastatic spinal malignancy with pathological fracture* - Metastatic spinal malignancy typically causes **vertebral body destruction** but often **spares the intervertebral disc space**, which is involved in this case. - The presence of a significant **paravertebral abscess** is a hallmark of an **infectious process** and is not typically associated with metastatic cancer.

Question 87: A 39-year-old woman with HIV infection (CD4 count 65 cells/mm³, not on ART) presents with a 5-week history of progressive headache and fever. MRI brain shows basal meningeal enhancement and multiple small enhancing lesions. Lumbar puncture shows: opening pressure 28 cm H₂O, white cells 45/μL (90% lymphocytes), protein 0.9 g/L, glucose 2.1 mmol/L (serum 5.5 mmol/L). India ink staining is positive. What is the most appropriate initial management?

A. Amphotericin B plus flucytosine for 2 weeks, then fluconazole consolidation
B. High-dose fluconazole monotherapy 800 mg daily for 6-8 weeks
C. Liposomal amphotericin B plus flucytosine for 2 weeks with therapeutic lumbar puncture (Correct Answer)
D. Ceftriaxone and aciclovir until bacterial and viral causes are excluded
E. Amphotericin B plus flucytosine for 6-8 weeks, then fluconazole maintenance

Explanation: ***Liposomal amphotericin B plus flucytosine for 2 weeks with therapeutic lumbar puncture*** - The diagnosis of **cryptococcal meningitis** is confirmed by positive **India ink staining** in an HIV patient with a low CD4 count; **liposomal amphotericin B** and **flucytosine** for 2 weeks is the recommended induction regimen. - Managing **raised intracranial pressure** (opening pressure >25 cm H₂O) with **therapeutic lumbar punctures** is a critical component of initial management to prevent mortality and neurological damage in cryptococcal meningitis. *Amphotericin B plus flucytosine for 2 weeks, then fluconazole consolidation* - While this option correctly outlines the antifungal classes and induction duration, it uses conventional **Amphotericin B** instead of **liposomal Amphotericin B**, which is preferred due to reduced **nephrotoxicity**. - Crucially, this option **fails to address the essential management of elevated intracranial pressure** (28 cm H₂O) with therapeutic lumbar punctures. *High-dose fluconazole monotherapy 800 mg daily for 6-8 weeks* - **Fluconazole monotherapy** is significantly less effective than combination therapy for induction and is associated with much higher **mortality rates** in HIV-associated cryptococcal meningitis. - Monotherapy is generally reserved for the **consolidation** or maintenance phase, or in very specific circumstances where combination therapy is not feasible. *Ceftriaxone and aciclovir until bacterial and viral causes are excluded* - This empirical regimen is inappropriate because the **India ink stain** has already provided a definitive diagnosis of **Cryptococcus neoformans** meningitis. - Delaying targeted **antifungal therapy** in a severely immunosuppressed patient with confirmed fungal meningitis can lead to rapid clinical deterioration and increased mortality. *Amphotericin B plus flucytosine for 6-8 weeks, then fluconazole maintenance* - The standard **induction duration** for cryptococcal meningitis is 2 weeks; extending this to 6-8 weeks would lead to unacceptable **toxicities** (e.g., bone marrow suppression, renal failure). - This regimen incorrectly skips the **consolidation phase** (typically 8 weeks of high-dose fluconazole) which follows induction and precedes long-term maintenance.

Question 88: A 62-year-old man with newly diagnosed sputum smear-positive pulmonary tuberculosis lives in a residential care home. He has been coughing for 6 weeks. The care home has 40 residents and 25 staff members. According to UK contact tracing guidelines, which of the following groups requires the most urgent assessment and screening?

A. All residents and staff members who have had any contact with the index case
B. Residents sharing the same dining room as the index case
C. Residents and staff with more than 8 hours cumulative close contact in enclosed spaces (Correct Answer)
D. All residents aged over 75 years regardless of contact duration
E. Staff members who have provided direct personal care to the index case

Explanation: ***Residents and staff with more than 8 hours cumulative close contact in enclosed spaces*** - UK guidelines for TB contact tracing prioritize individuals with **prolonged close contact** in enclosed spaces, typically defined as **8 hours or more cumulatively**, due to the higher risk of airborne transmission. - This group requires the most urgent assessment for **active TB symptoms** and **latent TB infection (LTBI) testing** to prevent further spread within the vulnerable care home population. *All residents and staff members who have had any contact with the index case* - Screening every individual with any contact would be **overly extensive** and **resource-intensive** without targeting the highest-risk individuals effectively. - Contact tracing aims to identify those with **significant exposure**, rather than all casual contacts, to optimize public health interventions. *Residents sharing the same dining room as the index case* - While sharing a dining room involves contact, it usually represents **intermittent and less intense exposure** compared to prolonged close contact in a confined setting. - This level of contact typically falls outside the primary criteria for **urgent, targeted screening** unless other risk factors or identified transmissions necessitate broader investigation. *All residents aged over 75 years regardless of contact duration* - Although older age is a risk factor for **progression to active TB** once infected, the initial priority for urgent screening is based on the **likelihood of acquiring infection** through significant exposure. - Screening based solely on age, without considering contact duration, would miss younger individuals with high exposure and over-screen older individuals with minimal contact. *Staff members who have provided direct personal care to the index case* - Providing direct personal care indicates close contact, but the **cumulative duration** of this exposure, particularly if it exceeds the 8-hour threshold in an enclosed space, is the key determinant for urgent screening. - This option focuses only on staff and might exclude other residents who had equally or more significant **cumulative exposure** with the index case.

Question 89: A 26-year-old woman presents to the emergency department with a 16-hour history of severe headache, photophobia, and vomiting. She has fever of 38.9°C, neck stiffness, and positive Kernig's sign. CT head scan is normal. Lumbar puncture shows: opening pressure 24 cm H₂O, white cells 680/μL (85% neutrophils), protein 1.2 g/L, glucose 1.8 mmol/L (serum glucose 5.2 mmol/L). Gram stain shows Gram-positive diplococci. What is the most likely causative organism?

A. Neisseria meningitidis
B. Streptococcus pneumoniae (Correct Answer)
C. Haemophilus influenzae type b
D. Listeria monocytogenes
E. Group B Streptococcus

Explanation: ***Streptococcus pneumoniae*** - The finding of **Gram-positive diplococci** on Gram stain from the CSF is the classic microbiological identification for *Streptococcus pneumoniae*. - This organism is the **most common cause** of bacterial meningitis in adults, consistent with the patient's acute symptoms, fever, and classic CSF findings of **neutrophilic pleocytosis**, elevated protein, and low glucose. *Neisseria meningitidis* - *Neisseria meningitidis* is a common cause of bacterial meningitis, but it appears as **Gram-negative diplococci** on Gram stain, not Gram-positive. - While it can present similarly, it is often associated with a **petechial or purpuric rash**, which is not described in this case. *Haemophilus influenzae type b* - *Haemophilus influenzae type b* is a **Gram-negative coccobacillus**, which contradicts the Gram-positive diplococci found in the patient's CSF. - The incidence of meningitis due to this organism has significantly decreased in developed countries due to widespread **Hib vaccination**. *Listeria monocytogenes* - *Listeria monocytogenes* is characterized as a **Gram-positive rod** (bacillus), not a diplococcus. - It primarily causes meningitis in specific populations, including **neonates, the elderly, pregnant women**, and **immunocompromised individuals**, which does not fit this healthy 26-year-old. *Group B Streptococcus* - While *Group B Streptococcus* are Gram-positive cocci, they typically appear in **chains** on Gram stain rather than as diplococci. - This organism is a primary cause of neonatal meningitis but is an **uncommon cause** of meningitis in healthy, non-pregnant adults.

Question 90: A 41-year-old man is diagnosed with smear-positive pulmonary tuberculosis. He reports drinking 80-90 units of alcohol per week and has stigmata of chronic liver disease on examination. Baseline blood tests show: bilirubin 32 μmol/L, ALT 88 U/L, AST 105 U/L, ALP 145 U/L, albumin 32 g/L, INR 1.4. Which one of the following treatment regimens is most appropriate for the initial phase?

A. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months
B. Isoniazid, rifampicin, and ethambutol for 2 months, avoiding pyrazinamide
C. Streptomycin, isoniazid, rifampicin, and ethambutol for 2 months (Correct Answer)
D. Rifampicin, levofloxacin, and ethambutol for 2 months
E. Isoniazid, ethambutol, and levofloxacin for 3 months

Explanation: ***Streptomycin, isoniazid, rifampicin, and ethambutol for 2 months*** - This patient has **chronic liver disease** (CLD) and synthetic dysfunction (elevated INR, low albumin), making **Pyrazinamide** contraindicated as it is the most **hepatotoxic** first-line drug. - UK guidelines (NICE/BTS) recommend a modified initial regimen replacing Pyrazinamide with **Streptomycin** or a fluoroquinolone when baseline liver function is significantly impaired. *Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months* - This is the standard quad-therapy for tuberculosis but is unsuitable here due to the presence of **stigmata of chronic liver disease** and high alcohol intake. - Including **Pyrazinamide** in this patient carries a high risk of precipitating **fulminant hepatic failure** or severe drug-induced liver injury. *Isoniazid, rifampicin, and ethambutol for 2 months, avoiding pyrazinamide* - While avoiding Pyrazinamide is correct, using only three drugs (HRE) in the intensive phase is generally insufficient for **smear-positive pulmonary TB** unless a fourth non-hepatotoxic drug is added. - Reducing the number of agents without adequate substitution increases the risk of developing **multi-drug resistant TB** (MDR-TB). *Rifampicin, levofloxacin, and ethambutol for 2 months* - This regimen excludes **Isoniazid**, which is a primary bactericidal agent and should be used if the liver disease allows for close monitoring. - Fluoroquinolone-based regimens are typically reserved for patients who cannot tolerate either **Rifampicin** or **Isoniazid**, or those with confirmed drug resistance. *Isoniazid, ethambutol, and levofloxacin for 3 months* - This regimen inappropriately excludes **Rifampicin**, which is the most potent sterilizing agent in the treatment of tuberculosis. - Excluding Rifampicin would significantly extend the total duration of treatment required (often up to 18-24 months) and is not the first-choice modification for **CLD**.

Question 91: According to current UK public health notification requirements, which of the following scenarios requires urgent notification to local health protection teams within 24 hours?

A. A positive interferon-gamma release assay (IGRA) in an asymptomatic healthcare worker
B. A positive culture for Mycobacterium tuberculosis from a lymph node biopsy
C. A CSF sample showing lymphocytic pleocytosis with low glucose in suspected tuberculous meningitis
D. Clinical suspicion of meningococcal disease before laboratory confirmation (Correct Answer)
E. A positive Mantoux test (18 mm induration) in a contact of an index case

Explanation: ***Clinical suspicion of meningococcal disease before laboratory confirmation***- **Meningococcal disease** is an urgent public health priority due to its rapid progression and potential for **outbreaks**, requiring notification within **24 hours** on clinical suspicion alone.- Immediate notification allows health protection teams to initiate **chemoprophylaxis** for close contacts to prevent secondary cases even before lab results are back.*A positive interferon-gamma release assay (IGRA) in an asymptomatic healthcare worker*- An **IGRA** measures the immune response to TB bacteria but indicates **Latent Tuberculosis Infection (LTBI)**, which is not a notifiable condition under UK law for urgent notification.- Only **active Tuberculosis** is generally notifiable to health protection teams, as latent infection does not pose an immediate public health transmission risk.*A positive culture for Mycobacterium tuberculosis from a lymph node biopsy*- While **active Tuberculosis** is a notifiable disease in the UK, it generally does not require the same **immediate, same-day notification** as meningococcal disease unless it's a specific outbreak or highly transmissible site (e.g., pulmonary).- Notification of TB is usually based on **clinical diagnosis** or **laboratory confirmation**, but it lacks the extreme time-sensitivity of invasive bacterial meningitis for immediate 24-hour notification based solely on this result.*A CSF sample showing lymphocytic pleocytosis with low glucose in suspected tuberculous meningitis*- Suspected **TB meningitis** is a serious clinical diagnosis, but the notification requirement is triggered by the **clinician's suspicion** of active TB rather than the CSF biochemistry alone.- Compared to **meningococcal disease**, the public health response for TB contacts is less urgent than the immediate prophylaxis required for *Neisseria meningitidis* exposure.*A positive Mantoux test (18 mm induration) in a contact of an index case*- A positive **Mantoux test** (Tuberculin Skin Test) indicates exposure or infection but is a screening tool for **latent TB**, not a diagnosis of active, immediately notifiable disease.- Positive screening tests in contacts are managed through **TB clinical services** for prophylaxis or monitoring rather than urgent 24-hour statutory notification.

Question 92: A 33-year-old man with HIV infection (CD4 count 180 cells/mm³) who has been on antiretroviral therapy for 6 months develops pulmonary tuberculosis. He is commenced on rifampicin, isoniazid, pyrazinamide, and ethambutol. His current ART regimen consists of tenofovir, emtricitabine, and efavirenz. What is the most appropriate management of his antiretroviral therapy?

A. Continue the current ART regimen unchanged (Correct Answer)
B. Stop ART completely until TB treatment is completed
C. Replace efavirenz with raltegravir due to drug interaction with rifampicin
D. Increase the dose of efavirenz to 800 mg daily
E. Replace efavirenz with boosted atazanavir

Explanation: ***Continue the current ART regimen unchanged*** - **Efavirenz (600 mg)** is the preferred non-nucleoside reverse transcriptase inhibitor (NNRTI) for co-administration with **rifampicin-based tuberculosis (TB) treatment** due to its favorable interaction profile. - Rifampicin is a potent **CYP3A4 inducer**, but standard-dose efavirenz maintains therapeutic levels, making dose adjustment typically unnecessary in adults. *Stop ART completely until TB treatment is completed* - Stopping ART in an HIV patient with a low **CD4 count (180 cells/mm³)** significantly increases the risk of mortality, AIDS progression, and further **opportunistic infections**. - Current guidelines strongly recommend **concurrent administration of ART and TB treatment** to improve survival and viral suppression. *Replace efavirenz with raltegravir due to drug interaction with rifampicin* - While **raltegravir** can be used with rifampicin, it requires a **dose increase to 800 mg twice daily** (from 400 mg twice daily) due to rifampicin's induction of UGT1A1. - Efavirenz is often preferred due to its established efficacy, once-daily dosing, and no need for dose adjustment with rifampicin in most adults. *Increase the dose of efavirenz to 800 mg daily* - Increasing the dose of efavirenz to **800 mg daily** is no longer routinely recommended, as studies have shown the standard **600 mg daily dose** is sufficient and efficacious when co-administered with rifampicin. - Higher doses of efavirenz are associated with increased **neuropsychiatric side effects** (e.g., dizziness, vivid dreams, insomnia) without providing additional clinical benefit. *Replace efavirenz with boosted atazanavir* - **Rifampicin** is a strong **CYP3A4 inducer** and drastically reduces plasma concentrations of most **protease inhibitors (PIs)**, including boosted atazanavir, leading to subtherapeutic levels and potential treatment failure. - Concomitant use of rifampicin with most boosted PIs is generally **contraindicated**; if a PI is essential, **rifabutin** is usually substituted for rifampicin as the anti-TB agent.

Question 93: A 47-year-old woman from Kazakhstan presents with a 12-week history of cough, fever, and weight loss. Chest X-ray shows bilateral upper zone cavitation. Three sputum samples are smear-positive for acid-fast bacilli. GeneXpert MTB/RIF testing detects Mycobacterium tuberculosis with rifampicin resistance. Culture and sensitivity testing is pending. What is the most appropriate initial management strategy according to UK guidelines?

A. Start standard four-drug therapy (RHZE) and await full culture sensitivities
B. Start rifampicin, isoniazid, pyrazinamide, and ethambutol plus moxifloxacin
C. Refer urgently to specialist TB centre and initiate empirical MDR-TB regimen (Correct Answer)
D. Start isoniazid, pyrazinamide, ethambutol, and levofloxacin pending sensitivities
E. Await full culture and drug sensitivity testing before commencing any treatment

Explanation: ***Refer urgently to specialist TB centre and initiate empirical MDR-TB regimen*** - The detection of **rifampicin resistance** via GeneXpert is a strong and rapid indicator of **Multidrug-Resistant TB (MDR-TB)**, necessitating urgent referral to a specialist TB center. - UK guidelines mandate initiating an **empirical MDR-TB regimen** immediately, often comprising multiple second-line drugs, especially given the patient's origin from a **high MDR-TB burden country** like Kazakhstan and severe clinical presentation, to prevent progression and transmission. *Start standard four-drug therapy (RHZE) and await full culture sensitivities* - This approach is inappropriate because **rifampicin resistance** has been confirmed by GeneXpert, rendering the **standard RHZE regimen** largely ineffective. - Continuing a regimen that includes an ineffective drug like rifampicin would act as **functional monotherapy**, promoting the development of further drug resistance and treatment failure. *Start rifampicin, isoniazid, pyrazinamide, and ethambutol plus moxifloxacin* - Prescribing **rifampicin** when resistance is confirmed is contraindicated and renders the core of this regimen ineffective. - Adding only **moxifloxacin** to an otherwise failing first-line regimen for suspected MDR-TB is insufficient and risks developing **fluoroquinolone resistance** without achieving adequate treatment. *Start isoniazid, pyrazinamide, ethambutol, and levofloxacin pending sensitivities* - This regimen is inadequate for confirmed **rifampicin-resistant TB**, as most cases of rifampicin resistance are also resistant to **isoniazid** (making it MDR-TB). - An empirical MDR-TB regimen requires a more comprehensive approach, often involving **multiple second-line agents** from different classes, not just one fluoroquinolone. *Await full culture and drug sensitivity testing before commencing any treatment* - Delaying treatment for the several weeks required for **phenotypic culture and sensitivity results** is unsafe for a patient with symptomatic, smear-positive, cavitary, and potentially MDR-TB. - Immediate treatment initiation is critical to prevent **clinical deterioration**, reduce **mortality**, and minimize ongoing **public health transmission** from a highly infectious patient.

Question 94: A 9-month-old infant is brought to the emergency department with a 14-hour history of fever, high-pitched crying, and reluctance to feed. On examination, temperature is 39.2°C, heart rate 165 bpm, respiratory rate 45/min. The fontanelle is bulging and tense. The infant appears drowsy but irritable when handled. A non-blanching purpuric rash is noted on the trunk and limbs. What is the most appropriate immediate antimicrobial management before lumbar puncture?

A. Intravenous ceftriaxone 80 mg/kg plus intravenous aciclovir 20 mg/kg
B. Intramuscular benzylpenicillin 300 mg followed by urgent transfer
C. Intravenous ceftriaxone 80 mg/kg plus intravenous amoxicillin 300 mg/kg per day (Correct Answer)
D. Intravenous cefotaxime 50 mg/kg plus intravenous vancomycin 15 mg/kg
E. Intravenous ceftriaxone 80 mg/kg as a single agent

Explanation: ***Intravenous ceftriaxone 80 mg/kg plus intravenous amoxicillin 300 mg/kg per day*** - The infant presents with classic features of **bacterial meningitis** and **meningococcal septicaemia**, indicated by fever, a **bulging fontanelle**, and a **non-blanching purpuric rash**. - While usually prioritized for those under 3 months, **amoxicillin** is added to a **third-generation cephalosporin** to provide essential coverage against **Listeria monocytogenes**, which is inherently resistant to cephalosporins. *Intravenous ceftriaxone 80 mg/kg plus intravenous aciclovir 20 mg/kg* - **Aciclovir** is indicated for suspected **herpetic encephalitis**, which typically presents with focal neurological signs or seizures rather than a purpuric rash. - This combination lacks **amoxicillin**, leaving the patient potentially unprotected against **Listeria** if guidelines for infants are being strictly followed. *Intramuscular benzylpenicillin 300 mg followed by urgent transfer* - **Intramuscular benzylpenicillin** is the treatment of choice in a **primary care** or pre-hospital setting when meningococcal disease is suspected and transfer is delayed. - Since the patient is already in the **emergency department**, definitive intravenous broad-spectrum antibiotics should be started immediately instead of single-agent penicillin. *Intravenous cefotaxime 50 mg/kg plus intravenous vancomycin 15 mg/kg* - **Vancomycin** is often added in regions with high rates of **penicillin-resistant Streptococcus pneumoniae**, but it is not the standard first-line addition for pediatric meningitis in many UK-based protocols unless specific resistance is suspected. - This regimen fails to include **amoxicillin**, which is the specific agent required to treat **Listeria monocytogenes**. *Intravenous ceftriaxone 80 mg/kg as a single agent* - While **ceftriaxone** provides excellent coverage for **Neisseria meningitidis** and **Streptococcus pneumoniae**, it has no activity against **Listeria**. - In the context of an infant presenting with serious systemic infection, dual therapy is preferred to ensure the broadest possible **bacterial coverage** until cultures return.

Question 95: A 56-year-old man with smear-positive pulmonary tuberculosis has been receiving rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months. His baseline liver function tests were normal. He now presents with jaundice, nausea, and abdominal discomfort. Blood tests show: bilirubin 85 μmol/L, ALT 450 U/L, AST 420 U/L, ALP 180 U/L. Which one of the following is the most appropriate immediate management?

A. Continue all four drugs and add ursodeoxycholic acid for hepatoprotection
B. Stop all anti-tuberculosis drugs immediately and arrange urgent hepatology review (Correct Answer)
C. Continue rifampicin and ethambutol only, stop isoniazid and pyrazinamide
D. Reduce the doses of all four drugs by 50% and monitor liver function weekly
E. Stop isoniazid only and continue with the remaining three drugs

Explanation: ***Stop all anti-tuberculosis drugs immediately and arrange urgent hepatology review*** - The patient presents with **clinical jaundice** (bilirubin 85 μmol/L) and significantly elevated **ALT (450 U/L)** and **AST (420 U/L)**, indicating severe **drug-induced liver injury (DILI)**. - Current guidelines mandate immediate cessation of all potentially hepatotoxic anti-TB drugs (Rifampicin, Isoniazid, Pyrazinamide) in the presence of symptomatic hepatitis with **jaundice** to prevent progression to **acute liver failure**. *Continue all four drugs and add ursodeoxycholic acid for hepatoprotection* - Continuing all four drugs in the face of severe, symptomatic **hepatotoxicity** is dangerous and can lead to **life-threatening liver failure**. - **Ursodeoxycholic acid** is primarily used for cholestatic liver diseases and has no proven role in the acute management of **drug-induced hepatocellular injury** caused by anti-TB medications. *Continue rifampicin and ethambutol only, stop isoniazid and pyrazinamide* - While **Isoniazid** and **Pyrazinamide** are major contributors to hepatotoxicity, **Rifampicin** can also cause and exacerbate liver injury, often with a cholestatic or mixed pattern. - In severe DILI with jaundice, all hepatotoxic drugs must be stopped. A sequential reintroduction protocol, under specialist supervision, can be considered only after liver function has significantly improved. *Reduce the doses of all four drugs by 50% and monitor liver function weekly* - Reducing the dose is inadequate for managing acute, symptomatic **drug-induced liver injury** and does not mitigate the risk of ongoing hepatic damage. - This approach also carries the risk of developing **drug resistance** if the drug levels fall below therapeutic ranges, and weekly monitoring is too infrequent for acute, worsening hepatitis; immediate cessation is required. *Stop isoniazid only and continue with the remaining three drugs* - Although **Isoniazid** is a common cause of toxicity, it is impossible to definitively pinpoint a single causative drug without withdrawal and reintroduction, especially since **Pyrazinamide** is often considered the most hepatotoxic, and **Rifampicin** also contributes. - Continuing other hepatotoxic drugs like **Pyrazinamide** and **Rifampicin** in a patient with severe DILI and **jaundice** risks further liver damage and potentially fatal complications.

Question 96: A 43-year-old woman with rheumatoid arthritis is about to commence tocilizumab (IL-6 inhibitor) therapy. Screening investigations show: interferon-gamma release assay (IGRA) positive, chest X-ray normal, no symptoms of active tuberculosis. She has no history of previous tuberculosis treatment. What is the most appropriate management regarding tuberculosis before starting immunosuppressive therapy?

A. Start tocilizumab immediately as chest X-ray is normal and there are no symptoms
B. Commence isoniazid 300 mg daily for 6 months before starting tocilizumab
C. Commence rifampicin and isoniazid for 3 months before starting tocilizumab (Correct Answer)
D. Perform CT thorax and bronchoscopy to exclude active disease before any treatment decisions
E. Commence full four-drug anti-tuberculosis therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) for 2 months before starting tocilizumab

Explanation: ***Commence rifampicin and isoniazid for 3 months before starting tocilizumab*** - This patient has **latent tuberculosis infection (LTBI)**, as indicated by a **positive IGRA** and normal chest X-ray; treatment is mandatory before starting **IL-6 inhibitors** like tocilizumab to prevent reactivation. - The **3-month Rifampicin and Isoniazid (3RH)** regimen is a preferred LTBI strategy due to higher completion rates and similar efficacy compared to longer monotherapy courses. *Start tocilizumab immediately as chest X-ray is normal and there are no symptoms* - Proceeding without treating LTBI carries a high risk of **active TB reactivation** once biologic immunosuppression is introduced. - Guidelines mandate that prophylaxis should ideally be initiated for at least **one month** (some experts suggest completion) prior to starting biologics. *Commence isoniazid 300 mg daily for 6 months before starting tocilizumab* - While **monotherapy with Isoniazid** for 6 months is an acceptable alternative for LTBI, it is generally less preferred than the shorter 3-month combined regimen. - This option is less optimal in this context compared to the **shorter, more effective duration** provided by the combination of Rifampicin and Isoniazid. *Perform CT thorax and bronchoscopy to exclude active disease before any treatment decisions* - Invasive procedures and advanced imaging are **not indicated** if the patient is asymptomatic and the standard screening **chest X-ray** is normal. - These investigations are reserved for cases with **suspicious radiographic findings** or clinical symptoms of pulmonary tuberculosis. *Commence full four-drug anti-tuberculosis therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) for 2 months before starting tocilizumab* - **Four-drug therapy (RIPE)** is the intensive phase treatment for **active tuberculosis**, not the prophylaxis required for latent infection. - Using this regimen for LTBI results in **unnecessary toxicity** and does not follow established screening and preventative protocols.

Question 97: A 31-year-old man presents with a 7-week history of headache, fever, and personality change. He is a recent immigrant from India. On examination, GCS is 13/15, temperature 38.2°C, and he has bilateral cranial nerve VI palsies. MRI brain shows basal meningeal enhancement and multiple tuberculomas. Lumbar puncture: opening pressure 28 cmH₂O, WBC 280/mm³ (85% lymphocytes), protein 3.2 g/L, glucose 1.4 mmol/L (plasma glucose 5.6 mmol/L). GeneXpert MTB/RIF on CSF is positive for M. tuberculosis with rifampicin sensitivity. He is started on rifampicin, isoniazid, pyrazinamide, and ethambutol with adjunctive dexamethasone. What is the most important additional immediate management to prevent permanent neurological sequelae?

A. Serial lumbar punctures to reduce intracranial pressure
B. Urgent neurosurgical consultation for ventriculoperitoneal shunt insertion (Correct Answer)
C. Increase dexamethasone dose to 16 mg daily for more potent anti-inflammatory effect
D. Add moxifloxacin as a fifth drug to improve CSF penetration
E. Immediate loading with intravenous phenytoin for seizure prophylaxis

Explanation: ***Urgent neurosurgical consultation for ventriculoperitoneal shunt insertion***- This patient exhibits signs of **obstructive hydrocephalus**, including raised intracranial pressure (28 cmH₂O), **GCS 13/15**, and **bilateral VI nerve palsies**.- Urgent neurosurgical intervention is vital to prevent **permanent neurological sequelae** or death caused by the basal exudates characteristic of **tuberculous meningitis**.*Serial lumbar punctures to reduce intracranial pressure*- While serial lumbar punctures may temporarily alleviate pressure in **communicating hydrocephalus**, they are insufficient for the definitive management of **obstructive hydrocephalus**.- This approach is more commonly used in **cryptococcal meningitis** rather than as a primary surgical solution for TB-related CSF obstruction.*Increase dexamethasone dose to 16 mg daily for more potent anti-inflammatory effect*- The patient is already on **adjunctive dexamethasone**, which is the gold standard to reduce meningeal inflammation and mortality in **TB meningitis**.- Increasing the dose beyond standard protocols (usually 0.4mg/kg/day tapering over 6-8 weeks) does not replace the need for **surgical decompression** of hydrocephalus.*Add moxifloxacin as a fifth drug to improve CSF penetration*- Since the GeneXpert confirmed **rifampicin sensitivity**, the standard intensive phase (RHZE) is appropriate and adequate.- Adding a **fluoroquinolone** like moxifloxacin is generally reserved for **drug-resistant tuberculosis** and does not address the mechanical issue of raised intracranial pressure.*Immediate loading with intravenous phenytoin for seizure prophylaxis*- **Prophylactic anti-epileptic drugs** are not routinely recommended in the management of TB meningitis unless the patient experiences active seizures.- This intervention does not address the primary threat to this patient's neurological status, which is **hydrocephalus** and basal meningeal enhancement.

Question 98: Which one of the following adverse effects associated with anti-tuberculosis medications requires immediate and permanent discontinuation of the causative drug?

A. Asymptomatic hyperuricaemia with serum uric acid 520 μmol/L in a patient taking pyrazinamide
B. Transient elevation of ALT to 2.5 times the upper limit of normal without symptoms in a patient taking rifampicin
C. Orange discolouration of urine and contact lenses in a patient taking rifampicin
D. Thrombocytopenia with platelet count of 45 × 10⁹/L in a patient taking rifampicin (Correct Answer)
E. Mild peripheral neuropathy with normal vitamin B6 levels in a patient taking isoniazid

Explanation: ***Thrombocytopenia with platelet count of 45 × 10⁹/L in a patient taking rifampicin*** - **Rifampicin-induced thrombocytopenia** is an immune-mediated reaction that is life-threatening and requires **immediate and permanent discontinuation**. - Re-exposure to the drug can cause a severe, rapid drop in platelet count and **fatal hemorrhage**, making it a strict contraindication for future use. *Asymptomatic hyperuricaemia with serum uric acid 520 μmol/L in a patient taking pyrazinamide* - **Pyrazinamide** commonly inhibits the excretion of uric acid, but **asymptomatic hyperuricaemia** does not necessitate stopping the drug. - Treatment is only discontinued if the patient develops clinical symptoms of **acute gouty arthritis**. *Transient elevation of ALT to 2.5 times the upper limit of normal without symptoms in a patient taking rifampicin* - Most guidelines recommend stopping treatment only if **ALT exceeds 5 times** the upper limit of normal (ULN) if asymptomatic, or **3 times ULN** if symptoms are present. - Minor, **asymptomatic elevations** in liver enzymes are common during the initial phase of therapy and often resolve without intervention. *Orange discolouration of urine and contact lenses in a patient taking rifampicin* - This is a **harmless, expected side effect** of rifampicin due to its metabolic properties and is not a sign of toxicity. - Patients should be counseled that it can permanently stain **soft contact lenses**, but it never requires discontinuation of therapy. *Mild peripheral neuropathy with normal vitamin B6 levels in a patient taking isoniazid* - **Peripheral neuropathy** is a known side effect of **Isoniazid** due to interference with pyridoxine metabolism, but it is often reversible. - It is primarily managed by adding or increasing **Pyridoxine (Vitamin B6)** supplementation rather than permanently stopping the life-saving medication.

Question 99: A 52-year-old man presents with a 4-week history of headache and confusion. He has HIV infection with a CD4 count of 45 cells/mm³ and is not currently on antiretroviral therapy. CT head shows multiple ring-enhancing lesions. Lumbar puncture shows: WBC 12/mm³ (80% lymphocytes), protein 0.8 g/L, glucose 3.2 mmol/L (plasma glucose 5.8 mmol/L). Toxoplasma serology is IgG positive. He is started on sulfadiazine and pyrimethamine. After 10 days of treatment there is no clinical improvement and repeat CT shows progression of lesions. What is the most appropriate next step in management?

A. Add corticosteroids to reduce cerebral oedema
B. Switch to alternative anti-toxoplasma therapy with clindamycin
C. Arrange stereotactic brain biopsy for tissue diagnosis (Correct Answer)
D. Start empirical anti-tuberculosis therapy for CNS tuberculosis
E. Commence high-dose intravenous aciclovir for viral encephalitis

Explanation: ***Arrange stereotactic brain biopsy for tissue diagnosis*** - In HIV patients with a **CD4 count <100 cells/mm³** and **multiple ring-enhancing lesions**, failure to respond to empirical **sulfadiazine and pyrimethamine** after 10-14 days necessitates a biopsy. - This step is crucial to rule out **Primary CNS Lymphoma (PCNSL)**, which frequently mimics toxoplasmosis radiologically and requires a definitive tissue diagnosis for appropriate management. *Add corticosteroids to reduce cerebral oedema* - Corticosteroids can cause a temporary, often significant, **regression of CNS lymphoma** lesions, which may be referred to as the 'vanishing tumor' effect, thereby confounding subsequent diagnostic efforts via biopsy. - While they might alleviate **cerebral edema** and mass effect, they do not address the underlying pathology and could delay or obscure the definitive diagnosis. *Switch to alternative anti-toxoplasma therapy with clindamycin* - The patient showed **no clinical or radiological improvement** on first-line, highly effective anti-toxoplasma therapy (sulfadiazine and pyrimethamine), making it unlikely that the condition is toxoplasmosis. - Switching to an alternative such as clindamycin would delay the critical diagnostic workup needed to identify other life-threatening conditions like **PCNSL**. *Start empirical anti-tuberculosis therapy for CNS tuberculosis* - **CNS Tuberculosis** typically presents with meningeal inflammation (basal meningitis) or solitary tuberculomas, rather than multiple ring-enhancing lesions with this specific clinical course and failure of toxo treatment. - Empirical **anti-tuberculosis therapy** without a tissue diagnosis in this context is not the most appropriate step before excluding other primary differential diagnoses like PCNSL via biopsy. *Commence high-dose intravenous aciclovir for viral encephalitis* - **Viral encephalitis**, particularly HSV, typically causes **temporal lobe** involvement and presents with acute focal neurological deficits, seizures, or diffuse encephalopathy, rather than multiple discrete ring-enhancing lesions. - The imaging findings and the chronic nature of symptoms are less consistent with the presentation of acute **viral encephalitis** requiring aciclovir.

Question 100: A 5-year-old girl presents with a 6-hour history of fever, headache, and drowsiness. On examination, she has GCS 12/15, temperature 39.5°C, and a petechial rash on her trunk. Blood cultures are taken and intravenous ceftriaxone 80 mg/kg is commenced. Lumbar puncture shows turbid CSF with opening pressure 24 cmH₂O. Which prophylactic measure for household contacts is most appropriate?

A. Ciprofloxacin 500 mg single dose for all household contacts (Correct Answer)
B. Rifampicin 600 mg twice daily for 2 days for all household contacts
C. Meningococcal ACWY vaccine for all household contacts within 24 hours
D. Benzylpenicillin 1.2 g intramuscularly single dose for all household contacts
E. No chemoprophylaxis required as index patient has received intravenous antibiotics

Explanation: ***Ciprofloxacin 500 mg single dose for all household contacts*** - **Ciprofloxacin** is now the preferred agent for **meningococcal chemoprophylaxis** in the UK as a single dose is highly effective at eradicating **nasopharyngeal carriage**. - It is favored over other options due to better compliance, fewer **drug interactions**, and safety profile in various populations. *Rifampicin 600 mg twice daily for 2 days for all household contacts* - While effective, **rifampicin** is now considered a second-line alternative due to the requirement for **multiple doses** and potential for significant **drug interactions** via enzyme induction. - It also has the inconvenience of potentially staining bodily fluids like urine or tears orange, which decreases patient compliance. *Meningococcal ACWY vaccine for all household contacts within 24 hours* - Vaccination is used as an **adjunct** to chemoprophylaxis to prevent late-onset secondary cases, but it does not provide the **immediate protection** required for acute exposure. - Chemoprophylaxis remains the primary intervention to rapidly eliminate the **bacterial reservoir** in close contacts. *Benzylpenicillin 1.2 g intramuscularly single dose for all household contacts* - **Benzylpenicillin** is effective for treating invasive disease but does not reliably eradicate **nasopharyngeal carriage** of Neisseria meningitidis. - It is not recommended for **prophylaxis** because it fails to prevent the spread of the pathogen from asymptomatic carriers to others. *No chemoprophylaxis required as index patient has received intravenous antibiotics* - Even though the index patient is being treated, **household contacts** remain at a significantly higher risk of developing the disease from the same source or from carriage. - Chemoprophylaxis must be administered to all **close contacts** regardless of the patient's treatment status to break the chain of transmission.

Question 101: A 38-year-old healthcare worker has recently completed BCG vaccination after a negative tuberculin skin test. She now works in a respiratory ward with frequent exposure to patients with tuberculosis. Six months later, she develops a persistent cough. Chest X-ray shows right upper lobe consolidation. What is the most appropriate initial diagnostic approach?

A. Perform interferon-gamma release assay (IGRA) test
B. Perform Mantoux test with 2 TU tuberculin
C. Obtain three sputum samples for acid-fast bacilli smear and culture (Correct Answer)
D. Arrange high-resolution CT chest to assess for tuberculosis
E. Start empirical four-drug anti-tuberculosis therapy pending investigations

Explanation: ***Obtain three sputum samples for acid-fast bacilli smear and culture*** - The patient presents with clinical signs (persistent cough) and radiological findings (right upper lobe consolidation) highly suggestive of **active pulmonary tuberculosis**. - **Sputum AFB smear** and **culture** are the **gold standard** for confirming active TB, allowing for **microbiological diagnosis** and crucial **drug susceptibility testing**. *Perform interferon-gamma release assay (IGRA) test* - **IGRA** is primarily used to diagnose **latent TB infection** and cannot reliably differentiate between latent infection and active disease. - While BCG vaccination does not affect IGRA results, it is not the initial diagnostic test for a symptomatic patient with signs of **active pulmonary disease**. *Perform Mantoux test with 2 TU tuberculin* - The **Mantoux test** (Tuberculin Skin Test) is expected to be **false-positive** in this patient due to her recent **BCG vaccination**. - Like IGRA, this test screens for **latent infection** and is insufficient for diagnosing **active clinical tuberculosis**. *Arrange high-resolution CT chest to assess for tuberculosis* - Although **HRCT** provides detailed anatomical imaging of lung pathology, it cannot provide a **microbiological diagnosis** or confirm the presence of *Mycobacterium tuberculosis*. - Imaging should not delay the essential step of **sputum collection** for definitive diagnosis in a symptomatic patient with suspected active TB. *Start empirical four-drug anti-tuberculosis therapy pending investigations* - **Empirical treatment** is generally reserved for critically ill patients or those with high clinical suspicion where diagnostic samples are unobtainable or results are significantly delayed. - Starting therapy prematurely can hinder **culture growth** and the ability to perform **drug susceptibility testing**, which is vital for effective treatment.

Question 102: A 65-year-old woman with type 2 diabetes presents with confusion, fever, and left-sided focal seizures. CT head shows a right temporal lobe lesion with surrounding oedema. Lumbar puncture shows: WBC 520/mm³ (70% lymphocytes), protein 0.9 g/L, glucose 3.8 mmol/L (plasma glucose 8.2 mmol/L), and red blood cells 850/mm³. PCR is positive for herpes simplex virus type 1. She is started on intravenous aciclovir. What additional immediate treatment is most likely to improve neurological outcome?

A. Intravenous dexamethasone 10 mg every 6 hours
B. Intravenous levetiracetam 1000 mg and continuation of prophylactic anti-epileptic therapy (Correct Answer)
C. Intravenous immunoglobulin 0.4 g/kg daily for 5 days
D. Urgent neurosurgical decompression
E. Plasma exchange therapy

Explanation: ***Intravenous levetiracetam 1000 mg and continuation of prophylactic anti-epileptic therapy*** - Seizures are a frequent complication in **Herpes Simplex Encephalitis (HSE)**, significantly impacting neurological outcomes, making immediate **seizure control** a primary goal. - **Levetiracetam** is an effective anti-epileptic choice due to its rapid action, broad spectrum, and favorable drug interaction profile, crucial for patients with complex medical needs. *Intravenous dexamethasone 10 mg every 6 hours* - The routine use of **corticosteroids** like **dexamethasone** in **HSE** is controversial and not generally recommended, unlike in certain forms of bacterial meningitis. - There is insufficient evidence to support that **corticosteroids** improve long-term neurological outcomes in viral encephalitis, and they might even potentially complicate viral clearance. *Intravenous immunoglobulin 0.4 g/kg daily for 5 days* - **Intravenous immunoglobulin (IVIG)** therapy is primarily indicated for **autoimmune encephalitis** and other immune-mediated neurological disorders, not for acute viral infections. - **IVIG** has no established role in the direct treatment of active **HSV-1 encephalitis** as it does not target viral replication or acute infection. *Urgent neurosurgical decompression* - **Neurosurgical decompression** is a last-resort intervention reserved for life-threatening conditions such as severe **intracranial hypertension** or brain herniation. - While there is focal oedema, the immediate management of **HSE** focuses on antiviral therapy and seizure control, with surgery considered only for extreme, refractory cases. *Plasma exchange therapy* - **Plasma exchange (PLEX)** is an immunomodulatory therapy used for conditions like **autoimmune neurological disorders** or specific demyelinating diseases. - It is not indicated for the treatment of acute **viral encephalitis** and would not address the underlying HSV infection or its associated complications like seizures.

Question 103: A 27-year-old man from Nigeria presents with a 10-week history of progressive headache, vomiting, and personality change. He has been in the UK for 8 months. On examination, he is confused with GCS 13/15, temperature 37.8°C, and bilateral papilloedema. CT head shows hydrocephalus with basal enhancement. Lumbar puncture after normal coagulation: opening pressure 32 cmH₂O, WBC 180/mm³ (90% lymphocytes), protein 2.2 g/L, glucose 1.8 mmol/L (plasma glucose 5.4 mmol/L). India ink stain is positive. What is the most important initial investigation to guide treatment duration and prognosis?

A. Cryptococcal antigen titre in cerebrospinal fluid
B. HIV test with CD4 count (Correct Answer)
C. Mycobacterium tuberculosis PCR on cerebrospinal fluid
D. Cerebrospinal fluid culture for Cryptococcus species identification
E. Repeat lumbar puncture in 2 weeks to assess treatment response

Explanation: ***HIV test with CD4 count***- Confirmation of **HIV status** is the most critical next step because **cryptococcal meningitis** is an AIDS-defining illness, and management depends heavily on the level of **immunosuppression**.- The **CD4 count** guides the duration of antifungal therapy, the timing of **antiretroviral therapy (ART)** to avoid IRIS, and the necessity of **secondary prophylaxis**.*Cryptococcal antigen titre in cerebrospinal fluid*- While a high **cryptococcal antigen (CrAg) titre** (>1:1024) is associated with a higher **fungal burden** and poorer prognosis, it does not dictate the overall treatment framework as much as HIV status.- It is useful for diagnosis and monitoring, but it does not change the fundamental need to identify the underlying **immunodeficiency**.*Mycobacterium tuberculosis PCR on cerebrospinal fluid*- Although **basal enhancement** and hydrocephalus can be seen in **TB meningitis**, the **positive India ink** stain specifically identifies encapsulated yeasts, confirming Cryptococcus.- TB PCR is a valuable adjunct in endemic regions, but it would not be the primary guide for **treatment duration** of a confirmed fungal infection.*Cerebrospinal fluid culture for Cryptococcus species identification*- **CSF culture** is the gold standard for diagnosis and provides **antifungal susceptibility** testing, but it takes days to yield results.- While important for confirming the species (e.g., **C. neoformans** vs. **C. gattii**), it does not provide the same prognostic and longitudinal management guidance as knowing the patient's **HIV status**.*Repeat lumbar puncture in 2 weeks to assess treatment response*- A repeat LP is often performed at 2 weeks to confirm **CSF sterilization** (clearance of the fungus), but this is a monitoring step rather than an initial investigation.- Assessing **treatment response** is secondary to identifying the primary cause of the patient's susceptibility to such an **opportunistic infection**.

Question 104: A 32-year-old man presents to the emergency department with a 12-hour history of severe headache, fever of 39.2°C, and two episodes of vomiting. He has photophobia and neck stiffness. He had a splenectomy 5 years ago following a road traffic accident. Blood cultures are taken. What is the most appropriate immediate antibiotic regimen before lumbar puncture results are available?

A. Intravenous ceftriaxone 2 g
B. Intravenous cefotaxime 2 g and intravenous amoxicillin 2 g
C. Intravenous benzylpenicillin 2.4 g
D. Intravenous vancomycin 1 g and intravenous ceftriaxone 2 g (Correct Answer)
E. Intravenous meropenem 2 g

Explanation: ***Intravenous vancomycin 1 g and intravenous ceftriaxone 2 g***- Asplenic patients are at a significantly increased risk of severe infections with **encapsulated bacteria**, particularly **Streptococcus pneumoniae**, including strains that may be **penicillin-resistant**.- Empirical treatment for meningitis in asplenic individuals mandates a broad-spectrum approach, combining a **third-generation cephalosporin** (ceftriaxone) with **vancomycin** to cover potential resistant pneumococcal strains before sensitivities are known.*Intravenous ceftriaxone 2 g*- While ceftriaxone provides excellent coverage for **Neisseria meningitidis** and sensitive **Streptococcus pneumoniae**, it is insufficient alone for an asplenic patient.- It lacks coverage for **penicillin-resistant S. pneumoniae**, which is a major concern in individuals without a functional spleen.*Intravenous cefotaxime 2 g and intravenous amoxicillin 2 g*- Cefotaxime is similar to ceftriaxone but, like ceftriaxone alone, does not adequately cover **resistant S. pneumoniae** in this high-risk patient.- **Amoxicillin** is typically added for **Listeria monocytogenes** coverage, which is primarily a concern in the very young, very old, or severely immunocompromised (e.g., cell-mediated immunity deficits), rather than asplenic patients without other specific risk factors.*Intravenous benzylpenicillin 2.4 g*- Benzylpenicillin is effective against sensitive **S. pneumoniae** and **N. meningitidis** and is often used pre-hospital for suspected meningococcal disease.- It offers no coverage for **penicillin-resistant S. pneumoniae**, making it an inadequate choice for initial empirical management in an asplenic patient.*Intravenous meropenem 2 g*- Meropenem is a broad-spectrum carbapenem, often reserved for severe infections, multi-drug resistant pathogens, or patients with a severe **beta-lactam allergy**.- It is not the standard first-line empirical regimen for community-acquired meningitis in an asplenic patient when a combination of a third-generation cephalosporin and vancomycin is appropriate.

Question 105: A 48-year-old woman with smear-positive pulmonary tuberculosis has been on rifampicin, isoniazid, pyrazinamide, and ethambutol for 6 weeks. She now complains of reduced visual acuity and difficulty distinguishing red and green colours. Visual acuity testing shows deterioration from 6/6 to 6/18 bilaterally. What is the most likely cause and appropriate action?

A. Rifampicin-induced optic neuritis; stop rifampicin immediately and refer to ophthalmology
B. Ethambutol-induced optic neuropathy; stop ethambutol immediately and refer to ophthalmology (Correct Answer)
C. Isoniazid-induced peripheral neuropathy affecting optic nerve; add pyridoxine supplementation
D. Tuberculous choroiditis; continue treatment and add oral prednisolone
E. Pyrazinamide-induced optic neuritis; stop pyrazinamide and continue with three drugs

Explanation: ***Ethambutol-induced optic neuropathy; stop ethambutol immediately and refer to ophthalmology***- **Ethambutol** is well-known for causing **dose-dependent optic neuropathy**, typically presenting with decreased **visual acuity** and **red-green color blindness** (dyschromatopsia).- The medication must be **discontinued immediately** to prevent irreversible vision loss, followed by an urgent **ophthalmology referral** for formal assessment.*Rifampicin-induced optic neuritis; stop rifampicin immediately and refer to ophthalmology*- **Rifampicin** is not associated with optic neuritis; it is primarily known for causing **orange discoloration** of body fluids and potential **hepatotoxicity**.- Stopping the wrong medication would fail to address the toxic source and risk inadequate treatment of the **tuberculosis** infection.*Isoniazid-induced peripheral neuropathy affecting optic nerve; add pyridoxine supplementation*- **Isoniazid** typically causes **peripheral neuropathy** (numbness/tingling) rather than optic neuropathy; this is managed with **pyridoxine (Vitamin B6)**.- While Isoniazid can rarely cause optic issues, the classic presentation of **red-green color loss** is specifically diagnostic for ethambutol toxicity.*Tuberculous choroiditis; continue treatment and add oral prednisolone*- **Tuberculous choroiditis** would likely present with different ophthalmoscopic findings such as **choroidal tubercles** and is usually seen in disseminated or miliary TB.- The bilateral, symmetric deterioration of **color vision** while on RIPE therapy is a hallmark of drug toxicity rather than a new inflammatory infectious complication.*Pyrazinamide-induced optic neuritis; stop pyrazinamide and continue with three drugs*- **Pyrazinamide** is most commonly associated with **hyperuricemia** (leading to gout) and **hepatotoxicity**, not visual disturbances.- Optic neuritis is not a recognized side effect of pyrazinamide, so stopping it would be clinically inappropriate in this context.

Question 106: A 55-year-old man with end-stage renal failure on haemodialysis presents with fever, confusion, and neck stiffness. Blood cultures are taken and lumbar puncture is performed. CSF shows: WBC 1200/mm³ (80% neutrophils), protein 1.8 g/L, glucose 2.1 mmol/L (plasma glucose 6.2 mmol/L). Gram stain shows Gram-positive cocci in chains. Which antibiotic regimen provides the most appropriate empirical cover?

A. Intravenous ceftriaxone 2 g every 12 hours
B. Intravenous cefotaxime 2 g every 6 hours and intravenous vancomycin 1 g every 12 hours (Correct Answer)
C. Intravenous benzylpenicillin 2.4 g every 4 hours and intravenous gentamicin 5 mg/kg once daily
D. Intravenous meropenem 2 g every 8 hours
E. Intravenous ceftazidime 2 g every 8 hours and intravenous vancomycin 1 g once daily

Explanation: ***Intravenous cefotaxime 2 g every 6 hours and intravenous vancomycin 1 g every 12 hours***- Empirical treatment for suspected **bacterial meningitis** requires a third-generation cephalosporin and **vancomycin** to provide cover against **penicillin-resistant Streptococcus pneumoniae**.- Gram-positive cocci in chains specifically point toward **Streptococcus species**, and this combination ensures adequate CNS penetration and broad-spectrum coverage for common pathogens.*Intravenous ceftriaxone 2 g every 12 hours*- While ceftriaxone is a standard treatment for meningitis, monotherapy carries the risk of treatment failure if **penicillin-resistant pneumococcus** is the causative agent.- In the setting of **end-stage renal failure**, many clinicians prefer agents with more frequent dosing or specific metabolic profiles, though both cephalosporins require careful monitoring.*Intravenous benzylpenicillin 2.4 g every 4 hours and intravenous gentamicin 5 mg/kg once daily*- **Benzylpenicillin** is insufficient as empirical therapy due to the high global prevalence of **penicillin-resistant S. pneumoniae**.- **Gentamicin** has very poor **penetration into the cerebrospinal fluid (CSF)** and is not indicated for the primary treatment of bacterial meningitis.*Intravenous meropenem 2 g every 8 hours*- Meropenem is generally reserved for **multi-drug resistant** organisms or cases where there are contraindications to cephalosporins.- It does not provide superior coverage compared to the **cefotaxime/vancomycin** combination for community-acquired streptococcal meningitis.*Intravenous ceftazidime 2 g every 8 hours and intravenous vancomycin 1 g once daily*- **Ceftazidime** is primarily utilized for its activity against **Pseudomonas aeruginosa** and has significantly weaker activity against **Gram-positive cocci** like S. pneumoniae.- **Vancomycin** dosing once daily is appropriate for maintenance in **haemodialysis**, but the initial empirical regimen must prioritize the correct choice of cephalosporin for the identified Gram stain.

Question 107: According to UK notification requirements, which one of the following clinical scenarios mandates urgent notification to the UK Health Security Agency (UKHSA) by the attending clinician?

A. A 45-year-old man with culture-confirmed pulmonary tuberculosis who is smear-negative and clinically improving on treatment
B. A 28-year-old woman diagnosed with latent tuberculosis infection based on a positive interferon-gamma release assay and normal chest X-ray
C. A 35-year-old man with suspected bacterial meningitis who has received the first dose of intravenous ceftriaxone in the emergency department (Correct Answer)
D. A 50-year-old woman with tuberculous lymphadenitis confirmed by biopsy but with negative sputum samples
E. A 60-year-old man with viral meningitis confirmed by PCR detection of enterovirus in cerebrospinal fluid

Explanation: ***A 35-year-old man with suspected bacterial meningitis who has received the first dose of intravenous ceftriaxone in the emergency department*** - **Suspected bacterial meningitis** is a medical emergency that requires **urgent notification** to the UKHSA based on clinical suspicion, even before laboratory confirmation. - Immediate notification is essential for public health interventions, such as **chemoprophylaxis** for close contacts and managing potential outbreaks. *A 45-year-old man with culture-confirmed pulmonary tuberculosis who is smear-negative and clinically improving on treatment* - While **active pulmonary tuberculosis** is a notifiable disease, it generally requires notification within **three days** rather than the urgent immediate notification required for meningitis. - Being **smear-negative** and clinically improving reduces the immediate public health risk compared to acute bacterial pathogens. *A 28-year-old woman diagnosed with latent tuberculosis infection based on a positive interferon-gamma release assay and normal chest X-ray* - **Latent tuberculosis infection (LTBI)** is not a notifiable condition under UK regulations as there is no active disease and no risk of transmission. - Notification is only required for **active tuberculosis** (pulmonary or extrapulmonary) where clinical symptoms or diagnostic evidence of disease are present. *A 50-year-old woman with tuberculous lymphadenitis confirmed by biopsy but with negative sputum samples* - Extrapulmonary tuberculosis, such as **tuberculous lymphadenitis**, is notifiable but does not carry the same **urgent** timeframe as acute bacterial meningitis. - Since it is non-infectious to others (negative sputum), the public health priority for **contact tracing** is less acute than for meningococcal disease. *A 60-year-old man with viral meningitis confirmed by PCR detection of enterovirus in cerebrospinal fluid* - **Viral meningitis** is generally not a notifiable disease unless it is caused by a specific notifiable pathogen like **measles**, **mumps**, or **poliovirus**. - Enteroviral meningitis, while clinically significant for the patient, does not trigger the same **statutory notification** requirements as bacterial meningitis.

Question 108: A 35-year-old woman from the Philippines presents with a 12-week history of cough, weight loss, and night sweats. Chest X-ray shows bilateral upper zone cavitation. Three sputum samples are smear-positive for acid-fast bacilli. Molecular testing (Xpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. What is the most appropriate initial management?

A. Start standard four-drug therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) pending full culture sensitivities
B. Start modified therapy with isoniazid, pyrazinamide, ethambutol, and moxifloxacin, and refer urgently to MDR-TB specialist service (Correct Answer)
C. Start five-drug therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, streptomycin) at higher doses
D. Wait for full culture and sensitivity results before starting any treatment
E. Start standard four-drug therapy and add rifabutin to replace rifampicin

Explanation: ***Start modified therapy with isoniazid, pyrazinamide, ethambutol, and moxifloxacin, and refer urgently to MDR-TB specialist service*** - Detection of **rifampicin resistance** by **Xpert MTB/RIF** indicates likely **Multidrug-Resistant TB (MDR-TB)**, necessitating immediate consultation with a specialist.- A **fluoroquinolone (moxifloxacin)** is essential to replace rifampicin in the initial regimen for suspected MDR-TB, alongside other effective first-line drugs like isoniazid, pyrazinamide, and ethambutol (if susceptible).*Start standard four-drug therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) pending full culture sensitivities* - The **Xpert MTB/RIF** test has already identified **rifampicin resistance**, making the standard rifampicin-containing regimen ineffective and inappropriate.- Administering **rifampicin** when resistance is known could lead to treatment failure and potentially foster further drug resistance.*Start five-drug therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, streptomycin) at higher doses* - This option still includes **rifampicin**, which is ineffective due to confirmed resistance, and simply increasing its dose does not overcome this.- **Streptomycin** is not typically added as a primary countermeasure for rifampicin resistance and does not constitute appropriate initial MDR-TB therapy in this context.*Wait for full culture and sensitivity results before starting any treatment* - The patient has active, **smear-positive pulmonary TB** with cavitation and is highly infectious, demanding immediate therapeutic intervention to prevent disease progression and transmission.- **Xpert MTB/RIF** provides rapid, reliable results for **rifampicin resistance**, allowing for prompt initiation of an effective modified regimen without delay.*Start standard four-drug therapy and add rifabutin to replace rifampicin* - There is significant **cross-resistance** between **rifampicin** and **rifabutin**, meaning that if rifampicin is resistant, rifabutin is highly likely to be resistant as well.- Replacing rifampicin with rifabutin in the context of detected rifampicin resistance is an ineffective strategy and delays proper **MDR-TB** treatment.

Question 109: A 22-year-old woman presents with a 10-hour history of severe headache, fever, and photophobia. She has a non-blanching purpuric rash on her legs. Blood cultures are taken and intravenous ceftriaxone is commenced. Lumbar puncture shows: opening pressure 28 cmH₂O, WBC 2400/mm³ (95% neutrophils), protein 2.8 g/L, glucose 1.2 mmol/L (plasma glucose 5.8 mmol/L). Gram stain shows Gram-negative diplococci. Which additional immediate treatment should be given?

A. Intravenous dexamethasone 10 mg every 6 hours for 4 days (Correct Answer)
B. Intravenous aciclovir 10 mg/kg every 8 hours
C. Intramuscular benzylpenicillin 1.2 g stat dose
D. Intravenous vancomycin 1 g every 12 hours
E. Intravenous immunoglobulin 2 g/kg over 5 days

Explanation: ***Intravenous dexamethasone 10 mg every 6 hours for 4 days***- This patient's presentation with headache, fever, photophobia, a non-blanching purpuric rash, and CSF findings with Gram-negative diplococci is highly suggestive of **bacterial meningitis**, specifically **meningococcal meningitis**.- **Dexamethasone** is a crucial **adjunctive therapy** in bacterial meningitis, particularly when administered **before or concurrently with antibiotics**, to reduce inflammation and prevent complications such as **hearing loss** and other neurological sequelae.*Intravenous aciclovir 10 mg/kg every 8 hours*- **Aciclovir** is an **antiviral medication** primarily used for **herpes simplex encephalitis** or other severe viral infections of the CNS.- The **CSF analysis** (high white blood cells with neutrophil predominance, low glucose) and positive **Gram stain** for **Gram-negative diplococci** definitively indicate a **bacterial infection**, not a viral one.*Intramuscular benzylpenicillin 1.2 g stat dose*- **Intramuscular benzylpenicillin** is a common **pre-hospital** antibiotic given by emergency services or GPs for suspected **meningococcal disease** to initiate early treatment.- Since the patient is already receiving **intravenous ceftriaxone**, a powerful third-generation cephalosporin, an additional stat dose of penicillin is **superfluous** and not part of the standard in-hospital management.*Intravenous vancomycin 1 g every 12 hours*- **Vancomycin** is typically added to empiric meningitis regimens when there is a high suspicion of **penicillin-resistant *Streptococcus pneumoniae*** or other resistant Gram-positive organisms.- The **Gram stain result** showing **Gram-negative diplococci** (most likely *Neisseria meningitidis*) makes vancomycin unnecessary as ceftriaxone is highly effective against this pathogen.*Intravenous immunoglobulin 2 g/kg over 5 days*- **Intravenous immunoglobulin (IVIG)** is used for immune deficiencies, autoimmune conditions, or certain severe infections complicated by immune dysregulation, such as toxic shock syndrome.- There is **no established role** for **IVIG** in the immediate management of acute **bacterial meningitis** to alter its course or prevent neurological complications.

Question 110: A 40-year-old man with newly diagnosed pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 2 weeks, he develops severe pruritus without rash. His liver function tests and full blood count are normal. What is the most appropriate management?

A. Continue all medications and add oral antihistamines (Correct Answer)
B. Stop all tuberculosis medications immediately and refer to specialist
C. Replace pyrazinamide with levofloxacin
D. Replace rifampicin with rifabutin
E. Stop ethambutol and continue with three-drug therapy

Explanation: ***Continue all medications and add oral antihistamines*** - **Pruritus without rash** is a common minor side effect, particularly associated with **rifampicin**, and does not mandate treatment interruption if **liver function tests (LFTs)** are normal. - The most appropriate management is **symptomatic relief** using **antihistamines**, allowing the patient to continue the essential intensive-phase regimen. *Stop all tuberculosis medications immediately and refer to specialist* - This approach is reserved for severe reactions such as **drug-induced liver injury (DILI)**, **Stevens-Johnson Syndrome**, or a generalized **toxic rash**. - Since the patient has **normal LFTs** and no rash, stopping all four drugs unnecessarily risks **treatment failure** and the development of **drug resistance**. *Replace pyrazinamide with levofloxacin* - **Pyrazinamide** is often the culprit for arthralgia or hepatotoxicity, but it is not specifically indicated for replacement in isolated pruritis with normal LFTs. - Modifying the standard **first-line therapy** is not recommended for minor side effects that can be managed conservatively. *Replace rifampicin with rifabutin* - **Rifampicin** induces minor skin itching, but replacing it with **rifabutin** is typically reserved for patients with severe intolerance or specific **drug-drug interactions** (e.g., in HIV patients). - Both drugs are in the same class and may share side-effect profiles; switching is premature without evidence of a severe **hypersensitivity reaction**. *Stop ethambutol and continue with three-drug therapy* - **Ethambutol** is primarily associated with **optic neuritis** rather than dermatological side effects or itching. - Reducing the regimen to a **three-drug therapy** during the intensive phase without a clinical indication compromises the sterilization of the infection.

Question 111: A 31-year-old woman is diagnosed with smear-positive pulmonary tuberculosis at 14 weeks of pregnancy. Culture confirms fully drug-sensitive Mycobacterium tuberculosis. She has no other medical problems and normal baseline blood tests. What is the most appropriate initial anti-tuberculous treatment regimen for this patient?

A. Rifampicin, isoniazid, and ethambutol (omit pyrazinamide throughout pregnancy)
B. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months (Correct Answer)
C. Defer treatment until after delivery to avoid teratogenic effects
D. Rifampicin, isoniazid, and ethambutol for 9 months (extended duration due to omitting pyrazinamide)
E. Rifampicin, isoniazid, pyrazinamide, and moxifloxacin (avoid ethambutol in pregnancy)

Explanation: ***Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months***- Standard treatment for **pulmonary tuberculosis** in pregnancy is identical to that for non-pregnant adults, utilizing the full **four-drug regimen**.- First-line drugs including **isoniazid**, **rifampicin**, **pyrazinamide**, and **ethambutol** have been shown to be safe and are not associated with teratogenic effects.*Rifampicin, isoniazid, and ethambutol (omit pyrazinamide throughout pregnancy)*- Omission of **pyrazinamide** is unnecessary as current evidence supports its safety and efficacy in pregnant women.- Excluding pyrazinamide from the intensive phase usually necessitates an extension of the total treatment duration beyond **6 months**, which is less optimal.*Defer treatment until after delivery to avoid teratogenic effects*- Untreated tuberculosis poses a significant risk to both mother and fetus, increasing rates of **preterm labor**, **low birth weight**, and **maternal mortality**.- The benefits of early initiation of **anti-tuberculous therapy** far outweigh the theoretical risks of medication exposure during pregnancy.*Rifampicin, isoniazid, and ethambutol for 9 months (extended duration due to omitting pyrazinamide)*- While a 9-month regimen is an alternative when pyrazinamide cannot be used, it is not the **optimal initial regimen** since pyrazinamide is recommended for use and safe in pregnancy.- Using the standard **6-month regimen** including pyrazinamide ensures better compliance and faster sterilization of the sputum, improving treatment outcomes.*Rifampicin, isoniazid, pyrazinamide, and moxifloxacin (avoid ethambutol in pregnancy)*- **Ethambutol** is considered safe in pregnancy and is a standard component of first-line therapy to prevent drug resistance.- **Fluoroquinolones** like moxifloxacin are generally avoided in pregnancy due to concerns regarding **fetal cartilage damage** unless treating drug-resistant TB, which is not the case here.

Question 112: A 50-year-old man presents with a 6-week history of headache, low-grade fever, and gradually progressive confusion. He has type 2 diabetes mellitus treated with metformin. MRI brain shows basal meningeal enhancement and multiple small tuberculomas. Lumbar puncture shows: opening pressure 32 cmH2O, CSF protein 3.2 g/L, glucose 1.4 mmol/L (plasma 6.8 mmol/L), white cells 145/mm³ (85% lymphocytes). Ziehl-Neelsen stain is negative. CSF is sent for TB culture and GeneXpert. Which additional investigation would be most useful for rapid confirmation of tuberculous meningitis?

A. CSF adenosine deaminase level (Correct Answer)
B. Repeat lumbar puncture for larger volume CSF analysis
C. Serum interferon-gamma release assay
D. CSF lactate level
E. Tuberculin skin test

Explanation: ***CSF adenosine deaminase level***- The clinical presentation, MRI findings of **basal meningeal enhancement** and **tuberculomas**, and CSF analysis (high protein, low glucose, lymphocytosis) are highly suggestive of **tuberculous meningitis (TBM)**. - **CSF Adenosine Deaminase (ADA)** is a rapid, highly sensitive, and specific biochemical marker for TBM, produced by activated T-lymphocytes, and can provide quick confirmation when conventional methods like **Ziehl-Neelsen stain** and **GeneXpert** may be negative or delayed.*Repeat lumbar puncture for larger volume CSF analysis*- While a larger volume of CSF can improve the yield for **acid-fast bacilli (AFB) smear** and culture, it is not a *rapid* diagnostic method as cultures take weeks to grow.- Given the **elevated intracranial pressure (32 cmH2O)** and the presence of **tuberculomas**, a repeat lumbar puncture carries inherent risks and would not provide immediate diagnostic confirmation.*Serum interferon-gamma release assay*- **Interferon-gamma release assays (IGRAs)**, such as QuantiFERON-TB Gold, detect a prior immune response to *Mycobacterium tuberculosis* but cannot distinguish between **latent TB infection** and **active disease**.- A positive IGRA indicates exposure to TB but does not confirm **tuberculous meningitis** as the cause of the patient's current neurological symptoms.*CSF lactate level*- **CSF lactate** is a non-specific marker of anaerobic metabolism that can be elevated in various forms of meningitis, including bacterial, fungal, and sometimes TBM.- It lacks the specificity to *rapidly confirm* **tuberculous meningitis** over other infectious or inflammatory causes of meningeal enhancement in this clinical context.*Tuberculin skin test*- The **tuberculin skin test (TST)** or **Mantoux test** has limited sensitivity in acute TBM, with false negatives occurring in up to 50% of active cases, particularly in patients with **anergy** or immunosuppression.- It is also a delayed test, requiring 48-72 hours for interpretation, thus not qualifying as a **rapid investigation** for urgent diagnosis.

Question 113: A 36-year-old man from Somalia with newly diagnosed HIV infection (CD4 count 110 cells/mm³, viral load 145,000 copies/mL) is diagnosed with disseminated tuberculosis affecting lungs and lymph nodes. Sputum culture confirms fully drug-sensitive Mycobacterium tuberculosis. He is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. When is the most appropriate time to initiate antiretroviral therapy?

A. Immediately, concurrently with anti-tuberculous therapy
B. After 2 weeks of anti-tuberculous therapy (Correct Answer)
C. After 2 months of anti-tuberculous therapy
D. After completion of the initial intensive phase and continuation phase of TB treatment
E. Wait until TB treatment is completed before starting antiretroviral therapy

Explanation: ***After 2 weeks of anti-tuberculous therapy*** - In patients with **CD4 counts <50 cells/mm³**, ART should be started within 2 weeks; for those with **CD4 <200 cells/mm³**, evidence supports early initiation (within 2-8 weeks) to reduce **mortality**. - Given the patient's low CD4 count (110 cells/mm³), early initiation balances the prevention of further **opportunistic infections** against the risk of **Immune Reconstitution Inflammatory Syndrome (IRIS)**. *Immediately, concurrently with anti-tuberculous therapy* - Starting both regimens on the same day is avoided to establish tolerance to **anti-tuberculous drugs** and clarify the cause of any potential **adverse drug reactions**. - Immediate start significantly increases the **pill burden** and the risk of severe **overlap toxicities** before the patient is stable. *After 2 months of anti-tuberculous therapy* - Delaying ART until the end of the **intensive phase** (2 months) is only considered in patients with higher CD4 counts (>500 cells/mm³) to avoid **drug-drug interactions**. - In advanced HIV (CD4 110), waiting 8 weeks significantly increases the risk of **AIDS-defining illnesses** and death compared to earlier initiation. *After completion of the initial intensive phase and continuation phase of TB treatment* - This approach is incorrect as it leaves the patient **severely immunosuppressed** for the entire 6-month duration of TB therapy. - Waiting this long for a patient with a **viral load of 145,000** and low CD4 count would lead to unacceptably high **mortality rates**. *Wait until TB treatment is completed before starting antiretroviral therapy* - Delaying ART until TB is fully cured is contraindicated in almost all **HIV/TB co-infection** cases regardless of CD4 count. - Long-term outcomes are significantly worse when **HIV replication** is left unchecked for the duration of a 6-9 month TB treatment course.

Question 114: A 58-year-old man with a history of splenectomy 10 years ago following trauma presents with a 24-hour history of fever, headache, and confusion. On examination, he has a GCS of 13, temperature 38.9°C, and neck stiffness. CT head shows no contraindications to lumbar puncture. Lumbar puncture reveals: protein 1.8 g/L, glucose 1.6 mmol/L (plasma 5.4 mmol/L), white cells 2400/mm³ (88% neutrophils). Gram stain shows Gram-positive diplococci. Which additional antimicrobial should be added to standard empirical bacterial meningitis therapy for this patient?

A. Vancomycin (Correct Answer)
B. Ampicillin
C. Gentamicin
D. Metronidazole
E. Azithromycin

Explanation: ***Vancomycin***- The patient's history of **splenectomy** places him at high risk for overwhelming post-splenectomy infection (OPSI), particularly from **encapsulated bacteria** like **Streptococcus pneumoniae**. The **Gram-positive diplococci** on Gram stain strongly suggest this pathogen.- **Vancomycin** is crucial to add to standard empirical meningitis therapy (typically a third-generation cephalosporin like ceftriaxone) because of the high prevalence of **penicillin-resistant Streptococcus pneumoniae**, especially in high-risk patients such as those who are asplenic.*Ampicillin*- This antibiotic is primarily added to empirical meningitis regimens to cover **Listeria monocytogenes**, which is a concern in specific populations like those over 50 years old, pregnant, or immunocompromised.- However, **Listeria** typically appears as **Gram-positive rods** or coccobacilli, which does not match the **Gram-positive diplococci** found in this patient's CSF, making it a less likely pathogen here.*Gentamicin*- **Gentamicin** is an **aminoglycoside antibiotic** primarily used for Gram-negative bacterial infections or for synergistic treatment in some Gram-positive infections like endocarditis.- It has **poor penetration into the central nervous system (CNS)** and is therefore not indicated as an additional agent for empirical treatment of bacterial meningitis, especially for suspected **Streptococcus pneumoniae**.*Metronidazole*- **Metronidazole** is highly effective against **anaerobic bacteria** and some parasites, and it is commonly used for conditions like brain abscesses, not for acute bacterial meningitis from typical pathogens.- It has **no significant activity** against the common bacterial causes of community-acquired meningitis, such as **Streptococcus pneumoniae**.*Azithromycin*- **Azithromycin** is a **macrolide antibiotic** typically used for atypical respiratory infections, certain sexually transmitted diseases, or other specific bacterial infections.- It does not achieve sufficient **cerebrospinal fluid (CSF) concentrations** and lacks reliable activity against **Streptococcus pneumoniae**, particularly against resistant strains, making it unsuitable for treating acute bacterial meningitis.

Question 115: A 21-year-old university student presents with a 12-hour history of severe headache, fever, neck stiffness, and photophobia. Blood pressure is 118/75 mmHg, heart rate 102/min, temperature 38.7°C, GCS 15, no focal neurological signs, no rash. CT head is normal. Lumbar puncture shows: opening pressure 24 cmH2O, clear CSF, protein 0.65 g/L, glucose 3.2 mmol/L (plasma 5.8 mmol/L), white cells 380/mm³ (75% lymphocytes). Gram stain is negative. What is the most likely causative organism?

A. Enterovirus (Correct Answer)
B. Streptococcus pneumoniae
C. Neisseria meningitidis
D. Listeria monocytogenes
E. Herpes simplex virus

Explanation: ***Enterovirus*** - The CSF profile showing **lymphocytic pleocytosis** (75% lymphocytes), **normal CSF glucose** (ratio 0.55, typically > 0.5), and mildly elevated protein is highly characteristic of **viral (aseptic) meningitis**. - **Enteroviruses** are the most common cause of viral meningitis in young adults and typically present with acute meningeal symptoms without focal neurological deficits or rash, matching this patient's presentation. *Streptococcus pneumoniae* - **Bacterial meningitis**, including that caused by *S. pneumoniae*, typically presents with **neutrophilic pleocytosis** (> 80% neutrophils), significantly **low CSF glucose** (often < 40% of plasma glucose), and markedly elevated protein. - The presence of predominant lymphocytes and normal glucose in the CSF strongly argues against *S. pneumoniae* as the causative agent here. *Neisseria meningitidis* - While common in university students, *N. meningitidis* usually causes **bacterial meningitis** with a more fulminant course and frequently presents with a **petechial rash**, which is absent in this patient. - CSF findings would typically include a high white cell count with a significant **neutrophil predominance** and **low CSF glucose**, unlike the lymphocytic picture and normal glucose seen. *Listeria monocytogenes* - *Listeria monocytogenes* meningitis is primarily seen in specific vulnerable populations: **neonates**, **elderly** (> 60 years), pregnant women, and **immunocompromised** individuals. This 21-year-old healthy student does not fit these risk factors. - Although Listeria can sometimes cause a mixed or even lymphocytic CSF pleocytosis, the patient's demographic and clear presentation for typical viral meningitis make it less likely. *Herpes simplex virus* - While **HSV-2** can cause recurrent lymphocytic meningitis, **HSV-1** typically causes **encephalitis**, which is characterized by altered mental status, focal neurological deficits, or seizures, none of which are present in this patient (GCS 15, no focal signs). - The clinical picture of classic meningeal irritation without encephalopathy, coupled with a benign GCS and clear CSF, makes an enterovirus more probable than HSV.

Question 116: A 34-year-old woman with pulmonary tuberculosis is on treatment with rifampicin, isoniazid, pyrazinamide, and ethambutol. She develops jaundice 4 weeks into treatment. Blood tests show: bilirubin 85 μmol/L, ALT 420 U/L, ALP 180 U/L, INR 1.3. She is clinically well apart from jaundice. Viral hepatitis screen is negative. Which anti-tuberculous medication should be reintroduced first after liver function tests improve?

A. Ethambutol (Correct Answer)
B. Rifampicin
C. Isoniazid
D. Pyrazinamide
E. All four drugs should be reintroduced simultaneously at reduced doses

Explanation: ***Ethambutol*** - **Ethambutol** is not considered hepatotoxic and is often continued or the first to be reintroduced because it does not contribute to **drug-induced liver injury (DILI)**. - According to standard guidelines, once **transaminases** fall below 2 times the upper limit of normal, drugs are reintroduced sequentially starting with the agent least likely to cause further liver damage. *Rifampicin* - **Rifampicin** is typically reintroduced second (after ethambutol) because it is the most critical bactericidal component of the regimen despite being potentially **hepatotoxic**. - It is less likely to cause a significant rise in **ALT** compared to isoniazid or pyrazinamide, although it may cause **transient cholestasis**. *Isoniazid* - **Isoniazid** is usually reintroduced third, as it is a common cause of **idiosyncratic hepatotoxicity** and requires careful monitoring of liver enzymes upon restart. - If a reaction occurs during its reintroduction, it identifies isoniazid as the **culprit drug**, requiring a modification of the long-term treatment plan. *Pyrazinamide* - **Pyrazinamide** is the most **hepatotoxic** of the first-line drugs and is therefore reintroduced last or omitted entirely if the previous drugs were tolerated. - Due to its high risk of causing severe **liver injury**, many clinicians avoid reintroducing it if the initial hepatitis was clinically significant (jaundice or high ALT). *All four drugs should be reintroduced simultaneously at reduced doses* - Simultaneous reintroduction is contraindicated because it prevents the identification of the specific **offending agent** that caused the hepatitis. - A **sequential reintroduction** strategy with a 3–7 day gap between drugs is the standard of care to ensure patient safety and **regimen tolerability**.

Question 117: What is the primary reason for adding pyridoxine (vitamin B6) supplementation to tuberculosis treatment regimens containing isoniazid?

A. To prevent peripheral neuropathy caused by isoniazid (Correct Answer)
B. To enhance the bactericidal activity of isoniazid
C. To reduce the risk of hepatotoxicity from rifampicin
D. To prevent optic neuritis caused by ethambutol
E. To improve absorption of anti-tuberculous medications

Explanation: ***To prevent peripheral neuropathy caused by isoniazid***- **Isoniazid** interferes with the metabolism of **pyridoxine** (vitamin B6) by inhibiting its conversion to the active form, **pyridoxal phosphate**, which is crucial for nerve function.- This interference leads to a deficiency, causing **peripheral neuropathy**, and pyridoxine supplementation is essential to prevent this dose-limiting neurotoxicity.*To enhance the bactericidal activity of isoniazid*- **Pyridoxine** supplementation is solely for mitigating **isoniazid-induced toxicity** and does not directly enhance the **bactericidal activity** or efficacy of the drug.- The mechanism of action of **isoniazid** against *Mycobacterium tuberculosis* is independent of vitamin B6 levels.*To reduce the risk of hepatotoxicity from rifampicin*- **Hepatotoxicity** is a significant side effect of both **rifampicin** and isoniazid, but **pyridoxine** does not offer protection against liver damage.- Management of drug-induced hepatotoxicity primarily involves monitoring liver enzymes and adjusting drug regimens, not vitamin B6 supplementation.*To prevent optic neuritis caused by ethambutol*- **Optic neuritis** is a well-known adverse effect specifically associated with **ethambutol** treatment, causing visual disturbances.- **Pyridoxine** has no known role in preventing or treating **ethambutol-induced optic neuropathy**.*To improve absorption of anti-tuberculous medications*- **Pyridoxine** supplementation does not influence the **absorption**, **bioavailability**, or **pharmacokinetics** of any anti-tuberculosis medications.- Its role is specific to counteracting the **neurotoxic side effect** of isoniazid, not to improve drug delivery.

Question 118: A 45-year-old man from Pakistan completes 6 months of treatment for fully drug-sensitive pulmonary tuberculosis with the standard four-drug regimen (2 months of rifampicin, isoniazid, pyrazinamide, and ethambutol, followed by 4 months of rifampicin and isoniazid). He was adherent to therapy throughout. His chest X-ray at completion shows improvement with some residual fibrotic changes but no cavitation. Sputum smears and cultures at treatment completion are negative. What is the most appropriate ongoing management?

A. Continue rifampicin and isoniazid for a further 3 months
B. Clinical and radiological review at 12 months post-treatment (Correct Answer)
C. Monthly sputum cultures for 6 months
D. Start prophylactic isoniazid for 6 months
E. No further follow-up required

Explanation: ***Clinical and radiological review at 12 months post-treatment***- For patients completing a standard 6-month regimen for **drug-sensitive tuberculosis** with negative end-of-treatment cultures, guidelines recommend a follow-up review at **12 months** to monitor for relapse.- This follow-up ensures the identification of the **2-3% of patients** who may experience recurrence despite successful initial therapy and documented adherence.*Continue rifampicin and isoniazid for a further 3 months*- Extending treatment to **9 months** is generally reserved for patients with **cavitary disease** and positive cultures at 2 months, which is not the case here.- The patient has already completed the standard **curative phase** for fully drug-sensitive TB with favorable clinical and microbiological responses.*Monthly sputum cultures for 6 months*- Routine **microbiological monitoring** after the completion of treatment is not indicated if the end-of-treatment sputum smears and cultures are negative.- Serial cultures offer low diagnostic yield in an **asymptomatic patient** with negative results at the time of discharge from care.*Start prophylactic isoniazid for 6 months*- **Isoniazid monotherapy** is used for latent TB infection, not for patients who have just successfully completed a full **combination therapy** for active disease.- There is no clinical benefit to adding **prophylaxis** after the intensive and continuation phases have sterilized the active lesions.*No further follow-up required*- While the response is excellent, complete discharge without any follow-up is inappropriate due to the small but significant risk of **relapse** within the first year.- Patients must still be educated on **red-flag symptoms** like fever or weight loss and undergo a scheduled final assessment to confirm sustained cure.

Question 119: A 28-year-old woman presents to the emergency department with an 8-hour history of severe headache, fever, photophobia, and vomiting. She has a non-blanching purpuric rash on her legs. Glasgow Coma Scale is 14 (E4 V4 M6). Blood pressure is 95/60 mmHg, heart rate 118/min, temperature 39.1°C. What is the most appropriate immediate management?

A. Immediate CT head followed by lumbar puncture and antibiotics
B. Blood cultures, then immediate lumbar puncture, followed by antibiotics
C. Immediate IV ceftriaxone and supportive care without lumbar puncture (Correct Answer)
D. Blood cultures, IV ceftriaxone, then lumbar puncture after CT head
E. IV benzylpenicillin, blood cultures, and immediate lumbar puncture

Explanation: ***Immediate IV ceftriaxone and supportive care without lumbar puncture***- The presence of **fever**, **meningeal signs** (headache, photophobia, vomiting), **reduced GCS (14)**, and a **non-blanching purpuric rash** in a hemodynamically unstable patient (BP 95/60, HR 118) is highly indicative of **meningococcal septicaemia**.- In such critically ill patients with suspected **meningococcal disease**, immediate administration of **intravenous broad-spectrum antibiotics** (like ceftriaxone) is life-saving, and **lumbar puncture is contraindicated** or significantly delayed due to the risk of herniation and treatment delay.*Immediate CT head followed by lumbar puncture and antibiotics*- Performing an **immediate CT head** unnecessarily delays the administration of crucial, life-saving **antibiotics** in a patient with clinical signs of **sepsis** and suspected bacterial meningitis.- **Lumbar puncture** should not be performed immediately in a patient with **reduced GCS** and signs of shock, as it poses risks and delays the primary treatment of antibiotics.*Blood cultures, then immediate lumbar puncture, followed by antibiotics*- While **blood cultures** are important for diagnosis, they should not delay the **immediate administration of empirical intravenous antibiotics** in a patient with suspected **meningococcal sepsis**.- **Immediate lumbar puncture** is contraindicated and dangerous in this patient due to **reduced GCS (14)** and signs of **shock**, increasing the risk of cerebral herniation.*Blood cultures, IV ceftriaxone, then lumbar puncture after CT head*- Although giving **IV ceftriaxone** is correct, delaying it for **blood cultures** is less ideal than immediate administration, and mandating a **CT head** before **lumbar puncture** still introduces dangerous delays in antibiotic initiation for severe sepsis.- In cases of severe **meningococcal septicaemia** with instability, diagnosis is primarily clinical and confirmed by **blood cultures** and **PCR**, often precluding the need for a lumbar puncture.*IV benzylpenicillin, blood cultures, and immediate lumbar puncture*- While **benzylpenicillin** is an option, **ceftriaxone** is generally the preferred first-line **empiric antibiotic** for suspected bacterial meningitis in a hospital setting due to its broader spectrum and excellent CNS penetration.- **Immediate lumbar puncture** is unequivocally contraindicated in this patient due to **hemodynamic compromise** and **reduced GCS**, as it can exacerbate clinical instability and delay critical treatment.

Question 120: A 52-year-old man is diagnosed with smear-positive pulmonary tuberculosis. Molecular testing (GeneXpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. Culture and full drug susceptibility testing are pending. He has no history of previous TB treatment and has not lived in a high MDR-TB prevalence area. What is the most appropriate initial management while awaiting full susceptibility results?

A. Start isoniazid, pyrazinamide, ethambutol, and moxifloxacin (Correct Answer)
B. Start standard four-drug therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol
C. Wait for full culture and susceptibility results before starting treatment
D. Start isoniazid, rifampicin, pyrazinamide, ethambutol, and moxifloxacin
E. Start bedaquiline, linezolid, and cycloserine

Explanation: ***Start isoniazid, pyrazinamide, ethambutol, and moxifloxacin*** - The detection of **rifampicin resistance** by GeneXpert is a critical finding, strongly indicating **Multidrug-Resistant TB (MDR-TB)**; thus, treatment must be modified immediately to include a **fluoroquinolone** like moxifloxacin. - **Isoniazid** is included empirically because some rifampicin-resistant strains remain sensitive to it, providing a robust initial regimen and contributing to preventing further drug resistance. *Start standard four-drug therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol* - Continuing **rifampicin** when molecular testing has confirmed resistance is inappropriate as it renders the drug ineffective, leading to **treatment failure** and sustained infectivity. - Standard therapy is inadequate for **MDR-TB** and would permit the development of additional resistance to the remaining first-line drugs. *Wait for full culture and susceptibility results before starting treatment* - The patient is **smear-positive**, indicating high infectiousness, and delaying treatment poses a significant **public health risk** for community transmission. - Full culture and susceptibility results can take several weeks, and immediate empirical treatment based on rapid molecular results is vital to prevent clinical deterioration and reduce infectivity. *Start isoniazid, rifampicin, pyrazinamide, ethambutol, and moxifloxacin* - Including **rifampicin** in the regimen when **rifampicin resistance** has been detected by **GeneXpert MTB/RIF** is clinically unsound and offers no therapeutic benefit, while potentially increasing drug toxicity. - Effective management for suspected MDR-TB relies on assembling at least four effective drugs to which the strain is likely **susceptible**, not retaining ineffective agents. *Start bedaquiline, linezolid, and cycloserine* - Initiating newer or potent second-line agents like **bedaquiline** is typically reserved for confirmed MDR-TB or extensively drug-resistant (XDR-TB), often following a **multidisciplinary team (MDT) review**. - These drugs generally carry higher **toxicity** and costs, making them secondary options to an established empirical MDR regimen while awaiting comprehensive phenotypic results.

Question 121: A 65-year-old man with newly diagnosed pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. He takes warfarin for atrial fibrillation. His baseline INR is 2.4 (therapeutic range 2.0-3.0). Three days after starting anti-tuberculous therapy, his INR is checked and found to be 1.3. What is the most appropriate management of his anticoagulation?

A. Increase warfarin dose and monitor INR closely (Correct Answer)
B. Switch from warfarin to dabigatran
C. Stop rifampicin and use a three-drug regimen
D. Switch from warfarin to low molecular weight heparin
E. Continue current warfarin dose and recheck INR in one week

Explanation: ***Increase warfarin dose and monitor INR closely*** - **Rifampicin** is a potent inducer of **cytochrome P450 enzymes** (specifically **CYP2C9**), which increases the metabolism of warfarin and leads to a subtherapeutic **INR**. - The correct approach is to titrate the **warfarin dose upward** (often by 50-100%) and perform frequent **INR monitoring** to mitigate the increased risk of thromboembolism from atrial fibrillation. *Switch from warfarin to dabigatran* - **Dabigatran** is a substrate of **P-glycoprotein**, which is also induced by **rifampicin**, leading to significantly reduced levels of the anticoagulant. - Switching to **DOACs** is generally avoided during rifampicin therapy as their concentrations become unpredictable and often inadequate. *Stop rifampicin and use a three-drug regimen* - **Rifampicin** is the cornerstone of **short-course chemotherapy** for tuberculosis; omitting it reduces treatment efficacy and increases the required duration from 6 to 18-24 months. - Clinical guidelines prioritize managing drug interactions over sacrificing the most effective **anti-TB medications** needed to prevent resistance. *Switch from warfarin to low molecular weight heparin* - While **LMWH** does not interact with P450 enzymes, it requires **daily subcutaneous injections**, which is impractical for long-term use during a 6-month TB treatment course. - It is generally reserved for short-term bridging or acute situations rather than chronic management of **atrial fibrillation** in stable patients. *Continue current warfarin dose and recheck INR in one week* - Continuing the same dose is dangerous as the current **INR of 1.3** is significantly below the therapeutic range, placing the patient at immediate risk of **ischemic stroke**. - Waiting one week to recheck is inappropriate because the inducing effect of **rifampicin** begins within days and requires prompt adjustment to achieve a stable anticoagulation state.

Question 122: A 33-year-old woman from Romania presents with a 3-month history of progressive headache, confusion, and personality change. She has HIV infection with a CD4 count of 85 cells/mm³ and is not on antiretroviral therapy. MRI brain shows multiple ring-enhancing lesions with surrounding oedema in the basal ganglia and cerebral cortex. Lumbar puncture shows: opening pressure 19 cmH2O, protein 0.8 g/L, glucose 3.1 mmol/L (plasma 5.4 mmol/L), white cells 45/mm³ (80% lymphocytes). CSF cryptococcal antigen is negative. What is the most appropriate initial empirical antimicrobial therapy?

A. Rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone
B. Ceftriaxone and aciclovir
C. Pyrimethamine, sulfadiazine, and folinic acid (Correct Answer)
D. Liposomal amphotericin B and flucytosine
E. Co-trimoxazole and prednisolone

Explanation: ***Pyrimethamine, sulfadiazine, and folinic acid*** - In a patient with advanced **HIV (CD4 <100)** presenting with a subacute onset of neurological symptoms and **multiple ring-enhancing lesions** in the basal ganglia, **Cerebral Toxoplasmosis** is the most likely diagnosis. - This combination is the gold standard empirical therapy for active toxoplasmosis, with **folinic acid** added to prevent bone marrow suppression caused by **pyrimethamine**. *Rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone* - This is the standard treatment for **Tuberculous meningitis**. While tuberculomas can cause ring-enhancing lesions, the CSF glucose is typically much lower, and the basal ganglia involvement is more characteristic of Toxoplasmosis in this CD4 count. - The progressive headache, confusion, and personality change over 3 months are less specific for acute TB meningitis, and Toxoplasmosis is statistically more common in this specific clinical and immunological setting. *Ceftriaxone and aciclovir* - This regimen targets **bacterial meningitis** (ceftriaxone) and **herpes simplex encephalitis** (aciclovir). - The subacute presentation, **multiple ring-enhancing lesions**, and lymphocytic pleocytosis with only mildly decreased CSF glucose are not typical for acute bacterial meningitis or HSE, which often has temporal lobe involvement. *Liposomal amphotericin B and flucytosine* - This is the induction treatment for **Cryptococcal meningitis**. - The **negative CSF cryptococcal antigen** explicitly rules out cryptococcal infection as the cause of the patient's symptoms. *Co-trimoxazole and prednisolone* - **Co-trimoxazole** can be used as an alternative or for prophylaxis of toxoplasmosis, but **pyrimethamine and sulfadiazine** are generally considered the first-line empirical therapy for active CNS toxoplasmosis due to superior efficacy. - Prednisolone may be considered for significant mass effect, but it is not the primary antimicrobial agent, and **co-trimoxazole** is not the preferred initial empirical treatment over the gold standard regimen.

Question 123: According to UK notification requirements, which of the following conditions must be notified to the local health protection team within 24 hours of clinical suspicion, before laboratory confirmation?

A. Pulmonary tuberculosis
B. Meningococcal septicaemia (Correct Answer)
C. Latent tuberculosis infection
D. Aseptic meningitis
E. Extrapulmonary tuberculosis without central nervous system involvement

Explanation: ***Meningococcal septicaemia***- Under the **Health Protection Regulations 2010**, meningococcal disease must be notified as soon as it is clinically suspected to allow for immediate **chemoprophylaxis** of close contacts.- It is classified as an **urgent notification** because of its high mortality rate and potential for rapid spread, requiring notification often by telephone within **24 hours**.*Pulmonary tuberculosis*- While a **notifiable disease**, it generally requires notification within **three working days** after a diagnosis is confirmed or strongly suspected.- It does not carry the same level of immediate public health emergency as **invasive meningococcal disease** and does not require a 24-hour notification on raw clinical suspicion alone.*Latent tuberculosis infection*- This condition represents an **asymptomatic state** where the bacteria are persistent but not causing active disease; it is **not a notifiable condition** in the UK.- Reporting is restricted to **active tuberculosis** cases that pose a current risk of transmission to others.*Aseptic meningitis*- Typical **viral (aseptic) meningitis** is not specifically listed as a notifiable disease unless it is caused by a specific pathogen that is itself notifiable, such as **mumps** or **measles**.- Only **acute meningitis** (typically bacterial) is listed for urgent notification due to the high risk of clusters and severe outcomes.*Extrapulmonary tuberculosis without central nervous system involvement*- Similar to pulmonary TB, this is notifiable but falls under the standard **three-day reporting** period rather than the urgent clinical suspicion category.- Notification usually awaits more definitive **diagnostic investigations** rather than initial clinical suspicion at the point of presentation.

Question 124: A 42-year-old man with pulmonary tuberculosis has been on standard four-drug therapy for 8 weeks. His sputum culture from diagnosis has now grown Mycobacterium tuberculosis fully sensitive to all first-line agents. Sputum smears at 8 weeks remain positive. He reports good adherence and directly observed therapy confirms this. Liver function tests and renal function are normal. What is the most appropriate next step in management?

A. Continue current therapy and repeat sputum smears at 12 weeks (Correct Answer)
B. Add a fluoroquinolone to the current regimen
C. Switch to second-line anti-tuberculous therapy
D. Increase the dose of rifampicin
E. Perform therapeutic drug monitoring

Explanation: ***Continue current therapy and repeat sputum smears at 12 weeks*** - Sputum smear conversion is expected by **8 weeks (2 months)** in most patients with drug-sensitive TB, but a delay is not uncommon and does not automatically indicate treatment failure or drug resistance, especially with confirmed **adherence**. - Standard guidelines recommend continuing the current regimen and reassessing sputum microscopy at the **end of 3 months (12 weeks)** before considering further investigations or changes to therapy. *Add a fluoroquinolone to the current regimen* - Adding a single new drug to a failing or slowly responding regimen in active TB can rapidly lead to the development of **acquired drug resistance** to the newly added drug. - Since the organism is confirmed **fully sensitive** to first-line agents, there is no clinical indication for the empirical addition of a second-line drug at this stage. *Switch to second-line anti-tuberculous therapy* - Switching to **second-line anti-tuberculous therapy** is reserved for confirmed cases of **multidrug-resistant TB (MDR-TB)**, extensively drug-resistant TB (XDR-TB), or severe intolerance to first-line agents. - In this scenario, the *M. tuberculosis* isolate is **fully sensitive** to all first-line agents, and there is no evidence of intolerance, making a premature switch inappropriate. *Increase the dose of rifampicin* - Increasing the dose of **rifampicin** beyond standard weight-based recommendations is generally not advised unless there are specific pharmacokinetic reasons, such as confirmed **malabsorption** or drug-drug interactions. - Empirically increasing the dose without evidence of sub-therapeutic levels or malabsorption could increase the risk of dose-dependent adverse effects, particularly **hepatotoxicity**. *Perform therapeutic drug monitoring* - **Therapeutic drug monitoring (TDM)** is typically considered in patients with underlying comorbidities that affect drug pharmacokinetics, such as **HIV co-infection**, diabetes, renal/hepatic impairment, or suspected malabsorption. - Given that the patient has **normal liver and renal function** and confirmed **good adherence** through directly observed therapy (DOT), TDM is not the immediate priority over continued clinical and microbiological observation.

Question 125: A 7-year-old girl presents with a 2-month history of low-grade fever, weight loss, and progressive drowsiness. Her parents recently immigrated from India. On examination, she has neck stiffness and bilateral papilloedema. Lumbar puncture shows: opening pressure 28 cmH2O, CSF protein 2.4 g/L, glucose 1.8 mmol/L (plasma glucose 5.2 mmol/L), white cells 180/mm³ (90% lymphocytes). Ziehl-Neelsen stain is negative. Which organism is most likely to be identified on CSF culture?

A. Mycobacterium tuberculosis (Correct Answer)
B. Streptococcus pneumoniae
C. Neisseria meningitidis
D. Listeria monocytogenes
E. Cryptococcus neoformans

Explanation: ***Mycobacterium tuberculosis***- The subacute presentation of **low-grade fever**, **weight loss**, and **progressive drowsiness** over 2 months, especially in a child whose parents recently immigrated from **India** (a TB-endemic area), is highly characteristic of **Tuberculous Meningitis (TBM)**.- The CSF findings of **lymphocytic pleocytosis** (90% lymphocytes), **very high protein** (2.4 g/L), **very low glucose** (1.8 mmol/L, with a plasma glucose of 5.2 mmol/L), and **raised opening pressure** (28 cmH2O) with **papilloedema** are the hallmarks of TBM, even if the Ziehl-Neelsen stain is negative due to low bacillary load.*Streptococcus pneumoniae*- This typically presents with an **acute onset** of symptoms (hours to days), including high fever, severe headache, and rapid deterioration, not a 2-month history.- CSF analysis would predominantly show a **neutrophilic pleocytosis** (high percentage of neutrophils) rather than the lymphocytic predominance seen here.*Neisseria meningitidis*- This also causes an **acute bacterial meningitis**, often associated with a characteristic **non-blanching purpuric rash** and rapid progression to sepsis.- Similar to S. pneumoniae, its CSF profile would typically demonstrate a prominent **neutrophilic pleocytosis**.*Listeria monocytogenes*- This organism commonly affects **neonates**, the **elderly**, or **immunocompromised** individuals; it's less common as a primary cause in an immunocompetent 7-year-old with this specific chronic presentation.- While it can cause a mixed or lymphocytic CSF picture, the strong epidemiological link to a TB-endemic area and the chronic systemic symptoms make **tuberculosis** a much more likely diagnosis.*Cryptococcus neoformans*- This is primarily an opportunistic pathogen, most commonly causing meningitis in **immunocompromised** patients, particularly those with HIV/AIDS.- Although it can present subacutely with lymphocytic pleocytosis and low glucose, the absence of overt immunocompromise and the strong epidemiological history point away from cryptococcal infection in favor of **TBM**.

Question 126: A 49-year-old man presents with a 7-week history of cough, weight loss, and night sweats. He is a recent migrant from Pakistan. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Sputum microscopy shows acid-fast bacilli. HIV test is negative. He is commenced on rifampicin 600 mg, isoniazid 300 mg, pyrazinamide 2 g, and ethambutol 1200 mg daily. Three days later he develops severe nausea, vomiting, right upper quadrant pain, and jaundice. Blood tests show: bilirubin 145 μmol/L, ALT 856 U/L, ALP 198 U/L, albumin 38 g/L. Which is the most appropriate immediate management?

A. Stop all anti-tuberculous medications and monitor liver function daily until ALT <100 U/L, then reintroduce drugs sequentially starting with rifampicin (Correct Answer)
B. Stop pyrazinamide only, continue other three drugs, and monitor liver function
C. Stop rifampicin, isoniazid, and pyrazinamide; continue ethambutol; start streptomycin and levofloxacin
D. Continue all four drugs but reduce doses by 50% and add ursodeoxycholic acid for hepatoprotection
E. Stop all anti-tuberculous medications; start steroids to treat drug-induced hepatitis

Explanation: ***Stop all anti-tuberculous medications and monitor liver function daily until ALT <100 U/L, then reintroduce drugs sequentially starting with rifampicin*** - The patient presents with severe **drug-induced liver injury (DILI)**, indicated by **jaundice** (bilirubin 145 μmol/L) and a significantly elevated **ALT (856 U/L)**, necessitating the immediate cessation of all potentially hepatotoxic anti-tuberculous drugs. - The standard management for severe DILI involves withdrawing all suspected drugs and monitoring liver function until it significantly improves, followed by **sequential reintroduction** of drugs, often starting with **rifampicin** under close observation. *Stop pyrazinamide only, continue other three drugs, and monitor liver function* - While **pyrazinamide** is highly hepatotoxic, **isoniazid** and **rifampicin** are also significant contributors to DILI, and continuing them in the presence of acute liver injury carries a high risk of **fulminant hepatic failure**. - When severe, symptomatic DILI occurs, the general guideline is to stop all potentially hepatotoxic drugs to prevent further liver damage. *Stop rifampicin, isoniazid, and pyrazinamide; continue ethambutol; start streptomycin and levofloxacin* - This approach involves discontinuing the main hepatotoxic drugs but immediately introducing a more complex alternative regimen with **streptomycin** and **levofloxacin**. - The immediate priority in severe DILI is to remove all offending agents and allow the liver to recover, rather than immediately initiating a new multi-drug regimen, which should be done once liver function stabilizes. *Continue all four drugs but reduce doses by 50% and add ursodeoxycholic acid for hepatoprotection* - Continuing all four anti-tuberculous drugs, even at reduced doses, during acute severe DILI is highly dangerous and risks progression to **acute liver failure**. - Reducing doses increases the risk of developing **drug-resistant tuberculosis** due to subtherapeutic drug levels, and **ursodeoxycholic acid** lacks sufficient evidence to protect against severe DILI from TB drugs. *Stop all anti-tuberculous medications; start steroids to treat drug-induced hepatitis* - While steroids might be considered in very specific, severe autoimmune-like DILI cases, they are not standard treatment for typical **drug-induced hepatitis** and can be detrimental. - Administering **corticosteroids** in a patient with active **pulmonary tuberculosis** can lead to immunosuppression, potentially worsening the underlying infection or causing dissemination.

Question 127: Which one of the following clinical features in a patient with bacterial meningitis carries the highest risk of poor neurological outcome?

A. Delay in antibiotic administration of more than 3 hours after presentation
B. Presence of focal neurological signs at presentation
C. Glasgow Coma Scale score of less than 11 on admission (Correct Answer)
D. Seizures occurring within the first 24 hours of presentation
E. CSF white cell count of less than 1000 cells/μL

Explanation: ***Glasgow Coma Scale score of less than 11 on admission***- A **low admission GCS** is the single most powerful independent predictor of **mortality** and long-term **neurological sequelae** in bacterial meningitis.- It reflects severe cerebral dysfunction from **cerebral edema**, raised intracranial pressure, or encephalitis, with mortality rates reaching up to 40%.*Delay in antibiotic administration of more than 3 hours after presentation*- While **early antibiotics** are critical, a delay usually becomes a significant predictor of severe poor outcome when it exceeds **6 hours**.- Although detrimental, it is considered a secondary risk factor compared to the baseline **neurological status** at presentation.*Presence of focal neurological signs at presentation*- These signs indicate localized brain damage such as **arteritis**, **infarction**, or abscess formation but are less sensitive predictors of overall outcome than global consciousness.- Focal deficits are often associated with specific complications rather than being the primary driver of **overall mortality**.*Seizures occurring within the first 24 hours of presentation*- Early **seizures** are common in the acute phase of meningitis but often resolve once the **underlying infection** is treated.- While they represent cortical irritation, they do not correlate as strongly with permanent **neurological disability** as a low GCS score.*CSF white cell count of less than 1000 cells/μL*- A **low CSF pleocytosis** is a poor prognostic sign, particularly in **Streptococcus pneumoniae** infections, as it suggests an overwhelmed immune response.- Despite being a marker of severity, it is less reliable than the **clinical GCS score** for assessing the immediate risk of a poor neurological outcome.

Question 128: A 62-year-old man presents with a 10-day history of fever, headache, photophobia, and neck stiffness. Lumbar puncture shows: opening pressure 28 cmH₂O, CSF protein 3.5 g/L, glucose 1.8 mmol/L (plasma glucose 6.2 mmol/L), white cell count 320 cells/μL (85% lymphocytes). CSF Gram stain and India ink are negative. CSF tuberculosis PCR (Xpert MTB/RIF) is negative. Cryptococcal antigen is negative. He is started on empirical treatment. What additional investigation is most likely to establish the diagnosis?

A. Repeat lumbar puncture and send larger volume of CSF for tuberculosis culture (Correct Answer)
B. Serum and CSF antibody testing for Lyme disease
C. CSF viral PCR panel including enterovirus and herpes viruses
D. Blood cultures for Brucella species
E. MRI brain and spinal cord with gadolinium contrast for neurosarcoidosis

Explanation: ***Repeat lumbar puncture and send larger volume of CSF for tuberculosis culture*** - The patient presents with **subacute meningitis** and a CSF profile characterized by **lymphocytic pleocytosis**, markedly **low glucose** (hypoglycorrhachia), and very **high protein**. This combination is highly suggestive of **Tuberculous Meningitis (TBM)**. - The initial **Xpert MTB/RIF** has limited sensitivity in CSF. To confirm TBM, **Mycobacterium tuberculosis culture** from a larger volume (5-10 mL) of CSF, often obtained through **serial lumbar punctures**, is crucial as it remains the **gold standard** and significantly increases diagnostic yield. *Serum and CSF antibody testing for Lyme disease* - While **Lyme neuroborreliosis** can cause lymphocytic meningitis, it typically presents with less severe **hypoglycorrhachia** and usually involves symptoms like cranial neuropathies or radiculopathy, which are not explicitly mentioned here. - The extremely high protein and profound glucose reduction seen in this patient's CSF are less characteristic of Lyme disease and point more strongly towards a granulomatous or severe infectious process. *CSF viral PCR panel including enterovirus and herpes viruses* - **Viral meningitis** is typically associated with **normal CSF glucose** and only mild-to-moderate elevation in CSF **protein** levels, despite showing lymphocytic pleocytosis. - The severe **hypoglycorrhachia** (1.8 mmol/L) and very high **protein** (3.5 g/L) observed in this patient's CSF make common viral etiologies, such as enteroviruses and herpesviruses, highly unlikely. *Blood cultures for Brucella species* - **Neurobrucellosis** is a differential for chronic meningitis with a similar CSF profile (lymphocytic pleocytosis, low glucose, high protein), but it is geographically limited and often linked to specific **epidemiological risks** (e.g., unpasteurized dairy, animal contact). - While a possibility, **Tuberculous Meningitis** is a statistically more common and globally prevalent cause of this specific and severe CSF presentation, necessitating its primary and rigorous exclusion. *MRI brain and spinal cord with gadolinium contrast for neurosarcoidosis* - **Neurosarcoidosis** can mimic TBM by causing chronic meningitis with similar CSF findings and imaging abnormalities like basal leptomeningeal enhancement. - However, **neurosarcoidosis** is a diagnosis of exclusion. Given the highly suggestive CSF findings for a treatable and aggressive infection like TBM, infectious causes must be thoroughly ruled out first due to the urgency of treatment and risk of neurological damage.

Question 129: A 35-year-old man with advanced HIV infection (CD4 count 25 cells/mm³, viral load 185,000 copies/mL) who is not on antiretroviral therapy presents with a 4-week history of headache, fever, and confusion. CT head shows multiple ring-enhancing lesions in the basal ganglia with surrounding oedema. Lumbar puncture is deferred. Toxoplasma serology is IgG positive. He is started on sulfadiazine, pyrimethamine, and folinic acid for presumed cerebral toxoplasmosis. After how many weeks of treatment should he have a repeat CT head to assess response, and what action should be taken if there is no improvement?

A. Repeat CT at 1 week; if no improvement, perform brain biopsy to exclude CNS lymphoma
B. Repeat CT at 2 weeks; if no improvement, switch to second-line toxoplasmosis treatment with clindamycin and pyrimethamine
C. Repeat CT at 2 weeks; if no improvement, perform brain biopsy to exclude alternative diagnosis such as CNS lymphoma (Correct Answer)
D. Repeat CT at 4 weeks; if no improvement, add adjunctive corticosteroids to reduce cerebral oedema
E. Repeat CT at 6 weeks; if no improvement, perform lumbar puncture and CSF analysis for alternative diagnoses

Explanation: ***Repeat CT at 2 weeks; if no improvement, perform brain biopsy to exclude alternative diagnosis such as CNS lymphoma*** - In advanced **HIV** patients with **multiple ring-enhancing lesions** in the basal ganglia and **Toxoplasma IgG positivity**, empirical treatment for **cerebral toxoplasmosis** is initiated. Clinical and radiological improvement is typically expected within **10-14 days** of appropriate therapy. - If there is no clinical or radiological improvement after **2 weeks** of specific anti-toxoplasmosis treatment, an **alternative diagnosis** becomes highly likely, most commonly **Primary CNS Lymphoma (PCNSL)**, necessitating a **brain biopsy** for definitive diagnosis. *Repeat CT at 1 week; if no improvement, perform brain biopsy to exclude CNS lymphoma* - A **1-week** interval is generally considered too short to reliably assess a definitive radiological response to anti-toxoplasma therapy, as significant changes may not be evident this early. - Performing an invasive **brain biopsy** prematurely at 1 week risks unnecessary procedures, as many patients will show improvement if given adequate time (up to 2 weeks). *Repeat CT at 2 weeks; if no improvement, switch to second-line toxoplasmosis treatment with clindamycin and pyrimethamine* - Failure to respond to the **first-line therapy (sulfadiazine and pyrimethamine)** for presumed toxoplasmosis in an advanced HIV patient should raise strong suspicion for an **alternative diagnosis**, rather than simply assuming drug resistance. - In this clinical scenario, especially with a very low CD4 count (<50 cells/mm³), **Primary CNS Lymphoma** is a crucial differential diagnosis that switching anti-toxoplasma drugs would delay, potentially worsening prognosis. *Repeat CT at 4 weeks; if no improvement, add adjunctive corticosteroids to reduce cerebral oedema* - Waiting **4 weeks** to reassess response in a patient with progressive neurological symptoms and an immunocompromised status is unacceptably long and could lead to significant clinical deterioration or irreversible damage. - While **corticosteroids** reduce cerebral edema, they can also cause a transient reduction in tumor size in **CNS lymphoma** (the "vanishing tumor" effect), potentially obscuring the diagnosis and making a subsequent biopsy less conclusive. *Repeat CT at 6 weeks; if no improvement, perform lumbar puncture and CSF analysis for alternative diagnoses* - A **6-week** delay for reassessment is far too long for a patient with acute neurological confusion and suspected cerebral mass lesions, increasing the risk of severe complications and delaying appropriate treatment. - **Lumbar puncture** might be contraindicated in the presence of **multiple ring-enhancing lesions** with surrounding edema and potential mass effect, as it carries a significant risk of **herniation** if there is elevated intracranial pressure.

Question 130: A 54-year-old man from India who moved to the UK 8 months ago presents with a 4-week history of productive cough and night sweats. Chest X-ray shows bilateral upper lobe consolidation with cavitation. Three sputum samples are positive for acid-fast bacilli on microscopy. He is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 4 weeks of treatment, culture results become available showing Mycobacterium tuberculosis with isoniazid resistance (katG gene mutation) but sensitive to rifampicin, pyrazinamide, and ethambutol. What is the most appropriate modification to his treatment regimen?

A. Continue rifampicin, pyrazinamide, and ethambutol for 2 months, then rifampicin and ethambutol for 10 months (total 12 months)
B. Stop isoniazid, continue rifampicin, pyrazinamide, and ethambutol for 2 months, then rifampicin and ethambutol for 7 months (total 9 months)
C. Stop isoniazid, add levofloxacin, continue rifampicin, pyrazinamide, ethambutol, and levofloxacin for 2 months, then rifampicin, ethambutol, and levofloxacin for 10 months (Correct Answer)
D. Continue rifampicin, isoniazid, pyrazinamide, and ethambutol for full 6 months (isoniazid resistance with katG mutation does not require treatment change)
E. Stop isoniazid, add levofloxacin, continue rifampicin, pyrazinamide, ethambutol, and levofloxacin for 6 months, then rifampicin and levofloxacin for 3 months (total 9 months)

Explanation: ***Stop isoniazid, add levofloxacin, continue rifampicin, pyrazinamide, ethambutol, and levofloxacin for 2 months, then rifampicin, ethambutol, and levofloxacin for 10 months***- For **isoniazid-resistant TB (Hr-TB)**, World Health Organization (WHO) and NICE guidelines recommend adding a **fluoroquinolone (levofloxacin)** and extending the total duration to **12 months**.- The **katG mutation** confers high-level resistance, necessitating the addition of a potent bactericidal agent like levofloxacin to prevent the development of multidrug-resistant TB (MDR-TB).*Continue rifampicin, pyrazinamide, and ethambutol for 2 months, then rifampicin and ethambutol for 10 months (total 12 months)*- While this regimen covers the extended duration, it lacks the **fluoroquinolone** needed to bolster the regimen in the absence of effective isoniazid.- Omitting the fluoroquinolone in the presence of **high-level resistance** (katG) increases the risk of treatment failure and further resistance.*Stop isoniazid, continue rifampicin, pyrazinamide, and ethambutol for 2 months, then rifampicin and ethambutol for 7 months (total 9 months)*- A **9-month regimen** without a fluoroquinolone is generally considered inadequate for high-level isoniazid-resistant strains with **extensive disease** or cavitation.- Modern protocols emphasize a **12-month duration** when treating isoniazid resistance to ensure complete sterilization of cavitary lesions.*Continue rifampicin, isoniazid, pyrazinamide, and ethambutol for full 6 months (isoniazid resistance with katG mutation does not require treatment change)*- This statement is incorrect as a **katG mutation** specifically causes **high-level resistance**, rendering isoniazid clinically ineffective.- Continuing a standard 6-month course would essentially be **triple therapy**, which is insufficient for a patient with high bacillary load and cavitation.*Stop isoniazid, add levofloxacin, continue rifampicin, pyrazinamide, ethambutol, and levofloxacin for 6 months, then rifampicin and levofloxacin for 3 months (total 9 months)*- Although this regimen correctly introduces a **fluoroquinolone**, the total duration of **9 months** is shorter than the recommended 12 months for Hr-TB.- The intensive phase for Hr-TB typically transitions after **2 months** of pyrazinamide, not 6 months, followed by a longer continuation phase.

Question 131: What is the primary mechanism by which corticosteroids improve outcomes when given as adjunctive therapy in acute bacterial meningitis?

A. Direct antimicrobial effect through enhanced neutrophil function
B. Reduction in blood-brain barrier permeability through stabilization of cerebrovascular endothelium
C. Inhibition of host inflammatory response that causes vasculitis and cytotoxic oedema (Correct Answer)
D. Enhanced penetration of antibiotics into the cerebrospinal fluid
E. Prevention of seizures through direct neuronal membrane stabilization

Explanation: ***Inhibition of host inflammatory response that causes vasculitis and cytotoxic oedema*** - Corticosteroids, particularly **dexamethasone**, suppress the intense **inflammatory response** in the subarachnoid space, which is primarily responsible for the tissue damage in bacterial meningitis. - By reducing the release of pro-inflammatory cytokines, they mitigate **cerebral oedema**, **vasculitis**, and neuronal damage, thereby improving neurological outcomes and reducing mortality. *Direct antimicrobial effect through enhanced neutrophil function* - Corticosteroids are **immunosuppressive** and tend to inhibit, rather than enhance, **neutrophil migration** and function. - They do not possess any **direct bactericidal or bacteriostatic** properties; their role is immunomodulatory, not antimicrobial. *Reduction in blood-brain barrier permeability through stabilization of cerebrovascular endothelium* - While corticosteroids do stabilize the **blood-brain barrier** (BBB) by reducing inflammation, this is a secondary effect of their overall anti-inflammatory action. - The primary clinical benefit is derived from preventing the **downstream damage** caused by the host inflammatory response to bacterial lysis, not solely BBB stabilization. *Enhanced penetration of antibiotics into the cerebrospinal fluid* - Corticosteroids can actually **decrease antibiotic penetration** into the cerebrospinal fluid (CSF) by reducing meningeal inflammation and thus making the **blood-brain barrier less permeable**. - Despite this, the overall benefit of reducing inflammation outweighs the potential for slightly reduced antibiotic entry for certain pathogens. *Prevention of seizures through direct neuronal membrane stabilization* - Corticosteroids do not directly stabilize neuronal membranes to prevent seizures. - Their indirect role in seizure prevention is by reducing **cerebral inflammation** and oedema, which can otherwise predispose to seizure activity.

Question 132: A 28-year-old healthcare worker who is 10 weeks pregnant has been exposed to a patient with smear-positive pulmonary tuberculosis during an unprotected bronchoscopy procedure. A tuberculin skin test performed shows 18 mm induration at 48 hours. Chest X-ray is normal and she is asymptomatic. What is the most appropriate management?

A. Rifampicin and isoniazid for 3 months started immediately
B. Defer treatment until after delivery, then give isoniazid for 6 months
C. Isoniazid with pyridoxine for 6 months started immediately (Correct Answer)
D. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months
E. Rifampicin and isoniazid for 3 months started in the second trimester

Explanation: ***Isoniazid with pyridoxine for 6 months started immediately*** - The patient has **Latent Tuberculosis Infection (LTBI)** confirmed by a **positive Tuberculin Skin Test (18 mm)**, recent high-risk exposure to smear-positive TB, and no signs of active disease (asymptomatic, normal Chest X-ray). - **Isoniazid (INH)** for 6-9 months, along with **Pyridoxine (Vitamin B6)** to prevent **peripheral neuropathy**, is the recommended regimen for LTBI in pregnant women, and immediate treatment is crucial for recent high-risk exposures. *Rifampicin and isoniazid for 3 months started immediately* - While **Rifampicin and Isoniazid for 3 months** is an alternative regimen for LTBI, **INH monotherapy** for 6-9 months is generally preferred in pregnancy due to its well-established safety profile. - Data on the safety of **rifampicin** during pregnancy is less extensive compared to isoniazid, making INH monotherapy the more conservative and often preferred choice. *Defer treatment until after delivery, then give isoniazid for 6 months* - Deferring treatment is only considered for those with **remote exposure** or low-risk LTBI; for **recent, high-risk exposure**, immediate treatment is recommended. - Pregnancy itself can increase the risk of **progression from LTBI to active tuberculosis**, and delaying treatment significantly raises the risk of maternal morbidity and congenital TB. *Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months* - This is the standard **multi-drug regimen for active tuberculosis**, which the patient does not have, as indicated by a normal chest X-ray and absence of symptoms. - Using **four drugs** for LTBI is unnecessary and increases the risk of **drug toxicity**, particularly **pyrazinamide**, which has limited safety data in pregnancy and is generally avoided. *Rifampicin and isoniazid for 3 months started in the second trimester* - Although some clinicians might consider delaying treatment until the **second trimester**, for a **recent high-risk exposure**, immediate treatment is generally recommended even in the first trimester. - Delaying treatment creates a window of vulnerability for **progression to active disease** during pregnancy, which carries higher risks than immediate, appropriate LTBI therapy.

Question 133: A 12-month-old infant is brought to the emergency department with a 6-hour history of fever, irritability, and refusing feeds. On examination, temperature is 39.5°C, heart rate 165 bpm, respiratory rate 45 breaths/minute, capillary refill time 4 seconds, and the fontanelle is bulging. The infant is lethargic but arousable. What is the most appropriate immediate antibiotic therapy before lumbar puncture?

A. Intravenous ceftriaxone 80 mg/kg
B. Intravenous cefotaxime 50 mg/kg plus intravenous amoxicillin 50 mg/kg (Correct Answer)
C. Intravenous benzylpenicillin 50 mg/kg
D. Intravenous ceftriaxone 80 mg/kg plus intravenous vancomycin 15 mg/kg
E. Intravenous cefotaxime 50 mg/kg plus intravenous aciclovir 20 mg/kg

Explanation: ***Intravenous cefotaxime 50 mg/kg plus intravenous amoxicillin 50 mg/kg*** - This combination is the preferred empirical treatment for suspected **bacterial meningitis** in infants to ensure broad coverage, including for **Listeria monocytogenes**. - Cefotaxime (a **third-generation cephalosporin**) covers common pathogens like *S. pneumoniae* and Gram-negatives, while amoxicillin specifically targets **Listeria**, crucial in infants, especially given the severe presentation. *Intravenous ceftriaxone 80 mg/kg* - Ceftriaxone is a potent third-generation cephalosporin but, as a single agent, fails to provide adequate coverage for **Listeria monocytogenes**. - In infants, particularly those under 3 months, **cefotaxime** is often preferred over ceftriaxone to avoid potential **bilirubin displacement** and kernicterus, although the risk is lower at 12 months. *Intravenous benzylpenicillin 50 mg/kg* - Benzylpenicillin primarily covers Gram-positive organisms and *Listeria* but lacks sufficient **Gram-negative coverage** (e.g., *E. coli*, *H. influenzae*). - It is generally insufficient as a sole empirical agent in the hospital setting for an infant with undifferentiated severe meningitis, especially without clear meningococcal disease indicators. *Intravenous ceftriaxone 80 mg/kg plus intravenous vancomycin 15 mg/kg* - This regimen is reserved for situations with a high suspicion of **penicillin-resistant Streptococcus pneumoniae** or in specific high-risk scenarios not indicated here. - It is not the standard first-line empirical regimen for community-acquired meningitis in this age group and **does not cover Listeria monocytogenes**. *Intravenous cefotaxime 50 mg/kg plus intravenous aciclovir 20 mg/kg* - Aciclovir is used for suspected **HSV encephalitis**, which would typically present with more focal neurological signs rather than general signs of sepsis and meningitis. - While cefotaxime covers some bacterial pathogens, the addition of aciclovir is not the immediate priority for broad empirical coverage in this critically ill infant, and this regimen still **lacks coverage for Listeria monocytogenes**.

Question 134: A 45-year-old woman with chronic kidney disease stage 4 (eGFR 22 mL/min/1.73m²) is diagnosed with drug-sensitive pulmonary tuberculosis. She weighs 70 kg. What is the most appropriate modification to standard anti-tuberculous therapy for this patient?

A. Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 2 g three times weekly, ethambutol 15 mg/kg three times weekly (Correct Answer)
B. Rifampicin 450 mg once daily, isoniazid 200 mg once daily, pyrazinamide omitted, ethambutol 15 mg/kg three times weekly
C. Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide omitted, ethambutol 25 mg/kg once daily
D. Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 1.5 g once daily, ethambutol 15 mg/kg once daily
E. Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 1.5 g once daily, moxifloxacin 400 mg once daily (avoid ethambutol)

Explanation: ***Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 2 g three times weekly, ethambutol 15 mg/kg three times weekly***- In patients with **eGFR < 30 mL/min**, **rifampicin** and **isoniazid** do not require dose adjustments as they are primarily metabolized by the liver.- **Pyrazinamide** and **ethambutol** require a reduction in frequency to **three times weekly** (instead of daily) to prevent toxic accumulation and side effects like **optic neuritis**.*Rifampicin 450 mg once daily, isoniazid 200 mg once daily, pyrazinamide omitted, ethambutol 15 mg/kg three times weekly*- **Rifampicin** and **isoniazid** are under-dosed here; standard dosing (600mg/300mg) should be maintained regardless of renal function for a 70 kg adult.- Omitting **pyrazinamide** unnecessarily complicates the regimen and typically requires extending the total duration of treatment to 9 months.*Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide omitted, ethambutol 25 mg/kg once daily*- Daily dosing of **ethambutol** at 25 mg/kg in a patient with stage 4 CKD poses a very high risk of irreversible **optic neuropathy**.- There is no clinical indication to omit **pyrazinamide** in renal failure if the frequency is adjusted correctly to three times per week.*Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 1.5 g once daily, ethambutol 15 mg/kg once daily*- Chronic daily administration of **pyrazinamide** and **ethambutol** is contraindicated when **eGFR is below 30 mL/min** due to decreased renal clearance.- Failure to adjust the frequency to **thrice weekly** leads to significant drug accumulation and increased risk of **hepatotoxicity** and uremic symptoms.*Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 1.5 g once daily, moxifloxacin 400 mg once daily (avoid ethambutol)*- Standard first-line therapy (RHEZ) is preferred for **drug-sensitive tuberculosis**; **moxifloxacin** is generally reserved for drug-resistant cases or intolerance.- Maintaining daily **pyrazinamide** in this patient is inappropriate and ignores the necessary frequency adjustments required for severe **renal impairment**.

Question 135: According to UK public health guidelines, which of the following individuals exposed to a case of confirmed meningococcal meningitis requires chemoprophylaxis?

A. A nurse who performed nasopharyngeal suctioning on the patient without wearing a face mask (Correct Answer)
B. A medical student who examined the patient wearing gloves and an apron only
C. A ward cleaner who cleaned the patient's room after discharge
D. A doctor who intubated the patient wearing full PPE including FFP3 mask
E. A relative who visited the patient for 30 minutes in hospital after antibiotic treatment had been started

Explanation: ***A nurse who performed nasopharyngeal suctioning on the patient without wearing a face mask*** - **Chemoprophylaxis** is indicated for healthcare workers who have direct, intimate exposure to **respiratory secretions** (e.g., suctioning or intubation) without using a **surgical face mask**. - This exposure carries a significant risk of **droplet transmission** from the index case to the mucosal surfaces of the healthcare worker. *A medical student who examined the patient wearing gloves and an apron only* - Routine clinical examination is not considered a high-risk exposure unless there is **significant contact** with respiratory droplets within a 1-meter range. - **Gloves and aprons** protect against contact transmission, but the absence of mask use during a standard exam does not mandate prophylaxis unless an **aerosol-generating procedure** occurred. *A ward cleaner who cleaned the patient's room after discharge* - *Neisseria meningitidis* is a fragile organism that does not survive well in the **external environment**; therefore, indirect contact via environmental surfaces is not a risk. - Prophylaxis is reserved for **close contacts** during the infectious period, not for housekeeping staff performing terminal cleaning. *A doctor who intubated the patient wearing full PPE including FFP3 mask* - Although intubation is a high-risk procedure, the use of **appropriate personal protective equipment (PPE)** effectively mitigates the risk of transmission. - If a mask (surgical or **FFP3**) is worn correctly during the procedure, the healthcare worker is not considered to have had a **significant exposure** requiring antibiotics. *A relative who visited the patient for 30 minutes in hospital after antibiotic treatment had been started* - Patients are generally considered non-infectious **24 hours after** starting appropriate systemic **antibiotic therapy** (e.g., ceftriaxone). - Prophylaxis is only indicated for household-type contacts who spent significant time with the case in the **7 days prior** to onset or for transient contacts with exposures lasting over **one hour**.

Question 136: A 58-year-old man with a recent diagnosis of acute myeloid leukaemia who completed his first cycle of intensive chemotherapy 14 days ago presents with a 48-hour history of severe headache, confusion, and fever. On examination, temperature is 38.7°C, he is confused with GCS 14/15, and has mild neck stiffness. Blood tests show neutrophil count 0.2 × 10⁹/L. CT head is normal. Lumbar puncture shows: opening pressure 24 cmH₂O, CSF protein 0.9 g/L, glucose 3.1 mmol/L (plasma glucose 5.8 mmol/L), white cell count 85 cells/μL (95% lymphocytes). Gram stain is negative. What is the most appropriate empirical antimicrobial therapy while awaiting further CSF results?

A. Intravenous ceftriaxone and dexamethasone
B. Intravenous ceftazidime, amikacin, and amphotericin B
C. Intravenous meropenem, vancomycin, and aciclovir
D. Intravenous meropenem, amikacin, and amphotericin B (Correct Answer)
E. Intravenous ceftriaxone, vancomycin, and amphotericin B

Explanation: ***Intravenous meropenem, amikacin, and amphotericin B*** - This patient is in a state of **profound neutropenia** (neutrophils 0.2 × 10⁹/L), which increases susceptibility to **Gram-negative bacilli** (including *Pseudomonas*), ***Listeria monocytogenes***, and fungal pathogens. Meropenem covers *Pseudomonas* and *Listeria*. - The combination of **meropenem** (broad-spectrum antibacterial with good CSF penetration) and **amikacin** (potently covers Gram-negative bacteria like *Pseudomonas*) is crucial for bacterial coverage, while **amphotericin B** is essential for high-risk fungal pathogens such as *Candida* and *Cryptococcus* in this immunocompromised state. *Intravenous ceftriaxone and dexamethasone* - **Ceftriaxone** lacks adequate coverage for ***Pseudomonas aeruginosa*** and ***Listeria monocytogenes***, both of which are critical pathogens to cover empirically in a neutropenic patient with meningitis. - **Dexamethasone** is generally avoided in neutropenic patients with meningitis as it can further compromise the immune system and is primarily indicated for *Streptococcus pneumoniae* in immunocompetent individuals. *Intravenous ceftazidime, amikacin, and amphotericin B* - While **ceftazidime** provides good coverage for *Pseudomonas*, it lacks activity against ***Listeria monocytogenes***, which is a significant pathogen in immunocompromised patients, including those with neutropenia. - **Meropenem** is generally preferred over ceftazidime in this setting due to its broader spectrum of activity, including better coverage for *Listeria* and some anaerobic bacteria. *Intravenous meropenem, vancomycin, and aciclovir* - **Aciclovir** is an antiviral agent targeting HSV encephalitis; however, in a neutropenic patient with lymphocytic pleocytosis, fungal or severe bacterial infections (including *Listeria*) are more concerning and require broader empirical coverage than what aciclovir provides. - This regimen critically **lacks empirical antifungal coverage**, which is mandatory for a severely neutropenic patient presenting with signs of central nervous system infection. *Intravenous ceftriaxone, vancomycin, and amphotericin B* - **Ceftriaxone** is not suitable for neutropenic meningitis due to its lack of reliable coverage against ***Pseudomonas aeruginosa*** and ***Listeria monocytogenes***. - While vancomycin covers MRSA and amphotericin B covers fungi, the significant risk of **Gram-negative bacterial infection** (especially *Pseudomonas*) associated with post-chemotherapy neutropenia is not adequately addressed by ceftriaxone.

Question 137: A 37-year-old man from Bangladesh who has been in the UK for 2 years presents with a 3-month history of cough, fever, and weight loss. Chest X-ray shows bilateral upper lobe cavitation. Three sputum samples are smear-positive for acid-fast bacilli. GeneXpert MTB/RIF testing is positive for Mycobacterium tuberculosis with rifampicin resistance detected. What is the most appropriate initial treatment regimen?

A. Isoniazid, pyrazinamide, ethambutol, and levofloxacin for 2 months, then isoniazid and ethambutol for 10 months
B. Refer to specialist MDR-TB service for individualized treatment regimen based on full drug susceptibility testing (Correct Answer)
C. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months
D. Bedaquiline, linezolid, levofloxacin, cycloserine, and clofazimine for 9-12 months
E. Streptomycin, isoniazid, pyrazinamide, and ethambutol for 2 months, then isoniazid and ethambutol for 16 months

Explanation: ***Refer to specialist MDR-TB service for individualized treatment regimen based on full drug susceptibility testing*** - Detection of **rifampicin resistance** on GeneXpert is a critical marker for **multidrug-resistant tuberculosis (MDR-TB)**, requiring urgent referral to specialized services. - Management of RR-TB/MDR-TB is complex and must be tailored based on **full drug susceptibility testing (DST)** to ensure an effective and safe drug combination. *Isoniazid, pyrazinamide, ethambutol, and levofloxacin for 2 months, then isoniazid and ethambutol for 10 months* - This is an outdated approach for isoniazid monoresistance; it is insufficient when **rifampicin resistance** is confirmed. - Starting treatment without a specialist's guidance in this context risks the development of further **drug resistance**. *Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months* - This is the standard 6-month regimen for **drug-sensitive tuberculosis**, which will fail in a patient with confirmed **rifampicin resistance**. - Using this regimen in the presence of resistance poses a high risk of clinical failure and the ongoing **transmission** of resistant strains. *Bedaquiline, linezolid, levofloxacin, cycloserine, and clofazimine for 9-12 months* - While these are components of modern **MDR-TB regimens**, the specific combination should not be started empirically before **full DST** results are available. - Treatment selection must be supervised by a specialist to manage the high risk of **toxicity** and ensure compliance with the latest WHO/NICE guidelines. *Streptomycin, isoniazid, pyrazinamide, and ethambutol for 2 months, then isoniazid and ethambutol for 16 months* - **Streptomycin** is rarely used in modern first-line practice due to the risk of **ototoxicity** and nephrotoxicity. - This regimen lacks a potent rifamycin or a modern MDR-TB backbone, making it inappropriate for treating **rifampicin-resistant** organisms.

Question 138: A 6-year-old boy presents to the emergency department with a 5-hour history of fever, headache, vomiting, and drowsiness. On examination, he has a temperature of 39.2°C, Glasgow Coma Scale score of 13/15, neck stiffness, and a non-blanching purpuric rash on his trunk and lower limbs. Which of the following is the correct sequence of immediate management steps in the first 30 minutes?

A. Blood cultures, lumbar puncture, intravenous ceftriaxone, intravenous fluids
B. Intravenous ceftriaxone, blood cultures, intravenous fluids, CT head before lumbar puncture (Correct Answer)
C. Intravenous ceftriaxone, blood cultures, intravenous fluids, lumbar puncture
D. Blood cultures, CT head, lumbar puncture, intravenous ceftriaxone
E. Intravenous benzylpenicillin, immediate lumbar puncture, blood cultures, intravenous fluids

Explanation: ***Intravenous ceftriaxone, blood cultures, intravenous fluids, CT head before lumbar puncture*** - In a child with suspected **meningococcal sepsis** and features of severe infection (fever, drowsiness, neck stiffness, non-blanching purpuric rash), immediate administration of **intravenous ceftriaxone** is paramount to improve clinical outcomes and prevent rapid deterioration. - The patient's **drowsiness (GCS 13/15)** suggests possible **raised intracranial pressure (ICP)**, making a **CT head** mandatory before a **lumbar puncture** to rule out brain herniation risk. Blood cultures and IV fluids are concurrent essential steps. *Blood cultures, lumbar puncture, intravenous ceftriaxone, intravenous fluids* - Delaying the administration of **intravenous antibiotics** (ceftriaxone) to perform investigations like blood cultures and lumbar puncture is highly dangerous and increases mortality in suspected bacterial meningitis. - A **lumbar puncture** should not be the second step when there are clinical signs of **intracranial hypertension** (drowsiness) or widespread meningococcemia, as it poses a significant risk of **herniation**. *Intravenous ceftriaxone, blood cultures, intravenous fluids, lumbar puncture* - While starting with **intravenous ceftriaxone** is correct, directly proceeding to a **lumbar puncture** without prior imaging is unsafe given the patient's **drowsiness (GCS 13/15)**. - A **CT head** is required to assess for **raised ICP** or cerebral mass lesions before a lumbar puncture in patients with altered mental status or focal neurological signs, to prevent **brain herniation**. *Blood cultures, CT head, lumbar puncture, intravenous ceftriaxone* - This sequence is incorrect because it critically delays the administration of **intravenous ceftriaxone**, placing it as the last step. - In suspected bacterial meningitis or sepsis, **empirical antibiotics** should be administered as an absolute priority, and diagnostic steps should never cause a delay in this life-saving intervention. *Intravenous benzylpenicillin, immediate lumbar puncture, blood cultures, intravenous fluids* - While **benzylpenicillin** is used, **ceftriaxone** is the preferred **empirical broad-spectrum antibiotic** in the hospital setting for suspected bacterial meningitis due to its wider coverage. - An **immediate lumbar puncture** is strongly contraindicated due to the patient's **drowsiness** (indicating potential raised ICP) and the presence of a **non-blanching purpuric rash**, which can indicate **coagulopathy** or a severe disseminated infection with high herniation risk.

Question 139: A 31-year-old woman from Pakistan presents with a 5-week history of headache, low-grade fever, and progressive confusion. On examination, she has photophobia, neck stiffness, and bilateral papilloedema. Lumbar puncture shows opening pressure 32 cmH₂O, CSF protein 2.8 g/L, glucose 1.2 mmol/L (plasma glucose 6.5 mmol/L), white cell count 450 cells/μL (80% lymphocytes). A CT head shows basal meningeal enhancement and hydrocephalus. What is the most important additional investigation to guide long-term management?

A. HIV serology (Correct Answer)
B. Serum cryptococcal antigen
C. CSF India ink staining
D. CSF tuberculosis culture and molecular testing
E. MRI brain with gadolinium contrast

Explanation: ***HIV serology*** - In a patient with highly suspected **tuberculous meningitis (TBM)**, identifying **HIV coinfection** is crucial as it significantly complicates clinical management, particularly regarding drug-drug interactions with **rifampicin** and the timing of antiretroviral therapy (ART). - **HIV status** is the most important factor in determining the long-term prognosis, the need for adjunctive steroids, and the management of complications like **Immune Reconstitution Inflammatory Syndrome (IRIS)**. *Serum cryptococcal antigen* - This test is primarily for **Cryptococcal meningitis**, which can occur in immunocompromised individuals but often presents with a less dramatic rise in **CSF protein** and less prominent **basal enhancement** compared to TBM. - While important in differential diagnosis, the patient's clinical and CSF profile strongly points towards TBM, making HIV status a more critical determinant for long-term management. *CSF India ink staining* - This technique is used to visualize the capsule of **Cryptococcus neoformans** but has lower sensitivity than antigen testing for diagnosing cryptococcal meningitis. - It is not relevant for the diagnosis or long-term management of TBM, which is strongly suggested by the clinical presentation and imaging findings. *CSF tuberculosis culture and molecular testing* - While **NAAT (e.g., GeneXpert)** and traditional culture are essential for **confirming the diagnosis** of TBM and assessing drug resistance, they are part of the initial diagnostic workup, not an *additional* investigation to guide long-term systemic management once TBM is highly suspected. - These tests confirm the pathogen, but HIV status guides the overall treatment strategy for the patient's underlying immune state. *MRI brain with gadolinium contrast* - MRI with contrast offers superior anatomical detail compared to CT, better visualizing subtle meningeal inflammation, **tuberculomas**, or infarcts associated with TBM. - Although it provides valuable diagnostic and prognostic information regarding CNS complications, it does not provide the systemic information needed to structure the **long-term drug regimen** and overall management strategy in the same way HIV status does.

Question 140: A 42-year-old man with pulmonary tuberculosis is taking rifampicin, isoniazid, pyrazinamide, and ethambutol. He develops sudden onset visual disturbance with difficulty distinguishing between red and green colours. Visual acuity testing shows decreased central vision bilaterally. What is the most appropriate immediate management step?

A. Continue current treatment and reassure the patient that symptoms will resolve
B. Stop ethambutol and arrange urgent ophthalmology review (Correct Answer)
C. Stop rifampicin and check liver function tests
D. Add pyridoxine supplementation and continue all medications
E. Stop all anti-tuberculous medications and arrange urgent neurology review

Explanation: ***Stop ethambutol and arrange urgent ophthalmology review***- This patient is experiencing **ethambutol-induced optic neuritis**, characterized by bilateral **decreased visual acuity** and **impaired red-green color vision**.- Ethambutol must be **stopped immediately** to prevent permanent vision loss, as this toxicity is dose-dependent and typically reversible if caught early.*Continue current treatment and reassure the patient that symptoms will resolve*- Ignoring these symptoms can lead to **irreversible blindness** and permanent **optic nerve atrophy**.- Reassurance is inappropriate because visual disturbances are a serious **adverse effect** requiring active intervention, not an expected minor side effect.*Stop rifampicin and check liver function tests*- Rifampicin is primarily associated with **hepatotoxicity** (elevated LFTs) and orange discoloration of secretions, not visual impairment.- Stopping rifampicin would unnecessarily weaken the **antitubercular regimen** while failing to address the cause of the eye pathology.*Add pyridoxine supplementation and continue all medications*- **Pyridoxine (Vitamin B6)** is used to prevent or treat **peripheral neuropathy** caused by **isoniazid**, which presents with tingling or numbness.- Supplementation will not prevent or treat the **optic neuropathy** caused by ethambutol toxicity.*Stop all anti-tuberculous medications and arrange urgent neurology review*- It is not necessary to stop the entire therapeutic regimen; only the **offending agent (ethambutol)** needs to be withdrawn.- An **ophthalmology review** is the correct specialist referral for visual acuity and color vision testing, rather than neurology.

Question 141: A 46-year-old woman with smear-positive pulmonary tuberculosis has been receiving rifampicin, isoniazid, pyrazinamide, and ethambutol for 8 weeks. She is clinically improving with resolution of symptoms. Repeat sputum samples at 8 weeks remain smear-positive for acid-fast bacilli. Culture from initial samples has now grown Mycobacterium tuberculosis fully sensitive to all first-line drugs. What is the most appropriate next step in management?

A. Continue current four-drug regimen for a further 4 weeks before reassessing
B. Switch to second-line therapy as this represents treatment failure
C. Stop pyrazinamide and ethambutol, continue rifampicin and isoniazid for 4 months (Correct Answer)
D. Add a fluoroquinolone to the current regimen
E. Repeat drug sensitivity testing as resistance may have developed

Explanation: ***Stop pyrazinamide and ethambutol, continue rifampicin and isoniazid for 4 months***- Standard treatment for **drug-sensitive pulmonary tuberculosis** consists of an 8-week intensive phase (rifampicin, isoniazid, pyrazinamide, ethambutol) followed by a **continuation phase** of 4 months with rifampicin and isoniazid, which the patient is now entering.- Despite persistent smear positivity at 8 weeks, the patient is **clinically improving**, and the initial isolate was **fully sensitive** to first-line drugs, suggesting that the remaining acid-fast bacilli are likely non-viable or slowly clearing.*Continue current four-drug regimen for a further 4 weeks before reassessing*- Extending the **intensive phase** beyond 8 weeks is not typically indicated for patients with **drug-sensitive TB** who are clinically improving.- Prolonged use of **pyrazinamide** and **ethambutol** increases the risk of side effects, such as hepatotoxicity and optic neuritis, without clear additional benefit in sensitive cases.*Switch to second-line therapy as this represents treatment failure*- **Treatment failure** in TB is generally defined by persistent culture positivity or clinical deterioration after a more prolonged period of adequate treatment (e.g., 4 months) or by confirmed drug resistance.- Given the patient's **clinical improvement** and the documented **drug sensitivity**, switching to second-line drugs is premature and inappropriate.*Add a fluoroquinolone to the current regimen*- Adding a single drug to an existing regimen, especially if the regimen is not fully effective, is poor practice as it can rapidly lead to the development of **drug resistance** to the newly added agent.- There is no indication for adding a **fluoroquinolone** at this stage, as the patient has drug-sensitive TB and is clinically improving.*Repeat drug sensitivity testing as resistance may have developed*- While **acquired drug resistance** is a concern in TB treatment, it is usually suspected in cases of **clinical deterioration** or persistent culture positivity (not just smear positivity) after several months of treatment.- Given the clinical improvement and initial full sensitivity, repeating **drug sensitivity testing** is not the immediate next step, but rather transitioning to the continuation phase.

Question 142: A 61-year-old man from Zimbabwe with newly diagnosed HIV infection (CD4 count 55 cells/mm³, viral load 450,000 copies/mL) presents with a 5-week history of headache, fever, and progressive confusion. Lumbar puncture shows: opening pressure 35 cmH2O, white cells 30 cells/mm³ (lymphocytes), protein 1.8 g/L, glucose 1.6 mmol/L. CSF cryptococcal antigen is positive with titre 1:2048. He is started on intravenous amphotericin B and oral flucytosine. Antiretroviral therapy is being considered. When is the most appropriate time to initiate ART in this patient?

A. Immediately, alongside antifungal therapy
B. After 2 weeks of antifungal induction therapy
C. After completion of induction therapy and starting fluconazole consolidation (approximately 4-6 weeks) (Correct Answer)
D. After 3 months of antifungal therapy
E. After cryptococcal antigen titre becomes negative

Explanation: ***After completion of induction therapy and starting fluconazole consolidation (approximately 4-6 weeks)*** - In **cryptococcal meningitis**, initiating ART prematurely can lead to severe **Immune Reconstitution Inflammatory Syndrome (IRIS)**, specifically **neuroinflammatory IRIS**, which significantly increases mortality. - Delaying ART until 4-6 weeks allows for a reduction in the **fungal burden** and stabilization of intracranial pressure, thereby minimizing the risk of a severe inflammatory response. *Immediately, alongside antifungal therapy* - Immediate ART initiation in active cryptococcal meningitis is associated with a significantly **higher mortality rate** due to exacerbated inflammation in the central nervous system. - This approach can worsen **intracranial pressure** and contribute to neurological deterioration before the antifungal therapy has had sufficient time to reduce the pathogen load. *After 2 weeks of antifungal induction therapy* - Clinical trials, such as the **COAT trial**, have shown that initiating ART at 2 weeks in patients with cryptococcal meningitis results in **increased mortality** compared to later initiation. - At 2 weeks, the patient is often still in a critical phase of antifungal treatment, and the risk of **cryptococcal IRIS** remains substantial. *After 3 months of antifungal therapy* - Delaying ART for as long as 3 months is generally **too long** and leaves the patient susceptible to other opportunistic infections due to continued severe immunosuppression. - The current guidelines recommend initiating ART sooner than 3 months to improve overall outcomes, provided the risk of IRIS is minimized by adequate antifungal treatment. *After cryptococcal antigen titre becomes negative* - **Cryptococcal antigen (CrAg)** can persist in the CSF and serum for many months, or even years, despite successful antifungal treatment and clinical improvement. - Therefore, waiting for the CrAg titre to become negative is not a practical or recommended criterion for timing ART initiation; clinical and laboratory parameters, along with the completion of induction therapy, guide the decision.

Question 143: A 23-year-old man with no significant past medical history presents with fever, severe headache, and neck stiffness. Lumbar puncture shows: opening pressure 24 cmH2O, white cells 1250 cells/mm³ (95% neutrophils), protein 1.5 g/L, glucose 2.5 mmol/L (plasma 5.2 mmol/L). Gram stain shows Gram-negative diplococci. Blood and CSF cultures are sent. He is started on intravenous ceftriaxone. After 24 hours of treatment, he becomes increasingly drowsy and confused. Repeat CT head shows cerebral oedema. What is the most likely cause of his clinical deterioration?

A. Development of subdural empyema
B. Inappropriate antibiotic choice
C. Cerebral venous sinus thrombosis
D. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (Correct Answer)
E. Rifampicin resistance requiring treatment modification

Explanation: ***Syndrome of inappropriate antidiuretic hormone secretion (SIADH)*** - **SIADH** is a common complication of **bacterial meningitis**, occurring due to excessive **ADH release** triggered by meningeal inflammation, leading to **dilutional hyponatremia**. - This hyponatremia exacerbates pre-existing **cerebral oedema**, worsening the patient's neurological status and causing symptoms like **drowsiness** and **confusion**. *Development of subdural empyema* - **Subdural empyema** typically manifests with focal **neurological deficits**, persistent fever, and potentially seizures, often requiring surgical drainage. - A **repeat CT head** would usually reveal a well-defined purulent collection, not generalized **cerebral oedema**. *Inappropriate antibiotic choice* - **Ceftriaxone** is a highly effective first-line antibiotic for **meningitis** caused by **Gram-negative diplococci** (e.g., *Neisseria meningitidis*). - The initial clinical and CSF findings strongly suggest appropriate treatment, and deterioration is more likely due to **complications of meningitis** itself rather than antibiotic failure. *Cerebral venous sinus thrombosis* - **Cerebral venous sinus thrombosis** is a rare but severe complication of meningitis that can cause **raised intracranial pressure**, focal neurological deficits, and **venous infarcts**. - While it can lead to oedema, it is less common than **SIADH** and typically presents with specific imaging findings such as the **delta sign** or absent flow in a sinus. *Rifampicin resistance requiring treatment modification* - **Rifampicin** is primarily used for **post-exposure prophylaxis** of close contacts of patients with **meningococcal meningitis**, not for the treatment of active infection. - Resistance of *Neisseria meningitidis* to **third-generation cephalosporins** like ceftriaxone is extremely rare and not the most probable cause of clinical deterioration in this scenario.

Question 144: A 31-year-old healthcare worker is identified as a contact of a patient with smear-positive pulmonary tuberculosis. She had documented BCG vaccination as a child. She is asymptomatic and has no past history of TB. Her Mantoux test shows 18 mm induration. Chest X-ray is normal. Interferon-gamma release assay (IGRA) is positive. She is currently 8 weeks pregnant. What is the most appropriate management?

A. Start isoniazid prophylaxis immediately for 3 months
B. Start isoniazid prophylaxis immediately for 6 months with pyridoxine
C. Defer treatment for latent TB infection until after delivery (Correct Answer)
D. Start rifampicin and isoniazid for 3 months immediately
E. Observe without treatment and repeat chest X-ray in 6 months

Explanation: ***Defer treatment for latent TB infection until after delivery*** - In immunocompetent pregnant women with **latent tuberculosis infection (LTBI)**, treatment is typically postponed until after delivery to minimize the risk of **drug-induced hepatotoxicity** and fetal exposure. - The risk of progression to **active TB** during pregnancy is low compared to the potential adverse effects of treatment on the mother and fetus in a non-high-risk patient. *Start isoniazid prophylaxis immediately for 3 months* - A 3-month **isoniazid** course is not a standard standalone regimen for LTBI and lacks the necessary **pyridoxine** supplementation for a pregnant patient. - Immediate initiation is unnecessary as she lacks high-risk factors like **HIV infection** or recent known conversion within a high-risk setting. *Start isoniazid prophylaxis immediately for 6 months with pyridoxine* - While 6 months of **isoniazid with pyridoxine** is a valid regimen for LTBI, it is reserved for pregnant patients at high risk of rapid progression to active disease. - For this asymptomatic healthcare worker with a normal **chest X-ray**, the risks of immediate treatment generally outweigh the benefits until the postpartum period. *Start rifampicin and isoniazid for 3 months immediately* - Combination therapy with **rifampicin and isoniazid** is an alternative for LTBI, but immediate use in pregnancy is limited to patients with high risk of **disease progression**. - Standard guidelines favor waiting until after delivery to avoid exposing the fetus to multiple drugs and the mother to cumulative **liver toxicity**. *Observe without treatment and repeat chest X-ray in 6 months* - Observation alone is insufficient because positive **IGRA** and TST (18mm) confirm **latent TB infection**, which requires treatment eventually. - Simple observation fails to address the approximately 10% lifetime risk of progression to **active tuberculosis**, which is highest in the first two years after exposure.

Question 145: A 7-year-old boy who recently emigrated from India is diagnosed with tuberculous meningitis. MRI brain shows basal exudates and communicating hydrocephalus. Lumbar puncture shows: opening pressure 28 cmH2O, white cells 250 cells/mm³ (80% lymphocytes), protein 2.5 g/L, glucose 1.5 mmol/L (plasma 5.0 mmol/L). He is started on rifampicin, isoniazid, pyrazinamide, and ethambutol along with adjunctive therapy. What is the recommended duration of treatment for this patient?

A. 6 months
B. 9 months
C. 12 months (Correct Answer)
D. 18 months
E. 24 months

Explanation: ***12 months*** - **Tuberculous meningitis** requires a prolonged treatment course of **12 months** (2 months intensive phase, 10 months continuation phase) because of the high risk of relapse and poor **CNS drug penetration**.- International guidelines (WHO/NICE) recommend this duration to ensure eradication of the bacilli and to prevent **neurological sequelae** in complex cases involving basal exudates and hydrocephalus.*6 months*- This is the standard duration for **uncomplicated pulmonary tuberculosis**, which is insufficient for central nervous system involvement.- Shorter courses are associated with significantly higher rates of **treatment failure** and recurrence in meningitis cases.*9 months*- While sometimes used for **bone and joint tuberculosis** or intensive pulmonary cases, it does not meet the standard of care for **CNS tuberculosis**.- Clinical outcomes for meningitis are superior with the extended **10-month continuation phase** (totaling 12 months).*18 months*- This extended duration is typically reserved for cases of **multidrug-resistant TB (MDR-TB)** rather than drug-sensitive strains.- Standard quadruple therapy for sensitive TB does not require such a long course unless there is **delayed clinical response** or resistance.*24 months*- This duration is generally utilized for **extensively drug-resistant TB (XDR-TB)** or extremely complex, non-responsive intracranial tuberculomas.- It is not indicated for the initial management of a standard pediatric case of **tuberculous meningitis**.

Question 146: A 53-year-old man is diagnosed with drug-sensitive pulmonary tuberculosis and starts rifampicin, isoniazid, pyrazinamide, and ethambutol. He takes warfarin for atrial fibrillation and has been stable on 5 mg daily with INR consistently 2.0-3.0. Three days after starting TB treatment, his INR is 1.2. What is the most appropriate management of his anticoagulation?

A. Continue warfarin at the same dose and recheck INR in 2 weeks
B. Increase warfarin dose incrementally and monitor INR closely until therapeutic range achieved (Correct Answer)
C. Switch to a direct oral anticoagulant (DOAC) such as apixaban
D. Stop warfarin and start subcutaneous low molecular weight heparin
E. Add aspirin 75 mg daily to warfarin and continue same dose

Explanation: ***Increase warfarin dose incrementally and monitor INR closely until therapeutic range achieved*** - **Rifampicin** is a potent inducer of **cytochrome P450 (CYP2C9)** enzymes, which significantly increases the metabolism of **warfarin**, leading to a subtherapeutic **INR**. - An **INR** of 1.2 is below the therapeutic range (2.0-3.0) for atrial fibrillation, necessitating an **incremental increase in warfarin dose** and close **INR monitoring** to restore effective anticoagulation. *Continue warfarin at the same dose and recheck INR in 2 weeks* - The current **INR** of 1.2 indicates a significant and rapid drug-drug interaction, leaving the patient **subtherapeutic** and at high risk for **thromboembolic events**. - Delaying dose adjustment for two weeks would prolong this period of inadequate anticoagulation, which is clinically unsafe for a patient with **atrial fibrillation**. *Switch to a direct oral anticoagulant (DOAC) such as apixaban* - **Rifampicin** is also a strong inducer of **P-glycoprotein (P-gp)** and **CYP3A4**, which metabolize most **DOACs** (including apixaban), leading to significantly reduced **DOAC concentrations**. - This interaction would render the **DOAC** ineffective, leaving the patient unprotected from **stroke**, and unlike warfarin, DOAC levels are not routinely monitored to guide dose adjustments in this setting. *Stop warfarin and start subcutaneous low molecular weight heparin* - While **low molecular weight heparin (LMWH)** is effective and its anticoagulation is not affected by **rifampicin**, it is generally impractical for the long-term (6-month) duration of **tuberculosis treatment** due to the need for daily injections. - **LMWH** is typically reserved for acute anticoagulation, bridging therapy, or when oral anticoagulation is contraindicated or ineffective, which is not the primary issue here. *Add aspirin 75 mg daily to warfarin and continue same dose* - Adding **aspirin** to an already subtherapeutic **warfarin** regimen would increase the **bleeding risk** without correcting the underlying problem of inadequate **INR** for **atrial fibrillation**. - Antiplatelet therapy with **aspirin** is not a substitute for therapeutic anticoagulation with a vitamin K antagonist in the management of **atrial fibrillation**.

Question 147: A 16-year-old girl presents to the emergency department with a 6-hour history of severe headache, fever, vomiting, and photophobia. She is drowsy but responds to voice. Her flatmates mention she had cold symptoms a few days ago. On examination: temperature 38.9°C, heart rate 125/min, blood pressure 100/65 mmHg, GCS 13/15, positive neck stiffness, no rash, no focal neurological signs. CT head is normal. What is the most appropriate next step in management?

A. Perform lumbar puncture immediately before starting antibiotics
B. Administer intravenous ceftriaxone and dexamethasone, then perform lumbar puncture (Correct Answer)
C. Administer intravenous aciclovir only and perform lumbar puncture
D. Start oral antibiotics and discharge with safety netting advice
E. Arrange urgent MRI brain before any treatment

Explanation: ***Administer intravenous ceftriaxone and dexamethasone, then perform lumbar puncture*** - In suspected **bacterial meningitis**, immediate administration of **intravenous antibiotics** is crucial and should not be delayed by diagnostic procedures once contraindications like raised intracranial pressure are ruled out by a normal CT head and absence of focal neurological signs. - **Dexamethasone** is given concurrently with or just before the first dose of antibiotics to reduce inflammation and the risk of **neurological complications** such as hearing loss. *Perform lumbar puncture immediately before starting antibiotics* - While a **lumbar puncture** is essential for definitive diagnosis and identifying the causative organism, delaying antibiotic treatment in a patient with a **GCS of 13**, fever, neck stiffness, and signs of sepsis could lead to increased morbidity and mortality. - **Blood cultures** should be drawn, but **empiric antibiotics** must be started within the 'golden hour' for suspected bacterial meningitis. *Administer intravenous aciclovir only and perform lumbar puncture* - **Aciclovir** is an antiviral agent primarily used for **herpes simplex encephalitis**. While viral meningitis can present similarly, the rapid progression, high fever, and significant meningeal signs warrant broad-spectrum bacterial coverage as the priority. - Relying solely on aciclovir without bacterial coverage in a patient with suspected bacterial meningitis could be fatal, as bacterial meningitis is a medical emergency requiring prompt and aggressive antibiotic therapy. *Start oral antibiotics and discharge with safety netting advice* - This patient presents with severe symptoms including **drowsiness** (GCS 13), **photophobia**, **neck stiffness**, and signs of **systemic inflammatory response** (fever, tachycardia, hypotension), indicating a severe infection requiring urgent inpatient management. - **Oral antibiotics** are insufficient to treat severe infections like meningitis due to poor penetration into the **cerebrospinal fluid** and inadequate systemic levels. *Arrange urgent MRI brain before any treatment* - An **urgent CT head** has already been performed and is normal, effectively ruling out mass lesions, hydrocephalus, or significant cerebral edema that would contraindicate an immediate lumbar puncture or necessitate delayed treatment. - Waiting for an **MRI brain** would cause a critical delay in administering life-saving antibiotics for suspected bacterial meningitis, which is a time-sensitive emergency.

Question 148: A 29-year-old pregnant woman at 20 weeks gestation is diagnosed with active pulmonary tuberculosis. Sputum microscopy is positive for acid-fast bacilli, and GeneXpert MTB/RIF confirms rifampicin-sensitive Mycobacterium tuberculosis. She is otherwise well with normal liver function. What is the most appropriate anti-tuberculosis treatment regimen for this patient?

A. Rifampicin, isoniazid, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months (Correct Answer)
B. Delay treatment until after delivery
C. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months
D. Rifampicin and isoniazid for 9 months
E. Isoniazid and ethambutol for 18 months

Explanation: ***Rifampicin, isoniazid, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months*** - This regimen is the standard recommended treatment for **active pulmonary tuberculosis** in **pregnant women** with drug-sensitive TB, especially in regions where pyrazinamide is typically avoided due to limited safety data. - **Ethambutol** is included in the intensive phase to ensure adequate coverage and prevent resistance. **Pyridoxine (Vitamin B6)** supplementation is crucial to prevent **isoniazid-induced peripheral neuropathy**. *Delay treatment until after delivery* - **Delaying treatment** for active pulmonary tuberculosis in pregnancy poses significant risks, including disease progression in the mother, increased maternal and fetal morbidity, and potential for **congenital tuberculosis** in the neonate. - The benefits of treating active TB far outweigh the risks associated with **anti-TB medications** during pregnancy. Prompt treatment is crucial to protect both mother and child. *Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months* - While this is the standard initial regimen for **non-pregnant adults** with drug-sensitive TB, **pyrazinamide** is generally **avoided during pregnancy** in some guidelines due to insufficient data on its **teratogenicity**, despite some international bodies considering it safe. - Choosing a regimen without pyrazinamide in pregnancy, but including ethambutol, is a common cautious approach to reduce theoretical fetal risks, especially when rifampicin sensitivity is confirmed. *Rifampicin and isoniazid for 9 months* - A **two-drug regimen** for the entire duration is generally considered **inadequate** for treating active pulmonary tuberculosis, as it increases the risk of **treatment failure** and the development of **drug resistance**. - An intensive phase with at least **three drugs** (including ethambutol in this case, due to pregnancy considerations) is essential to rapidly reduce the bacterial load and prevent resistance. *Isoniazid and ethambutol for 18 months* - This regimen **omits rifampicin**, a critically important and potent **bactericidal drug** that significantly shortens the duration of TB treatment. Without rifampicin, treatment effectiveness is severely compromised. - An 18-month duration is excessively long for **rifampicin-sensitive TB** and is typically reserved for more complex cases, such as **multidrug-resistant TB (MDR-TB)**, which is not indicated here.

Question 149: A 67-year-old man with type 2 diabetes mellitus presents with a 4-day history of fever, confusion, and photophobia. CT head shows no mass lesion or raised intracranial pressure. Lumbar puncture reveals: white cells 1850 cells/mm³ (92% neutrophils), protein 2.8 g/L, glucose 1.2 mmol/L (plasma 8.5 mmol/L). Blood cultures and CSF Gram stain show Gram-positive diplococci. He has documented severe penicillin allergy (anaphylaxis). What is the most appropriate antimicrobial therapy?

A. Intravenous ceftriaxone and dexamethasone
B. Intravenous vancomycin, rifampicin, and dexamethasone (Correct Answer)
C. Intravenous meropenem and dexamethasone
D. Intravenous chloramphenicol and dexamethasone
E. Intravenous ciprofloxacin and dexamethasone

Explanation: ***Intravenous vancomycin, rifampicin, and dexamethasone*** - Given the patient's documented **anaphylaxis** to penicillin, beta-lactam antibiotics like cephalosporins and carbapenems are contraindicated due to the risk of **cross-reactivity**. - **Vancomycin** provides coverage for **Gram-positive diplococci** (*Streptococcus pneumoniae*), and **rifampicin** is added to enhance CSF penetration and provide synergistic activity, especially important with variable vancomycin CSF levels and potential resistance. **Dexamethasone** is standard adjunctive therapy. *Intravenous ceftriaxone and dexamethasone* - **Ceftriaxone** is a third-generation cephalosporin, which is a beta-lactam antibiotic and carries a significant risk of **cross-reactivity** in patients with severe penicillin allergy (anaphylaxis). - While it is a standard first-line treatment for bacterial meningitis, it must be avoided in this patient to prevent a potentially fatal **allergic reaction**. *Intravenous meropenem and dexamethasone* - **Meropenem** is a carbapenem, another class of beta-lactam antibiotics, which also carries a risk of **cross-reactivity** with penicillin, particularly in cases of anaphylaxis. - Therefore, it is not a safe or appropriate alternative for treating bacterial meningitis in a patient with a documented severe penicillin allergy. *Intravenous chloramphenicol and dexamethasone* - Although **chloramphenicol** has good **CSF penetration** and activity against *S. pneumoniae*, its use is largely limited due to severe adverse effects, notably **bone marrow suppression** (aplastic anemia). - It is generally reserved for situations where other safer and equally effective options are unavailable, which is not the case here with vancomycin/rifampicin. *Intravenous ciprofloxacin and dexamethasone* - **Ciprofloxacin**, a fluoroquinolone, generally has **suboptimal bactericidal activity** against *Streptococcus pneumoniae* in the context of meningitis. - It is not considered a reliable first-line agent for pneumococcal meningitis due to concerns about achieving adequate **CSF concentrations** and its efficacy against high bacterial loads.

Question 150: A 48-year-old homeless man with alcohol dependency presents with a 6-week history of cough, weight loss, and night sweats. Chest X-ray shows bilateral upper zone cavitation. Three sputum samples are sent for acid-fast bacilli. What is the minimum number of positive sputum smears required to classify this patient as having smear-positive pulmonary tuberculosis for public health notification purposes?

A. All three sputum samples must be positive
B. At least two out of three sputum samples must be positive (Correct Answer)
C. At least one out of three sputum samples must be positive
D. Only one sample is needed if it is strongly positive (3+ or 4+)
E. Positive smear is not required if GeneXpert MTB/RIF is positive

Explanation: ***At least two out of three sputum samples must be positive*** - According to **WHO** and public health guidelines, a patient is classified as **smear-positive pulmonary TB** if at least **two** sputum samples are positive for **Acid-Fast Bacilli (AFB)** on microscopy. - This classification is critical for assessing **infectivity**, prioritizing **contact tracing**, and determining the urgency of **respiratory isolation**. *All three sputum samples must be positive* - Requiring all three samples to be positive would be insensitive for diagnosis and delay **public health notification**. - Two positive smears are sufficient to confirm high bacterial load and define a **notifiable case** of smear-positive TB. *At least one out of three sputum samples must be positive* - While a single positive smear is clinically significant and warrants treatment, traditional **public health classification** typically requires two for the "smear-positive" label. - In specific regions, a single positive smear may suffice if there is clear **radiological evidence** (like upper zone cavitation), but it is not the standard three-sample rule definition. *Only one sample is needed if it is strongly positive (3+ or 4+)* - The **grading of the smear** (e.g., 3+ or 4+) indicates a high bacterial burden but does not legally change the requirement from two samples to one for official classification. - Consistency across **multiple samples** is used to reduce the risk of laboratory error or environmental contaminant misinterpretation. *Positive smear is not required if GeneXpert MTB/RIF is positive* - **GeneXpert MTB/RIF** is a molecular test and classifies a patient as "**bacteriologically confirmed**," not necessarily "**smear-positive**." - Smear status is specifically monitored via **microscopy** because it is a better predictor of how **contagious** the patient is compared to nucleic acid amplification tests.

Question 151: A 42-year-old man with HIV infection (CD4 count 65 cells/mm³) presents with a 3-week history of headache, fever, and confusion. CT head shows basal meningeal enhancement. Lumbar puncture reveals opening pressure 32 cmH2O, white cells 45 cells/mm³ (lymphocytes), protein 1.2 g/L, glucose 1.8 mmol/L (plasma 5.2 mmol/L). India ink stain is positive. What is the most appropriate initial management strategy?

A. Intravenous amphotericin B and oral flucytosine for 2 weeks, followed by fluconazole consolidation (Correct Answer)
B. Oral fluconazole 400 mg daily for 6 weeks
C. Intravenous ceftriaxone and vancomycin
D. Standard four-drug anti-tuberculosis therapy
E. Intravenous aciclovir and empirical antibacterial therapy

Explanation: ***Intravenous amphotericin B and oral flucytosine for 2 weeks, followed by fluconazole consolidation*** - The patient's **HIV infection** with a very **low CD4 count (65 cells/mm³)**, characteristic CSF findings, and a **positive India ink stain** unequivocally diagnose **Cryptococcal meningitis**. - The recommended **induction therapy** for severe Cryptococcal meningitis involves a combination of **liposomal amphotericin B** and **flucytosine** for at least 2 weeks, followed by **fluconazole consolidation** and maintenance, as this regimen significantly reduces mortality and fungal load. *Oral fluconazole 400 mg daily for 6 weeks* - **Fluconazole monotherapy** is insufficient and associated with higher treatment failure rates for the **induction phase** of severe Cryptococcal meningitis, especially in immunocompromised patients. - Fluconazole is primarily used for the **consolidation and maintenance phases** after the intensive initial induction therapy, not as primary induction. *Intravenous ceftriaxone and vancomycin* - This regimen targets **acute bacterial meningitis**, which typically presents with a more rapid onset and a predominance of neutrophils in the CSF. - These antibiotics have **no antifungal activity** and would be entirely ineffective against *Cryptococcus neoformans*, which was confirmed by the India ink stain. *Standard four-drug anti-tuberculosis therapy* - While **Tuberculous meningitis** can mimic Cryptococcal meningitis with similar CSF findings and **basal meningeal enhancement** in immunocompromised patients. - The **positive India ink stain** specifically identifies *Cryptococcus*, making anti-tuberculosis therapy an inappropriate initial management strategy in this case. *Intravenous aciclovir and empirical antibacterial therapy* - **Aciclovir** is an antiviral agent used for conditions like **herpes simplex encephalitis**, which typically presents with different clinical and radiological features, often with focal neurological signs. - This treatment strategy lacks the essential **antifungal coverage** required to effectively treat **Cryptococcal meningitis**, a fungal infection confirmed by the laboratory results.

Question 152: A 3-year-old girl presents with a 24-hour history of fever, irritability, and refusing to walk. On examination, she is drowsy with a temperature of 39.5°C and has positive Kernig's sign. Lumbar puncture shows: opening pressure 25 cmH2O, white cell count 850 cells/mm³ (85% lymphocytes), protein 0.8 g/L, glucose 2.8 mmol/L (plasma glucose 5.5 mmol/L). What is the most appropriate interpretation of these cerebrospinal fluid findings?

A. Normal cerebrospinal fluid
B. Bacterial meningitis
C. Viral meningitis (Correct Answer)
D. Tuberculous meningitis
E. Partially treated bacterial meningitis

Explanation: ***Viral meningitis*** - The CSF findings of **lymphocytic pleocytosis** (85% lymphocytes), moderately elevated protein (0.8 g/L), and a **normal to mildly reduced CSF glucose ratio** (0.51) are highly characteristic of viral meningitis. - The elevated opening pressure (25 cmH2O) and fever, irritability, and positive Kernig's sign support an inflammatory meningeal process, which is consistent with a viral etiology. *Normal cerebrospinal fluid* - Normal CSF would show a **white cell count** of <5 cells/mm³, a protein level <0.45 g/L, and an opening pressure <20 cmH2O. - This patient's CSF has a significantly elevated white cell count (850 cells/mm³), elevated protein, and elevated opening pressure, clearly indicating **pathology**. *Bacterial meningitis* - Bacterial meningitis typically presents with a **neutrophilic pleocytosis** (predominance of neutrophils) and a **markedly low CSF glucose** (ratio <0.4 or absolute value <2.2 mmol/L). - The white cell count is usually much higher (often >1000 cells/mm³) with more significantly elevated protein (>1.0 g/L), which differs from these findings. *Tuberculous meningitis* - While it can present with **lymphocytic pleocytosis**, tuberculous meningitis is characterized by **very low CSF glucose** (often <1.5 mmol/L) and **very high protein levels** (often >1-5 g/L). - The clinical course is typically **subacute or chronic** (weeks to months), rather than the acute 24-hour presentation seen in this patient. *Partially treated bacterial meningitis* - This condition might show a shift towards **lymphocytic predominance** in the CSF, but the **glucose level** usually remains significantly low due to the initial bacterial consumption. - There is no history provided in the clinical scenario to suggest the patient received **antibiotic treatment** prior to the lumbar puncture.

Question 153: A 58-year-old man with previously treated pulmonary tuberculosis develops recurrent disease. Culture and sensitivity testing reveals resistance to rifampicin and isoniazid, but sensitivity to ethambutol, pyrazinamide, and fluoroquinolones. What is the minimum recommended duration of treatment for his multidrug-resistant tuberculosis?

A. 6 months
B. 9 months
C. 12 months
D. 18 months (Correct Answer)
E. 24 months

Explanation: ***18 months*** - Multidrug-resistant tuberculosis (**MDR-TB**), defined by resistance to both **rifampicin and isoniazid**, requires a significantly prolonged treatment course compared to drug-sensitive TB. - Global guidelines (e.g., WHO) typically recommend a minimum total duration of **18 to 20 months** for conventional, individualized regimens to ensure effective bacterial clearance and prevent relapse, often counted from the date of culture conversion. *6 months* - This duration is the standard for **drug-sensitive pulmonary TB** treated with the standard first-line regimen (RIPE). - It is insufficient for **MDR-TB** because the core first-line drugs (rifampicin and isoniazid) are ineffective, leading to a high risk of treatment failure if used. *9 months* - A **9-month shorter regimen** exists for MDR-TB but is reserved for specific patient populations, particularly those without prior exposure to second-line drugs or resistance to **fluoroquinolones**. - It is not the universal minimum recommended duration for all MDR-TB cases, especially those with a history of previous treatment. *12 months* - This duration is generally considered inadequate for standard **MDR-TB** management due to the slower bactericidal activity of second-line drugs and the high risk of **treatment failure** and relapse. - While newer regimens are being explored, 12 months is not the established minimum for this patient profile. *24 months* - Treatment for **MDR-TB** can extend to **24 months** or longer in complex situations, such as **Extensively Drug-Resistant TB (XDR-TB)** or severe, extensive disease. - However, it is not the *minimum* recommended duration for all MDR-TB; rather, it is reserved for the most challenging cases where prolonged therapy is deemed necessary.

Question 154: A 25-year-old man presents to the emergency department with a 10-hour history of fever, severe headache, and vomiting. On examination, he has a temperature of 39.2°C, heart rate 118/min, blood pressure 95/60 mmHg, and a non-blanching purpuric rash on his lower limbs. Which organism is most likely responsible for his clinical presentation?

A. Streptococcus pneumoniae
B. Neisseria meningitidis (Correct Answer)
C. Haemophilus influenzae
D. Listeria monocytogenes
E. Mycobacterium tuberculosis

Explanation: ***Neisseria meningitidis***- The presence of a **non-blanching purpuric rash** combined with fever, headache, and signs of **septic shock** (hypotension and tachycardia) is the hallmark presentation of **meningococcal septicaemia**.- This Gram-negative diplococcus is a leading cause of bacterial meningitis in **young adults** and requires immediate treatment with intravenous **ceftriaxone**.*Streptococcus pneumoniae*- While it is the most common cause of bacterial meningitis in adults, it typically presents without the characteristic **purpuric rash** seen in this patient.- It is more frequently associated with predisposing factors like **pneumonia**, **otitis media**, or **splenectomy**.*Haemophilus influenzae*- The incidence of meningitis caused by this organism has significantly decreased due to the widespread use of the **Hib vaccine**.- It usually affects **unvaccinated children** and lacks the rapidly progressive hemorrhagic rash characteristic of meningococcus.*Listeria monocytogenes*- This organism typically causes meningitis in specific high-risk groups, including the **elderly**, **pregnant women**, and the **immunocompromised**.- The clinical onset is often less hyperacute than meningococcal disease and is frequently associated with ingestion of **contaminated food**.*Mycobacterium tuberculosis*- Tuberculous meningitis generally follows a **subacute or chronic** course, with symptoms developing over weeks rather than hours.- Clinical findings usually include **basal meningitis**, cranial nerve palsies, and a more gradual decline in mental status compared to acute bacterial causes.

Question 155: A 34-year-old woman with pulmonary tuberculosis is currently on rifampicin, isoniazid, pyrazinamide, and ethambutol. She develops painful, red eyes with blurred vision. Ophthalmology examination reveals bilateral optic neuritis. Which medication is most likely responsible for this complication?

A. Rifampicin
B. Isoniazid
C. Pyrazinamide
D. Ethambutol (Correct Answer)
E. Streptomycin

Explanation: ***Ethambutol***- **Ethambutol** is classically associated with **dose-dependent optic neuritis**, leading to **decreased visual acuity**, **painful red eyes**, and **blurred vision**, often with **red-green color blindness**.- Patients on this drug must undergo baseline and periodic **ophthalmological screening** as the condition is usually reversible upon drug discontinuation.*Rifampicin*- Primary side effects include **hepatotoxicity** and a harmless **orange discoloration** of body fluids like urine, tears, and sweat.- It acts as a potent **cytochrome P450 inducer**, but it does not typically cause visual impairment or optic nerve damage.*Isoniazid*- Most commonly associated with **peripheral neuropathy** due to **pyridoxine (vitamin B6)** deficiency and potential hepatotoxicity.- While it can occasionally cause rare neurological issues, it is not the primary cause of sudden-onset **optic neuritis** in standard multidrug therapy.*Pyrazinamide*- The most frequent adverse effects are **hyperuricemia**, which may precipitate **gouty arthritis**, and hepatotoxicity.- It does not have any reported association with **ophthalmic toxicity** or blurred vision.*Streptomycin*- Known for its **ototoxicity**, which can lead to permanent hearing loss or **vestibular dysfunction** (vertigo and ataxia).- It is also associated with **nephrotoxicity** but does not cause the inflammatory changes in the optic nerve seen in this patient.

Question 156: A 36-year-old man from Bangladesh completes 6 months of treatment for drug-sensitive pulmonary tuberculosis with rifampicin, isoniazid, pyrazinamide, and ethambutol (2 months) followed by rifampicin and isoniazid (4 months). He is clinically well. End-of-treatment chest X-ray shows residual upper lobe fibrosis but no active disease. Sputum samples are smear and culture negative. He asks about risk of recurrence. Which factor most significantly increases his risk of TB relapse after treatment completion?

A. Presence of cavitation on initial chest X-ray
B. Country of origin with high TB prevalence
C. Residual radiological changes on chest X-ray
D. Positive sputum culture at 2 months of treatment (Correct Answer)
E. Duration of symptoms before diagnosis

Explanation: ***Positive sputum culture at 2 months of treatment*** - A **positive sputum culture** after the 2-month intensive phase is the most significant microbiological predictor of **TB relapse**, as it reflects a high persistent **bacillary load**. - Patients failing to achieve **culture conversion** by 2 months have a relapse risk significantly higher (approx. 5-10%) than those who convert early. *Presence of cavitation on initial chest X-ray* - While **cavitation** indicates a higher initial bacterial burden and is associated with delayed clearance, it is a baseline factor rather than a measure of treatment response. - It serves as an independent risk factor but is statistically less predictive of relapse than the **microbiological status** at the end of the intensive phase. *Country of origin with high TB prevalence* - Being from a high-prevalence area like **Bangladesh** increases the lifetime risk of **re-infection** with a new strain but does not necessarily increase the risk of **relapse** of the original strain. - Relapse is primarily determined by the efficacy of the treatment regimen and the patient's individual **immune response** to the initial infection. *Residual radiological changes on chest X-ray* - **Residual fibrosis** or scarring is a common sequela of healed pulmonary TB occurring in up to 50% of patients and does not imply the presence of **viable bacilli**. - As long as **sputum cultures** are negative at the end of treatment, these stable radiographic findings do not increase the risk of the disease returning. *Duration of symptoms before diagnosis* - A longer duration of symptoms before starting therapy may correlate with more extensive **lung tissue damage**, but it is not a direct predictor of treatment failure. - The **rate of clearance** of the organism during the first 8 weeks of therapy is a much more robust indicator of long-term cure than the pre-treatment symptom duration.

Question 157: A 51-year-old man from Zimbabwe with newly diagnosed HIV (CD4 count 45 cells/mm³, viral load 450,000 copies/mL) presents with a 4-week history of headache, confusion, and fever. Cryptococcal antigen (CrAg) in serum and CSF is positive. Opening pressure on LP is 38 cmH2O. He is started on liposomal amphotericin B and flucytosine. When is the most appropriate time to initiate antiretroviral therapy?

A. Immediately, alongside antifungal therapy
B. After 2 weeks of antifungal therapy
C. After 4-6 weeks of antifungal therapy (Correct Answer)
D. After completion of induction therapy (2 weeks) and consolidation therapy (8 weeks)
E. Only after CSF cryptococcal antigen becomes negative

Explanation: ***After 4-6 weeks of antifungal therapy***- Guidelines recommend deferring **antiretroviral therapy (ART)** for 4-6 weeks in patients with **cryptococcal meningitis** to reduce the risk of **Immune Reconstitution Inflammatory Syndrome (IRIS)**.- Clinical trials (like the **COAT trial**) demonstrated that earlier initiation of ART is associated with a significantly **higher mortality** rate due to intracranial complications associated with IRIS.*Immediately, alongside antifungal therapy*- Starting ART immediately is contraindicated because it poses an extremely high risk of **IRIS**, which can lead to fatal brain swelling and **raised intracranial pressure**.- This approach is typically only reserved for other opportunistic infections like **Pneumocystis pneumonia (PCP)** or toxoplasmosis, but not for fungal meningitis.*After 2 weeks of antifungal therapy*- While 2 weeks marks the end of the **induction phase**, studies show that initiating ART at this point still carries an unacceptably high risk of lethal **meningeal inflammation**.- Delaying further allows the **fungal burden** to decrease significantly before the immune system begins its recovery.*After completion of induction therapy (2 weeks) and consolidation therapy (8 weeks)*- Waiting a total of 10 weeks is unnecessarily long and increases the risk of other **AIDS-defining illnesses** or death due to profound immunosuppression.- The optimal balance to prevent both **IRIS** and opportunistic infections is achieved by starting ART between the **4th and 6th week**.*Only after CSF cryptococcal antigen becomes negative*- **Cryptococcal antigen (CrAg)** in the CSF can remain positive for months or years, even with successful treatment, and is not a marker for timing ART.- Treatment success is monitored via **CSF culture negativity** rather than the clearance of the polysaccharide antigen itself.

Question 158: A 29-year-old woman presents with headache, fever, and photophobia. LP shows: opening pressure 24 cmH2O, CSF clear with 450 white cells/mm³ (85% lymphocytes), protein 0.8 g/L, glucose 3.2 mmol/L (plasma glucose 5.8 mmol/L). She was treated with IV aciclovir for suspected HSV encephalitis. CSF PCR is negative for HSV, VZV, and enteroviruses. Blood and CSF cultures are sterile at 48 hours. She improves clinically. What is the most likely diagnosis?

A. Partially treated bacterial meningitis
B. Tuberculous meningitis
C. Viral meningitis with false-negative PCR (Correct Answer)
D. Fungal meningitis
E. Neurosarcoidosis

Explanation: ***Viral meningitis with false-negative PCR***\n - The CSF profile shows **lymphocytic pleocytosis**, mildly elevated protein, and a **normal glucose ratio** (>0.5), which is classic for a viral etiology.\n - While **PCR** is highly sensitive for HSV, VZV, and enteroviruses, it can be **falsely negative** depending on the timing of the lumbar puncture or the specific viral agent involved; spontaneous clinical improvement further supports this diagnosis.\n*Partially treated bacterial meningitis*\n - This typically presents with a **neutrophilic predominance** initially and a significant **drop in CSF glucose**, which are not seen here.\n - The patient improved clinically without receiving **antibiotics**, making a bacterial cause highly unlikely.\n*Tuberculous meningitis*\n - Tuberculous meningitis usually presents with a very high protein level and **markedly low glucose** (less than 50% of plasma glucose).\n - The clinical course of TB meningitis is typically **subacute or chronic** and does not resolve rapidly without specific anti-tubercular therapy.\n*Fungal meningitis*\n - Often caused by **Cryptococcus**, it is primarily seen in **immunocompromised patients** and usually features low glucose levels.\n - Fungal infections follow an **indolent course** rather than the acute presentation and rapid improvement described in this case.\n*Neurosarcoidosis*\n - This is a rare **granulomatous disease** that usually presents with cranial nerve palsies or chronic symptoms rather than acute fever and photophobia.\n - While it can cause **lymphocytic pleocytosis**, it would not typically show sudden clinical improvement without **steroid treatment**.

Question 159: A 44-year-old woman with rheumatoid arthritis on methotrexate and newly commenced tocilizumab (IL-6 inhibitor) undergoes screening for latent tuberculosis. Mantoux test shows 18 mm induration at 48 hours. Chest X-ray shows calcified granuloma in the right upper zone but no active disease. Interferon-gamma release assay is positive. She has no symptoms of active TB. What is the most appropriate management?

A. Commence isoniazid monotherapy for 6 months; continue tocilizumab
B. Commence rifampicin and isoniazid for 3 months; defer tocilizumab until completed (Correct Answer)
C. No treatment required; continue tocilizumab with regular monitoring
D. Commence rifampicin monotherapy for 4 months; defer tocilizumab for 2 months
E. Treat as active tuberculosis with four-drug therapy; discontinue tocilizumab

Explanation: ***Commence rifampicin and isoniazid for 3 months; defer tocilizumab until completed***- The patient presents with **latent tuberculosis infection (LTBI)**, confirmed by a positive **Mantoux test** (18mm induration), positive **IGRA**, and a **calcified granuloma** on Chest X-ray, all in the absence of active symptoms. This necessitates treatment before immunosuppressive biologics.- A 3-month course of **rifampicin and isoniazid** is a standard and effective regimen for LTBI, particularly beneficial for patients starting **biologic therapy** (like tocilizumab) where deferring the biologic until treatment completion is crucial to prevent **reactivation**.*Commence isoniazid monotherapy for 6 months; continue tocilizumab*- While **isoniazid monotherapy** for 6-9 months is a valid treatment for LTBI, continuing **tocilizumab** (an IL-6 inhibitor) concurrently significantly increases the risk of **TB reactivation** before the prophylactic treatment has had time to be fully effective.- Biologic agents should generally be withheld or deferred until the completion of LTBI treatment or at least until a substantial portion of the treatment (e.g., 1-2 months) has been completed, to ensure adequate protection.*No treatment required; continue tocilizumab with regular monitoring*- This approach is incorrect as the patient has clear evidence of **latent tuberculosis infection** (positive Mantoux, positive IGRA, calcified granuloma) and is on powerful **immunosuppressive therapy** (tocilizumab).- Continuing tocilizumab without treating LTBI would significantly increase her risk of developing **active tuberculosis**, which can be severe and life-threatening in immunocompromised individuals.*Commence rifampicin monotherapy for 4 months; defer tocilizumab for 2 months*- **Rifampicin monotherapy** for 4 months is an acceptable alternative regimen for LTBI, offering a shorter duration than isoniazid monotherapy.- However, deferring tocilizumab for only **2 months** while on a 4-month regimen may still leave the patient vulnerable to reactivation during the remaining treatment period or shortly after re-initiation of the biologic; completing the full LTBI treatment before re-starting the biologic is generally safer.*Treat as active tuberculosis with four-drug therapy; discontinue tocilizumab*- This patient does not have **active tuberculosis**; the chest X-ray shows only a **calcified granuloma** and she is asymptomatic. Four-drug therapy (e.g., RIPE: rifampicin, isoniazid, pyrazinamide, ethambutol) is indicated only for active disease.- Treating LTBI with an aggressive four-drug regimen meant for active TB is excessive and carries a higher risk of **drug toxicity** (especially hepatotoxicity) without additional benefit for latent disease.

Question 160: A 19-year-old previously healthy university student is admitted with suspected meningococcal meningitis and treated with IV ceftriaxone. Blood cultures grow Neisseria meningitidis serogroup W. He makes a full recovery. His flatmates (5 students) are concerned about their risk. What is the most appropriate chemoprophylaxis for the close contacts?

A. Single dose of intramuscular ceftriaxone 250 mg
B. Oral ciprofloxacin 500 mg single dose (Correct Answer)
C. Oral rifampicin 600 mg twice daily for 2 days
D. No chemoprophylaxis required as the patient received ceftriaxone
E. Oral azithromycin 500 mg single dose

Explanation: ***Oral ciprofloxacin 500 mg single dose***- A **single dose of oral ciprofloxacin** is the **first-line choice** for **meningococcal chemoprophylaxis** in close contacts due to its high efficacy in eradicating **nasopharyngeal carriage** of *Neisseria meningitidis*.- Its single-dose regimen improves **compliance** and convenience, making it ideal for managing close contacts like flatmates.*Single dose of intramuscular ceftriaxone 250 mg*- While **ceftriaxone** is effective for prophylaxis, the **intramuscular route** is generally reserved for specific populations, such as **pregnant women** or children, or when oral options are not feasible.- For healthy adult contacts, an oral agent is preferred due to its **less invasive** nature and ease of administration.*Oral rifampicin 600 mg twice daily for 2 days*- **Rifampicin** requires a **multi-dose regimen** (four doses over two days), which can lead to **reduced compliance** compared to single-dose options.- It also has a greater potential for **drug interactions** (due to CYP450 induction) and causes harmless but distinctive **orange discoloration** of body fluids.*No chemoprophylaxis required as the patient received ceftriaxone*- The **treatment of the index patient** with ceftriaxone successfully treats their infection but does not eliminate the risk for **close contacts** who may already be asymptomatically colonized.- **Chemoprophylaxis** aims to eradicate carriage in contacts to prevent secondary cases and stop further transmission within the close-contact group.*Oral azithromycin 500 mg single dose*- **Azithromycin** is an alternative agent for **meningococcal chemoprophylaxis**, particularly in situations where resistance to other first-line agents is a concern or when there are contraindications.- However, it is not consistently the **primary recommended agent** over ciprofloxacin in all national guidelines for routine prophylaxis of *Neisseria meningitidis* close contacts.

Question 161: A 58-year-old man with diabetes mellitus presents with a 7-week history of cough, weight loss, and night sweats. Chest X-ray shows right upper lobe consolidation with cavitation. Sputum microscopy shows acid-fast bacilli. Sputum GeneXpert MTB/RIF detects Mycobacterium tuberculosis with rifampicin resistance. Culture and sensitivity are pending. What is the most appropriate initial management?

A. Start standard four-drug therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) and adjust when sensitivities available
B. Start rifampicin, isoniazid, pyrazinamide, ethambutol, and add moxifloxacin as fifth drug
C. Refer immediately to specialist TB service and start MDR-TB regimen (Correct Answer)
D. Await full culture and sensitivity results before starting treatment
E. Start isoniazid, pyrazinamide, ethambutol, and moxifloxacin (omit rifampicin only)

Explanation: ***Refer immediately to specialist TB service and start MDR-TB regimen*** - The detection of **rifampicin resistance** by **GeneXpert MTB/RIF** indicates a high likelihood of **multidrug-resistant tuberculosis (MDR-TB)**, requiring urgent specialist consultation and initiation of an appropriate regimen. - MDR-TB regimens are complex, involve **second-line anti-TB drugs**, and must be tailored by specialists to ensure efficacy and prevent further resistance. *Start standard four-drug therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) and adjust when sensitivities available* - Starting a regimen that includes **rifampicin** when molecular testing has already confirmed resistance will lead to **treatment failure** and could worsen drug resistance. - Standard therapy is inappropriate for suspected **MDR-TB** and would not effectively treat the patient, allowing disease progression and transmission. *Start rifampicin, isoniazid, pyrazinamide, ethambutol, and add moxifloxacin as fifth drug* - Including **rifampicin** in the regimen is ineffective given the confirmed resistance, and adding a single drug to a failing regimen is a common cause of **acquired drug resistance**. - Management of confirmed or suspected **MDR-TB** requires a comprehensive, specifically designed regimen involving multiple effective second-line agents, not merely augmenting a failing first-line regimen. *Await full culture and sensitivity results before starting treatment* - Delaying treatment in a patient with active, **sputum AFB-positive**, and **cavitary pulmonary TB** increases the risk of disease progression, poor outcomes, and transmission to others. - **GeneXpert** provides rapid and reliable detection of *M. tuberculosis* and **rifampicin resistance**, which is sufficient to initiate empirical **MDR-TB treatment** while awaiting phenotypic sensitivities. *Start isoniazid, pyrazinamide, ethambutol, and moxifloxacin (omit rifampicin only)* - While rifampicin is omitted, **rifampicin resistance** often correlates with **isoniazid resistance**, making this an inadequate regimen for probable **MDR-TB**. - This regimen lacks the necessary number and types of **effective second-line drugs** required for treating MDR-TB and should not be initiated without specialist guidance.

Question 162: A 65-year-old woman with chronic lymphocytic leukaemia on ibrutinib presents with a 4-day history of fever, headache, and drowsiness. She is confused and has neck stiffness. Lumbar puncture shows: CSF white cells 120/mm³ (70% lymphocytes, 30% neutrophils), protein 0.9 g/L, glucose 2.8 mmol/L (plasma glucose 5.4 mmol/L). Gram stain is negative. Urgent CSF PCR is positive for Listeria monocytogenes. What is the most appropriate antibiotic therapy?

A. IV ceftriaxone
B. IV amoxicillin and gentamicin (Correct Answer)
C. IV vancomycin and ceftriaxone
D. IV meropenem
E. IV co-trimoxazole

Explanation: ***IV amoxicillin and gentamicin*** - High-dose **IV amoxicillin** (or ampicillin) is the treatment of choice for **Listeria monocytogenes** because the organism is naturally resistant to cephalosporins. - **Gentamicin** is added for its **synergistic effect**, enhancing bactericidal activity, which is crucial in treating **meningitis**, especially in immunocompromised patients like this one with CLL on ibrutinib. *IV ceftriaxone* - **Listeria** is inherently **resistant** to all generations of cephalosporins, including **ceftriaxone**, making it an ineffective monotherapy for *Listeria* meningitis. - While ceftriaxone covers common meningitis pathogens like *N. meningitidis* and *S. pneumoniae*, it must be combined with ampicillin or amoxicillin in at-risk groups (elderly, immunocompromised) to ensure *Listeria* coverage. *IV vancomycin and ceftriaxone* - This combination is standard **empiric therapy** for community-acquired bacterial meningitis to cover resistant *S. pneumoniae* and *N. meningitidis*, but it lacks appropriate activity against **Listeria**. - **Vancomycin** has poor central nervous system penetration and suboptimal clinical efficacy against *Listeria* compared to penicillins. *IV meropenem* - Although **meropenem** has some in vitro activity against *Listeria*, it is not considered the first-line gold standard for confirmed *Listeria* meningitis. - It is usually reserved for patients with severe allergies to penicillins or those with co-infections involving **extended-spectrum beta-lactamase (ESBL)**-producing organisms. *IV co-trimoxazole* - **Co-trimoxazole** (Trimethoprim-sulfamethoxazole) is an effective alternative for treating *Listeria* infections, particularly in patients with a severe **penicillin allergy**. - However, it remains a **second-line** option compared to the established efficacy and safety profile of high-dose amoxicillin/ampicillin for **Listeria meningitis**.

Question 163: A 47-year-old man from Nepal presents with a 6-week history of fever, headache, and progressive confusion. MRI brain shows ring-enhancing lesions in the basal ganglia. Lumbar puncture shows: opening pressure 25 cmH2O, CSF clear with 180 white cells/mm³ (80% lymphocytes), protein 1.2 g/L, glucose 1.9 mmol/L (plasma glucose 5.5 mmol/L). Ziehl-Neelsen stain is negative. What is the most appropriate next investigation to confirm the diagnosis?

A. CSF auramine stain
B. Repeat Ziehl-Neelsen stain on larger CSF volume
C. CSF GeneXpert MTB/RIF (Correct Answer)
D. CSF culture on Löwenstein-Jensen medium
E. Serum tuberculosis interferon-gamma release assay

Explanation: ***CSF GeneXpert MTB/RIF*** - This is the most appropriate next step because it is a **rapid molecular diagnostic test** with significantly higher sensitivity than microscopy for **tuberculous meningitis (TBM)**, especially in endemic regions like Nepal. - It provides results within hours and can simultaneously detect **rifampicin resistance**, which is crucial for initiating appropriate treatment early in this subacute presentation with concerning CSF findings and ring-enhancing lesions. *CSF auramine stain* - While slightly more sensitive than **Ziehl-Neelsen stain**, it still relies on a high bacterial load and often yields **false negatives** in paucibacillary conditions like TBM. - It does not offer the same diagnostic yield or drug sensitivity information provided by **nucleic acid amplification tests** like GeneXpert. *Repeat Ziehl-Neelsen stain on larger CSF volume* - Although repeating the stain on a **large volume (at least 6ml)** can marginally increase yield, the sensitivity remains poor (often below 20%) compared to molecular methods for TBM. - This approach is time-consuming and labor-intensive, delaying more definitive diagnostic methods like the **GeneXpert** which offers both speed and improved sensitivity. *CSF culture on Löwenstein-Jensen medium* - This remains the **gold standard** for confirming Mycobacterium tuberculosis; however, results take **4 to 8 weeks** to grow, which is too slow for acute management. - Due to the high mortality and morbidity of TBM, waiting for culture results is not appropriate for immediate clinical decision-making and diagnostic confirmation. *Serum tuberculosis interferon-gamma release assay* - A positive **IGRA (e.g., QuantiFERON)** merely indicates prior exposure to M. tuberculosis and cannot distinguish between **latent infection** and active central nervous system disease like TBM. - While it has a high **negative predictive value** for active TB, it lacks the specificity and diagnostic power to confirm active TBM in a patient with acute neurological symptoms.

Question 164: A 27-year-old man presents to the emergency department with a 14-hour history of headache, fever, photophobia, and vomiting. He is confused with a GCS of 13. Blood pressure is 110/70 mmHg. There is no rash. CT head is normal. Lumbar puncture shows: opening pressure 32 cmH2O, CSF cloudy with 2400 white cells/mm³ (90% neutrophils), protein 2.4 g/L, glucose 1.5 mmol/L (plasma glucose 6.0 mmol/L). He has already received IV ceftriaxone. What additional immediate treatment should be given?

A. Intrathecal gentamicin
B. IV dexamethasone (Correct Answer)
C. IV aciclovir
D. IV vancomycin
E. IV meropenem

Explanation: ***IV dexamethasone*** - Adjunctive **IV dexamethasone** is crucial in confirmed or highly suspected **bacterial meningitis** to reduce cerebral inflammation, prevent neurological complications like hearing loss, and improve survival. - It should be administered shortly before or concurrently with the first dose of antibiotics to be most effective, especially against *Streptococcus pneumoniae*. *Intrathecal gentamicin* - **Intrathecal antibiotics** are not a standard empirical treatment for bacterial meningitis and carry significant risks, including neurotoxicity and arachnoiditis. - Gentamicin has poor penetration into the CSF when given intravenously and is not typically used as first-line for meningitis, let alone intrathecally. *IV aciclovir* - **IV aciclovir** is the primary treatment for suspected **herpes simplex encephalitis**, which is a viral infection. - The patient's CSF profile (high **neutrophils**, low **glucose**) is highly indicative of bacterial, not viral, meningitis, which typically shows lymphocytic predominance and normal glucose. *IV vancomycin* - **IV vancomycin** is added to ceftriaxone only if there is a high prevalence of **penicillin-resistant *S. pneumoniae*** in the region, or in patients with specific risk factors like recent neurosurgery or severe penicillin allergy. - In a previously healthy young adult without such risk factors, ceftriaxone alone is generally considered sufficient initial empirical coverage for common bacterial pathogens. *IV meropenem* - **IV meropenem** is a broad-spectrum carbapenem reserved for cases with suspected **multidrug-resistant organisms**, severe penicillin allergy, or when first-line therapies like ceftriaxone fail. - There is no specific indication in this case for meropenem over ceftriaxone, which has already been administered and is appropriate for common community-acquired meningitis pathogens.

Question 165: A 32-year-old pregnant woman at 24 weeks gestation develops tuberculous meningitis. CT head shows basal meningeal enhancement and hydrocephalus. Which anti-tuberculosis drug regimen is most appropriate for initial management?

A. Rifampicin, isoniazid, pyrazinamide, and ethambutol (Correct Answer)
B. Rifampicin, isoniazid, pyrazinamide, and streptomycin
C. Rifampicin, isoniazid, and ethambutol only (avoid pyrazinamide)
D. Rifampicin and isoniazid only with extended duration
E. Standard four-drug therapy with addition of moxifloxacin

Explanation: ***Rifampicin, isoniazid, pyrazinamide, and ethambutol*** - This standard **four-drug regimen** is the recommended initial intensive phase treatment for **tuberculous meningitis** and is generally considered safe for use during **pregnancy**. - **Pyrazinamide** and **isoniazid** are crucial for their excellent **CSF penetration** and potent **bactericidal activity**, essential for effective treatment of CNS infections and preventing severe sequelae. *Rifampicin, isoniazid, pyrazinamide, and streptomycin* - **Streptomycin** is an **aminoglycoside** that is strictly **contraindicated** in pregnancy due to its established risk of **fetal ototoxicity**, which can cause permanent damage to the eighth cranial nerve. - Ethambutol is the preferred fourth agent over streptomycin in pregnant patients to avoid this severe adverse effect on the fetus. *Rifampicin, isoniazid, and ethambutol only (avoid pyrazinamide)* - While historical concerns existed, current **WHO and international guidelines** confirm that **pyrazinamide** is safe and an essential component of the intensive phase for severe forms of TB, including meningitis, in **pregnancy**. - Omitting pyrazinamide significantly weakens the regimen, increasing the risk of **treatment failure**, prolonged illness, and worse neurological outcomes in TB meningitis. *Rifampicin and isoniazid only with extended duration* - A two-drug regimen is insufficient for the **intensive phase** of **tuberculous meningitis** due to the high bacillary load and the critical need for rapid, potent bactericidal activity to prevent neurological damage. - This approach substantially increases the risk of **drug resistance** development and **treatment failure** in a severe, life-threatening condition like TB meningitis. *Standard four-drug therapy with addition of moxifloxacin* - **Moxifloxacin** (a fluoroquinolone) is generally avoided in **pregnancy** due to theoretical concerns regarding adverse effects on **fetal cartilage development**, although human data are limited. - The standard four-drug regimen (RIPE) is highly effective for drug-susceptible TB; adding moxifloxacin is typically reserved for **drug-resistant TB** or specific intolerances, which are not indicated here.

Question 166: A 56-year-old man with newly diagnosed smear-positive pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. He is also taking warfarin for atrial fibrillation. Two weeks later, his INR has decreased from 2.8 to 1.2. What is the most appropriate management?

A. Stop rifampicin and use alternative anti-tuberculosis regimen
B. Increase the warfarin dose and monitor INR closely (Correct Answer)
C. Switch from warfarin to a direct oral anticoagulant
D. Continue current therapy and accept subtherapeutic anticoagulation
E. Stop warfarin and start therapeutic dose low molecular weight heparin

Explanation: ***Increase the warfarin dose and monitor INR closely*** - **Rifampicin** is a potent **inducer of Cytochrome P450 enzymes**, primarily **CYP2C9**, which significantly increases the metabolism of **warfarin**, leading to a subtherapeutic **INR**. - The most appropriate management involves **increasing the warfarin dose** to counteract this increased metabolism, coupled with **frequent INR monitoring** to ensure the patient maintains a therapeutic anticoagulation range. *Stop rifampicin and use alternative anti-tuberculosis regimen* - **Rifampicin** is a critical component of first-line **tuberculosis treatment**, and stopping it without a compelling medical contraindication significantly increases the risk of **treatment failure** and the development of **drug resistance**. - It is generally preferred to manage drug interactions by adjusting the interacting medication (warfarin) rather than compromising the efficacy of the **life-saving anti-TB regimen**. *Switch from warfarin to a direct oral anticoagulant* - Most **Direct Oral Anticoagulants (DOACs)** are substrates for **CYP3A4** and/or **P-glycoprotein (P-gp)**, both of which are also potently induced by **rifampicin**. - Therefore, switching to a DOAC would likely lead to similarly **reduced DOAC levels** and **subtherapeutic anticoagulation**, rendering them an unreliable alternative in this context. *Continue current therapy and accept subtherapeutic anticoagulation* - An **INR of 1.2** is well below the therapeutic range (typically 2.0-3.0) for a patient with **atrial fibrillation**, leaving them at a significantly **increased risk of thromboembolic events**, such as stroke. - Allowing subtherapeutic anticoagulation is clinically unacceptable and dangerous, as it fails to protect the patient from the very condition warfarin is prescribed to prevent. *Stop warfarin and start therapeutic dose low molecular weight heparin* - While **low molecular weight heparin (LMWH)** is not affected by rifampicin's enzyme induction, it requires **daily subcutaneous injections**, making it an impractical and less convenient option for long-term outpatient anticoagulation compared to oral warfarin. - LMWH is typically reserved for acute situations, bridging therapy, or when oral anticoagulants are contraindicated, rather than as a primary solution for managing chronic drug-drug interactions in stable patients.

Question 167: A 5-year-old girl is brought to the emergency department with fever, headache, and neck stiffness. She received her routine childhood vaccinations. Lumbar puncture shows: opening pressure 28 cmH2O, CSF white cells 850/mm³ (95% polymorphs), protein 1.8 g/L, glucose 1.8 mmol/L (plasma glucose 5.2 mmol/L). Gram stain shows Gram-positive diplococci. What is the most likely explanation for this infection occurring despite vaccination?

A. Vaccine failure due to inadequate immune response
B. Infection with a non-vaccine serotype (Correct Answer)
C. Waning immunity requiring a booster dose
D. Underlying immunodeficiency
E. The vaccine does not protect against this organism

Explanation: ***Infection with a non-vaccine serotype***- The lumbar puncture findings of **high CSF white cells (predominantly polymorphs)**, **low glucose**, and **high protein**, along with **Gram-positive diplococci** on stain, are highly indicative of **Streptococcus pneumoniae** meningitis.- The **pneumococcal conjugate vaccine (PCV)**, like PCV13, covers the most common and virulent serotypes, but *Streptococcus pneumoniae* has numerous other serotypes (over 90). Infection with a strain not included in the vaccine is a recognized phenomenon, especially due to **serotype replacement**.*Vaccine failure due to inadequate immune response*- **Primary vaccine failure** implies the child did not develop a sufficient immune response to the vaccine antigens, which is possible but less statistically probable in an otherwise healthy child who received routine vaccinations.- This typically means a lack of **antibody production** despite exposure to the vaccine, which is not suggested by the clinical context alone.*Waning immunity requiring a booster dose*- The **pneumococcal conjugate vaccine** provides robust and generally long-lasting protection against the included serotypes after the routine childhood schedule, which includes a booster dose around 12 months of age.- In a healthy 5-year-old, **antibody titers** for the vaccine-covered serotypes are usually still at protective levels, making waning immunity a less likely explanation for infection with a specific serotype at this age.*Underlying immunodeficiency*- While an **underlying immunodeficiency** (e.g., complement deficiency, asplenia, antibody deficiency) would increase susceptibility to encapsulated bacteria like *S. pneumoniae*, the clinical presentation does not suggest **recurrent infections** or other features typical of a primary immunodeficiency.- In an otherwise healthy child with no prior history of severe or unusual infections, this is a less likely explanation than exposure to an uncovered serotype.*The vaccine does not protect against this organism*- This statement is incorrect because the **pneumococcal conjugate vaccine (PCV)** is specifically designed to protect against **Streptococcus pneumoniae**, the organism strongly implicated by the Gram-positive diplococci and clinical picture.- The vaccine significantly reduces the incidence of **invasive pneumococcal disease**, including meningitis, caused by the serotypes it targets.

Question 168: A 38-year-old woman with systemic lupus erythematosus on prednisolone 20 mg daily presents with a 5-week history of cough, night sweats, and weight loss. Chest X-ray shows bilateral upper lobe consolidation with cavitation. Three sputum samples are AFB-positive. Which additional investigation should be performed before starting anti-tuberculosis therapy?

A. Serum angiotensin-converting enzyme level
B. CT chest with contrast
C. Bronchoscopy with bronchoalveolar lavage
D. HIV test (Correct Answer)
E. Interferon-gamma release assay

Explanation: ***HIV test***- It is standard practice to offer **HIV testing** to all patients newly diagnosed with **tuberculosis** (TB), as TB is an **AIDS-defining illness**.- Knowing the HIV status is critical before initiating therapy because it influences the timing of **Antiretroviral Therapy (ART)**, the risk of **Immune Reconstitution Inflammatory Syndrome (IRIS)**, and the monitoring for drug interactions.*Serum angiotensin-converting enzyme level*- This test is used to support a diagnosis of **sarcoidosis**, which can mimic TB but would not typically show **AFB-positive** sputum.- ACE levels are neither sensitive nor specific for TB infections and do not guide TB management.*CT chest with contrast*- While CT can provide detailed anatomical views of **cavitation** or lymphadenopathy, it is not required when TB is already confirmed by **sputum AFB smear**.- It does not change the immediate management or the clinical decision to start **anti-tuberculosis therapy**.*Bronchoscopy with bronchoalveolar lavage*- This procedure is indicated if sputum samples are negative or cannot be produced but clinical suspicion for TB remains high.- Since the patient already has three **AFB-positive** sputum samples, the diagnosis is confirmed and invasive procedures are unnecessary.*Interferon-gamma release assay*- IGRA is primarily used for the detection of **latent TB infection** or in cases where diagnostic clarity is lacking.- It is not helpful in this scenario because the patient has **active TB disease** confirmed by microscopy, and the test cannot distinguish between latent and active infection.

Question 169: A 15-year-old boy presents with a 12-hour history of fever, severe headache, and vomiting. He has a non-blanching purpuric rash on his trunk and lower limbs. His blood pressure is 85/50 mmHg and heart rate is 128 bpm. Which organism is the most likely causative agent?

A. Streptococcus pneumoniae
B. Neisseria meningitidis (Correct Answer)
C. Haemophilus influenzae type b
D. Listeria monocytogenes
E. Group B Streptococcus

Explanation: ***Neisseria meningitidis*** - This organism is the classic cause of **meningococcemia**, characterized by a **non-blanching purpuric rash** and rapid progression to **septic shock** (low blood pressure and tachycardia). - It is a leading cause of bacterial meningitis in **adolescents** and young adults, often involving **meningitis** symptoms like fever, headache, and vomiting. *Streptococcus pneumoniae* - While it is the most common cause of bacterial meningitis in all ages, it typically presents with **pneumonia** or ear infections rather than a **purpuric rash**. - It generally does not cause the severe **vascular damage** and vasculitis seen with meningococcal infections. *Haemophilus influenzae type b* - This was historically a major cause of meningitis, but its incidence has significantly decreased due1 to widespread **Hib vaccination** protocols. - It usually presents with symptoms of meningitis or **epiglottitis** but lacks the characteristic widespread **haemorrhagic rash**. *Listeria monocytogenes* - This pathogen primarily affects **neonates**, the **elderly**, and **immunocompromised** individuals, often transmitted through contaminated food. - It is not associated with the classic **purpuric rash** seen in healthy adolescents presenting with acute sepsis. *Group B Streptococcus* - This is the most common cause of meningitis in **neonates** (acquired during birth) but is an unlikely cause in a 15-year-old. - It typically presents as **early-onset sepsis** or late-onset meningitis in infants rather than purpuric shock in teenagers.

Question 170: A 42-year-old man with pulmonary tuberculosis is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 3 weeks of treatment, he develops painful, red eyes with photophobia and blurred vision. Examination reveals bilateral anterior uveitis. Which medication is most likely responsible for this adverse effect?

A. Rifampicin
B. Isoniazid
C. Pyrazinamide
D. Ethambutol (Correct Answer)
E. None of these medications cause this adverse effect

Explanation: ***Ethambutol*** - **Ethambutol** is a primary anti-tubercular drug well-known for causing **ocular toxicity**, including **optic neuritis** and, less commonly, **anterior uveitis**. - The patient's symptoms of **painful, red eyes**, **photophobia**, and **blurred vision**, along with bilateral **anterior uveitis**, are classic presentations of ocular adverse effects attributed to Ethambutol. *Rifampicin* - **Rifampicin** is commonly associated with **hepatotoxicity** and a harmless **orange-red discoloration** of urine, sweat, and tears. - It does not typically cause **ocular inflammation** or conditions like **uveitis**. *Isoniazid* - **Isoniazid** is primarily linked to **peripheral neuropathy** (prevented by co-administration of **pyridoxine/Vitamin B6**) and **hepatotoxicity**. - It does not commonly cause **anterior uveitis** or the specific ocular symptoms described. *Pyrazinamide* - **Pyrazinamide** is known for causing **hepatotoxicity** and **hyperuricemia**, which can precipitate **gouty arthritis**. - It is not associated with **ocular inflammation**, **uveitis**, or **visual disturbances**. *None of these medications cause this adverse effect* - This statement is incorrect because **Ethambutol** is a well-established cause of **ocular toxicity**, including **optic neuritis** and **uveitis**. - The patient's symptoms are directly attributable to a known adverse effect of one of the prescribed medications.

Question 171: A 55-year-old woman with end-stage renal failure on peritoneal dialysis presents with a 3-day history of fever, headache, and confusion. She has a history of recurrent peritonitis episodes. Lumbar puncture shows: glucose 2.5 mmol/L (serum 5.8 mmol/L), protein 1.5 g/L, white cells 580/mm³ (85% neutrophils). Gram stain shows Gram-positive cocci in clusters. Blood cultures grow methicillin-resistant Staphylococcus aureus (MRSA). She has normal hearing and no documented aminoglycoside allergy. What is the most appropriate antimicrobial regimen for this patient?

A. Intravenous vancomycin with dose adjustment for renal function and therapeutic drug monitoring
B. Intravenous linezolid 600 mg twice daily for 14 days (Correct Answer)
C. Intravenous teicoplanin with loading doses then maintenance dosing guided by levels
D. Intravenous daptomycin 10 mg/kg once daily
E. Intravenous vancomycin plus rifampicin for synergy

Explanation: ***Intravenous linezolid 600 mg twice daily for 14 days***- **Linezolid** is the preferred agent for **MRSA meningitis** due to its excellent **CSF penetration** (approximately 70%), which is crucial for treating CNS infections.- It does not require **dose adjustment** for **renal impairment**, making it an ideal choice for patients with **end-stage renal failure**.*Intravenous vancomycin with dose adjustment for renal function and therapeutic drug monitoring*- **Vancomycin** has notoriously poor **CSF penetration** (10-20%), making it difficult to achieve adequate bactericidal concentrations in the meninges.- In patients with **renal failure**, **vancomycin** requires careful **dose adjustment** and **therapeutic drug monitoring (TDM)** to prevent **nephrotoxicity** and **ototoxicity**, adding complexity.*Intravenous teicoplanin with loading doses then maintenance dosing guided by levels*- **Teicoplanin**, similar to vancomycin, is a large glycopeptide with very poor **central nervous system penetration**, rendering it ineffective for treating **bacterial meningitis**.- It is generally not recommended for CNS infections due to its inability to achieve sufficient bactericidal concentrations in the **cerebrospinal fluid (CSF)**.*Intravenous daptomycin 10 mg/kg once daily*- **Daptomycin** does not effectively penetrate the **blood-brain barrier** and is therefore contraindicated for the treatment of **meningitis**.- Its high protein binding and large molecular size prevent it from reaching therapeutic levels in the **cerebrospinal fluid (CSF)**.*Intravenous vancomycin plus rifampicin for synergy*- While **rifampicin** has good **CNS penetration**, the primary anti-MRSA agent, **vancomycin**, still suffers from poor **CSF bioavailability**.- Adding **rifampicin** might be considered for synergistic effect in some MRSA infections, but **linezolid monotherapy** is superior for **MRSA meningitis** due to its inherent excellent CSF penetration.

Question 172: A 39-year-old homeless man with alcohol dependency presents with a 5-week history of productive cough, haemoptysis, weight loss, and drenching night sweats. Chest X-ray shows bilateral upper lobe cavitation with a large cavity (4 cm) in the right upper lobe. Three sputum samples are smear-positive (3+ acid-fast bacilli). He is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. Culture at 6 weeks grows Mycobacterium tuberculosis fully sensitive to all first-line drugs. After 2 months of treatment, he remains sputum smear-positive. What is the most appropriate modification to his treatment regimen?

A. Continue the four-drug intensive phase for a third month, then switch to rifampicin and isoniazid for 7 months (Correct Answer)
B. Continue current four-drug regimen for total of 9 months without a continuation phase
C. Switch to second-line therapy with a fluoroquinolone, injectable agent, and three other drugs
D. Add a fluoroquinolone to the current four-drug regimen for the remainder of treatment
E. Continue with rifampicin and isoniazid only for 10 months

Explanation: ***Continue the four-drug intensive phase for a third month, then switch to rifampicin and isoniazid for 7 months*** - In patients with **extensive cavitary disease** and a high bacterial burden, the **intensive phase** is often extended if sputum remains positive at 2 months to ensure adequate clearance. - Current guidelines for **cavitary TB** with delayed conversion recommend a total treatment duration of **9 to 10 months** to prevent relapse, specifically extending the continuation phase to 7 months. *Continue current four-drug regimen for total of 9 months without a continuation phase* - Maintaining the **full quadruple therapy** (including pyrazinamide and ethambutol) for the entire duration increases the risk of **toxicity** like hepatotoxicity and optic neuritis without proven extra benefit. - Standard protocols always involve transitioning to a **continuation phase** with fewer drugs once the initial high-load bacterial population is reduced. *Switch to second-line therapy with a fluoroquinolone, injectable agent, and three other drugs* - This approach is reserved for **MDR-TB** (multi-drug resistant tuberculosis), whereas this patient’s isolate is **fully sensitive** to all first-line drugs. - Switching to second-line agents is unnecessary and subjects the patient to significantly more **toxic side effects** and less effective medications. *Add a fluoroquinolone to the current four-drug regimen for the remainder of treatment* - Adding a single drug to a failing or slow-responding regimen violates the principle of TB therapy and can lead to **acquired drug resistance**. - Fluoroquinolones are not indicated as a standalone addition for delayed sputum conversion in fully sensitive TB. *Continue with rifampicin and isoniazid only for 10 months* - Transitioning to **continuation phase** (RI only) when the patient is still smear-positive at 2 months is premature and risks treatment failure due to insufficient bactericidal activity. - The patient's high bacterial burden (cavitary disease, 3+ AFB, delayed conversion) requires a more aggressive, extended intensive phase, not a reduced regimen.

Question 173: A 22-year-old university student presents to the emergency department with an 18-hour history of severe headache, photophobia, vomiting, and neck stiffness. Temperature is 39.2°C. There are no skin lesions. Lumbar puncture shows: opening pressure 32 cmH2O, glucose 1.9 mmol/L (serum 5.4 mmol/L), protein 2.4 g/L, white cells 2400/mm³ (95% neutrophils). Gram stain is negative. He is started on ceftriaxone and aciclovir. Blood and CSF cultures remain negative at 48 hours, and HSV PCR is negative. What is the most likely explanation for the negative microbiological results?

A. The patient has tuberculous meningitis with low bacterial load
B. Prior antibiotic administration before lumbar puncture has rendered cultures negative (Correct Answer)
C. The causative organism is Listeria monocytogenes which requires special culture media
D. The patient has viral meningitis and the neutrophilic predominance is atypical
E. The causative organism is Neisseria meningitidis which is fastidious and died during transport

Explanation: ***Prior antibiotic administration before lumbar puncture has rendered cultures negative*** - The patient's CSF profile (low **glucose**, high **protein**, and high **neutrophil** count) is classic for **bacterial meningitis**, but **prior antibiotics** can rapidly sterilize CSF, leading to negative cultures. - Even a single dose of a broad-spectrum antibiotic like **ceftriaxone** can significantly reduce the yield of Gram stains and cultures within 2–4 hours of administration. *The patient has tuberculous meningitis with low bacterial load* - **Tuberculous meningitis** typically presents with a more **subacute** prodrome (weeks, not 18 hours) and usually shows **lymphocytic pleocytosis**. - While CSF protein is high and glucose is low in TB, the extreme **neutrophilic predominance** (95%) seen here is highly unusual for Mycobacterium tuberculosis. *The causative organism is Listeria monocytogenes which requires special culture media* - **Listeria monocytogenes** is an uncommon cause of meningitis in a healthy 22-year-old student, typically affecting **neonates**, the **elderly**, or **immunocompromised** patients. - Listeria grows well on standard blood agar and does not require highly specialized media; it would likely have grown if present and not inhibited by antibiotics. *The patient has viral meningitis and the neutrophilic predominance is atypical* - **Viral meningitis** is usually associated with a **lymphocytic predominance** and **normal glucose** levels; the very low glucose (1.9 mmol/L) and high pressure here strongly favor a bacterial etiology. - While early viral meningitis can show neutrophils, the severity of the biochemical abnormalities (protein 2.4 g/L) is much more consistent with a **bacterial pathogen**. *The causative organism is Neisseria meningitidis which is fastidious and died during transport* - Although **Neisseria meningitidis** is fastidious, modern hospital laboratories use enriched media and transport protocols that make complete culture failure due to transport alone less likely than antibiotic interference. - Given the clinical urgency and standard of care, the administration of antibiotics prior to the procedure remains the most statistically likely reason for sterile cultures in a **purulent CSF** sample.

Question 174: A 46-year-old man with smear-positive pulmonary tuberculosis has been receiving standard four-drug therapy for 8 weeks. His initial isolate showed susceptibility to all first-line drugs. He reports good adherence to treatment. Repeat sputum microscopy at 8 weeks remains smear-positive (2+ acid-fast bacilli). Repeat culture from week 6 shows growth of Mycobacterium tuberculosis. What is the most appropriate interpretation and management at this stage?

A. This represents treatment failure; the regimen should be changed to second-line drugs immediately
B. This is expected; continue current regimen and repeat sputum culture at 3 months (Correct Answer)
C. This suggests drug resistance; molecular testing for resistance mutations should be performed urgently and treatment modified
D. This indicates non-adherence; directly observed therapy should be instituted and treatment extended
E. This suggests laboratory contamination; treatment should be stopped and samples repeated

Explanation: ***This is expected; continue current regimen and repeat sputum culture at 3 months*** - In patients with **drug-susceptible TB** and high bacterial load (2+ smear), it is not uncommon for sputum to remain **culture-positive at 2 months**; conversion typically occurs by the end of the intensive phase.- **Treatment failure** is officially defined by positive cultures at **4 months** or later, so continuing the standard regimen while monitoring is the correct clinical pathway.*This represents treatment failure; the regimen should be changed to second-line drugs immediately* - **Treatment failure** cannot be diagnosed at only 8 weeks; diagnosing it prematurely leads to the unnecessary use of more toxic **second-line agents**.- Changing the regimen requires confirmed **drug susceptibility testing (DST)** results showing resistance or clinical/bacteriologic failure at a later stage.*This suggests drug resistance; molecular testing for resistance mutations should be performed urgently and treatment modified* - While resistance is a concern, the initial isolate confirmed **full susceptibility**, and the patient reports **good adherence**, making resistance less likely at this stage.- **Molecular testing** is not indicated as an emergency at 8 weeks because a persistent positive culture at this point is a known variation in patients with **extensive cavitary disease**.*This indicates non-adherence; directly observed therapy should be instituted and treatment extended* - The patient specifically reports **good adherence**, and persistent positivity at 2 months occurs in roughly 15-20% of patients even with perfect compliance.- While **Directly Observed Therapy (DOT)** is a standard of care, it is not an "interpretation" of the 2-month smear result, nor is automatic extension of treatment warranted yet.*This suggests laboratory contamination; treatment should be stopped and samples repeated* - A persistent **AFB smear (2+)** and a positive culture at week 6 are consistent findings in an active infection and are highly unlikely to be purely due to **contamination**.- **Stopping TB treatment** in a patient who was recently smear-positive is dangerous and could lead to rapid clinical deterioration and the development of **drug resistance**.

Question 175: A 63-year-old woman presents with confusion, fever, and right-sided focal seizures. She has a background of type 2 diabetes and chronic sinusitis. CT head shows a right temporal lobe lesion with surrounding oedema. Lumbar puncture shows: opening pressure 22 cmH2O, glucose 3.2 mmol/L (serum 7.8 mmol/L), protein 1.2 g/L, white cells 425/mm³ (65% neutrophils, 35% lymphocytes), red cells 85/mm³. Gram stain shows Gram-positive cocci in chains. What is the most appropriate initial antimicrobial regimen?

A. Intravenous ceftriaxone, vancomycin, and dexamethasone
B. Intravenous benzylpenicillin and metronidazole
C. Intravenous ceftriaxone and metronidazole (Correct Answer)
D. Intravenous ceftriaxone, metronidazole, and aciclovir
E. Intravenous meropenem and vancomycin

Explanation: ***Intravenous ceftriaxone and metronidazole***- The patient presents with clinical features highly suggestive of a **brain abscess** (confusion, fever, focal seizures, temporal lobe lesion) likely originating from **chronic sinusitis**.- The Gram stain showing **Gram-positive cocci in chains** points towards **Streptococcus species**. **Ceftriaxone** effectively covers these and other potential Gram-negative organisms, while **metronidazole** provides excellent coverage for **anaerobic bacteria**, which are common in sinogenic infections and brain abscesses.*Intravenous ceftriaxone, vancomycin, and dexamethasone*- **Vancomycin** is typically added for suspected **MRSA** or in post-neurosurgical infections. The Gram stain (Gram-positive cocci in chains) and community-acquired nature do not strongly suggest MRSA.- **Dexamethasone** is generally avoided in **brain abscesses** as it can impair **antibiotic penetration** into the abscess cavity, although it is used in bacterial meningitis for inflammation reduction.*Intravenous benzylpenicillin and metronidazole*- While **benzylpenicillin** covers Streptococcus species, it has a narrower spectrum compared to ceftriaxone and may not adequately cover potential **Gram-negative bacteria** associated with sinogenic infections.- **Ceftriaxone** is preferred due to its superior **central nervous system (CNS) penetration**, broader spectrum, and convenient once-daily dosing for prolonged treatment regimens required for brain abscesses.*Intravenous ceftriaxone, metronidazole, and aciclovir*- **Aciclovir** is the treatment for **Herpes Simplex Encephalitis (HSE)**. The presence of **Gram-positive cocci** on Gram stain definitively indicates a bacterial infection, making aciclovir inappropriate.- The **CSF findings** (low glucose, high protein, neutrophil predominance) are highly consistent with **bacterial infection**, not viral encephalitis.*Intravenous meropenem and vancomycin*- This broad-spectrum regimen is typically reserved for severe, **hospital-acquired infections**, post-operative cases, or infections involving **multidrug-resistant (MDR)** organisms.- For a **community-acquired brain abscess** secondary to sinusitis, ceftriaxone and metronidazole provide appropriate targeted coverage, minimizing the risk of developing **antibiotic resistance** associated with overly broad-spectrum antibiotics.

Question 176: A 35-year-old man from Afghanistan presents with a 10-week history of fever, night sweats, and back pain. MRI spine shows destruction of T10-T11 vertebrae with paraspinal abscess formation and spinal cord compression. He is neurologically intact. Three sputum samples are negative for acid-fast bacilli. What is the most appropriate immediate management approach?

A. Start four-drug anti-TB therapy and arrange urgent neurosurgical decompression within 24 hours (Correct Answer)
B. Perform CT-guided biopsy of the paraspinal abscess, await microbiology results before starting treatment
C. Start four-drug anti-TB therapy with high-dose corticosteroids and arrange elective surgical review
D. Start broad-spectrum antibiotics for bacterial spondylodiscitis and arrange MRI-guided biopsy
E. Perform urgent open biopsy and debridement with immediate four-drug anti-TB therapy

Explanation: ***Start four-drug anti-TB therapy and arrange urgent neurosurgical decompression within 24 hours*** - The presence of **spinal cord compression** on MRI, even without immediate neurological deficits, is a neurosurgical emergency requiring urgent decompression to prevent irreversible neurological damage. - Given the patient's origin (Afghanistan), chronic systemic symptoms (fever, night sweats), and imaging findings (vertebral destruction, paraspinal abscess), **Pott's disease** is highly suspected, necessitating immediate empirical **four-drug anti-TB therapy**. *Perform CT-guided biopsy of the paraspinal abscess, await microbiology results before starting treatment* - Delaying treatment to wait for definitive **microbiology results** is contraindicated in the presence of active **spinal cord compression**, as rapid neurological deterioration can occur. - While a **biopsy** is important for diagnosis, it should not precede urgent surgical decompression and empirical anti-TB treatment in this emergent scenario. *Start four-drug anti-TB therapy with high-dose corticosteroids and arrange elective surgical review* - An **elective surgical review** is inappropriate and dangerous for **spinal cord compression**; urgent intervention is required to prevent permanent neurological deficits like paraplegia. - While **corticosteroids** might be used in specific TB manifestations, they do not alleviate mechanical cord compression and are not a substitute for urgent surgical decompression. *Start broad-spectrum antibiotics for bacterial spondylodiscitis and arrange MRI-guided biopsy* - The clinical picture (chronic symptoms, night sweats, paraspinal abscess, endemic origin) is highly suggestive of **tuberculosis** rather than typical pyogenic bacterial spondylodiscitis. - Starting broad-spectrum antibiotics alone fails to address the critical and immediate threat of **spinal cord compression**, which requires mechanical relief. *Perform urgent open biopsy and debridement with immediate four-drug anti-TB therapy* - While open surgery and anti-TB therapy are essential, the most critical immediate component when **spinal cord compression** is present is **neurosurgical decompression** to relieve pressure on the spinal cord. - The term

Question 177: A 4-year-old boy presents with a 12-hour history of fever, irritability, and drowsiness. On examination, he has a capillary refill time of 4 seconds, heart rate 155/min, blood pressure 85/50 mmHg, and a spreading non-blanching purpuric rash on his legs and trunk. He is managed in the emergency department with immediate antibiotics. His 18-month-old sibling attends the same nursery and has no symptoms. What is the most appropriate prophylaxis for the sibling?

A. Single dose of intramuscular ceftriaxone 125 mg
B. Oral ciprofloxacin 250 mg single dose
C. Oral rifampicin 10 mg/kg twice daily for 2 days (Correct Answer)
D. Oral azithromycin 10 mg/kg once daily for 3 days
E. No prophylaxis required as the sibling is asymptomatic

Explanation: ***Oral rifampicin 10 mg/kg twice daily for 2 days*** - The index case has **meningococcal septicaemia** (fever, shock, and purpuric rash), which requires urgent **chemoprophylaxis** for all close household contacts to eradicate nasopharyngeal carriage. - **Rifampicin** is a standard first-line choice for children, typically administered for 2 days to prevent secondary cases in high-risk contacts. *Single dose of intramuscular ceftriaxone 125 mg* - **Ceftriaxone** is an effective alternative for prophylaxis and is useful for pregnant women or when oral medication is not tolerated. - While it is a valid option, **Rifampicin** or **Ciprofloxacin** are more frequently used as initial oral choices for household contacts in clinical guidelines. *Oral ciprofloxacin 250 mg single dose* - **Ciprofloxacin** is a common choice for adult prophylaxis due to the convenience of a **single dose** and lack of interaction with oral contraceptives. - However, the dose provided (250 mg) is incorrect for a child, and **Rifampicin** remains a traditional primary choice for pediatric populations in many protocols. *Oral azithromycin 10 mg/kg once daily for 3 days* - **Azithromycin** is not a standard recommended regimen for the chemoprophylaxis of **Neisseria meningitidis**. - It is more commonly used for the prevention of secondary cases in **Pertussis** or used for generic bacterial respiratory infections. *No prophylaxis required as the sibling is asymptomatic* - Prophylaxis is mandatory for **household contacts** regardless of symptoms, as the risk of secondary disease is highest in the first 7 days. - Asymptomatic carriers can transmit the bacteria to vulnerable individuals; therefore, treatment is aimed at **eradication of carriage** rather than treating active disease.

Question 178: A 28-year-old healthcare worker sustains a needlestick injury from a patient with confirmed multidrug-resistant tuberculosis (resistant to rifampicin and isoniazid). The healthcare worker has no symptoms and chest X-ray is normal. Mantoux test performed 48 hours ago shows 8 mm induration. She has no documented BCG vaccination. What is the most appropriate management for this exposed healthcare worker?

A. Observe clinically with chest X-ray every 3 months for 2 years
B. Start treatment with moxifloxacin and ethambutol for 6 months
C. Repeat Mantoux test in 6 weeks and treat if positive
D. Arrange interferon-gamma release assay (IGRA) and treat with levofloxacin and ethambutol if positive (Correct Answer)
E. Start treatment with pyrazinamide and ethambutol for 9 months

Explanation: ***Arrange interferon-gamma release assay (IGRA) and treat with levofloxacin and ethambutol if positive*** - An **IGRA** is recommended to confirm **Latent TB Infection (LTBI)**, as it is more specific than the Mantoux test and remains unaffected by BCG status. - For **MDR-TB exposure**, the preventive regimen must be tailored to the source's sensitivity; a combination of a **fluoroquinolone** (like levofloxacin) and **ethambutol** is standard when isoniazid and rifampicin resistance is confirmed. *Observe clinically with chest X-ray every 3 months for 2 years* - **Active monitoring** alone is insufficient for a known high-risk **MDR-TB exposure** in a healthcare setting, especially with a positive Mantoux test. - Current guidelines favor the treatment of **latent infection** to prevent progression to active, life-threatening multidrug-resistant disease, rather than just observation. *Start treatment with moxifloxacin and ethambutol for 6 months* - While this regimen is a valid choice for **MDR-LTBI**, it should only be initiated after **confirming infection** with an IGRA or a significant TST, rather than empirical treatment. - Immediate treatment without further confirmation (like IGRA) or specialized **expert consultation** is not the standard first step for an 8mm TST in this high-risk context. *Repeat Mantoux test in 6 weeks and treat if positive* - The current induration of **8 mm** is already considered significant for a healthcare worker with recent **high-risk contact** to active TB, even without BCG. - Delaying for a repeat test risks the window period for early **chemoprophylaxis** and is unnecessary when an IGRA can provide more immediate and reliable clarity. *Start treatment with pyrazinamide and ethambutol for 9 months* - **Pyrazinamide** is often poorly tolerated for long-term prophylaxis and has higher rates of **hepatotoxicity** compared to fluoroquinolones. - Modern protocols for **MDR-LTBI** generally favor fluoroquinolone-based regimens due to better evidence of efficacy and a superior side-effect profile for prophylaxis.

Question 179: A 43-year-old man with HIV infection (CD4 count 95 cells/mm³, not on antiretroviral therapy) presents with a 3-week history of headache and fever. CT head shows multiple ring-enhancing lesions. Lumbar puncture shows: opening pressure 19 cmH2O, glucose 2.8 mmol/L (serum 5.2 mmol/L), protein 0.65 g/L, white cells 12/mm³ (lymphocytes). India ink stain is positive. Serum cryptococcal antigen titre is 1:2048. What is the most appropriate initial management strategy?

A. Liposomal amphotericin B and flucytosine for 2 weeks, then fluconazole consolidation (Correct Answer)
B. Oral fluconazole 800 mg daily for 10 weeks
C. Liposomal amphotericin B monotherapy for 6 weeks
D. Voriconazole and flucytosine for 2 weeks, then fluconazole consolidation
E. Liposomal amphotericin B and flucytosine for 4-6 weeks, then fluconazole consolidation

Explanation: ***Liposomal amphotericin B and flucytosine for 2 weeks, then fluconazole consolidation*** - The preferred induction regimen for **cryptococcal meningitis** in HIV patients is combination therapy with **liposomal amphotericin B** and **flucytosine** for at least 14 days. - Combination therapy is superior to monotherapy as it ensures rapid sterilization of the **CSF** and reduces the risk of mortality and treatment failure. *Oral fluconazole 800 mg daily for 10 weeks* - **Fluconazole monotherapy** is considered suboptimal and is generally only used for induction in cases where amphotericin B and flucytosine are unavailable or contraindicated. - It lacks the **fungicidal potency** required to treat high fungal burdens effectively, as evidenced by the high **antigen titre** in this patient. *Liposomal amphotericin B monotherapy for 6 weeks* - While amphotericin is fungicidal, using it as **monotherapy** is associated with worse clinical outcomes compared to the combination with flucytosine. - Prolonged administration of amphotericin B without transitioning to oral agents unnecessarily increases the risk of **nephrotoxicity** and electrolyte imbalances. *Voriconazole and flucytosine for 2 weeks, then fluconazole consolidation* - **Voriconazole** is not the standard of care or first-line agent for the induction phase of cryptococcal meningitis. - Guidelines prioritize **amphotericin-based regimens** due to better-established efficacy and survival data in this specific patient population. *Liposomal amphotericin B and flucytosine for 4-6 weeks, then fluconazole consolidation* - An induction period of **4-6 weeks** is typically discouraged in favor of a 2-week induction followed by a transition to oral agents to minimize hospital stay and drug toxicity. - Longer induction is usually reserved only for patients who fail to show **clinical improvement** or fail to achieve **CSF sterilization** after the initial 2 weeks.

Question 180: A 31-year-old woman from Pakistan presents with a 6-week history of progressive headache, low-grade fever, and confusion. She is currently 20 weeks pregnant. MRI brain shows basal meningeal enhancement and hydrocephalus. CSF analysis shows: glucose 1.8 mmol/L (serum 4.5 mmol/L), protein 2.5 g/L, white cells 180/mm³ (80% lymphocytes). ZN stain is pending. Which combination represents the most appropriate initial treatment regimen for this patient?

A. Isoniazid, rifampicin, ethambutol, pyridoxine, and prednisolone
B. Isoniazid, rifampicin, pyrazinamide, ethambutol, and dexamethasone
C. Isoniazid, rifampicin, ethambutol, levofloxacin, pyridoxine, and dexamethasone (Correct Answer)
D. Rifampicin, ethambutol, levofloxacin, and prednisolone
E. Isoniazid, rifampicin, streptomycin, pyridoxine, and prednisolone

Explanation: ***Isoniazid, rifampicin, ethambutol, levofloxacin, pyridoxine, and dexamethasone*** - This patient presents with classic features of **tuberculous meningitis (TBM)**, indicated by basal enhancement, high CSF protein, low glucose, and **lymphocyte-predominant** pleocytosis. - In **pregnancy**, pyrazinamide is often substituted with a **fluoroquinolone** like levofloxacin due to safety concerns; **dexamethasone** is added to reduce mortality from CNS inflammation, and **pyridoxine** prevents isoniazid-induced neuropathy. *Isoniazid, rifampicin, ethambutol, pyridoxine, and prednisolone* - While this contains several core components, it lacks a fourth active antimicrobial agent required for the **intensive phase** of TBM treatment. - **Dexamethasone** is generally preferred over prednisolone in CNS tuberculosis due to its superior penetration and clinical evidence base for reducing **intracranial pressure**. *Isoniazid, rifampicin, pyrazinamide, ethambutol, and dexamethasone* - **Pyrazinamide** is traditionally avoided or used with caution in pregnancy in some regional guidelines (like the UK) due to limited human safety data despite WHO recommendations. - Additionally, this option lacks **pyridoxine** (Vitamin B6), which is essential in pregnancy to prevent **peripheral neuropathy** caused by isoniazid. *Rifampicin, ethambutol, levofloxacin, and prednisolone* - This regimen is incorrect because it excludes **isoniazid**, which is a critical bactericidal agent for treating sensitive strains of **Mycobacterium tuberculosis**. - The absence of **pyridoxine** and the use of the weaker steroid prednisolone makes this an suboptimal choice for managing severe TBM. *Isoniazid, rifampicin, streptomycin, pyridoxine, and prednisolone* - **Streptomycin** is strictly **contraindicated in pregnancy** because it is known to cause fetal **ototoxicity** (damage to the eighth cranial nerve). - This regimen also lacks a fourth agent like ethambutol or a fluoroquinolone commonly used when traditional combinations are modified.

Question 181: A 67-year-old man with poorly controlled diabetes mellitus and chronic kidney disease stage 4 presents with a 2-day history of fever, severe headache, confusion, and photophobia. Lumbar puncture shows: opening pressure 28 cmH2O, CSF glucose 2.1 mmol/L (serum glucose 8.2 mmol/L), protein 1.8 g/L, white cells 850/mm³ (90% polymorphs). Gram stain shows Gram-positive diplococci. He is started on IV ceftriaxone. What additional antimicrobial agent should be added to his treatment regimen?

A. Vancomycin (Correct Answer)
B. Aciclovir
C. Gentamicin
D. Metronidazole
E. Ciprofloxacin

Explanation: ***Vancomycin***- The CSF findings (low glucose, high protein, polymorphonuclear pleocytosis, and **Gram-positive diplococci**) are highly suggestive of **bacterial meningitis**, specifically caused by **Streptococcus pneumoniae**.- In older patients (>=50 years) or those with comorbidities (like poorly controlled diabetes and CKD) or in areas with high rates of **penicillin-resistant *S. pneumoniae***, **vancomycin** should be added empirically to a third-generation cephalosporin (like ceftriaxone) to ensure adequate coverage until antibiotic sensitivities are known.*Aciclovir*- This is an **antiviral agent** specifically used for **herpes simplex encephalitis** (HSE), which typically presents with different CSF profiles (e.g., lymphocytic pleocytosis) and clinical features (e.g., focal neurological deficits).- The presence of **Gram-positive diplococci** on CSF Gram stain strongly indicates a bacterial, not viral, etiology for the meningitis.*Gentamicin*- This is an **aminoglycoside antibiotic** primarily active against **Gram-negative bacteria** and has poor **blood-brain barrier penetration** in adults, making it unsuitable for meningitis treatment.- It is not indicated for empirical therapy of community-acquired bacterial meningitis and would not cover the identified **Gram-positive diplococci** effectively in the CNS.*Metronidazole*- Metronidazole is primarily effective against **anaerobic bacteria** and some protozoa.- While anaerobes can cause CNS infections (e.g., brain abscesses), Gram-positive diplococci are typically aerobic or facultative anaerobic, and metronidazole is not a standard empirical treatment for **pneumococcal meningitis**.*Ciprofloxacin*- Ciprofloxacin is a **fluoroquinolone** with broad-spectrum activity, but it is not a first-line empirical agent for **bacterial meningitis** in this context.- It does not provide superior or essential added coverage for **resistant *S. pneumoniae*** compared to vancomycin when combined with ceftriaxone for this high-risk patient.

Question 182: A 52-year-old man from Zimbabwe presents with a 3-month history of cough, weight loss, and night sweats. Chest X-ray shows bilateral upper lobe cavitation. Three sputum samples are collected for TB investigation. Ziehl-Neelsen staining shows acid-fast bacilli. The laboratory reports that nucleic acid amplification testing (NAAT) will be performed. What is the primary purpose of NAAT in this clinical scenario?

A. To determine the drug susceptibility profile of the organism
B. To differentiate Mycobacterium tuberculosis from non-tuberculous mycobacteria (Correct Answer)
C. To quantify the bacterial load for monitoring treatment response
D. To identify specific genetic mutations associated with virulence
E. To determine whether the patient has latent or active infection

Explanation: ***To differentiate Mycobacterium tuberculosis from non-tuberculous mycobacteria***- While **Ziehl-Neelsen staining** confirms the presence of **acid-fast bacilli (AFB)**, it cannot distinguish between **M. tuberculosis complex** and **non-tuberculous mycobacteria (NTM)**.- **NAAT** provides rapid, highly sensitive **species identification** within hours, allowing for immediate confirmation of TB before **culture results** (which take weeks) are available.*To determine the drug susceptibility profile of the organism*- Although some **NAAT assays** (like Xpert MTB/RIF) can detect **rifampicin resistance**, the primary diagnostic purpose in this scenario, following AFB smear, is **species confirmation**.- Comprehensive **drug susceptibility testing (DST)** often still relies on **phenotypic culture-based methods** to cover a full range of anti-TB drugs.*To quantify the bacterial load for monitoring treatment response*- **NAAT** is a qualitative tool used for initial diagnosis, detecting the presence of bacterial DNA; it can remain positive due to **non-viable DNA** even after successful treatment.- **Sputum smear microscopy** and **culture conversion** are the standard methods for monitoring a patient's **response to therapy** and assessing bacterial load.*To identify specific genetic mutations associated with virulence*- **NAAT** targets specific conserved DNA sequences for **species identification** rather than evaluating **virulence factors** or pathogenicity genes.- Understanding **virulence** is generally a clinical or research focus and does not typically guide the standard diagnostic algorithm for **active TB**.*To determine whether the patient has latent or active infection*- The diagnosis of **active infection** is already strongly suggested by the clinical symptoms (**cough, weight loss, night sweats**), **bilateral upper lobe cavitation** on CXR, and the positive **AFB smear**.- **NAAT** identifies the pathogen in clinical samples of symptomatic patients, while tests like **IGRA** or **Mantoux tests** are used for screening **latent TB infection**.

Question 183: A 26-year-old woman presents to the emergency department with a 24-hour history of fever, severe headache, photophobia, and neck stiffness. She develops a widespread non-blanching purpuric rash. Blood cultures are taken and empirical antibiotics are commenced. According to UK public health guidelines, within what timeframe must this case be notified to the local Health Protection Team?

A. Within 24 hours by telephone and in writing within 3 days (Correct Answer)
B. Within 3 days by telephone or in writing
C. Immediately by telephone followed by written notification within 24 hours
D. Within 48 hours by telephone
E. Within 7 days in writing only

Explanation: ***Within 24 hours by telephone and in writing within 3 days*** - **Meningococcal disease**, presenting with a purpuric rash and meningeal signs, is a **Category 1 notifiable disease** in the UK, requiring urgent public health action. - UK public health guidelines (e.g., Health Protection Regulations 2010) mandate **initial oral/telephone notification** to the local Health Protection Team within **24 hours** to facilitate rapid contact tracing and chemoprophylaxis, followed by **formal written notification** within **3 days**. *Within 3 days by telephone or in writing* - This timeframe is **too slow** for highly infectious and severe conditions like suspected meningococcal septicaemia, which necessitate immediate intervention. - While written notification within 3 days is correct, it **must be preceded** by an urgent verbal report within 24 hours. *Immediately by telephone followed by written notification within 24 hours* - While an immediate telephone call is clinically best practice for such severe cases, the **formal statutory deadline** for the written notification is **3 days**, not 24 hours. - This option incorrectly states the official timeframe for the **written component** according to public health regulations. *Within 48 hours by telephone* - A **48-hour delay** for telephone notification is not compliant with guidelines for diseases requiring immediate public health response to prevent further spread. - This option also **omits the requirement** for a subsequent written notification, which is a mandatory part of the reporting process. *Within 7 days in writing only* - **Written-only notification** is reserved for less urgent notifiable diseases that do not pose an immediate public health threat requiring rapid action. - A **7-day delay** for a serious, highly transmissible infection like meningococcal disease would be entirely inappropriate and **compromise public safety**.

Question 184: A 34-year-old woman with pulmonary tuberculosis is currently receiving rifampicin, isoniazid, pyrazinamide, and ethambutol. Which of the following medication side effects requires routine monitoring with monthly ophthalmology assessments during the intensive phase of treatment?

A. Rifampicin-induced optic neuritis
B. Isoniazid-induced peripheral neuropathy affecting vision
C. Pyrazinamide-induced colour vision disturbance
D. Ethambutol-induced optic neuropathy (Correct Answer)
E. Rifampicin-induced uveitis

Explanation: ***Ethambutol-induced optic neuropathy*** - **Ethambutol** is well-known for causing dose-dependent **optic neuropathy**, which manifests as decreased visual acuity and **red-green color blindness**. - Routine monthly monitoring of **visual acuity** and color perception is mandatory because the toxicity is often reversible if the drug is discontinued immediately. *Rifampicin-induced optic neuritis* - **Rifampicin** typically causes harmless **orange discoloration** of body fluids and potential hepatotoxicity rather than nerve inflammation. - Optic neuritis is not a recognized side effect of rifampicin, making regular ophthalmic screening for this drug unnecessary. *Isoniazid-induced peripheral neuropathy affecting vision* - **Isoniazid** (INH) commonly causes **peripheral neuropathy** due to competitive inhibition of **pyridoxine (Vitamin B6)**, primarily affecting the limbs. - Vision loss is not a standard presentation of INH-induced peripheral neuropathy; prevention involves co-administration of **pyridoxine supplementation**. *Pyrazinamide-induced colour vision disturbance* - **Pyrazinamide** is primarily associated with **hyperuricemia** (which may trigger gout) and potential **hepatotoxicity**. - It has no known clinical association with **color vision disturbances** or other ophthalmic toxicities. *Rifampicin-induced uveitis* - While **rifabutin** (a related drug) is known to cause **uveitis**, **rifampicin** does not typically cause intraocular inflammation. - Monitoring for uveitis is not a standard requirement for patients undergoing the standard **RIPE** regimen for pulmonary tuberculosis.

Question 185: A 48-year-old man from Bangladesh presents with a 2-month history of productive cough, fever, and weight loss. Chest X-ray shows bilateral upper zone infiltrates with cavitation. Sputum microscopy shows acid-fast bacilli. GeneXpert MTB/RIF assay detects Mycobacterium tuberculosis with rifampicin resistance. Culture subsequently confirms rifampicin and isoniazid resistance (MDR-TB), but sensitivity to fluoroquinolones and second-line injectables. What is the minimum recommended duration of treatment for this patient?

A. 9 months total with at least 5 months after culture conversion
B. 12 months total with at least 6 months after culture conversion
C. 18 months total with at least 12 months after culture conversion (Correct Answer)
D. 20 months total with at least 16 months after culture conversion
E. 24 months with at least 18 months after culture conversion

Explanation: ***18 months total with at least 12 months after culture conversion***- For traditional individualized **MDR-TB** regimens, the standard treatment duration is a minimum of **18 months**, ensuring sufficient time to prevent relapse.- Monitoring requires at least **12 months** of therapy following the first documented negative culture (**culture conversion**) to ensure the eradication of dormant bacilli, especially in patients with **cavitary disease**.*9 months total with at least 5 months after culture conversion*- This describes the **shorter MDR-TB regimen** (9-11 months), which is suitable for patients without **extensive disease** or specific resistance patterns.- The presence of **bilateral cavitation** in this patient indicates extensive disease, making them ineligible for the shorter regimen.*12 months total with at least 6 months after culture conversion*- This duration is insufficient for the management of **multidrug-resistant TB** and does not align with established **WHO guidelines** for either the shorter or longer regimens.- A 12-month course is generally not a recognized standard for the total duration of **MDR-TB** treatment, particularly for cases with **cavitary lesions**.*20 months total with at least 16 months after culture conversion*- While some older guidelines or specific complex cases might extend treatment to **20 months**, the current minimum recommended duration for the longer individualized regimen is **18 months**.- A requirement of **16 months post-culture conversion** is longer than the standard 12-month post-conversion requirement for most MDR-TB cases, even in the longer regimen.*24 months with at least 18 months after culture conversion*- This extended duration is typically reserved for **Extensively Drug-Resistant TB (XDR-TB)** or cases with extremely poor clinical response or very severe, extensive lung damage.- The patient's TB is sensitive to **fluoroquinolones** and second-line injectables, meaning it is **MDR-TB**, not XDR-TB, making 24 months an overestimation for the minimum duration.

Question 186: A 5-year-old girl presents with fever, headache, and neck stiffness. She is drowsy but rousable. Lumbar puncture shows: opening pressure 22 cmH₂O, white cells 800/mm³ (60% lymphocytes, 40% neutrophils), protein 1.2 g/L, glucose 3.1 mmol/L (plasma 5.8 mmol/L). Gram stain is negative. Bacterial culture is negative at 48 hours. Enterovirus PCR is positive. What is the most appropriate management?

A. Continue intravenous antibiotics for 7 days and add aciclovir
B. Stop all antimicrobials and provide supportive care (Correct Answer)
C. Continue intravenous antibiotics until bacterial culture negative at 5 days
D. Stop antibiotics but continue aciclovir for 14 days
E. Stop antibiotics, start pleconaril for enteroviral meningitis

Explanation: ***Stop all antimicrobials and provide supportive care*** - The patient has confirmed **Enterovirus meningitis** based on the positive PCR, negative Gram stain, and negative bacterial cultures at 48 hours. - **Supportive care** including hydration and analgesia is the standard of care as viral meningitis is typically self-limiting with an excellent prognosis. *Continue intravenous antibiotics for 7 days and add aciclovir* - Extended **antibiotic therapy** is unnecessary once bacterial meningitis is ruled out by negative 48-hour cultures and a positive viral PCR. - **Aciclovir** is used for Herpes Simplex Virus (HSV) encephalitis, not for enteroviral infections, and is not indicated here. *Continue intravenous antibiotics until bacterial culture negative at 5 days* - Standard practice allows for the cessation of empirical antibiotics if cultures remain negative at **48 hours** in a clinically stable patient with a viral diagnosis. - Unnecessary antibiotic use increases the risk of **drug side effects** and promotes **antimicrobial resistance**. *Stop antibiotics but continue aciclovir for 14 days* - While stopping antibiotics is correct, there is no clinical or laboratory evidence (such as temporal lobe changes or positive HSV PCR) to justify **aciclovir**. - **Enteroviruses** do not respond to aciclovir, making its continuation ineffective and potentially nephrotoxic. *Stop antibiotics, start pleconaril for enteroviral meningitis* - **Pleconaril** is not routinely recommended or licensed in many regions for standard enteroviral meningitis cases. - Management of this condition remains primarily **symptomatic**, with antivirals reserved only for severe complications or immunocompromised patients.

Question 187: A 35-year-old woman is diagnosed with latent tuberculosis infection (positive interferon-gamma release assay) during screening before starting adalimumab for Crohn's disease. Chest X-ray is normal. She has a history of isoniazid-induced hepatitis during previous TB prophylaxis 5 years ago (ALT peaked at 850 U/L). What is the most appropriate management?

A. Proceed with adalimumab without treating latent TB, as previous prophylaxis was partially completed
B. Treat with rifampicin monotherapy for 4 months, then start adalimumab (Correct Answer)
C. Treat with isoniazid for 6 months with weekly monitoring of liver function
D. No treatment for latent TB is needed if chest X-ray remains normal
E. Treat with rifampicin plus isoniazid for 3 months, then start adalimumab

Explanation: ***Treat with rifampicin monotherapy for 4 months, then start adalimumab***- **Rifampicin monotherapy** for 4 months is the preferred alternative for **latent TB infection (LTBI)** when isoniazid is contraindicated due to previous severe **hepatotoxicity**.- Treating LTBI is mandatory before initiating **TNF-alpha inhibitors** like adalimumab, as these biologics significantly increase the risk of TB **reactivation**.*Proceed with adalimumab without treating latent TB, as previous prophylaxis was partially completed*- TNF-alpha inhibitors carry a high risk of converting latent TB to **active disease**; therapy must not be started until LTBI is addressed.- Previous **prophylaxis was aborted** due to toxicity, meaning the patient remains at risk and requires a full alternative course.*Treat with isoniazid for 6 months with weekly monitoring of liver function*- Re-challenging with isoniazid is contraindicated after **severe drug-induced liver injury** (ALT 850 U/L is >15x the upper limit of normal).- Continuing isoniazid despite a history of **isoniazid-induced hepatitis** puts the patient at risk for **acute liver failure**.*No treatment for latent TB is needed if chest X-ray remains normal*- A **normal chest X-ray** is expected in latent TB; it does not rule out the presence of dormant bacilli that can reactivate under **immunosuppression**.- A positive **IGRA (Interferon-Gamma Release Assay)** confirms LTBI, necessitating treatment regardless of static imaging findings before starting biologics.*Treat with rifampicin plus isoniazid for 3 months, then start adalimumab*- Although a 3-month combination is a standard regimen, it is unsuitable here because it still contains **isoniazid**.- The patient's history of **life-threatening hepatotoxicity** requires a strictly **isoniazid-free** regimen to ensure safety.

Question 188: A 72-year-old man with a prosthetic aortic valve presents with fever, confusion, and neck stiffness. Lumbar puncture shows: white cells 3,200/mm³ (90% neutrophils), protein 4.1 g/L, glucose 1.1 mmol/L (plasma 6.8 mmol/L), Gram stain shows Gram-positive cocci in chains. Blood cultures grow Streptococcus gallolyticus (formerly S. bovis). What additional investigation is most important?

A. Echocardiography to assess for endocarditis
B. CT chest to exclude bronchogenic carcinoma
C. Colonoscopy (Correct Answer)
D. Bone marrow biopsy
E. Upper GI endoscopy

Explanation: ***Colonoscopy*** - Infection with **Streptococcus gallolyticus** (formerly **S. bovis**) is strongly associated with underlying **colorectal malignancy** or large adenomatous polyps. - Current guidelines mandate a **colonoscopy** in any patient with bacteremia or meningitis caused by this organism to screen for occult **colon cancer**. *Echocardiography to assess for endocarditis* - While **S. gallolyticus** is a common cause of **infective endocarditis**, especially in patients with prosthetic valves, this investigation is often part of the initial septic workup rather than the most distinct "additional" step linked to this specific bacteria. - Identifying endocarditis manages the current infection, but **colonoscopy** is critical for detecting the underlying source and potentially life-threatening malignancy. *CT chest to exclude bronchogenic carcinoma* - There is no clinical or microbiological association between **Streptococcus gallolyticus** and **bronchogenic carcinoma**. - This investigation would not be a routine response to **Gram-positive cocci** meningitis or bacteremia absent specific pulmonary symptoms. *Bone marrow biopsy* - **Bone marrow biopsy** is used for investigating hematological malignancies or unexplained cytopenias, which are not indicated by this presentation. - It does not assist in identifying the source of an **S. gallolyticus** infection, which is localized to the gastrointestinal tract. *Upper GI endoscopy* - Although the organism is of GI origin, the specific association is with **colonic pathology** rather than gastric or esophageal conditions. - An **upper GI endoscopy** (OGD) would be significantly less likely than a **colonoscopy** to yield a relevant diagnostic finding for this patient.

Question 189: A 44-year-old man from Somalia is diagnosed with pulmonary tuberculosis. Culture confirms Mycobacterium tuberculosis fully sensitive to first-line drugs. He has a BMI of 32 kg/m². After 2 months of rifampicin, isoniazid, pyrazinamide, and ethambutol, repeat sputum culture remains positive. What is the most likely explanation for treatment failure?

A. Development of acquired drug resistance during treatment
B. Inadequate drug dosing due to obesity
C. Non-adherence to treatment (Correct Answer)
D. Malabsorption of oral medications
E. Presence of HIV co-infection

Explanation: ***Non-adherence to treatment*** - **Non-adherence** is the most common cause of treatment failure and persistent positive cultures in patients undergoing therapy for **drug-sensitive tuberculosis**. - TB therapy involves a high **pill burden** and long duration, which frequently leads to poor compliance once the patient begins to feel clinically better. *Development of acquired drug resistance during treatment* - While possible, **acquired resistance** typically occurs as a secondary consequence of irregular self-administration or **non-adherence**. - It is less likely than simple non-adherence to be the *initial* explanation for a positive culture at the 2-month mark when the strain was initially **fully sensitive**. *Inadequate drug dosing due to obesity* - Standard **weight-band dosing** strategies for TB are designed to provide therapeutic levels even in patients with a higher **BMI**. - Although obesity can alter the volume of distribution, it is rarely the primary cause of complete **treatment failure** if the patient is taking the medication regularly. *Malabsorption of oral medications* - **Malabsorption** is a rare cause of failure and is usually associated with underlying gastrointestinal disorders like **Crohn's disease** or advanced **HIV/AIDS**. - This should only be considered after **adherence** has been strictly verified through **Directly Observed Therapy (DOT)**. *Presence of HIV co-infection* - While **HIV co-infection** can complicate the clinical course and increase the risk of disseminated disease, it does not inherently prevent **sputum conversion** if medications are taken correctly. - In the absence of other symptoms of **immunosuppression**, it is statistically less likely to cause a positive 2-month culture than patient non-compliance.

Question 190: A 14-year-old boy presents with a 6-hour history of fever, severe headache, neck stiffness, and photophobia. Lumbar puncture shows: white cells 1,800/mm³ (80% neutrophils), protein 2.8 g/L, glucose 2.2 mmol/L (plasma 5.5 mmol/L). Gram stain is negative. PCR confirms Neisseria meningitidis serogroup W. He is treated successfully with intravenous ceftriaxone. Which prophylactic antibiotic should be given to his household contacts?

A. No prophylaxis needed as he has already received ceftriaxone
B. Oral rifampicin 600mg twice daily for 2 days
C. Oral ciprofloxacin 500mg single dose (Correct Answer)
D. Intramuscular ceftriaxone 250mg single dose
E. Oral azithromycin 500mg single dose

Explanation: ***Oral ciprofloxacin 500mg single dose*** - **Ciprofloxacin** is a highly effective and generally well-tolerated agent for **meningococcal chemoprophylaxis** in adults and children over 12, given as a **single oral dose**. - Its efficacy stems from excellent penetration into the **nasopharyngeal mucosa**, where *Neisseria meningitidis* colonizes, leading to rapid eradication of the carrier state and reduced transmission risk. *No prophylaxis needed as he has already received ceftriaxone* - The patient's treatment with **ceftriaxone** targets the systemic infection but does not reliably eradicate **nasopharyngeal carriage** of *Neisseria meningitidis* in the treated individual or prevent transmission to close contacts. - **Household contacts** are at significantly increased risk of developing **meningococcal disease** due to close exposure to respiratory droplets from the index case, necessitating prompt **chemoprophylaxis**. *Oral rifampicin 600mg twice daily for 2 days* - **Rifampicin** is an effective prophylactic agent but requires a **multi-dose regimen** (typically 4 doses over 2 days), which can lead to lower compliance compared to single-dose options. - It has significant drug interactions, including with **oral contraceptives**, and can cause **red-orange discoloration** of urine and tears, making it less preferred as a first-line agent where single-dose options are available. *Intramuscular ceftriaxone 250mg single dose* - **Intramuscular ceftriaxone** is an effective single-dose prophylactic option, particularly suitable for **pregnant women** and young children (under 12 years) for whom oral ciprofloxacin is contraindicated. - However, for routine prophylaxis in healthy adults and adolescents, the **oral route** is preferred over an invasive **intramuscular injection** due to convenience and patient preference. *Oral azithromycin 500mg single dose* - **Azithromycin** is not a recommended agent for **meningococcal chemoprophylaxis** according to major guidelines (e.g., UKHSA, CDC), as there is insufficient evidence for its efficacy in eradicating *Neisseria meningitidis* carriage. - While a macrolide, its role in prophylaxis for **invasive meningococcal disease** is not established, unlike for other bacterial infections such as pertussis or chlamydia.

Question 191: A 52-year-old woman is diagnosed with smear-positive pulmonary tuberculosis. She has been taking warfarin for recurrent deep vein thrombosis secondary to antiphospholipid syndrome. Standard four-drug anti-tuberculous therapy is commenced. What is the most appropriate management of her anticoagulation?

A. Continue warfarin at the same dose and monitor INR weekly until stable
B. Increase warfarin dose by 50% due to rifampicin interaction and monitor INR closely
C. Switch to low molecular weight heparin for the duration of TB treatment (Correct Answer)
D. Switch to a direct oral anticoagulant (DOAC) such as apixaban
E. Stop anticoagulation as the thrombotic risk is lower during acute infection

Explanation: ***Switch to low molecular weight heparin for the duration of TB treatment***- **Rifampicin** is a potent inducer of **Cytochrome P450 enzymes**, which significantly accelerates **warfarin metabolism**, making the **INR** nearly impossible to stabilize.- **Low molecular weight heparin (LMWH)** is the safest choice because its metabolism is not affected by the **P450 system**, ensuring stable therapeutic anticoagulation for high-risk conditions like **Antiphospholipid Syndrome (APS)**.*Continue warfarin at the same dose and monitor INR weekly until stable*- Maintaining the same dose is dangerous as **Rifampicin** induction decreases warfarin levels rapidly, leading to a **subtherapeutic INR** and high risk of recurrent **thrombosis**.- Routine monitoring is often insufficient to keep up with the magnitude of the interaction, which can require **warfarin dose increases** of 2 to 3 times the baseline.*Increase warfarin dose by 50% due to rifampicin interaction and monitor INR closely*- While increasing the dose is a theoretical strategy, the enzyme induction is **variable and unpredictable**, making it difficult to achieve a stable **therapeutic window**.- This approach carries a high risk of **treatment failure** or sudden **toxicity** if other medications are adjusted or TB therapy is interrupted.*Switch to a direct oral anticoagulant (DOAC) such as apixaban*- **Rifampicin** induces **P-glycoprotein (P-gp)** and **CYP3A4**, which significantly reduces the plasma concentration and efficacy of **DOACs**.- Furthermore, **DOACs** are generally discouraged in patients with **Triple-Positive Antiphospholipid Syndrome** due to an increased risk of arterial thrombotic events compared to warfarin.*Stop anticoagulation as the thrombotic risk is lower during acute infection*- This is incorrect as **acute infection** and inflammation actually create a **pro-thrombotic state**, increasing the risk of VTE.- Stopping therapy in a patient with **recurrent DVT** and **Antiphospholipid Syndrome** is contraindicated due to the extremely high risk of life-threatening **thromboembolism**.

Question 192: A 38-year-old man with AIDS (CD4 count 35 cells/mm³) presents with a 4-week history of headache and fever. MRI brain shows multiple ring-enhancing lesions with surrounding oedema in both cerebral hemispheres. He is started on treatment for presumed cerebral toxoplasmosis. After how many days of appropriate anti-toxoplasma therapy should clinical and radiological response be assessed to determine if the diagnosis is correct?

A. 7-10 days
B. 3-5 days
C. 10-14 days (Correct Answer)
D. 21-28 days
E. 6 weeks

Explanation: ***10-14 days***- In patients with **AIDS** and **multiple ring-enhancing lesions**, empirical therapy for **Toxoplasma gondii** is the standard first step, and a response is typically expected within **10-14 days**.- A lack of **clinical or radiological improvement** by the end of this period strongly suggests an alternative diagnosis, most commonly **Primary CNS Lymphoma (PCNSL)**.*3-5 days*- This duration is **too short** to observe significant radiological resolution of brain lesions and surrounding **oedema**.- Assessing too early may lead to unnecessary invasive procedures like a **brain biopsy** before the medication has had time to work.*7-10 days*- While some clinical improvement might start, **radiological assessment** at this stage is often premature and inconclusive.- Clinical guidelines specifically highlight the **two-week mark** (**10-14 days**) as the definitive window for evaluating treatment efficacy.*21-28 days*- Waiting nearly a month to assess response is dangerous, as it would cause a significant delay in diagnosing and treating **PCNSL** if toxoplasmosis is not the correct diagnosis.- If the diagnosis is incorrect, the patient's **neurological status** could deteriorate significantly during this prolonged observation period, increasing morbidity and mortality.*6 weeks*- This timeframe represents the typical duration of the **acute phase of induction therapy** for toxoplasmosis, not the initial assessment point for diagnostic confirmation.- Diagnosis verification must happen much earlier to ensure the patient is on the correct **antimicrobial or oncological regimen** and to prevent disease progression.

Question 193: A 26-year-old previously healthy woman presents to the emergency department with a 8-hour history of severe headache, fever (39.2°C), photophobia, and a non-blanching purpuric rash on her lower limbs. Blood pressure is 92/58 mmHg, heart rate 118 bpm. She is confused with GCS 13/15. What is the most appropriate immediate antibiotic management?

A. Intravenous ceftriaxone 2g plus intravenous amoxicillin 2g
B. Intravenous ceftriaxone 2g alone (Correct Answer)
C. Intramuscular benzylpenicillin 1.2g
D. Intravenous ceftriaxone 2g plus intravenous vancomycin 1g
E. Intravenous meropenem 2g plus intravenous vancomycin 1g

Explanation: ***Intravenous ceftriaxone 2g alone*** - This patient presents with classic **meningococcal disease**, characterized by fever, headache, meningism, and a **non-blanching purpuric rash**, along with signs of sepsis. - **Intravenous ceftriaxone** is the first-line empirical treatment in adults aged 18-50 as it effectively covers **Neisseria meningitidis** and **Streptococcus pneumoniae**, the most common pathogens in community-acquired bacterial meningitis in this age group. *Intravenous ceftriaxone 2g plus intravenous amoxicillin 2g* - **Amoxicillin** is added to cover **Listeria monocytogenes**, which typically affects neonates, the elderly (>50-60 years), pregnant women, or **immunocompromised** patients. - Since this patient is a **previously healthy 26-year-old**, empirical coverage for Listeria is not routinely indicated. *Intramuscular benzylpenicillin 1.2g* - This is primarily used in the **pre-hospital setting** by GPs or paramedics when **bacterial meningitis** is suspected and transfer to a hospital is delayed. - Once in the **Emergency Department**, intravenous broad-spectrum cephalosporins like **ceftriaxone** are the preferred standard of care due to broader coverage and route of administration. *Intravenous ceftriaxone 2g plus intravenous vancomycin 1g* - **Vancomycin** is usually added in regions with a high prevalence of **penicillin-resistant pneumococcus** or if the patient has specific risk factors (e.g., recent antibiotic use, history of resistant organisms). - It is not part of the standard initial empirical regimen for a healthy young adult with suspected community-acquired meningococcal sepsis in many regions. *Intravenous meropenem 2g plus intravenous vancomycin 1g* - **Meropenem** is a very broad-spectrum carbapenem typically reserved for **healthcare-associated meningitis**, severe **beta-lactam allergies**, or very resistant organisms. - This combination provides excessive coverage for **community-acquired meningitis** in a young, immunocompetent patient without specific risk factors.

Question 194: A 29-year-old woman from Ethiopia who migrated to the UK 6 months ago presents with a 12-week history of lower back pain, night sweats, and weight loss. MRI spine shows destruction of the T10-T11 vertebrae with paravertebral soft tissue collection and cord compression. What is the most appropriate initial management?

A. Start four-drug anti-tuberculous therapy and arrange urgent neurosurgical assessment (Correct Answer)
B. Perform CT-guided biopsy of the paravertebral collection before starting treatment
C. Start four-drug anti-tuberculous therapy and refer for outpatient physiotherapy
D. Arrange urgent surgical debridement and spinal stabilization before starting anti-tuberculous therapy
E. Start empirical broad-spectrum antibiotics for pyogenic osteomyelitis

Explanation: ***Start four-drug anti-tuberculous therapy and arrange urgent neurosurgical assessment*** - The patient's presentation with chronic back pain, night sweats, weight loss, vertebral destruction, and a paravertebral collection in a person from an endemic area is highly suggestive of **Pott's disease** (spinal tuberculosis). - **Cord compression** is a medical emergency requiring immediate initiation of **anti-tuberculous therapy** to control the infection and an urgent neurosurgical assessment to prevent permanent neurological deficits. *Perform CT-guided biopsy of the paravertebral collection before starting treatment* - While tissue diagnosis is important, delaying treatment for a biopsy when **neurological compromise** (cord compression) is present is inappropriate. - Empirical **anti-tuberculous therapy** should be started immediately based on high clinical and radiological suspicion in such urgent cases. *Start four-drug anti-tuberculous therapy and refer for outpatient physiotherapy* - Physiotherapy is a supportive measure but does not address the urgent need to manage **cord compression** or spinal instability. - Outpatient referral is insufficient as the patient requires inpatient monitoring and immediate intervention for their severe condition. *Arrange urgent surgical debridement and spinal stabilization before starting anti-tuberculous therapy* - Surgical intervention may be required, but it is generally performed *after* or concurrently with the initiation of **anti-tuberculous therapy**. - Starting medical therapy first helps to reduce the risk of **disease dissemination** during the surgical procedure. *Start empirical broad-spectrum antibiotics for pyogenic osteomyelitis* - The chronic 12-week history and constitutional symptoms (night sweats, weight loss) are more indicative of **tuberculosis** rather than acute pyogenic osteomyelitis. - The patient's origin from an **endemic region** for tuberculosis further points away from empirical treatment for pyogenic osteomyelitis.

Question 195: A 67-year-old man with chronic obstructive pulmonary disease presents with a 2-day history of fever, severe headache, and drowsiness. Lumbar puncture shows: white cells 2,400/mm³ (85% neutrophils), protein 3.2 g/L, glucose 1.4 mmol/L (plasma 7.8 mmol/L). Gram stain shows Gram-negative diplococci. He is started on intravenous ceftriaxone. Which additional immediate management is most important?

A. Add intravenous dexamethasone (Correct Answer)
B. Add intravenous vancomycin
C. Arrange repeat lumbar puncture in 48 hours
D. Give intramuscular benzylpenicillin
E. Notify public health authorities

Explanation: ***Add intravenous dexamethasone***- High-level evidence and clinical guidelines recommend **dexamethasone** should be administered with or just before the first dose of antibiotics in suspected **bacterial meningitis** to reduce inflammation.- It significantly decreases the risk of **neurological sequelae** and mortality by dampening the inflammatory response to bacterial lysis in the subarachnoid space.*Add intravenous vancomycin*- **Vancomycin** is typically added empirically if there is a suspicion of **penicillin-resistant Streptococcus pneumoniae**, which is not indicated by the Gram-negative diplococci seen here.- The Gram stain specifically points toward **Neisseria meningitidis**, for which **ceftriaxone** provides excellent coverage without the need for vancomycin.*Arrange repeat lumbar puncture in 48 hours*- A **repeat lumbar puncture** is not routinely recommended unless there is a failure to respond clinically to appropriate therapy after 48 hours.- Immediate management focuses on stabilizing the patient and preventing complications, not scheduled **CSF surveillance** in the acute phase.*Give intramuscular benzylpenicillin*- **IM benzylpenicillin** is primarily used as a pre-hospital treatment in the community when **meningococcal septicaemia** is suspected and hospital transfer is delayed.- Since the patient is already in the hospital receiving **intravenous ceftriaxone**, benzylpenicillin provides no additional benefit and is pharmacologically redundant.*Notify public health authorities*- While **notifying public health** is a mandatory statutory requirement for cases of **meningococcal disease**, it is not an immediate clinical priority for patient stabilization.- Clinical management to prevent **hearing loss** and brain injury (using steroids) takes precedence over administrative reporting in the immediate setting.

Question 196: A 32-year-old man with no past medical history presents with a 10-week history of cough, weight loss, and night sweats. Chest X-ray shows bilateral upper zone cavitation. Three sputum samples are smear-positive for acid-fast bacilli. Culture and sensitivity results are pending. He lives with his pregnant wife (22 weeks gestation) and two children aged 3 and 7 years. What is the most appropriate immediate management for his household contacts?

A. All household contacts should receive isoniazid prophylaxis immediately
B. Chest X-ray for all contacts, Mantoux test for children, prophylaxis only if tests abnormal
C. Mantoux test for all contacts, treat those with positive results
D. Observe all contacts clinically, arrange follow-up in 8 weeks for reassessment
E. Chest X-ray for wife, Mantoux test and prophylaxis for both children regardless of results (Correct Answer)

Explanation: ***Chest X-ray for wife, Mantoux test and prophylaxis for both children regardless of results*** - In smear-positive pulmonary TB cases, children **under 5 years** (like the 3-year-old) must receive immediate **chemoprophylaxis** after excluding active disease, regardless of initial test results, due to high risk of progression to **miliary TB or meningitis**. - The pregnant wife requires a **chest X-ray** (with shielding) as the first step to exclude active disease, while older children (like the 7-year-old) require **Mantoux testing** to determine if treatment for latent infection is necessary. *All household contacts should receive isoniazid prophylaxis immediately* - Prophylaxis is not given blindly to all adults; active TB must be **excluded first** using imaging or clinical assessment to avoid under-treating active disease. - For the wife and the 7-year-old, the decision to give prophylaxis typically depends on **screening results** (Mantoux or CXR) rather than being immediate and universal. *Chest X-ray for all contacts, Mantoux test for children, prophylaxis only if tests abnormal* - This approach is incorrect for the 3-year-old, as current guidelines mandate **primary prophylaxis** for children under 5 even if the initial Mantoux is negative. - Waiting for "abnormal tests" in very young children is dangerous because they can develop **disseminated disease** during the window period before a skin test becomes positive. *Mantoux test for all contacts, treat those with positive results* - This ignores the high-risk status of the **under-5 age group**, who require protection regardless of the initial Mantoux result during the "window period." - It also overlooks that a **chest X-ray** is the preferred initial screening tool for symptomatic or high-risk adults (like the wife) to rapidly rule out infectiousness. *Observe all contacts clinically, arrange follow-up in 8 weeks for reassessment* - Clinical observation alone is insufficient for **household contacts** of a smear-positive index case, which carries a very high transmission risk. - Delaying intervention by 8 weeks would miss the critical window to prevent **latent TB progression** in the vulnerable children.

Question 197: A 45-year-old woman presents with a 3-week history of progressive headache, vomiting, and confusion. She has no significant past medical history. Lumbar puncture reveals: opening pressure 28 cmH₂O, CSF protein 2.4 g/L, glucose 1.8 mmol/L (plasma glucose 6.2 mmol/L), white cells 250/mm³ (90% lymphocytes). India ink stain is positive. What additional investigation is most important before starting treatment?

A. CT chest to exclude pulmonary tuberculosis
B. HIV test (Correct Answer)
C. Serum cryptococcal antigen
D. MRI brain with gadolinium contrast
E. Tuberculin skin test

Explanation: ***HIV test*** - A **positive India ink stain** confirms **cryptococcal meningitis**, a defining opportunistic infection that rarely occurs in immunocompetent individuals. - Identifying **HIV status** is critical as it dictates the specific **treatment protocols**, timing of antiretroviral therapy, and management of **immune reconstitution inflammatory syndrome (IRIS)**. *CT chest to exclude pulmonary tuberculosis* - While **pulmonary TB** can coexist with HIV, the immediate diagnosis here is confirmed as fungal via **India ink**, making TB workup less urgent than baseline immune status evaluation. - **Lymphocytic pleocytosis** and low glucose profile overlap with TB, but the presence of **encapsulated yeasts** directs the primary focus away from tuberculosis. *Serum cryptococcal antigen* - This test is highly sensitive for screening but is redundant for primary diagnosis when **CSF India ink** and biochemical analysis have already confirmed the presence of the organism. - It may be used for **prognostication** or monitoring, but does not provide the essential underlying immune status information required for comprehensive management. *MRI brain with gadolinium contrast* - MRI is useful to identify complications like **cryptococcomas** or stroke but is not an essential investigation *before* starting induction antifungal therapy. - Although it may show **leptomeningeal enhancement**, the clinical and laboratory data provided are sufficient for immediate therapeutic intervention. *Tuberculin skin test* - The **Tuberculin skin test (Mantoux)** is often falsely negative (**anergy**) in patients with advanced immunosuppression or active meningitis. - It does not assist in the immediate management or confirmation of the **fungal etiology** established by the CSF findings.

Question 198: A 4-year-old child is diagnosed with tuberculous meningitis. Brain MRI shows basal meningeal enhancement and multiple tuberculomas. The child is started on appropriate anti-tuberculous therapy including rifampicin, isoniazid, pyrazinamide, and ethionamide. What is the recommended total duration of treatment for this child?

A. 6 months with four drugs throughout
B. 9 months with initial four-drug phase for 2 months
C. 12 months with initial four-drug phase for 2 months (Correct Answer)
D. 18 months with initial four-drug phase for 2 months
E. 24 months with initial four-drug phase for 3 months

Explanation: ***12 months with initial four-drug phase for 2 months*** - Standard treatment for **tuberculous meningitis** in children consists of a **2-month intensive phase** with four drugs (rifampicin, isoniazid, pyrazinamide, ethionamide) followed by a **10-month continuation phase**, totaling **12 months**. - This prolonged duration is crucial for adequate **central nervous system** penetration and sterilization, especially given the presence of **basal meningeal enhancement** and **tuberculomas**, which indicate severe disease. *6 months with four drugs throughout* - A **6-month regimen** is standard for uncomplicated pulmonary tuberculosis but is generally insufficient for severe **extrapulmonary TB**, particularly involving the **central nervous system**. - A shorter duration carries a higher risk of **relapse**, poor neurological outcomes, and the development of **drug resistance** in CNS TB. *9 months with initial four-drug phase for 2 months* - While a **9-month regimen** is sometimes used for less severe forms of **extrapulmonary TB** (e.g., bone and joint TB), it is not the recommended duration for **tuberculous meningitis**. - The severity and potential sequelae of CNS involvement necessitate a longer treatment course to ensure complete eradication and prevent neurological damage. *18 months with initial four-drug phase for 2 months* - An **18-month regimen** is typically reserved for cases of **multi-drug resistant (MDR-TB)** or highly complicated, extensive lesions with a very slow clinical response. - For drug-susceptible **tuberculous meningitis**, **12 months** is the established total duration, with longer regimens increasing the risk of **drug toxicity** without clear additional benefit. *24 months with initial four-drug phase for 3 months* - A **24-month duration** is excessively long for drug-susceptible **tuberculous meningitis** and significantly increases the risk of **adverse drug reactions** and poor adherence. - The intensive phase for pediatric TB meningitis is standardly **2 months**, not 3 months, before transitioning to a continuation phase.

Question 199: A 55-year-old man with newly diagnosed pulmonary tuberculosis is started on standard four-drug therapy. He has a background of gout for which he takes allopurinol. Two weeks into treatment, he develops a high fever, widespread erythematous rash with blistering, and painful mucosal ulceration affecting his mouth and eyes. Examination reveals extensive skin detachment affecting 40% of body surface area. What is the most likely causative drug?

A. Ethambutol
B. Isoniazid
C. Pyrazinamide (Correct Answer)
D. Rifampicin
E. Streptomycin

Explanation: ***Pyrazinamide*** - This patient presents with **Toxic Epidermal Necrolysis (TEN)**, defined by high fever, widespread blistering, painful mucosal ulceration, and extensive skin detachment affecting **40% body surface area**. - Among antitubercular drugs, **Pyrazinamide** is the most frequently associated with severe cutaneous adverse reactions like **SJS/TEN**, and the risk is significantly potentiated by concurrent **allopurinol** use. *Ethambutol* - The primary dose-dependent toxicity of this drug is **optic neuritis**, leading to decreased visual acuity and **red-green color blindness**. - While it can cause mild rashes, it is extremely rare for it to cause life-threatening **epidermal necrolysis**. *Isoniazid* - Most commonly associated with **hepatotoxicity** and **peripheral neuropathy** due to pyridoxine (Vitamin B6) deficiency. - Although it can cause hypersensitivity, it does not typically present with the dramatic **mucocutaneous detachment** seen in this patient. *Rifampicin* - Frequently causes minor side effects like **orange discoloration of secretions** and gastrointestinal upset, or more serious **cholestatic jaundice**. - While rarely implicated in skin reactions, it is much less common than **Pyrazinamide** as a trigger for **TEN**. *Streptomycin* - An aminoglycoside mainly associated with **ototoxicity** (vestibular and auditory damage) and **nephrotoxicity**. - It is not part of the standard initial four-drug oral regimen (RIPE) and is not known for causing **TEN**.

Question 200: A 23-year-old man presents with fever, severe headache, and neck stiffness. Lumbar puncture shows: white cells 2400 cells/mm³ (92% neutrophils), protein 3.1 g/L, glucose 0.8 mmol/L (plasma 5.2 mmol/L). Gram stain shows Gram-negative diplococci. He is treated with intravenous ceftriaxone and makes a good recovery. Blood PCR confirms Neisseria meningitidis serogroup B. Which statement regarding notification and prophylaxis is correct?

A. This is a notifiable disease; the laboratory will notify Public Health and arrange contact prophylaxis
B. This is a notifiable disease; the treating clinician must notify the local Health Protection Team urgently (Correct Answer)
C. Notification is only required if the patient dies or has long-term complications
D. This is not a notifiable disease as the patient has recovered with treatment
E. Notification is only required for serogroups A, C, W, and Y, not serogroup B

Explanation: ***This is a notifiable disease; the treating clinician must notify the local Health Protection Team urgently*** - **Meningococcal disease** is a legally notifiable condition, and the primary responsibility for notification rests with the **attending clinician** upon clinical suspicion. - Urgent notification to the **Health Protection Team (HPT)** is mandatory to facilitate rapid **contact tracing** and the administration of **chemoprophylaxis** to close contacts within 24 hours. *This is a notifiable disease; the laboratory will notify Public Health and arrange contact prophylaxis* - While laboratories have a duty to report identified pathogens, the **legal obligation** for urgent clinical notification remains with the **clinician**. - The **Health Protection Team**, rather than the laboratory staff, is responsible for coordinating the assessment and provision of **prophylaxis** to contacts. *Notification is only required if the patient dies or has long-term complications* - Notification is required for **all suspected and confirmed cases** of meningococcal disease, regardless of clinical outcome or severity. - Clinical notification should occur as soon as the diagnosis is suspected to prevent **secondary cases**, not following recovery or death. *This is not a notifiable disease as the patient has recovered with treatment* - The **notifiable status** of a disease is based on its public health risk and potential for outbreaks, which is not altered by the patient's individual **recovery**. - Recovery does not eliminate the need for **epidemiological surveillance** or the protection of close contacts who may still be at risk. *Notification is only required for serogroups A, C, W, and Y, not serogroup B* - **All serogroups** of *Neisseria meningitidis* are strictly notifiable under public health regulations. - Serogroup B remains a significant cause of **meningitis and septicaemia**, and cases trigger the same urgent **public health response** as other serogroups.

Question 201: A 56-year-old woman with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min/1.73m²) is diagnosed with drug-sensitive pulmonary tuberculosis. She weighs 55 kg. Standard four-drug therapy is commenced. Which aspect of her treatment requires the most careful monitoring and adjustment?

A. Reduce rifampicin dose by 50% due to renal impairment
B. Monitor visual acuity monthly due to increased risk of ethambutol toxicity (Correct Answer)
C. Increase pyrazinamide dose to compensate for renal excretion
D. Reduce isoniazid frequency to three times weekly
E. Monitor liver function weekly due to increased hepatotoxicity risk

Explanation: ***Monitor visual acuity monthly due to increased risk of ethambutol toxicity***- **Ethambutol** is primarily cleared by the **kidneys**; in patients with an eGFR of 25 mL/min/1.73m², the drug accumulates, significantly increasing the risk of **optic neuropathy**.- Monthly monitoring of **visual acuity** and **color vision** is essential to detect early signs of retrobulbar neuritis, and the dosing frequency should be adjusted (e.g., to three times weekly) in severe renal impairment.*Reduce rifampicin dose by 50% due to renal impairment*- **Rifampicin** is metabolized predominantly by the **liver** and excreted primarily through the biliary system, thus requiring no dose adjustment in patients with **renal impairment**.- Standard **weight-based dosing** of rifampicin should be maintained to ensure optimal therapeutic efficacy and prevent the emergence of **drug resistance**.*Increase pyrazinamide dose to compensate for renal excretion*- **Pyrazinamide** metabolites are renally excreted; therefore, in severe **renal impairment**, the dose should be **decreased** or the interval extended (e.g., three times weekly) to prevent drug accumulation and toxicity.- Increasing the dose would be dangerous, potentially leading to severe **hyperuricemia**, gout, and heightened **hepatotoxicity**.*Reduce isoniazid frequency to three times weekly*- **Isoniazid** is primarily metabolized in the **liver** via acetylation and its elimination is largely unaffected by **chronic kidney disease**.- While **pyridoxine (Vitamin B6)** supplementation is crucial to prevent peripheral neuropathy, the standard daily dosing of isoniazid generally remains appropriate in renal impairment.*Monitor liver function weekly due to increased hepatotoxicity risk*- While **hepatotoxicity** is a known risk with anti-TB regimens (especially isoniazid and pyrazinamide), chronic kidney disease is not typically an independent factor that necessitates *weekly* liver function monitoring over standard protocols.- The most immediate and specific drug-related toxicity requiring heightened vigilance in this patient, given her **eGFR of 25 mL/min/1.73m²**, is the renal accumulation of **ethambutol** and its associated **optic neuropathy**.

Question 202: A 14-year-old girl presents to the emergency department with a 4-hour history of fever, severe headache, and vomiting. On examination, she has a temperature of 39.2°C, Glasgow Coma Scale 14/15, photophobia, and neck stiffness. There is a petechial rash on her trunk and limbs. While preparing for lumbar puncture, she becomes increasingly drowsy with a GCS of 10/15. What is the most appropriate immediate management?

A. Proceed immediately with lumbar puncture before administering antibiotics
B. Arrange urgent CT head before lumbar puncture or antibiotics
C. Administer intravenous ceftriaxone immediately and defer lumbar puncture (Correct Answer)
D. Administer intravenous dexamethasone followed by antibiotics and perform LP when stable
E. Perform blood cultures, then lumbar puncture, then administer antibiotics

Explanation: ***Administer intravenous ceftriaxone immediately and defer lumbar puncture*** - The patient presents with classic signs of **meningitis** and **meningococcemia** (fever, headache, neck stiffness, photophobia, petechial rash). The **declining GCS** (from 14 to 10) indicates rapid neurological deterioration and potential **raised intracranial pressure** or impending herniation. - In cases of suspected bacterial meningitis with signs of raised intracranial pressure (e.g., declining GCS), **empirical broad-spectrum antibiotics** (like ceftriaxone) are the **highest priority** and should be administered immediately without delay for a lumbar puncture or CT scan. Lumbar puncture is contraindicated in this scenario due to the risk of **herniation**. *Proceed immediately with lumbar puncture before administering antibiotics* - Performing a **lumbar puncture** in a patient with a **rapidly deteriorating GCS** and signs highly suggestive of bacterial meningitis with complications like raised ICP or impending herniation is **contraindicated**. - This approach risks **brainstem herniation**, a fatal complication, and inappropriately delays the administration of **life-saving antibiotics**. *Arrange urgent CT head before lumbar puncture or antibiotics* - While a **CT head** is indicated to rule out mass lesions or severe edema before an LP in a patient with reduced consciousness, obtaining it must **not delay** the immediate administration of **empirical antibiotics**. - Delaying antibiotics for imaging significantly increases **morbidity and mortality** in bacterial meningitis, especially with signs of **septic shock** or rapid deterioration. *Administer intravenous dexamethasone followed by antibiotics and perform LP when stable* - While **dexamethasone** is often co-administered with antibiotics in bacterial meningitis to reduce inflammation and neurological sequelae, it is **not the absolute immediate priority** over bactericidal antibiotics. - The most critical first step for a patient in **septic shock** or with rapidly progressing meningitis is the prompt administration of **antibiotics**, which should not be delayed by other treatments. *Perform blood cultures, then lumbar puncture, then administer antibiotics* - While **blood cultures** are important for identifying the causative organism and guiding specific antibiotic therapy, they should **not significantly delay** the administration of empirical antibiotics in a critically ill patient. - This sequence is incorrect because the **lumbar puncture** is contraindicated by the patient's neurological deterioration, and delaying antibiotics for either cultures or LP is dangerous.

Question 203: A 39-year-old man who recently returned from visiting relatives in India for 3 months presents with a 6-week history of productive cough and weight loss. Chest X-ray shows right upper lobe cavitation. Sputum is smear-positive for acid-fast bacilli. Culture grows Mycobacterium tuberculosis fully sensitive to first-line drugs. He is started on rifampicin, isoniazid, pyrazinamide, and ethambutol. After 2 months, which is the appropriate continuation phase regimen?

A. Rifampicin and isoniazid for 4 months (Correct Answer)
B. Rifampicin, isoniazid, and ethambutol for 4 months
C. Rifampicin, isoniazid, and pyrazinamide for 4 months
D. Rifampicin and isoniazid for 7 months
E. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 4 months

Explanation: ***Rifampicin and isoniazid for 4 months*** - For **drug-sensitive pulmonary tuberculosis**, the standard regimen consists of a 2-month **intensive phase** (RHZE) followed by a 4-month **continuation phase** using only **rifampicin and isoniazid**. - Since the isolate is **fully sensitive** and the patient is completing the initial 2-month phase with full sensitivity to first-line drugs, the continuation phase aims to eliminate remaining bacilli while minimizing toxicity. *Rifampicin, isoniazid, and ethambutol for 4 months* - **Ethambutol** is primarily included in the initial intensive phase to prevent the development of resistance in case of unknown susceptibility. - Once the TB strain is confirmed to be **fully sensitive** to rifampicin and isoniazid, ethambutol is discontinued to reduce the risk of adverse effects like **optic neuritis**. *Rifampicin, isoniazid, and pyrazinamide for 4 months* - **Pyrazinamide** is critical for its early sterilizing activity, especially against intracellular bacilli in acidic environments, during the first 2 months. - Continuing pyrazinamide beyond 2 months is not recommended for drug-sensitive TB due to an increased risk of **hepatotoxicity** and **hyperuricemia** without significant additional therapeutic benefit. *Rifampicin and isoniazid for 7 months* - A **7-month continuation phase** (total 9 months of treatment) is typically reserved for specific high-risk scenarios, such as extensive cavitary disease that remains **culture-positive** at the end of the 2-month intensive phase, or certain forms of **extrapulmonary TB** (e.g., bone/joint or CNS TB). - For standard drug-sensitive **pulmonary tuberculosis** responding well, a total treatment duration of 6 months (2 intensive + 4 continuation) is highly effective and the standard of care. *Rifampicin, isoniazid, pyrazinamide, and ethambutol for 4 months* - Continuing the full **quadruple therapy** (RHZE) for the entire 6 months is not necessary for drug-sensitive tuberculosis and significantly increases the **pill burden** and the risk of drug-related adverse effects. - The standard guidelines recommend de-escalating to a two-drug regimen (rifampicin and isoniazid) in the continuation phase once drug sensitivity is confirmed.

Question 204: A 71-year-old man with Parkinson's disease presents with a 4-day history of fever, confusion, and photophobia. CT head shows no contraindication to lumbar puncture. LP shows: opening pressure 18 cmH2O, white cells 85 cells/mm³ (75% lymphocytes), protein 1.2 g/L, glucose 3.1 mmol/L (plasma 5.4 mmol/L). CSF Gram stain and bacterial culture are negative. CSF PCR is positive for herpes simplex virus type 1. He has been receiving intravenous aciclovir for 3 days. What is the recommended total duration of aciclovir treatment?

A. 5 days
B. 7 days
C. 10 days
D. 14 days (Correct Answer)
E. 21 days

Explanation: ***14 days*** - For confirmed **Herpes Simplex Virus (HSV) encephalitis** in an immunocompetent adult, current guidelines recommend a minimum duration of **14 to 21 days** of intravenous **aciclovir**. - This extended duration is crucial for eradicating the virus from the central nervous system, reducing severe neurological sequelae, and preventing **relapse**. *5 days* - A **5-day** course of **aciclovir** is typically inadequate for treating **HSV encephalitis**, a severe central nervous system infection. - This shorter duration is usually reserved for less severe mucocutaneous **herpes simplex virus** infections. *7 days* - A **7-day** course of **aciclovir** is the standard treatment for **HSV meningitis**, which usually has a more benign course and less direct parenchymal involvement than encephalitis. - For **encephalitis**, which involves inflammation of the brain parenchyma, a significantly longer duration is required to ensure viral clearance and improve outcomes. *10 days* - While longer than 5 or 7 days, a **10-day** course of **aciclovir** is generally considered insufficient for the treatment of **HSV encephalitis**. - Evidence suggests that a treatment duration of at least **14 days** is necessary to achieve optimal clinical response and minimize the risk of long-term neurological deficits. *21 days* - A **21-day** course of **aciclovir** is typically reserved for specific situations such as **neonatal HSV infection** or in severely **immunocompromised patients** with HSV encephalitis. - For the majority of immunocompetent adults, while a longer course might be considered in very severe or recalcitrant cases, **14 days** is generally sufficient and the established minimum standard.

Question 205: A 33-year-old woman who is 28 weeks pregnant presents with a 5-week history of cough, weight loss, and night sweats. Chest X-ray shows bilateral upper zone infiltrates with cavitation. Sputum samples are smear-positive for acid-fast bacilli. GeneXpert confirms Mycobacterium tuberculosis susceptible to rifampicin. What is the most appropriate initial treatment regimen?

A. Rifampicin, isoniazid, and ethambutol (defer pyrazinamide until after delivery)
B. Rifampicin, isoniazid, pyrazinamide, and ethambutol (Correct Answer)
C. Rifampicin and isoniazid only (defer other agents until after delivery)
D. Levofloxacin, ethambutol, and cycloserine (defer rifampicin until after delivery)
E. Defer all treatment until after delivery to minimise fetal risk

Explanation: ***Rifampicin, isoniazid, pyrazinamide, and ethambutol*** - The standard **four-drug regimen** (RIPE) is recommended for pregnant women because untreated tuberculosis poses a high risk of **maternal mortality**, fetal growth restriction, and **vertical transmission**. - All four first-line agents are considered **safe and non-teratogenic** during pregnancy; pyridoxine (vitamin B6) should be added to prevent **isoniazid-induced peripheral neuropathy**. *Rifampicin, isoniazid, and ethambutol (defer pyrazinamide until after delivery)* - Deferring **pyrazinamide** is unnecessary and results in a less effective regimen that would require a longer duration of treatment (9 months instead of 6). - Current **WHO and UK guidelines** confirm that pyrazinamide is safe for the fetus and essential for a rapid cure, especially in cavitary disease. *Rifampicin and isoniazid only (defer other agents until after delivery)* - Using only two drugs for active tuberculosis is inadequate and significantly increases the risk of developing **multidrug-resistant TB (MDR-TB)**. - An intensive phase with four drugs is mandatory to manage the high **bacillary load** typical of smear-positive, cavitary tuberculosis. *Levofloxacin, ethambutol, and cycloserine (defer rifampicin until after delivery)* - **Fluoroquinolones** like levofloxacin and second-line agents like **cycloserine** are usually avoided in pregnancy unless the patient has drug-resistant TB, which is not indicated here. - **Rifampicin** is a cornerstone of first-line therapy and should never be deferred in drug-susceptible cases as it is safe and highly effective. *Defer all treatment until after delivery to minimise fetal risk* - Delaying treatment is contraindicated as active, smear-positive TB is a life-threatening condition for the mother and a major hazard for **congenital TB**. - The risks associated with **untreated tuberculosis** far outweigh the potential adverse effects of the standard first-line antibiotic treatment.

Question 206: A 62-year-old man with chronic liver disease due to alcohol presents with fever, headache, and neck stiffness. Lumbar puncture shows: white cells 1200 cells/mm³ (85% neutrophils), protein 2.4 g/L, glucose 1.8 mmol/L (plasma 6.2 mmol/L). Blood cultures grow Gram-positive rods that are beta-haemolytic. Which antibiotic regimen should have been included in his initial empirical therapy?

A. Ceftriaxone and vancomycin
B. Ceftriaxone and amoxicillin (Correct Answer)
C. Benzylpenicillin and chloramphenicol
D. Ceftriaxone and metronidazole
E. Meropenem and gentamicin

Explanation: ***Ceftriaxone and amoxicillin*** - The patient has bacterial meningitis caused by **Listeria monocytogenes**, indicated by **Gram-positive rods** and **beta-haemolysis** in an immunocompromised host (chronic liver disease). - **Amoxicillin** (or ampicillin) must be added to standard therapy because **Listeria** is inherently resistant to all **cephalosporins**, including ceftriaxone. *Ceftriaxone and vancomycin* - This combination is standard empirical therapy for adults to cover **Streptococcus pneumoniae** and **Neisseria meningitidis**. - It lacks coverage for **Listeria monocytogenes**, which is a critical pathogen in patients over 50 or those with **chronic liver disease**. *Benzylpenicillin and chloramphenicol* - **Benzylpenicillin** is used for meningococcal disease but does not provide the broad-spectrum coverage required for empirical management of unknown bacterial meningitis. - **Chloramphenicol** is an alternative for **Listeria** in penicillin-allergic patients but is not part of the first-line empirical regimen in this clinical setting. *Ceftriaxone and metronidazole* - **Metronidazole** provides coverage against **anaerobes**, which are typically associated with **brain abscesses** rather than primary bacterial meningitis. - This regimen fails to address the **Gram-positive rods** (Listeria) identified in the patient's cultures. *Meropenem and gentamicin* - **Meropenem** has broad activity but **amoxicillin** remains the preferred agent for **Listeria** coverage in standard meningitis protocols. - **Gentamicin** is sometimes added for synergy in confirmed Listeria cases but is not the primary empirical partner for **ceftriaxone** in meningitis guidelines.

Question 207: A 19-year-old university student is admitted with suspected meningococcal meningitis. Blood cultures subsequently grow Neisseria meningitidis serogroup W. He makes a full recovery after treatment. Which of the following groups requires chemoprophylaxis?

A. All students living in the same university accommodation block
B. Only household contacts who have had direct contact with oral secretions (Correct Answer)
C. Healthcare workers who performed the initial clinical assessment without aerosol-generating procedures
D. All laboratory staff who handled the blood culture samples
E. Students who attended the same lectures in the 7 days before admission

Explanation: ***Only household contacts who have had direct contact with oral secretions***- **Chemoprophylaxis** is indicated for **close contacts** who have had prolonged or significant exposure to **respiratory secretions** within 7 days prior to symptom onset.- This includes **household members** or individuals with **significant transient contact** involving oral secretions, such as **intimate kissing** or sharing items contaminated with saliva.*All students living in the same university accommodation block*- **Mass prophylaxis** for an entire accommodation block is not generally recommended due to low transmission risk among those without prolonged intimate contact.- Public health guidelines prioritize **identified close contacts** (e.g., roommates) to prevent unnecessary **antibiotic use** and potential **resistance**.*Healthcare workers who performed the initial clinical assessment without aerosol-generating procedures*- Routine clinical assessment with standard precautions does not constitute a high-risk exposure for **Neisseria meningitidis** transmission to healthcare workers.- **Prophylaxis** for staff is typically reserved for direct exposure to **respiratory droplets** during **aerosol-generating procedures** (e.g., intubation) without proper **Personal Protective Equipment (PPE)**.*All laboratory staff who handled the blood culture samples*- Laboratory personnel are not routinely indicated for prophylaxis unless they experience a **laboratory accident** involving significant aerosol generation.- Adherence to **Standard Microbiological Practices** and the use of **Class II biological safety cabinets** effectively minimizes risk during routine blood culture handling.*Students who attended the same lectures in the 7 days before admission*- Attending the same lecture does not involve the **prolonged, close personal contact** necessary for **Neisseria meningitidis** transmission via large respiratory droplets.- **Neisseria meningitidis** is fragile and has poor survival outside the human host, making transmission in a **general lecture hall setting** highly unlikely.

Question 208: A 41-year-old woman presents with a 4-week history of productive cough, fever, and night sweats. Chest X-ray shows right upper lobe consolidation with cavitation. Three sputum samples are positive for acid-fast bacilli. GeneXpert MTB/RIF detects Mycobacterium tuberculosis with rifampicin resistance. While awaiting full drug sensitivity results, which treatment regimen should be commenced?

A. Rifampicin, isoniazid, pyrazinamide, and ethambutol
B. Isoniazid, pyrazinamide, ethambutol, and moxifloxacin
C. Levofloxacin, bedaquiline, linezolid, and cycloserine (Correct Answer)
D. Isoniazid, rifampicin, pyrazinamide, ethambutol, and levofloxacin
E. Moxifloxacin, bedaquiline, pretomanid, and linezolid

Explanation: ***Levofloxacin, bedaquiline, linezolid, and cycloserine*** - Patients with **rifampicin-resistant TB (RR-TB)** detected by **GeneXpert** are treated similarly to **MDR-TB** patients, as rifampicin resistance is a strong surrogate for isoniazid resistance. - **WHO guidelines** recommend an initial MDR regimen consisting of a **fluoroquinolone** (e.g., levofloxacin), **bedaquiline**, **linezolid**, and a fourth agent like **cycloserine** while awaiting comprehensive drug susceptibility testing (DST). *Rifampicin, isoniazid, pyrazinamide, and ethambutol* - This is the standard first-line **RIPE** regimen for drug-sensitive TB, which is contraindicated once **rifampicin resistance** is confirmed. - Continuing **rifampicin** in the presence of known resistance risks clinical failure and the development of further resistance to other first-line drugs. *Isoniazid, pyrazinamide, ethambutol, and moxifloxacin* - This regimen is inadequate because it assumes the patient remains sensitive to **isoniazid**, despite the high correlation between rifampicin resistance and **isoniazid resistance**. - Relying on **ethambutol** and **pyrazinamide** as the primary backbone is insufficient for treating cavitation and high bacterial loads in confirmed **RR-TB**. *Isoniazid, rifampicin, pyrazinamide, ethambutol, and levofloxacin* - Adding a **fluoroquinolone** to a failing first-line regimen does not overcome the resistance to **rifampicin** and likely resistance to **isoniazid**. - This approach violates the core principle of TB management: never add a single drug to a **failing or resistant regimen**. *Moxifloxacin, bedaquiline, pretomanid, and linezolid* - While the **BPaLM** regimen is a modern shorter treatment for MDR-TB, it typically requires confirmation of sensitivity patterns and compliance with specific national protocols. - In many clinical settings, the longer empirical MDR-TB regimen involving **levofloxacin**, **bedaquiline**, and **linezolid** remains the standard starting point until full DST results are provided.

Question 209: A 54-year-old man with HIV infection (CD4 count 45 cells/mm³) presents with a 3-week history of worsening headache and fever. CT head with contrast shows multiple ring-enhancing lesions in both cerebral hemispheres. Lumbar puncture is deferred due to mass effect. He is started on pyrimethamine, sulfadiazine, and folinic acid for presumed cerebral toxoplasmosis. After how many weeks should clinical and radiological response be assessed to determine if this diagnosis is correct?

A. 1 week
B. 2 weeks (Correct Answer)
C. 4 weeks
D. 6 weeks
E. 8 weeks

Explanation: ***2 weeks***- Guidelines recommend a trial of **empirical therapy** with pyrimethamine and sulfadiazine, with a formal clinical and radiological reassessment after **14 days**.- A documented improvement in symptoms and a reduction in the size of **ring-enhancing lesions** at this interval confirms the diagnosis and avoids the need for an invasive **brain biopsy**.*1 week*- Assessing at seven days is generally considered **too early** to observe definitive radiological changes in mass effect or lesion size.- While clinical stabilization may begin, a lack of significant change at this stage does not provide enough evidence to rule out **toxoplasmosis**.*4 weeks*- Delaying reassessment to one month risks allowing the progression of alternative diagnoses, such as **Primary CNS Lymphoma (PCNSL)**.- Early intervention for non-responding lesions is critical in **severely immunocompromised** patients with low CD4 counts.*6 weeks*- This duration is closer to the completion of the **acute phase** of treatment rather than the initial diagnostic reassessment phase.- Waiting this long for radiological confirmation would be clinically inappropriate if the patient is actually suffering from **malignancy** or **fungal abscesses**.*8 weeks*- An eight-week interval is typically associated with the transition to **maintenance therapy** (secondary prophylaxis) rather than diagnostic evaluation.- High mortality rates in **AIDS-related CNS infections** necessitate much earlier diagnostic confirmation to adjust the treatment plan if necessary.

Question 210: A 27-year-old woman presents with headache, fever, and confusion. Lumbar puncture shows: opening pressure 28 cmH2O, white cells 450 cells/mm³ (70% neutrophils), protein 1.8 g/L, glucose 1.2 mmol/L (plasma glucose 5.5 mmol/L). Gram stain shows Gram-positive diplococci. She is started on appropriate antimicrobial therapy. What additional treatment is most likely to improve her neurological outcome?

A. Intravenous dexamethasone 10 mg six-hourly for 4 days (Correct Answer)
B. Intravenous mannitol 20% 100 mL
C. Therapeutic lumbar puncture to reduce CSF pressure
D. Intravenous immunoglobulin 2 g/kg over 5 days
E. Oral acetazolamide 250 mg twice daily

Explanation: ***Intravenous dexamethasone 10 mg six-hourly for 4 days*** - Adjunctive **corticosteroids**, specifically **dexamethasone**, are recommended in adults with **bacterial meningitis**, especially when caused by **Streptococcus pneumoniae**, to reduce inflammation and improve neurological outcomes like hearing loss. - For optimal benefit, dexamethasone should be administered **concomitantly with or just before** the first dose of antibiotics to mitigate the inflammatory response triggered by bacterial lysis. *Intravenous mannitol 20% 100 mL* - **Mannitol** is an osmotic diuretic used for acute management of **severely elevated intracranial pressure** and cerebral edema, but it does not improve long-term neurological outcomes in bacterial meningitis. - Its use is typically reserved for critical situations with impending herniation and is not a routine adjunctive treatment for improving overall outcome in bacterial meningitis. *Therapeutic lumbar puncture to reduce CSF pressure* - While the opening pressure is elevated, **repeated therapeutic lumbar punctures** are not a standard or recommended treatment for managing intracranial pressure in acute bacterial meningitis. - This approach carries risks, including **brain herniation** if there is significant mass effect or obstructive hydrocephalus, and does not address the underlying inflammation effectively. *Intravenous immunoglobulin 2 g/kg over 5 days* - **Intravenous immunoglobulin (IVIG)** is primarily used in certain immunodeficiency states, autoimmune conditions, or severe sepsis/toxic shock syndrome, but it has **no proven role** in improving neurological outcomes in bacterial meningitis. - There is no evidence to support its routine use as an adjunctive therapy for acute bacterial meningitis. *Oral acetazolamide 250 mg twice daily* - **Acetazolamide** is a carbonic anhydrase inhibitor that reduces CSF production and is used in conditions like **idiopathic intracranial hypertension** or certain types of hydrocephalus. - It is not indicated for the acute management of elevated intracranial pressure or inflammation in **bacterial meningitis** and would be too slow-acting and insufficient for this severe condition.

Question 211: A 48-year-old man with recently diagnosed smear-positive pulmonary tuberculosis has been on standard four-drug therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) for 10 days. He now presents with sudden onset severe left-sided pleuritic chest pain. Chest X-ray shows a large left-sided pneumothorax. What is the most likely explanation for this complication?

A. Paradoxical reaction to anti-tuberculous therapy
B. Rupture of a subpleural tuberculous cavity (Correct Answer)
C. Drug-induced pulmonary toxicity from rifampicin
D. Secondary spontaneous pneumothorax from underlying emphysema
E. Hospital-acquired pneumonia with necrotising infection

Explanation: ***Rupture of a subpleural tuberculous cavity*** - Pneumothorax is a recognized complication of pulmonary **tuberculosis (TB)**, occurring most commonly due to the rupture of a **subpleural cavity** or necrotic focus into the pleural space. - In smear-positive patients with cavitary disease, this rupture creates a **bronchopleural fistula**, leading to acute **secondary spontaneous pneumothorax** early in the treatment course. *Paradoxical reaction to anti-tuberculous therapy* - A paradoxical reaction involves the **transient worsening** of symptoms or new inflammatory lesions (like lymphadenopathy) despite effective treatment. - While it reflects an **immune reconstitution**, it typically presents as fever or enlarging masses rather than an acute mechanical event like a large **pneumothorax**. *Drug-induced pulmonary toxicity from rifampicin* - **Rifampicin** is primarily associated with **hepatotoxicity** and various drug-drug interactions involving the P450 system. - It is not known to cause acute structural lung changes or **pleural complications** like pneumothorax. *Secondary spontaneous pneumothorax from underlying emphysema* - Although emphysema is a major cause of **secondary spontaneous pneumothorax**, the patient has a confirmed, active **smear-positive TB** infection. - The acute complication in the setting of active TB is statistically and clinically more likely to be due to **tuberculous cavitation** than incidental emphysema. *Hospital-acquired pneumonia with necrotising infection* - While **necrotizing pneumonia** can lead to pneumothorax, it typically presents with new-onset sepsis, purulent sputum, and distinct **infiltrates** on imaging. - The short duration of therapy (10 days) and the baseline diagnosis of **cavitary TB** point toward the TB itself as the primary cause of the pleural air.

Question 212: A 2-year-old girl is brought to the emergency department with a 3-hour history of fever, lethargy, and a non-blanching purpuric rash on her legs. She is tachycardic with a capillary refill time of 4 seconds. Blood pressure is 85/50 mmHg. After initial fluid resuscitation and blood cultures, which antibiotic should be administered immediately?

A. Intravenous ceftriaxone 80 mg/kg
B. Intravenous benzylpenicillin 300 mg
C. Intravenous cefotaxime 50 mg/kg and amoxicillin 50 mg/kg (Correct Answer)
D. Intramuscular benzylpenicillin 300 mg
E. Intravenous vancomycin 15 mg/kg

Explanation: ***Intravenous cefotaxime 50 mg/kg and amoxicillin 50 mg/kg*** - This combination is the standard empirical treatment for suspected **bacterial meningitis** or **septicaemia** in children under **3 years of age** because it provides coverage against common pathogens like **Neisseria meningitidis**, **Streptococcus pneumoniae** (cefotaxime), and crucially, **Listeria monocytogenes** (amoxicillin). - The clinical presentation of fever, lethargy, **non-blanching purpuric rash**, and signs of **shock** (tachycardia, prolonged capillary refill, hypotension) is highly suggestive of severe invasive bacterial disease requiring immediate broad-spectrum intravenous antibiotics. *Intravenous ceftriaxone 80 mg/kg* - While **ceftriaxone** is a potent third-generation cephalosporin effective against **Neisseria meningitidis** and **Streptococcus pneumoniae**, used as monotherapy it lacks coverage for **Listeria monocytogenes**. - **Listeria** is an important pathogen to empirically cover in children, particularly those under **3 months** of age, and often extended to under 3 years or based on local guidelines for suspected meningitis/sepsis. *Intravenous benzylpenicillin 300 mg* - **Intravenous benzylpenicillin** alone is not sufficient for comprehensive empirical treatment in a hospital setting for suspected sepsis with a purpuric rash, as it lacks broad-spectrum coverage against many common gram-negative organisms beyond **Neisseria meningitidis**. - Its primary appropriate use in this context is as an **emergency pre-hospital administration** by paramedics or GPs to patients with suspected meningococcal disease to improve outcomes before hospital arrival. *Intramuscular benzylpenicillin 300 mg* - **Intramuscular administration** of benzylpenicillin is specifically recommended for **pre-hospital emergency use** when intravenous access is difficult or delayed, typically in the community setting by a GP or paramedic. - Once the patient has arrived in the **Emergency Department** and IV access is established, the standard of care requires switching to a broad-spectrum intravenous antibiotic regimen. *Intravenous vancomycin 15 mg/kg* - **Vancomycin** is primarily used for infections involving **methicillin-resistant Staphylococcus aureus (MRSA)** or **penicillin-resistant Streptococcus pneumoniae**, or in patients with severe beta-lactam allergies. - It is not the first-line empirical antibiotic for suspected **meningococcal sepsis** and does not provide adequate sole coverage against **Neisseria meningitidis** or other potential gram-negative pathogens in this clinical scenario.

Question 213: A 36-year-old man from Vietnam presents with a 6-week history of malaise, weight loss, and back pain. He reports no respiratory symptoms. Examination reveals tenderness over the L2-L3 vertebrae and reduced straight leg raise bilaterally. MRI spine shows destruction of L2-L3 vertebral bodies with a paravertebral abscess. Which investigation is most likely to establish the diagnosis?

A. Blood cultures for Mycobacterium tuberculosis
B. Three early morning sputum samples for acid-fast bacilli
C. CT-guided biopsy of the affected vertebra (Correct Answer)
D. Mantoux tuberculin skin test
E. Interferon-gamma release assay (IGRA)

Explanation: ***CT-guided biopsy of the affected vertebra*** - This investigation is the **gold standard** for diagnosing **extrapulmonary tuberculosis**, specifically **Pott's disease** (spinal TB), as it allows for direct tissue sampling. - The biopsy enables **histopathological examination** (identifying **caseating granulomas**), **culture for *Mycobacterium tuberculosis***, and **molecular tests (e.g., PCR)**, providing definitive diagnosis and crucial **drug sensitivity testing**. *Blood cultures for Mycobacterium tuberculosis* - **Mycobacterium tuberculosis** is rarely isolated from blood cultures, especially in immunocompetent individuals with localized disease, making its **diagnostic yield very low**. - This test is primarily useful in cases of **disseminated (miliary) TB**, often seen in severely immunocompromised patients. *Three early morning sputum samples for acid-fast bacilli* - The patient reports **no respiratory symptoms**, indicating that **pulmonary involvement** is unlikely to be the primary site or a source for diagnosis in this case of isolated spinal disease. - Sputum samples are highly improbable to yield **acid-fast bacilli** in **Pott's disease** without co-existing active lung lesions. *Mantoux tuberculin skin test* - A **positive Mantoux test** only indicates **prior exposure** to *M. tuberculosis* or latent infection, and cannot differentiate between **latent and active tuberculosis**. - In individuals from endemic regions like Vietnam, prior **BCG vaccination** often leads to **false-positive results**, limiting its utility for diagnosing active disease. *Interferon-gamma release assay (IGRA)* - **IGRA** detects sensitization to *M. tuberculosis* antigens, indicating infection, but it cannot distinguish between **active disease** and **latent TB infection**. - This test provides no information regarding the **specific site of infection** or **antibiotic sensitivities**, which are essential for managing a complex case of vertebral destruction.

Question 214: A 6-year-old boy presents with fever, headache and vomiting. Lumbar puncture is performed. CSF analysis shows: glucose 3.2 mmol/L (plasma glucose 5.8 mmol/L), protein 0.6 g/L, white cell count 180 cells/mm³ (90% lymphocytes). Gram stain is negative. What is the most appropriate initial antimicrobial therapy?

A. Intravenous ceftriaxone and aciclovir (Correct Answer)
B. Intravenous benzylpenicillin and gentamicin
C. Intravenous ceftriaxone alone
D. Intravenous vancomycin and ceftriaxone
E. Oral amoxicillin

Explanation: ***Intravenous ceftriaxone and aciclovir***- The CSF analysis reveals a **lymphocytic pleocytosis** (90% lymphocytes) and near-normal glucose, which can represent **viral meningitis** or early/partially treated **bacterial meningitis**.- Empirical management must cover common bacterial pathogens with **ceftriaxone** while adding **aciclovir** to cover potential **herpes simplex virus (HSV)** encephalitis until cultures and PCR results are available.*Intravenous benzylpenicillin and gentamicin*- This regimen is typically used for **neonatal meningitis** to cover *Group B Streptococcus* and *Listeria*, but is not standard for a 6-year-old child.- In this age group, **ceftriaxone** is preferred for its superior coverage of *Streptococcus pneumoniae* and *Neisseria meningitidis*.*Intravenous ceftriaxone alone*- While ceftriaxone provides excellent coverage for **bacterial meningitis**, it lacks activity against viral pathogens like **HSV** or **VZV**.- Given the **lymphocytic predominance** in the CSF, viral encephalitis remains a critical differential that requires the addition of **aciclovir** for patient safety.*Intravenous vancomycin and ceftriaxone*- This combination is often used empirically in regions with high rates of **penicillin-resistant pneumococcus**, but it still fails to address the **viral** differential indicated by the 90% lymphocytes.- **Aciclovir** is specifically required because the clinical presentation and CSF profile are highly suggestive of a **viral etiology**.*Oral amoxicillin*- Oral antibiotics are inappropriate for suspected meningitis as they cannot achieve reliable **cerebrospinal fluid penetration** or therapeutic levels quickly enough.- **Intravenous therapy** is mandatory for any child suspected of having a serious **central nervous system infection** to prevent rapid neurological deterioration.

Question 215: A 41-year-old man from India who moved to the UK 6 months ago presents with a 10-week history of progressive headache, low-grade fever, and confusion. He has lost 8 kg in weight. CT head shows basal meningeal enhancement and hydrocephalus. Lumbar puncture reveals: opening pressure 32 cmH₂O, CSF glucose 1.2 mmol/L (serum 5.6 mmol/L), protein 3.2 g/L, white cells 240/mm³ (70% lymphocytes). Ziehl-Neelsen stain and TB PCR of CSF are negative. What is the most appropriate next step in management?

A. Repeat lumbar puncture to obtain larger CSF volume for TB culture and commence anti-tuberculosis therapy (Correct Answer)
B. Perform CT chest and commence four-drug anti-tuberculosis therapy empirically
C. Arrange brain MRI and neurosurgical assessment for possible ventriculoperitoneal shunt insertion before starting treatment
D. Request CSF cryptococcal antigen test and commence liposomal amphotericin B
E. Commence intravenous ceftriaxone and aciclovir pending further investigation results

Explanation: ***Repeat lumbar puncture to obtain larger CSF volume for TB culture and commence anti-tuberculosis therapy*** - This patient presents with classic features of **tuberculous (TB) meningitis**, including a subacute progressive course, **basal meningeal enhancement**, **lymphocytic pleocytosis**, and very **low CSF glucose**. The epidemiological link to an endemic area (India) further strengthens the diagnosis. - Given the low sensitivity of **CSF Ziehl-Neelsen stain and PCR** in TBM, empiric **anti-tuberculosis therapy** must be started immediately to prevent high mortality and morbidity, while concurrently obtaining a larger CSF volume for the more sensitive **TB culture**. *Perform CT chest and commence four-drug anti-tuberculosis therapy empirically* - While a **CT chest** may show evidence of active pulmonary TB in approximately 50% of TBM cases, it is not the most crucial immediate diagnostic step for the neurological infection itself. The priority remains confirming and optimally culturing the CNS pathogen. - Although empiric therapy is correct, obtaining a high-volume CSF sample for culture is paramount for definitive diagnosis and sensitivity testing, which this option does not prioritize as the immediate next step. *Arrange brain MRI and neurosurgical assessment for possible ventriculoperitoneal shunt insertion before starting treatment* - The elevated **intracranial pressure** (32 cmH₂O) and **hydrocephalus** indicate a need for monitoring and potential intervention; however, **delaying specific anti-tuberculosis therapy** for a neurosurgical assessment is inappropriate and carries a high risk of worsening outcomes. - The immediate priority is to initiate **anti-tuberculosis therapy** and corticosteroids to address the underlying inflammatory process causing the hydrocephalus and prevent further neurological damage. *Request CSF cryptococcal antigen test and commence liposomal amphotericin B* - **Cryptococcal meningitis** can present with similar CSF findings (lymphocytic pleocytosis, low glucose) and elevated ICP, especially in immunocompromised individuals. However, the patient's background and the characteristic **basal meningeal enhancement** on CT make **tuberculosis** significantly more likely. - Without explicit evidence of immunocompromise or other risk factors for fungal infection, empirically treating for cryptococcosis is less appropriate than for TB, given the strong clinical and epidemiological indicators for the latter. *Commence intravenous ceftriaxone and aciclovir pending further investigation results* - These medications target **acute bacterial meningitis** (ceftriaxone) and **herpes simplex encephalitis** (aciclovir). The patient's 10-week history of progressive symptoms clearly points to a **subacute or chronic process**, not an acute infection typically managed by these drugs. - The profound **lymphocytic pleocytosis** and extremely **low CSF glucose** are inconsistent with typical acute bacterial meningitis (usually neutrophilic predominance) and are more suggestive of a granulomatous infection like TB rather than a viral encephalitis where glucose is often normal.

Question 216: A 29-year-old woman presents with headache, fever, and photophobia. Lumbar puncture shows: opening pressure 18 cmH₂O, CSF glucose 3.1 mmol/L (serum 5.4 mmol/L), protein 0.65 g/L, white cells 580/mm³ (85% lymphocytes), red cells 15/mm³. Gram stain is negative. CSF PCR for enterovirus is positive. She is currently 10 weeks pregnant. What is the most appropriate management?

A. Commence intravenous aciclovir 10 mg/kg three times daily for 14 days
B. Commence oral pleconaril 400 mg three times daily for 7 days
C. Supportive management only with analgesia, antiemetics, and intravenous fluids (Correct Answer)
D. Commence intravenous immunoglobulin 0.4 g/kg daily for 5 days
E. Commence intravenous ceftriaxone 2 g twice daily until bacterial culture results confirmed negative

Explanation: ***Supportive management only with analgesia, antiemetics, and intravenous fluids*** - This patient presents with characteristic CSF findings for **viral meningitis**, including a **lymphocytic pleocytosis**, normal CSF glucose (CSF:blood glucose ratio 3.1/5.4 > 0.5), and moderately elevated protein. The diagnosis is confirmed by a **positive CSF PCR for enterovirus**. - **Enteroviral meningitis** in an immunocompetent individual, even during pregnancy, is typically a **self-limiting** illness that resolves within 7-10 days, making supportive care the most appropriate management. *Commence intravenous aciclovir 10 mg/kg three times daily for 14 days* - **Aciclovir** is an antiviral drug specifically active against **herpes simplex virus (HSV)** and **varicella-zoster virus (VZV)**, not enteroviruses. - The definitive diagnosis of enteroviral meningitis by PCR renders aciclovir therapy inappropriate and ineffective in this case. *Commence oral pleconaril 400 mg three times daily for 7 days* - **Pleconaril** is an investigational antiviral with activity against enteroviruses but is **not licensed or recommended** for routine clinical use due to concerns about efficacy and drug interactions. - Given that enteroviral meningitis usually resolves spontaneously, standard practice does not involve the use of unapproved antiviral agents. *Commence intravenous immunoglobulin 0.4 g/kg daily for 5 days* - **Intravenous immunoglobulin (IVIG)** is reserved for severe or chronic enteroviral infections, primarily in **immunocompromised patients** (e.g., those with B-cell deficiencies). - This patient is described as immunocompetent and presenting with typical, self-limiting viral meningitis, making IVIG unnecessary. *Commence intravenous ceftriaxone 2 g twice daily until bacterial culture results confirmed negative* - **Ceftriaxone** is an appropriate empirical antibiotic for suspected **bacterial meningitis**, but this diagnosis has been ruled out. - The **negative Gram stain**, **lymphocytic predominance** in the CSF, and especially the **positive enterovirus PCR** confirm a viral etiology, negating the need for antibiotic treatment.

Question 217: A 38-year-old man with cavitating pulmonary tuberculosis has been on treatment for 3 weeks with rifampicin, isoniazid, pyrazinamide, and ethambutol. His baseline liver function tests were normal. He now presents with jaundice. Blood tests show: bilirubin 156 μmol/L, ALT 420 U/L, AST 385 U/L, ALP 178 U/L. What is the most appropriate management approach?

A. Continue all four drugs and add ursodeoxycholic acid for hepatoprotection
B. Stop all anti-tuberculosis drugs until liver function normalizes, then reintroduce sequentially (Correct Answer)
C. Stop pyrazinamide only and continue with the other three drugs
D. Switch to a non-hepatotoxic regimen with streptomycin, ethambutol, and moxifloxacin
E. Reduce the doses of all anti-tuberculosis drugs by 50% and recheck liver function in 1 week

Explanation: ***Stop all anti-tuberculosis drugs until liver function normalizes, then reintroduce sequentially***- This patient is experiencing severe **drug-induced hepatotoxicity** characterized by **clinical jaundice** (bilirubin 156 μmol/L) and markedly elevated **transaminases** (ALT 420 U/L, AST 385 U/L, which are >5 times the upper limit of normal).- The immediate and most appropriate action is to **discontinue all hepatotoxic anti-tuberculosis drugs** (isoniazid, rifampicin, pyrazinamide) to prevent progression to **acute liver failure**. Once liver function normalizes, drugs can be carefully reintroduced one by one.*Continue all four drugs and add ursodeoxycholic acid for hepatoprotection*- Continuing the current **hepatotoxic regimen** in the presence of significant **jaundice** and elevated **transaminases** is extremely dangerous and could lead to irreversible liver damage or death.- **Ursodeoxycholic acid** is primarily used for cholestatic liver diseases and has no established role in the acute management or reversal of **anti-tuberculosis drug-induced hepatocellular injury**.*Stop pyrazinamide only and continue with the other three drugs*- While **pyrazinamide** is known for its high hepatotoxic potential, both **isoniazid** and **rifampicin** also contribute significantly to **liver injury** and must be stopped during severe hepatotoxicity.- Selective discontinuation is typically reserved for milder, asymptomatic elevations of liver enzymes, not for cases with overt **jaundice**.*Switch to a non-hepatotoxic regimen with streptomycin, ethambutol, and moxifloxacin*- While a **non-hepatotoxic regimen** might be considered, the primary and immediate management for severe DILI in a stable patient is to completely **withdraw the offending drugs** to allow liver recovery.- This alternative regimen is usually reserved as a temporary measure for critically ill patients or those with highly infectious disease needing continuous therapy, while awaiting liver function normalization and potential reintroduction of first-line drugs.*Reduce the doses of all anti-tuberculosis drugs by 50% and recheck liver function in 1 week*- **Dose reduction** is insufficient and unsafe when a patient presents with **clinical jaundice** and significantly elevated liver enzymes, as it continues the hepatotoxic insult.- Furthermore, using sub-therapeutic doses risks promoting the development of **drug-resistant tuberculosis**, which would complicate future treatment.

Question 218: A 8-month-old infant is brought to the emergency department with a 12-hour history of fever of 39.8°C, irritability, and poor feeding. There is no rash. Lumbar puncture is performed: CSF glucose 1.4 mmol/L (blood glucose 4.8 mmol/L), protein 2.8 g/L, white cells 1200/mm³ (90% polymorphs). Gram stain shows Gram-negative coccobacilli. Intravenous ceftriaxone is commenced. Which organism is most likely responsible for this presentation?

A. Neisseria meningitidis
B. Streptococcus pneumoniae
C. Haemophilus influenzae type b (Correct Answer)
D. Listeria monocytogenes
E. Group B Streptococcus

Explanation: ***Haemophilus influenzae type b*** - The presence of **Gram-negative coccobacilli** on Gram stain is the classic morphological description for *Haemophilus influenzae*. - The **CSF findings** (low glucose, high protein, high white cells with neutrophil predominance) confirm bacterial meningitis, which historically *H. influenzae type b* was a leading cause of in infants aged 3 months to 5 years. *Neisseria meningitidis* - While a major cause of meningitis, *Neisseria meningitidis* typically appears as **Gram-negative diplococci** (kidney-bean shaped), not coccobacilli. - It is frequently associated with a **purpuric or petechial rash**, which was specifically noted as absent in this patient. *Streptococcus pneumoniae* - This organism is a common cause of bacterial meningitis in children but would appear as **Gram-positive diplococci** (lancet-shaped). - The Gram stain showing Gram-negative coccobacilli definitively rules out *Streptococcus pneumoniae*. *Listeria monocytogenes* - This pathogen is characterized as a **Gram-positive bacillus** (rod-shaped) and typically affects neonates (under 3 months), the elderly, or immunocompromised individuals. - The Gram stain result of Gram-negative coccobacilli is inconsistent with *Listeria monocytogenes*. *Group B Streptococcus* - *Group B Streptococcus* appears as **Gram-positive cocci in chains** on microscopic examination. - It is the leading cause of **neonatal meningitis** but is rarely a cause of meningitis beyond 3-4 months of age.

Question 219: A 62-year-old woman with end-stage renal failure on haemodialysis presents with a 4-week history of fever, night sweats, and cough. Chest X-ray shows bilateral miliary shadowing. Sputum is positive for acid-fast bacilli and culture confirms Mycobacterium tuberculosis fully sensitive to first-line agents. She weighs 65 kg. What is the most appropriate dosing regimen for the intensive phase of treatment?

A. Rifampicin 600 mg, isoniazid 300 mg, pyrazinamide 1500 mg, ethambutol 800 mg - all given daily
B. Rifampicin 600 mg, isoniazid 300 mg, ethambutol 800 mg - given three times weekly post-dialysis, omit pyrazinamide
C. Rifampicin 450 mg, isoniazid 200 mg, pyrazinamide 1000 mg, ethambutol 600 mg - given three times weekly post-dialysis
D. Rifampicin 600 mg and isoniazid 300 mg given daily, pyrazinamide 1500 mg and ethambutol 1200 mg given three times weekly post-dialysis (Correct Answer)
E. Rifampicin 600 mg, isoniazid 300 mg given daily, omit pyrazinamide and ethambutol due to renal impairment

Explanation: ***Rifampicin 600 mg and isoniazid 300 mg given daily, pyrazinamide 1500 mg and ethambutol 1200 mg given three times weekly post-dialysis*** - **Rifampicin** and **isoniazid** are predominantly metabolized by the **liver**, so their standard daily doses do not require adjustment for **end-stage renal disease (ESRD)**. - **Pyrazinamide** and **ethambutol** are primarily renally excreted and are significantly dialyzable; thus, they should be given **three times weekly post-dialysis** to prevent accumulation and reduce the risk of toxicity. *Rifampicin 600 mg, isoniazid 300 mg, pyrazinamide 1500 mg, ethambutol 800 mg - all given daily* - Administering **pyrazinamide** and **ethambutol** daily in a patient with **ESRD** on haemodialysis would lead to severe drug accumulation and an increased risk of dose-dependent toxicities, such as **hepatotoxicity** and **optic neuritis**. - This regimen is only appropriate for patients with **normal renal function**, as ESRD necessitates significant dose adjustments for renally cleared medications. *Rifampicin 600 mg, isoniazid 300 mg, ethambutol 800 mg - given three times weekly post-dialysis, omit pyrazinamide* - **Rifampicin** and **isoniazid** are hepatically cleared and should be given daily; reducing their frequency to three times weekly risks **subtherapeutic levels** and the development of drug resistance. - **Pyrazinamide** is a critical component of the standard four-drug intensive phase for tuberculosis treatment and should not be omitted unless there is a specific contraindication. *Rifampicin 450 mg, isoniazid 200 mg, pyrazinamide 1000 mg, ethambutol 600 mg - given three times weekly post-dialysis* - This option provides **subtherapeutic doses** for rifampicin (target 600 mg) and isoniazid (target 300 mg) for a 65 kg patient, which could lead to **treatment failure** and the development of drug resistance. - Rifampicin and isoniazid, being **hepatically cleared**, do not require reduction in frequency to three times weekly; they should be administered daily to maintain effective drug concentrations. *Rifampicin 600 mg, isoniazid 300 mg given daily, omit pyrazinamide and ethambutol due to renal impairment* - Omitting two essential drugs (**pyrazinamide** and **ethambutol**) from the intensive phase of anti-TB treatment significantly reduces treatment efficacy, especially for **miliary tuberculosis**. - While these drugs require dose adjustment in **renal impairment**, the correct approach is to modify their **dosing interval** and administer them post-dialysis, not to omit them entirely.

Question 220: A 52-year-old man with HIV infection (CD4 count 180 cells/mm³, viral load undetectable on antiretroviral therapy) presents with a 3-week history of headache and fever. CT head with contrast shows multiple ring-enhancing lesions in the basal ganglia and thalamus. Lumbar puncture shows: opening pressure 24 cmH₂O, CSF glucose 2.6 mmol/L (serum 5.8 mmol/L), protein 0.85 g/L, white cells 45/mm³ (80% lymphocytes). India ink stain is positive. What is the most appropriate initial management?

A. Commence liposomal amphotericin B and flucytosine for 2 weeks followed by fluconazole (Correct Answer)
B. Commence high-dose fluconazole 1200 mg daily for 10 weeks
C. Commence pyrimethamine, sulfadiazine, and folinic acid for presumed toxoplasmosis
D. Commence tuberculosis therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol
E. Arrange urgent neurosurgical referral for stereotactic biopsy

Explanation: ***Commence liposomal amphotericin B and flucytosine for 2 weeks followed by fluconazole*** - The positive **India ink stain** in an HIV-positive patient definitively diagnoses **Cryptococcal meningitis**, despite the atypical presentation of **ring-enhancing lesions** (cryptococcomas). - The recommended initial management for cryptococcal meningitis is a 2-week induction phase with **liposomal amphotericin B** and **flucytosine**, followed by **fluconazole** for consolidation and maintenance. *Commence high-dose fluconazole 1200 mg daily for 10 weeks* - **High-dose fluconazole monotherapy** is not the standard induction therapy for cryptococcal meningitis, as it has a slower fungicidal effect and is associated with higher treatment failure rates and mortality compared to amphotericin-based regimens. - Fluconazole is primarily reserved for the **consolidation** and **maintenance** phases of cryptococcal meningitis treatment, after the initial induction phase with amphotericin B and flucytosine. *Commence pyrimethamine, sulfadiazine, and folinic acid for presumed toxoplasmosis* - Although **multiple ring-enhancing lesions** in the basal ganglia and thalamus are classic for **cerebral toxoplasmosis** in HIV patients, the definitive **positive India ink stain** specifically identifies *Cryptococcus neoformans* as the causative agent. - Toxoplasmosis would not result in a positive India ink stain, and initiating anti-toxoplasma therapy would delay appropriate treatment for the confirmed cryptococcal infection. *Commence tuberculosis therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol* - While **tuberculous meningitis** can present with headache, fever, lymphocytic pleocytosis, low CSF glucose, and sometimes ring-enhancing lesions, the definitive finding of a **positive India ink stain** specifically indicates **Cryptococcus**, not *Mycobacterium tuberculosis*. - The microbiological evidence directly points to a fungal infection, making empiric anti-tuberculosis therapy inappropriate as the initial management in this case. *Arrange urgent neurosurgical referral for stereotactic biopsy* - A **brain biopsy** is an invasive procedure that is not necessary when a clear diagnosis of **cryptococcal meningitis** has been established through less invasive means like CSF microscopy with **India ink stain**. - Biopsy is typically reserved for cases where the diagnosis remains unclear despite extensive non-invasive investigations, or if the patient fails to respond to appropriate empiric therapy.

Question 221: A 25-year-old medical student has recently completed a clinical placement in a respiratory ward. One of the patients she clerked has subsequently been diagnosed with smear-positive pulmonary tuberculosis. The student is asymptomatic with a normal chest X-ray. Her Mantoux test performed 2 years ago as part of pre-university screening was 3 mm. A new Mantoux test now shows 18 mm induration. What is the most appropriate interpretation and management?

A. This represents a false positive result; no action required as she is asymptomatic
B. This represents latent TB infection requiring isoniazid chemoprophylaxis for 6 months (Correct Answer)
C. This represents recent BCG vaccination effect; repeat testing in 6 weeks
D. This represents active TB disease requiring full four-drug anti-tuberculosis therapy
E. This indicates tuberculin conversion; commence rifampicin and isoniazid for 3 months

Explanation: ***This represents latent TB infection requiring isoniazid chemoprophylaxis for 6 months*** - A **tuberculin conversion** from 3 mm to 18 mm after recent exposure to a **smear-positive pulmonary tuberculosis** patient strongly indicates recent acquisition of **latent TB infection (LTBI)**. - For healthcare workers with recent LTBI, **isoniazid chemoprophylaxis for 6-9 months** is the standard treatment to prevent progression to active TB disease. *This represents a false positive result; no action required as she is asymptomatic* - An induration of **18 mm** following significant exposure is a **strongly positive** Mantoux test result, not a false positive, especially given the prior 3 mm reading. - While asymptomatic, individuals with LTBI still carry a significant **lifetime risk of reactivating** to active disease, making treatment crucial. *This represents recent BCG vaccination effect; repeat testing in 6 weeks* - The previous Mantoux result of 3 mm suggests that any prior **BCG vaccination effect** was minimal or had waned, making a subsequent 18 mm induration indicative of **true infection** after exposure, not a vaccine effect. - Repeating the test is unnecessary as the **tuberculin conversion** is already clear, and delay would increase the risk of disease progression. *This represents active TB disease requiring full four-drug anti-tuberculosis therapy* - The student is **asymptomatic** and has a **normal chest X-ray**, which effectively rules out **active pulmonary tuberculosis**. - **Full four-drug anti-tuberculosis therapy** is reserved for confirmed or highly suspected active disease, not for asymptomatic latent infection. *This indicates tuberculin conversion; commence rifampicin and isoniazid for 3 months* - While this option correctly identifies **tuberculin conversion** and proposes a valid **LTBI treatment regimen** (rifampicin and isoniazid for 3 months), the 6-month isoniazid regimen is often considered the more widely accepted and commonly practiced **first-line chemoprophylaxis** for recent converters in many guidelines.

Question 222: A 45-year-old man with known pulmonary tuberculosis has been on treatment with rifampicin, isoniazid, pyrazinamide, and ethambutol for 6 weeks. He presents to his GP with painless visual impairment and reduced colour vision, particularly difficulty distinguishing red from green. Visual acuity testing shows bilateral reduction. What is the most appropriate immediate action?

A. Continue all medications and reassure that this will resolve after completing treatment
B. Stop ethambutol immediately and arrange urgent ophthalmology review (Correct Answer)
C. Stop rifampicin immediately and arrange liver function tests
D. Stop isoniazid immediately and commence high-dose pyridoxine
E. Reduce the dose of all anti-tuberculosis medications by 50%

Explanation: ***Stop ethambutol immediately and arrange urgent ophthalmology review*** - The patient's symptoms of **painless visual impairment**, **reduced visual acuity**, and specific difficulty with **red-green colour discrimination** are hallmark signs of **ethambutol-induced optic neuropathy**. - Immediate cessation of ethambutol is crucial to prevent **irreversible vision loss**, and an urgent ophthalmology review is necessary to assess the severity and guide further management. *Continue all medications and reassure that this will resolve after completing treatment* - Continuing **ethambutol** despite ocular symptoms risks progression to **permanent blindness** as the damage can be irreversible if not detected and managed promptly. - Reassurance without action is inappropriate; **ethambutol-induced optic neuropathy** requires immediate medical intervention, not just waiting for treatment completion. *Stop rifampicin immediately and arrange liver function tests* - **Rifampicin** is associated with **hepatotoxicity** (elevated liver enzymes, jaundice) and harmless **orange discoloration** of bodily fluids, not visual impairment or optic neuropathy. - While liver function monitoring is standard with rifampicin, it is unrelated to the patient's specific **ocular symptoms**. *Stop isoniazid immediately and commence high-dose pyridoxine* - **Isoniazid** is known to cause **peripheral neuropathy**, which is often mitigated by co-administration of **pyridoxine (vitamin B6)**. - It is not the cause of **optic neuropathy** with red-green colour vision deficits, making this action incorrect for the presenting visual symptoms. *Reduce the dose of all anti-tuberculosis medications by 50%* - Reducing doses of all drugs without identifying the specific causative agent is not a standard approach and risks **treatment failure** and the development of **drug resistance**. - The correct action for drug toxicity involves identifying and stopping the offending agent, not broadly reducing all medication doses.

Question 223: A 33-year-old woman from Romania presents with a 2-month history of productive cough, fever, and weight loss. Chest X-ray shows right upper lobe cavitation with bilateral nodular infiltrates. Sputum microscopy shows acid-fast bacilli. GeneXpert MTB/RIF assay detects Mycobacterium tuberculosis with rifampicin resistance. Culture subsequently confirms multidrug-resistant TB with resistance to rifampicin and isoniazid, but sensitivity to fluoroquinolones and second-line injectables. What is the minimum recommended treatment duration for this patient?

A. 6 months
B. 9 months
C. 12 months
D. 18 months (Correct Answer)
E. 24 months

Explanation: ***18 months*** - For **Multidrug-resistant TB (MDR-TB)**, which is resistant to both **isoniazid** and **rifampicin**, the standard recommendation for conventional longer regimens is a minimum duration of **18 to 20 months**. - This prolonged course is essential due to the reduced potency of second-line drugs and the presence of **cavitation**, requiring treatment for at least **15-18 months after culture conversion**. *6 months* - This is the standard duration for **drug-sensitive TB**, utilizing the **RIPE** regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol). - It is entirely insufficient for **MDR-TB** where the core first-line bactericidal drugs, rifampicin and isoniazid, are ineffective. *9 months* - Shorter MDR-TB regimens (9-12 months) are reserved for carefully selected patients, typically without **cavitation** and with no prior exposure to second-line drugs or additional resistance. - Given the presence of **cavitation** and confirmed MDR-TB, a 9-month course would be inadequate and increase the risk of treatment failure. *12 months* - A **12-month** regimen does not meet the current **WHO guidelines** for the management of confirmed MDR-TB, especially in cases with **cavitation**. - Inadequate treatment duration significantly increases the risk of **relapse** and the potential development of more extensively drug-resistant forms of TB. *24 months* - While some highly complex cases, such as those with **extensive lung damage** or **extensively drug-resistant TB (XDR-TB)**, may require treatment up to 24 months, this is not the **minimum** recommended duration for the described MDR-TB. - The goal for conventional longer MDR-TB regimens is typically completion by **18-20 months** based on current guidelines.

Question 224: A 70-year-old man with type 2 diabetes mellitus presents with a 3-day history of fever, confusion, and neck stiffness. Lumbar puncture shows: opening pressure 28 cmH₂O, CSF glucose 1.8 mmol/L (serum glucose 8.2 mmol/L), protein 2.4 g/L, white cells 850/mm³ (95% polymorphs), Gram stain shows Gram-positive diplococci. He is started on intravenous ceftriaxone 2 g twice daily and dexamethasone. What additional antibiotic should be added to his regimen?

A. Intravenous amoxicillin 2 g four-hourly
B. Intravenous vancomycin 1 g twice daily (Correct Answer)
C. Intravenous metronidazole 500 mg three times daily
D. Intravenous gentamicin 5 mg/kg once daily
E. Intravenous meropenem 2 g three times daily

Explanation: ***Intravenous vancomycin 1 g twice daily*** - Gram-positive diplococci on Gram stain identifies **Streptococcus pneumoniae**, which often exhibits **penicillin resistance**; adding **vancomycin** provides essential coverage for resistant strains until sensitivities are known. - In patients over **50 years** or with comorbidities like **diabetes**, empirical therapy for meningitis requires dual coverage with **ceftriaxone** and **vancomycin** to ensure bactericidal activity against pneumococcus. *Intravenous amoxicillin 2 g four-hourly* - **Amoxicillin** is typically added to cover **Listeria monocytogenes** in elderly or immunocompromised patients, but this organism appears as **Gram-positive bacilli**, not diplococci. - While the patient's age and diabetes are risk factors for Listeria, the Gram stain specifically points toward pneumococcus, making vancomycin the prioritized addition for **resistance coverage**. *Intravenous metronidazole 500 mg three times daily* - This agent provides coverage against **anaerobes**, which are generally associated with **brain abscesses** or infections secondary to chronic ear/sinus disease rather than acute bacterial meningitis. - It has no clinical utility in the treatment of **Streptococcus pneumoniae** or other common causes of community-acquired meningitis. *Intravenous gentamicin 5 mg/kg once daily* - **Aminoglycosides** like gentamicin have very **poor penetration** across the blood-brain barrier into the **cerebrospinal fluid (CSF)**, even when the meninges are inflamed. - They are typically used for synergy in certain endocarditis cases or for specific **Gram-negative** infections but are not standard for pneumococcal meningitis. *Intravenous meropenem 2 g three times daily* - While a broad-spectrum carbapenem, **meropenem** is usually reserved for patients with severe **beta-lactam allergies** or those with highly resistant Gram-negative organisms. - Using it as an add-on to ceftriaxone for Gram-positive diplococci is unnecessary and does not align with standard **antimicrobial stewardship** guidelines for bacterial meningitis.

Question 225: A 58-year-old woman with rheumatoid arthritis is about to commence adalimumab (anti-TNF therapy). Pre-treatment screening shows: Mantoux test 8 mm induration, interferon-gamma release assay (IGRA) positive, chest X-ray normal, no respiratory symptoms, no previous history of tuberculosis. What is the most appropriate management regarding tuberculosis before starting adalimumab?

A. Start adalimumab immediately as the chest X-ray is normal
B. Commence isoniazid and rifampicin for 3 months, then start adalimumab
C. Commence isoniazid monotherapy for 6 months before starting adalimumab (Correct Answer)
D. Commence full four-drug anti-tuberculosis therapy for 2 months before starting adalimumab
E. Repeat IGRA test in 4 weeks and start adalimumab only if negative

Explanation: ***Commence isoniazid monotherapy for 6 months before starting adalimumab***- The positive **Mantoux test** (8 mm induration) and **interferon-gamma release assay (IGRA)** confirm **latent tuberculosis infection (LTBI)** in this high-risk patient, despite a normal chest X-ray and no symptoms.- Due to the high risk of **TB reactivation** with **anti-TNF therapy** like adalimumab, **prophylactic treatment** with **isoniazid monotherapy** for 6-9 months is mandatory, with adalimumab often initiated after at least one month of therapy.*Start adalimumab immediately as the chest X-ray is normal*- A **normal chest X-ray** only excludes **active pulmonary TB**; it does not rule out **latent TB infection**, which is confirmed by the positive Mantoux and IGRA tests.- Starting **TNF inhibitors** without treating LTBI significantly increases the risk of **TB reactivation**, which can be severe and contradicts established safety guidelines.*Commence isoniazid and rifampicin for 3 months, then start adalimumab*- While **isoniazid and rifampicin for 3 months** is an effective alternative regimen for LTBI, it is often considered in specific situations like higher risk of isoniazid resistance or intolerance.- For patients commencing **anti-TNF therapy**, guidelines generally advise starting the biologic after at least **one month of LTBI treatment** has been completed, not necessarily waiting for the full 3-month course.*Commence full four-drug anti-tuberculosis therapy for 2 months before starting adalimumab*- **Full four-drug anti-tuberculosis therapy** (e.g., RIPE regimen) is indicated for **active tuberculosis disease**, characterized by symptoms, abnormal imaging, or microbiological confirmation.- This patient has **latent TB infection**, not active disease, so administering multiple drugs for active TB would expose her to unnecessary **drug toxicities** like hepatotoxicity.*Repeat IGRA test in 4 weeks and start adalimumab only if negative*- The **IGRA test** is highly sensitive and specific for Mycobacterium tuberculosis infection. A positive result in this clinical context reliably indicates **latent TB infection** and does not require retesting.- Delaying necessary treatment for the LTBI and subsequent initiation of **adalimumab** for rheumatoid arthritis based on a redundant test would prolong her disease and risk.

Question 226: A 4-year-old boy is brought to the emergency department with a 5-hour history of fever, vomiting, drowsiness, and photophobia. On examination, he has a temperature of 39.5°C, Glasgow Coma Scale score of 13, and a petechial rash on his lower limbs. Lumbar puncture is performed. While awaiting CSF results, blood tests show: WBC 18.2 × 10⁹/L, neutrophils 15.4 × 10⁹/L, CRP 156 mg/L, procalcitonin 8.2 ng/mL. Which additional immediate management should be considered alongside antibiotic therapy?

A. Intravenous aciclovir 10 mg/kg three times daily
B. Intravenous dexamethasone 0.15 mg/kg four times daily for 4 days (Correct Answer)
C. Oral prednisolone 2 mg/kg once daily for 5 days
D. Intravenous immunoglobulin 2 g/kg as a single dose
E. Intrathecal gentamicin 5 mg once daily

Explanation: ***Intravenous dexamethasone 0.15 mg/kg four times daily for 4 days*** - Adjunctive **dexamethasone** is recommended in children older than 3 months with suspected **bacterial meningitis** to reduce the inflammatory response in the subarachnoid space. - Evidence shows it significantly reduces the risk of **neurological sequelae**, especially **hearing loss**, and should ideally be administered shortly before or with the first dose of antibiotics. *Intravenous aciclovir 10 mg/kg three times daily* - This treatment is used for **HSV encephalitis**, which usually presents with **focal neurological deficits** or seizures rather than a petechial rash. - The markedly elevated **CRP (156 mg/L)** and **procalcitonin** strongly favor a bacterial etiology over a viral one. *Oral prednisolone 2 mg/kg once daily for 5 days* - **Oral administration** is inappropriate in an acutely unwell child with a reduced **Glasgow Coma Scale** score and vomiting. - Standard protocols for meningitis require the specific dosing of **intravenous dexamethasone** to achieve rapid, reliable anti-inflammatory effects in the CNS. *Intravenous immunoglobulin 2 g/kg as a single dose* - **IVIG** is used in conditions like **Kawasaki disease** or ITP, but it has no established role in the routine management of acute bacterial meningitis. - It does not address the primary pathophysiology of **bacterial toxin release** and meningeal inflammation following antibiotic administration. *Intrathecal gentamicin 5 mg once daily* - **Intrathecal antibiotics** are not standard practice for community-acquired meningitis and carry risks of neurotoxicity and secondary infection. - Systemic high-dose **third-generation cephalosporins** (like ceftriaxone) provide adequate CSF penetration for most causative organisms like *N. meningitidis*.

Question 227: A 42-year-old homeless man with a history of alcohol dependency presents with a 6-week history of cough, weight loss, and night sweats. Chest X-ray shows bilateral upper zone cavitation. Sputum samples are positive for acid-fast bacilli on microscopy. He is commenced on standard quadruple anti-tuberculosis therapy. On day 5 of treatment, he reports tingling and numbness in his feet. Which medication should have been prescribed prophylactically to prevent this complication?

A. Thiamine 100 mg daily
B. Folic acid 5 mg daily
C. Pyridoxine 10 mg daily (Correct Answer)
D. Vitamin B12 1 mg intramuscularly monthly
E. Vitamin D 800 IU daily

Explanation: ***Pyridoxine 10 mg daily*** - Isoniazid, a key component of quadruple anti-tuberculosis therapy, inhibits the activation of **Vitamin B6 (Pyridoxine)**, leading to a drug-induced **peripheral neuropathy**. - Prophylaxis is mandatory for high-risk patients, including those with **alcohol dependency**, malnutrition, diabetes, or pregnancy, to prevent the tingling and numbness (paresthesia) observed here. *Thiamine 100 mg daily* - While essential in patients with alcohol dependency to prevent **Wernicke-Korsakoff syndrome**, it does not mitigate the neurotoxic effects of isoniazid. - Thiamine deficiency typically presents with **ataxia**, ophthalmoplegia, and confusion rather than isolated sensory neuropathy shortly after starting TB treatment. *Folic acid 5 mg daily* - Folic acid is primarily used to prevent **megaloblastic anemia** and neural tube defects; it is not depleted by standard anti-tuberculosis medications. - It is frequently co-administered with **methotrexate** in rheumatology but has no role in preventing isoniazid-induced side effects. *Vitamin B12 1 mg intramuscularly monthly* - Vitamin B12 deficiency causes **Subacute Combined Degeneration** of the spinal cord, characterized by loss of vibration and position sense. - While alcoholics may be malnourished, B12 does not interact with **isoniazid metabolism**, and its deficiency takes much longer than 5 days to manifest as new neurological symptoms. *Vitamin D 800 IU daily* - Vitamin D is vital for **bone health** and calcium homeostasis, especially in patients with poor sunlight exposure or malnutrition. - It does not provide protection against **nerve conduction** defects or the pyridoxine-depleting mechanisms of anti-TB drugs.

Question 228: A 26-year-old man presents to the emergency department with a 6-hour history of severe headache, fever of 39.2°C, neck stiffness, and a non-blanching purpuric rash on his trunk and limbs. Blood cultures are taken and empirical antibiotic therapy is commenced immediately. Which antibiotic regimen should be administered first-line in this scenario?

A. Intravenous benzylpenicillin 2.4 g four times daily
B. Intravenous ceftriaxone 2 g twice daily (Correct Answer)
C. Intravenous vancomycin 1 g twice daily plus ceftriaxone 2 g twice daily
D. Intravenous meropenem 2 g three times daily
E. Intramuscular benzylpenicillin 1.2 g single dose

Explanation: ***Intravenous ceftriaxone 2 g twice daily***- In a patient presenting with classic signs of **bacterial meningitis** and a **purpuric rash** (highly suggestive of **meningococcal disease**), **intravenous ceftriaxone** is the first-line empirical antibiotic due to its excellent **CSF penetration** and broad spectrum against *Neisseria meningitidis* and *Streptococcus pneumoniae*.- This regimen is well-established as the standard of care for empirical treatment of community-acquired bacterial meningitis in young adults, providing rapid and effective coverage.*Intravenous benzylpenicillin 2.4 g four times daily*- While effective against *Neisseria meningitidis*, **benzylpenicillin** has a narrower spectrum and may not adequately cover increasingly common **penicillin-resistant *Streptococcus pneumoniae***, which is a major concern in empirical meningitis therapy.- It is therefore not recommended as a first-line single agent for empirical treatment in the hospital setting where broader coverage is often required.*Intravenous vancomycin 1 g twice daily plus ceftriaxone 2 g twice daily*- This combination is typically reserved for situations where there is a high suspicion of **highly resistant *Streptococcus pneumoniae***, such as in immunocompromised patients, those with recent severe antibiotic exposure, or in regions with high rates of penicillin-resistant pneumococci.- For a previously healthy young adult presenting with suspected meningitis, **ceftriaxone monotherapy** is generally sufficient as initial empirical treatment unless specific risk factors for resistant organisms are present.*Intravenous meropenem 2 g three times daily*- **Meropenem** is a broad-spectrum carbapenem often reserved for treating **multi-drug resistant (MDR)** bacterial infections, severe beta-lactam allergies, or specific pathogens like *Listeria* (in older or immunocompromised patients).- Using such a broad-spectrum antibiotic as first-line in this scenario is generally not recommended due to concerns about **antimicrobial stewardship** and promoting resistance.*Intramuscular benzylpenicillin 1.2 g single dose*- This is the recommended **pre-hospital** empirical treatment for suspected meningococcal disease with a purpuric rash, administered by general practitioners or paramedics to provide immediate coverage before hospital transfer.- Once the patient reaches the emergency department, definitive **intravenous antibiotic therapy** with a drug like ceftriaxone should be initiated, rather than a single intramuscular dose.

Question 229: A 35-year-old woman with pulmonary tuberculosis is being treated with rifampicin, isoniazid, pyrazinamide, and ethambutol. She takes the combined oral contraceptive pill for contraception. What is the most appropriate advice regarding her contraception during tuberculosis treatment?

A. Continue the combined oral contraceptive pill as rifampicin does not affect its efficacy
B. Switch to a progesterone-only pill as this is not affected by rifampicin
C. Use additional barrier contraception or switch to a non-hormonal method (Correct Answer)
D. Double the dose of the combined oral contraceptive pill
E. Stop all contraception as tuberculosis medications cause temporary infertility

Explanation: ***Use additional barrier contraception or switch to a non-hormonal method*** - **Rifampicin** is a potent inducer of hepatic **cytochrome P450 enzymes**, which significantly increases the metabolism and reduces the efficacy of hormonal contraceptives, including the combined oral contraceptive pill. - Current guidelines recommend using **barrier methods** (like condoms) or non-hormonal options (such as the **copper intrauterine device [IUD]**) to prevent unintended pregnancy during treatment and for several weeks after cessation of rifampicin. *Continue the combined oral contraceptive pill as rifampicin does not affect its efficacy* - This statement is incorrect because **rifampicin** significantly reduces the serum concentrations of both **estrogen** and **progestogen** components of the combined oral contraceptive pill, leading to contraceptive failure. - Continuing the pill without additional measures puts the patient at high risk of **unwanted pregnancy**, which is particularly concerning while taking potentially teratogenic or hepatotoxic medications. *Switch to a progesterone-only pill as this is not affected by rifampicin* - The **progesterone-only pill (POP)** is also metabolized by the liver enzymes induced by **rifampicin**. - Its effectiveness is severely compromised by this **enzyme induction**, making it an unreliable sole method of contraception in this clinical scenario. *Double the dose of the combined oral contraceptive pill* - **Doubling the dose** of the combined oral contraceptive pill is generally no longer recommended due to variable individual responses to **enzyme induction** and potential for increased **side effects** without guaranteed contraceptive efficacy. - High-dose hormonal regimens increase the risk of adverse effects like **venous thromboembolism** without ensuring adequate contraceptive protection against rifampicin's effects. *Stop all contraception as tuberculosis medications cause temporary infertility* - **Tuberculosis medications**, including rifampicin and isoniazid, do not cause **infertility**; patients remain fertile throughout their treatment. - It is crucial to maintain effective contraception as pregnancy during multidrug therapy for tuberculosis requires specialized monitoring and careful consideration of drug safety.

Question 230: A 17-year-old student presents with a 10-hour history of fever, headache, photophobia, and a non-blanching rash. She is given IM benzylpenicillin by the GP and transferred to hospital. On arrival, she is alert, GCS 15, temperature 38.5°C, heart rate 105/min, blood pressure 110/70 mmHg. Blood cultures are taken. Lumbar puncture shows: white cell count 2,800/mm³ (92% neutrophils), protein 2.2 g/L, glucose 2.8 mmol/L. Gram stain shows no organisms. PCR is pending. What is the most appropriate immediate antibiotic treatment?

A. Continue with benzylpenicillin alone as already administered
B. Intravenous ceftriaxone 2g twice daily
C. Intravenous ceftriaxone and dexamethasone (Correct Answer)
D. Intravenous ceftriaxone, vancomycin, and aciclovir
E. Intravenous meropenem and vancomycin

Explanation: ***Intravenous ceftriaxone and dexamethasone*** - The clinical presentation (fever, headache, photophobia, non-blanching rash) and CSF findings (high white cell count with neutrophil predominance, elevated protein, low glucose) are highly suggestive of **bacterial meningitis**. **Intravenous ceftriaxone** is the recommended empirical antibiotic for this age group. - Adjunctive **dexamethasone** is crucial in bacterial meningitis to reduce inflammation and the risk of **neurological complications** such as hearing loss, especially when **pneumococcal meningitis** is suspected, and should be given with or just before the first dose of antibiotics. *Continue with benzylpenicillin alone as already administered* - Pre-hospital **intramuscular benzylpenicillin** is a critical initial measure for suspected meningococcal disease with a non-blanching rash, aiming to stabilize the patient, but it is not sufficient for definitive hospital treatment of bacterial meningitis. - For confirmed or highly suspected bacterial meningitis, a **third-generation cephalosporin** like ceftriaxone provides broader coverage, superior CSF penetration, and is the standard of care for optimal outcomes. *Intravenous ceftriaxone 2g twice daily* - While **intravenous ceftriaxone** is the correct antibiotic choice for empirical treatment of bacterial meningitis, this option is incomplete as it omits the vital adjunctive **dexamethasone** therapy. - Omitting **dexamethasone** in bacterial meningitis management can lead to poorer outcomes, including a higher incidence of **sensorineural hearing loss** and other focal neurological deficits, as per current guidelines. *Intravenous ceftriaxone, vancomycin, and aciclovir* - **Aciclovir** is indicated for suspected **viral encephalitis** (e.g., HSV encephalitis), which typically presents with altered consciousness, focal neurological signs, or seizures, not primarily a non-blanching rash and classic bacterial CSF picture. - **Vancomycin** is generally added empirically only in areas with high rates of **penicillin-resistant *S. pneumoniae*** or in specific high-risk groups (e.g., immunocompromised, recent neurosurgery), which is not routinely indicated in this patient's initial presentation. *Intravenous meropenem and vancomycin* - **Meropenem** is a carbapenem, a broad-spectrum antibiotic, usually reserved for patients with severe **beta-lactam allergy**, suspected **multi-drug resistant organisms**, or in very severe, complicated cases, which is not the initial empirical choice for an immunocompetent teenager. - This combination represents a very broad-spectrum approach that is typically reserved for more complex or resistant infections and is not the first-line empirical regimen for suspected bacterial meningitis in an otherwise healthy 17-year-old.

Question 231: A 31-year-old man with CD4 count 50 cells/mm³ presents with headache, fever, and confusion over 2 weeks. MRI shows meningeal enhancement. Lumbar puncture reveals opening pressure 32 cmH2O, white cell count 45/mm³ (90% lymphocytes), protein 1.1 g/L, glucose 2.0 mmol/L (plasma glucose 5.5 mmol/L). India ink stain is positive. Cryptococcal antigen titre is 1:2048. He is started on liposomal amphotericin B and flucytosine. What is the most important additional management to improve outcomes?

A. Add dexamethasone 8 mg four times daily
B. Perform therapeutic lumbar puncture to reduce CSF pressure to <20 cmH2O (Correct Answer)
C. Commence antiretroviral therapy within 72 hours of diagnosis
D. Add rifampicin to enhance antifungal activity
E. Administer intravenous mannitol to reduce intracranial pressure

Explanation: ***Perform therapeutic lumbar puncture to reduce CSF pressure to <20 cmH2O***- This patient has **cryptococcal meningitis** with severely **raised intracranial pressure** (opening pressure 32 cmH2O); aggressive management of pressure is vital for reducing mortality.- Serial **lumbar punctures** are indicated if the opening pressure is >25 cmH2O to prevent neurological complications like vision loss and cranial nerve palsies.*Add dexamethasone 8 mg four times daily*- High-dose **corticosteroids** are specifically **contraindicated** in HIV-associated cryptococcal meningitis as they increase mortality and decrease fungal clearance.- Unlike bacterial meningitis, steroids do not provide a benefit in preventing inflammatory damage in this fungal infection.*Commence antiretroviral therapy within 72 hours of diagnosis*- **ART initiation** should be delayed for at least **4 to 6 weeks** after starting antifungal therapy to prevent **Immune Reconstitution Inflammatory Syndrome (IRIS)**.- Early ART in cryptococcal meningitis is associated with significantly **higher mortality** compared to delayed initiation.*Add rifampicin to enhance antifungal activity*- **Rifampicin** has no role in the treatment of cryptococcosis and may actually lead to drug-drug interactions, such as lowering **fluconazole** levels.- It is primarily used in the treatment of **tuberculosis**, not fungal infections of the central nervous system.*Administer intravenous mannitol to reduce intracranial pressure*- **Mannitol** and other osmotic diuretics are not recommended for the long-term management of raised ICP in **cryptococcal meningitis**.- The elevated pressure is caused by **impaired CSF outflow** due to fungal polysaccharide load, which is best managed by physical **drainage of CSF**.

Question 232: A 23-year-old man completes 6 months of treatment for drug-sensitive pulmonary TB. His treatment included rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months. He was fully adherent. At treatment completion, he is asymptomatic. His chest X-ray shows residual fibrotic changes but no active disease. Sputum smears are negative. What is the most appropriate management?

A. Extend treatment with rifampicin and isoniazid for a further 3 months
B. Arrange follow-up chest X-ray in 3 months and annually for 2 years
C. Discharge from follow-up with written advice about recurrence symptoms (Correct Answer)
D. Commence isoniazid monotherapy for 3 months to prevent relapse
E. Arrange bronchoscopy to exclude residual infection

Explanation: ***Discharge from follow-up with written advice about recurrence symptoms*** - For a patient who has completed a standard **6-month course** for drug-sensitive TB and is **asymptomatic** with negative smears, routine clinical or radiological follow-up is not required according to **NICE guidelines**. - The priority is to provide **safety-netting** by educating the patient on the symptoms of **relapse** so they can self-refer if necessary. *Extend treatment with rifampicin and isoniazid for a further 3 months* - Extending treatment is unnecessary because the patient was **fully adherent** and successful completion of the **standard regimen** results in high cure rates. - **Residual fibrotic changes** on X-ray are common post-infection and do not indicate active disease requiring additional therapy. *Arrange follow-up chest X-ray in 3 months and annually for 2 years* - Routine **surveillance imaging** is not cost-effective or clinically recommended for uncomplicated, drug-sensitive pulmonary TB in patients who are **clinically well**. - Evidence shows that relapse is typically detected through **symptomatic presentation** rather than routine radiographic monitoring. *Commence isoniazid monotherapy for 3 months to prevent relapse* - There is no clinical indication for **isoniazid monotherapy** following a completed full course of treatment as it does not further reduce **relapse risk**. - Monotherapy after incomplete bacterial clearance would risk the development of **drug-resistant TB**. *Arrange bronchoscopy to exclude residual infection* - **Bronchoscopy** is an invasive procedure that is not indicated when **sputum smears are negative** and the patient is asymptomatic. - **Negative sputum smears** at the end of treatment are sufficient to confirm the success of the therapy in this clinical context.

Question 233: A 44-year-old woman with a history of pulmonary tuberculosis treated 8 years ago presents with progressive dyspnoea on exertion. Examination reveals reduced breath sounds and stony dullness to percussion in the right lower zone. Chest X-ray shows a large right-sided pleural effusion. Pleural fluid analysis reveals: protein 45 g/L, LDH 890 U/L, glucose 1.8 mmol/L, pH 7.28, lymphocyte predominance. Pleural fluid culture is negative at 72 hours. What is the most appropriate next investigation?

A. Pleural fluid adenosine deaminase (ADA) level (Correct Answer)
B. CT-guided pleural biopsy for histology and TB culture
C. Video-assisted thoracoscopic surgery (VATS) with pleural biopsy
D. Repeat pleural fluid culture at 6 weeks
E. Pleural fluid cytology for malignant cells

Explanation: ***Pleural fluid adenosine deaminase (ADA) level*** - The patient's pleural fluid analysis reveals a **lymphocytic exudate** with **low glucose** (1.8 mmol/L) and **low pH** (7.28), coupled with a history of **pulmonary tuberculosis**, which are classic indicators of **tuberculous pleuritis**. - **Pleural fluid ADA** is a highly sensitive and specific biomarker for **tuberculous pleuritis**, providing a rapid and cost-effective diagnostic tool before resorting to more invasive procedures. *CT-guided pleural biopsy for histology and TB culture* - While a **pleural biopsy** is highly diagnostic, it is a more invasive procedure compared to a biochemical fluid analysis like ADA measurement. - This investigation is typically considered if less invasive tests are inconclusive or when there is a need for tissue diagnosis, for instance, to rule out other pathologies or assess pleural thickening. *Video-assisted thoracoscopic surgery (VATS) with pleural biopsy* - **VATS** with biopsy is considered the **gold standard** for pleural disease diagnosis due to its ability to obtain adequate tissue for pathology, but it is a **surgical procedure** with associated risks. - It is usually reserved for cases where less invasive diagnostic methods have failed to provide a definitive diagnosis. *Repeat pleural fluid culture at 6 weeks* - Waiting for **Mycobacterium tuberculosis culture** results can take up to 6-8 weeks due to the slow growth rate of the organism, leading to significant delays in diagnosis and treatment initiation. - Rapid diagnostic tests like **ADA** are preferred as initial steps to guide prompt management decisions. *Pleural fluid cytology for malignant cells* - Although malignancy can cause a **lymphocytic exudative effusion**, the combination of **very low glucose** and **low pH** in a patient with a history of TB points more strongly towards **tuberculous pleuritis**. - While cytology is important to exclude malignancy, the immediate diagnostic priority, given the specific fluid characteristics and history, is to confirm or rule out active TB.

Question 234: A 7-year-old boy presents with fever, headache, and neck stiffness. LP shows: white cell count 3,200/mm³ (95% neutrophils), protein 3.5 g/L, glucose 1.5 mmol/L (plasma glucose 6.0 mmol/L). Gram stain shows Gram-negative diplococci. He is treated with IV ceftriaxone. Blood culture at 48 hours grows Neisseria meningitidis with MIC to penicillin of 0.25 mg/L. His clinical condition has improved. What is the most appropriate modification to antibiotic therapy?

A. Continue ceftriaxone for a total of 7 days
B. Switch to intravenous benzylpenicillin for a total of 7 days (Correct Answer)
C. Add rifampicin to ceftriaxone and continue for 7 days
D. Switch to oral ciprofloxacin to complete 7 days of therapy
E. Continue ceftriaxone for 14 days as there is reduced penicillin susceptibility

Explanation: ***Switch to intravenous benzylpenicillin for a total of 7 days***- **Benzylpenicillin** is the definitive treatment of choice for **Neisseria meningitidis** when the **MIC is ≤1 mg/L** (typically ≤0.5 mg/L in many guidelines), even with reduced susceptibility.- It provides excellent **CSF penetration** during inflammation and is a **narrower-spectrum**, highly **bactericidal** agent, adhering to antimicrobial stewardship principles once sensitivities are known.*Continue ceftriaxone for a total of 7 days*- While effective as empiric therapy, **ceftriaxone** is a broader-spectrum antibiotic; **antimicrobial stewardship** dictates switching to the more specific **benzylpenicillin** once *Neisseria meningitidis* is confirmed sensitive to penicillin.- Continuing ceftriaxone is less ideal when a narrower-spectrum agent like penicillin can be used effectively for the identified pathogen with an acceptable MIC.*Add rifampicin to ceftriaxone and continue for 7 days*- **Rifampicin** is primarily used for **chemoprophylaxis** to eliminate nasopharyngeal carriage in close contacts, not as an add-on for treating active meningococcal meningitis.- There is no evidence that adding rifampicin improves clinical outcomes in the acute treatment of **meningococcal meningitis** in this scenario.*Switch to oral ciprofloxacin to complete 7 days of therapy*- **Bacterial meningitis** requires high-dose **intravenous antibiotics** to achieve adequate **cerebrospinal fluid (CSF) concentrations** and effectively treat the infection.- **Oral ciprofloxacin** is typically used for **prophylaxis** of contacts and is generally insufficient for treating established meningitis due to inadequate systemic and CSF penetration.*Continue ceftriaxone for 14 days as there is reduced penicillin susceptibility*- The **MIC of 0.25 mg/L** for penicillin, while indicating reduced susceptibility, is still within the range considered treatable with standard high-dose **benzylpenicillin** for meningitis.- The standard duration for uncomplicated **meningococcal meningitis** is **7 days**; extending treatment to 14 days is unnecessary and not indicated solely based on this MIC.

Question 235: A 50-year-old man with multidrug-resistant tuberculosis (resistant to rifampicin and isoniazid) is being treated with a second-line regimen including levofloxacin, bedaquiline, linezolid, cycloserine, and ethambutol. After 3 months of treatment, he develops progressive hearing loss and tinnitus. Audiometry confirms bilateral high-frequency sensorineural hearing loss. What is the most likely causative drug and appropriate management?

A. Linezolid; stop linezolid and monitor for improvement (Correct Answer)
B. Cycloserine; reduce dose by 50% and check serum levels
C. Bedaquiline; continue treatment as hearing loss is reversible
D. Ethambutol; stop immediately and perform MRI brain
E. Levofloxacin; switch to moxifloxacin which has lower ototoxicity

Explanation: ***Linezolid; stop linezolid and monitor for improvement*** - **Linezolid** is a known cause of **mitochondrial toxicity**, which commonly presents as **bilateral high-frequency sensorineural hearing loss** and tinnitus, especially during prolonged treatment for MDR-TB. - The management involves **immediate cessation of linezolid** to prevent further auditory damage, although the hearing loss can often be irreversible. *Cycloserine; reduce dose by 50% and check serum levels* - **Cycloserine** is primarily associated with **neuropsychiatric side effects**, such as psychosis, depression, and seizures, due to its CNS penetration. - It is not a recognized cause of **ototoxicity** or hearing loss, so dose adjustment for this symptom would be inappropriate. *Bedaquiline; continue treatment as hearing loss is reversible* - **Bedaquiline**'s main adverse effects include **QT prolongation** and potential **hepatotoxicity**. - It does not cause hearing loss, and continuing a drug known to cause ototoxicity would be medically incorrect. *Ethambutol; stop immediately and perform MRI brain* - **Ethambutol** characteristically causes **optic neuritis**, leading to decreased visual acuity and red-green color blindness. - It does not cause high-frequency sensorineural hearing loss, and an **MRI brain** is not indicated for drug-induced ototoxicity. *Levofloxacin; switch to moxifloxacin which has lower ototoxicity* - **Fluoroquinolones** like levofloxacin are rarely implicated in ototoxicity; their more common severe adverse effects include **tendon rupture** and **QT prolongation**. - Switching to **moxifloxacin** would not resolve the hearing loss as both fluoroquinolones share similar (very low) ototoxicity profiles.

Question 236: A 19-year-old university student is diagnosed with meningococcal meningitis confirmed by blood culture growing Neisseria meningitidis serogroup W. He shares a house with 5 other students. Public health authorities are contacted. Which of the following household contacts requires antibiotic prophylaxis?

A. All household contacts who had more than 8 hours contact with the case in the 7 days before symptom onset
B. All household contacts regardless of duration of exposure in the 10 days before symptom onset (Correct Answer)
C. Only household contacts who had direct exposure to respiratory secretions in the 24 hours before diagnosis
D. Only household contacts who are unvaccinated against meningococcus
E. All household contacts within 14 days of symptom onset who spent more than 1 hour in close contact

Explanation: ***All household contacts regardless of duration of exposure in the 10 days before symptom onset***- Chemoprophylaxis is indicated for all individuals residing in the **same household** as a case of **Neisseria meningitidis** to eradicate carriage and prevent secondary cases.- Guidelines generally define the at-risk period as the **7 to 10 days** prior to the onset of symptoms, and all household members are treated due to the high risk of **nasopharyngeal colonization**.*All household contacts who had more than 8 hours contact with the case in the 7 days before symptom onset*- While the **7-day window** is relevant, the **8-hour threshold** typically applies to non-household contacts, such as those in a workplace or school environment.- **Household members** are considered high-risk by default and do not need to meet a specific hourly quota to qualify for antibiotics like **ciprofloxacin**.*Only household contacts who had direct exposure to respiratory secretions in the 24 hours before diagnosis*- Direct exposure to **respiratory secretions** (e.g., mouth-to-mouth resuscitation) is the criterion used for **healthcare workers**, not household contacts.- The risk window for family or housemates is much wider than **24 hours**, as the bacteria can be transmitted well before clinical diagnosis.*Only household contacts who are unvaccinated against meningococcus*- **Antibiotic prophylaxis** is required for all close contacts regardless of their **vaccination status**, as vaccines do not provide 100% protection against colonization.- While a vaccine may be offered as follow-up if the serogroup is covered (like **serogroup W**), it does not replace the immediate need for **chemoprophylaxis**.*All household contacts within 14 days of symptom onset who spent more than 1 hour in close contact*- A **14-day window** exceeds the standard incubation and transmission period monitored for immediate antibiotic intervention, which is usually capped at **7 to 10 days**.- The **1-hour contact** rule is not a standard guideline for determining prophylaxis; focus remains on the **intensity** of the living environment rather than specific minute counts.

Question 237: A 65-year-old woman presents with a 3-day history of fever, confusion, and right-sided weakness. MRI brain shows multiple ring-enhancing lesions in the left frontal and parietal lobes with surrounding oedema. Lumbar puncture reveals: white cell count 180/mm³ (70% lymphocytes, 30% neutrophils), protein 2.1 g/L, glucose 2.5 mmol/L (plasma glucose 5.8 mmol/L). She immigrated from India 6 months ago. What is the most appropriate initial investigation to confirm the diagnosis?

A. CSF Ziehl-Neelsen stain and TB culture
B. CSF polymerase chain reaction for Mycobacterium tuberculosis (Correct Answer)
C. Serum toxoplasma serology
D. Brain biopsy for histopathology and culture
E. CSF bacterial culture and fungal culture

Explanation: ***CSF polymerase chain reaction for Mycobacterium tuberculosis*** - The patient's presentation with **fever, confusion, focal neurological deficit**, **ring-enhancing lesions**, **lymphocytic pleocytosis**, **high CSF protein**, **low CSF glucose**, and recent immigration from **India** strongly suggests **tuberculous meningitis** or **CNS tuberculomas**. - **CSF PCR for M. tuberculosis** offers high **specificity** and **rapid results**, making it the most appropriate and timely initial investigation to confirm the diagnosis in this highly suspicious clinical context.*CSF Ziehl-Neelsen stain and TB culture* - **Ziehl-Neelsen (ZN) stain** has a very **low sensitivity** (10-20%) for detecting acid-fast bacilli in CSF, leading to frequent false negatives in tuberculous meningitis. - While **TB culture** is the gold standard, it requires **6-8 weeks** for results, which is too long for initial diagnosis and urgent treatment initiation in a severe neurological infection.*Serum toxoplasma serology* - **Toxoplasmosis** typically affects **immunocompromised individuals** (e.g., HIV/AIDS), a status not indicated for this patient, and often presents with **normal CSF glucose**. - While it can cause **ring-enhancing lesions**, the combination of profound **low CSF glucose**, **high protein**, and the epidemiological factor points away from toxoplasmosis as the primary concern.*Brain biopsy for histopathology and culture* - **Brain biopsy** is an **invasive procedure** with associated risks, generally reserved for cases where less invasive diagnostic methods, such as CSF analysis and imaging, are inconclusive. - It is not the appropriate **initial** investigation when a highly suggestive diagnosis, like tuberculous meningitis, can be confirmed more safely and rapidly with CSF studies.*CSF bacterial culture and fungal culture* - The CSF analysis showing a **lymphocytic predominance** (70% lymphocytes) combined with a **subacute presentation** makes acute bacterial meningitis less likely to be the primary diagnosis. - While **fungal infections** can cause similar CSF findings and ring-enhancing lesions, the strong epidemiological link to **tuberculosis** makes specific testing for *Mycobacterium tuberculosis* the most targeted and appropriate initial step.

Question 238: A 34-year-old pregnant woman at 16 weeks gestation is identified as a contact of her brother who has smear-positive pulmonary tuberculosis. She is asymptomatic and her chest X-ray with abdominal shielding is normal. Her interferon-gamma release assay is positive. She has no history of previous TB treatment. What is the most appropriate management?

A. Start isoniazid and pyridoxine immediately and continue throughout pregnancy (Correct Answer)
B. Defer treatment until after delivery and breastfeeding are completed
C. Start rifampicin and isoniazid for 3 months after delivery
D. Commence four-drug anti-tuberculous therapy immediately
E. Monitor with monthly chest X-rays and start treatment only if she develops active TB

Explanation: ***Start isoniazid and pyridoxine immediately and continue throughout pregnancy*** - This patient has **latent tuberculosis infection (LTBI)**, diagnosed by a **positive IGRA** and normal chest X-ray following recent contact with a positive case. Current guidelines recommend treatment during pregnancy for those with recent exposure to prevent progression to active disease. - **Isoniazid (INH)** is the preferred drug for LTBI in pregnancy, given for 6-9 months, and **pyridoxine (vitamin B6)** is co-administered to prevent **isoniazid-induced peripheral neuropathy**. *Defer treatment until after delivery and breastfeeding are completed* - Deferring treatment significantly increases the risk of **reactivation** to active TB during the postpartum period, which is a high-risk time due to physiological stress and potential immunosuppression. - Current guidelines favor treating LTBI in pregnancy, especially with recent exposure, to protect both the mother and the **fetus** from the greater risks associated with active disease. *Start rifampicin and isoniazid for 3 months after delivery* - While this is a shorter alternative regimen for LTBI, initiating it **postpartum** is inappropriate when a higher risk of progression is present during pregnancy. - Delaying treatment ignores the **recent contact history** and the high-risk status, which necessitates prompt intervention to prevent active TB development during pregnancy. *Commence four-drug anti-tuberculous therapy immediately* - This intensive regimen is reserved for **active TB disease** and is not indicated for **latent infection** with a normal chest X-ray and no symptoms. - Using four drugs unnecessarily increases the risk of **drug toxicity** and side effects for both the mother and the developing fetus when only LTBI is present. *Monitor with monthly chest X-rays and start treatment only if she develops active TB* - **Monthly chest X-rays** involve unnecessary radiation exposure to the fetus, even with shielding. - This approach is reactive and fails to prevent the morbidity and mortality associated with the progression to **active TB**, which is the primary goal of LTBI treatment in high-risk individuals.

Question 239: A 28-year-old man presents to the emergency department with sudden onset severe headache, fever of 39.2°C, and confusion. He has multiple small pustular lesions on his hands and face. Lumbar puncture shows: white cell count 2,400/mm³ (90% neutrophils), protein 2.8 g/L, glucose 1.8 mmol/L (plasma glucose 6.2 mmol/L). Gram stain shows Gram-positive cocci in clusters. He keeps pigeons as a hobby. What is the most appropriate empirical antibiotic therapy?

A. Intravenous ceftriaxone and vancomycin (Correct Answer)
B. Intravenous benzylpenicillin and gentamicin
C. Intravenous meropenem
D. Intravenous ceftriaxone and doxycycline
E. Intravenous flucloxacillin and rifampicin

Explanation: ***Intravenous ceftriaxone and vancomycin*** - The presence of **Gram-positive cocci in clusters** in the CSF, along with **pustular skin lesions**, strongly suggests **Staphylococcus aureus** meningitis, requiring empirical coverage for both MSSA and **MRSA**. - **Ceftriaxone** provides broad Gram-negative and MSSA coverage, while **vancomycin** is essential to cover potential **Methicillin-resistant Staphylococcus aureus (MRSA)** until sensitivities are available. *Intravenous benzylpenicillin and gentamicin* - This combination is not standard for staphylococcal meningitis as **benzylpenicillin** is ineffective against most strains of **Staphylococcus aureus** due to beta-lactamase production. - **Gentamicin** has poor **blood-brain barrier** penetration and is insufficient as a primary agent for meningitis. *Intravenous meropenem* - While **meropenem** provides broad-spectrum coverage, it lacks adequate activity against **MRSA**, which must be considered given the Gram-positive cocci in clusters. - It is generally reserved for **multi-drug resistant** Gram-negative infections or as a second-line agent in specific clinical scenarios. *Intravenous ceftriaxone and doxycycline* - **Doxycycline** might be considered if **psittacosis** (Chlamydia psittaci) was suspected due to pigeon exposure, but the CSF profile shows **neutrophilic pleocytosis** and cocci, diagnostic of bacterial meningitis. - It does not provide the necessary **bactericidal** activity or coverage required for a confirmed staphylococcal central nervous system infection. *Intravenous flucloxacillin and rifampicin* - **Flucloxacillin** is the drug of choice for **MSSA**, but it is inappropriate for empirical use here because it cannot cover **MRSA**. - **Rifampicin** is used as an adjunct in specific staphylococcal infections but should never be used as **monotherapy** or first-line empirical treatment without a backbone like vancomycin.

Question 240: A 58-year-old man with chronic kidney disease (eGFR 35 mL/min/1.73m²) is diagnosed with drug-sensitive pulmonary tuberculosis. He is started on standard four-drug therapy. Three weeks into treatment, he develops painful paraesthesia in both feet and difficulty walking. Examination reveals reduced ankle reflexes and impaired vibration sense distally. What is the most likely cause and appropriate management?

A. Isoniazid-induced peripheral neuropathy; add pyridoxine and continue treatment (Correct Answer)
B. Ethambutol toxicity; stop ethambutol immediately and check visual acuity
C. Rifampicin-induced neuropathy; reduce rifampicin dose by 50%
D. TB-related vasculitis; start prednisolone 40 mg daily
E. Uraemic neuropathy due to worsening renal function; arrange urgent dialysis

Explanation: ***Isoniazid-induced peripheral neuropathy; add pyridoxine and continue treatment***- **Isoniazid (INH)** interferes with **pyridoxine (Vitamin B6)** metabolism, leading to a distal symmetric polyneuropathy and painful **paraesthesia**, especially in patients with **chronic kidney disease**. - Treatment involves supplemental **pyridoxine** (usually 10-50mg daily), which addresses the deficiency while allowing the essential TB therapy to continue.*Ethambutol toxicity; stop ethambutol immediately and check visual acuity*- **Ethambutol** is primarily associated with **optic neuritis**, causing decreased visual acuity and **red-green color blindness**, rather than peripheral nerve symptoms.- While it requires monitoring in renal impairment, it does not explain the loss of **ankle reflexes** or **vibration sense** in the feet.*Rifampicin-induced neuropathy; reduce rifampicin dose by 50%*- **Rifampicin** is not typically associated with **peripheral neuropathy**; its main side effects are **hepatotoxicity** and orange-colored body fluids.- Reducing the dose by 50% is inappropriate and risks developing **drug resistance** without addressing the metabolic cause of the neuropathy.*TB-related vasculitis; start prednisolone 40 mg daily*- While TB can cause immune-mediated phenomena, a symmetrical **sensory-motor neuropathy** following drug initiation is highly pathognomonic for **drug toxicity** rather than vasculitis.- **Prednisolone** is used for TB meningitis or pericarditis, but is not the first-line treatment for standard treatment-induced nerve damage.*Uraemic neuropathy due to worsening renal function; arrange urgent dialysis*- **Uraemic neuropathy** generally occurs in patients with end-stage renal disease (eGFR <15); this patient's **eGFR of 35** makes isoniazid toxicity a more likely acute cause.- The sudden onset three weeks after starting **anti-tubercular therapy** strongly correlates with medication side effects rather than a sudden failure of renal filtration.

Question 241: A 22-year-old woman presents with a 12-hour history of severe headache, photophobia, and neck stiffness. Lumbar puncture reveals: opening pressure 28 cmH2O, CSF white cell count 850/mm³ (85% lymphocytes), protein 1.2 g/L, glucose 3.2 mmol/L (plasma glucose 5.8 mmol/L). Gram stain is negative. She had a similar episode 2 years ago that resolved spontaneously. What is the most likely diagnosis?

A. Tuberculous meningitis
B. Partially treated bacterial meningitis
C. Viral meningitis (Correct Answer)
D. Neurosarcoidosis
E. Listeria monocytogenes meningitis

Explanation: ***Viral meningitis*** - The CSF highlights a **lymphocytic pleocytosis** with a **normal glucose ratio** (CSF:plasma glucose ratio >0.5), which is the classic profile for a viral etiology. - The history of a **spontaneous resolution and recurrence** is highly characteristic of **HSV-2**, often referred to as **Mollaret’s meningitis**. *Tuberculous meningitis* - Typically presents with a **subacute onset** over weeks and significantly **lower CSF glucose** (usually <50% of plasma glucose). - The CSF protein in tuberculous cases is usually **markedly elevated** (often >1.5 g/L), much higher than seen in this patient. *Partially treated bacterial meningitis* - While it can show a shift toward lymphocytes, it usually still demonstrates a **neutrophil predominance** or significantly **depressed glucose levels**. - This diagnosis requires a history of **antibiotic use** prior to the lumbar puncture, which is not mentioned here. *Neurosarcoidosis* - This condition typically follows a **chronic or relapsing-remitting course** rather than an acute 12-hour presentation of meningism. - It is usually associated with other **systemic manifestations** like hilar lymphadenopathy, uveitis, or cranial nerve palsies. *Listeria monocytogenes meningitis* - Although it can present with a lymphocytic picture, it primarily affects **immunocompromised individuals** or those over the age of 50. - It typically causes a more severe clinical picture with **lower glucose** and would not resolve spontaneously without treatment.

Question 242: A 40-year-old woman with rheumatoid arthritis treated with methotrexate and infliximab undergoes screening for latent tuberculosis before starting therapy. Her Mantoux test shows 8 mm induration, and interferon-gamma release assay (IGRA) is positive. Chest X-ray is normal. She has no symptoms of active TB. What is the most appropriate management?

A. Start anti-TNF therapy immediately as the chest X-ray is normal
B. Commence isoniazid for 6 months before starting anti-TNF therapy (Correct Answer)
C. Commence full four-drug anti-tuberculous therapy for 6 months before starting anti-TNF therapy
D. Repeat the Mantoux test in 4 weeks to confirm the result
E. Perform a CT chest and bronchoscopy before making any treatment decisions

Explanation: ***Commence isoniazid for 6 months before starting anti-TNF therapy*** - A **positive IGRA** and a Mantoux test of **8 mm** in an immunosuppressed patient indicate **latent tuberculosis infection (LTBI)**, requiring prophylaxis before starting biologics. - Treating LTBI with **isoniazid (plus pyridoxine)** significantly reduces the risk of **TB reactivation**, which is a known complication of **anti-TNF** drugs like infliximab. *Start anti-TNF therapy immediately as the chest X-ray is normal* - A normal chest X-ray excludes active pulmonary disease but does not rule out **latent infection**, which can flare once **TNF-alpha** is inhibited. - Starting biologics without treating LTBI carries a high risk of life-threatening **disseminated tuberculosis** or miliary TB. *Commence full four-drug anti-tuberculous therapy for 6 months before starting anti-TNF therapy* - Full four-drug therapy (RIPE) is strictly reserved for **active tuberculosis** disease, which is not present here given the lack of symptoms and normal X-ray. - For LTBI, **monotherapy** (e.g., isoniazid) or dual therapy (e.g., rifampicin and isoniazid) is the standard of care to minimize **drug toxicity**. *Repeat the Mantoux test in 4 weeks to confirm the result* - Repeating the test is unnecessary because the **IGRA is already positive**, providing a more specific confirmation of infection than the Mantoux test. - In patients already on **methotrexate**, the skin test may even be **falsely negative** due to anergy, making any positive result clinically significant. *Perform a CT chest and bronchoscopy before making any treatment decisions* - These invasive or high-radiation investigations are not indicated when the patient has a **normal chest X-ray** and is **asymptomatic**. - Guidelines prioritize starting **chemoprophylaxis** based on immunological evidence (IGRA/TST) rather than searching for subclinical active disease via bronchoscopy.

Question 243: A 5-year-old girl is brought to the emergency department with a 4-hour history of high fever, drowsiness, and a non-blanching purpuric rash on her legs and trunk. She is tachycardic with a capillary refill time of 4 seconds. Blood pressure is 85/50 mmHg. Blood cultures are taken and she is given immediate intravenous ceftriaxone. Which statutory notification requirement applies in this case?

A. Notification to the UK Health Security Agency must be made within 3 working days of clinical diagnosis
B. Notification to the local Proper Officer must be made upon clinical suspicion, without waiting for laboratory confirmation (Correct Answer)
C. Notification is only required once laboratory confirmation of Neisseria meningitidis is obtained
D. Notification should be made to the General Medical Council within 24 hours
E. Notification is the responsibility of the microbiologist once blood culture results are available

Explanation: ***Notification to the local Proper Officer must be made upon clinical suspicion, without waiting for laboratory confirmation*** - Registered medical practitioners have a **statutory duty** to notify the **Proper Officer** (at the UK Health Security Agency) immediately upon clinical suspicion of a notifiable disease like **meningococcal septicaemia**, due to the rapid progression and high mortality. - Urgent notification allows for rapid **public health intervention**, such as identification of close contacts and administration of **chemoprophylaxis** to prevent further cases, which is critical in a serious condition like this. *Notification to the UK Health Security Agency must be made within 3 working days of clinical diagnosis* - While some notifications are non-urgent, suspected **meningococcal disease** requires **immediate notification** (usually within 24 hours or sooner) due to its life-threatening nature and potential for rapid spread. - Waiting **3 working days** would cause a dangerous and unacceptable delay in tracing contacts and providing necessary antibiotic prophylaxis, significantly increasing the risk of further morbidity and mortality. *Notification is only required once laboratory confirmation of Neisseria meningitidis is obtained* - Clinical suspicion alone, based on signs like high fever, drowsiness, and a **non-blanching purpuric rash**, is the legal trigger for notification, as waiting for **laboratory confirmation** like blood cultures delays crucial public health action. - The **Health Protection Regulations 2010** explicitly state that notification should not be delayed for definitive microbiology results, as early intervention is paramount. *Notification should be made to the General Medical Council within 24 hours* - The **General Medical Council (GMC)** is a regulatory body for doctors and does not handle **public health notifications** or infectious disease surveillance. - Sending notifications to the GMC instead of the **local Health Protection Team** or **Proper Officer** would prevent the necessary local outbreak management protocols from starting, endangering public health. *Notification is the responsibility of the microbiologist once blood culture results are available* - While laboratories have a separate duty to notify of identified organisms, the **primary responsibility** for notifying suspected clinical cases rests with the **attending clinician**. - Relying solely on the **microbiologist** would miss the opportunity for early intervention during the crucial window before laboratory results are finalized, which can take days.

Question 244: A 35-year-old asylum seeker from Eritrea presents with a 2-month history of cough, weight loss, and fever. Chest X-ray shows bilateral upper lobe cavitation. Sputum microscopy reveals acid-fast bacilli. He has no known drug allergies and HIV test is negative. What is the most appropriate initial treatment regimen for this patient?

A. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months (Correct Answer)
B. Rifampicin, isoniazid, and pyrazinamide for 6 months
C. Rifampicin and isoniazid for 9 months
D. Rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin for 2 months, followed by rifampicin, isoniazid, and ethambutol for 10 months
E. Moxifloxacin, isoniazid, pyrazinamide, and ethambutol for 6 months

Explanation: ***Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months*** - This is the standard **6-month first-line regimen** for **drug-sensitive pulmonary tuberculosis**, consisting of an initial **intensive phase** with four drugs (RIPE) and a **continuation phase** with two drugs (RI). - The inclusion of **ethambutol** in the initial phase is crucial, especially in patients from high-prevalence areas like Eritrea, to cover for potential **isoniazid resistance** until drug susceptibility results are available. *Rifampicin, isoniazid, and pyrazinamide for 6 months* - This regimen lacks **ethambutol** in the initial intensive phase, which is important for preventing development of **drug resistance** and ensuring adequate coverage against potentially resistant strains. - Omitting ethambutol without confirmed drug susceptibility can lead to a higher risk of **treatment failure** or selection of **multidrug-resistant TB (MDR-TB)**. *Rifampicin and isoniazid for 9 months* - This regimen lacks **pyrazinamide** and **ethambutol** in the initial phase, making it less effective in sterilizing lesions and preventing resistance, respectively. - A **9-month duration** with only two drugs for the entire course is an outdated and suboptimal approach for active pulmonary TB, leading to slower bacillary clearance and higher **relapse rates**. *Rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin for 2 months, followed by rifampicin, isoniazid, and ethambutol for 10 months* - **Streptomycin**, an injectable agent, is typically reserved for specific forms of **drug-resistant TB** or in cases of severe intolerance to oral drugs, due to its significant **ototoxicity** and **nephrotoxicity**. - A **12-month total duration** is excessively long for routine drug-sensitive pulmonary TB and is usually reserved for complex cases such as **TB meningitis** or disseminated disease. *Moxifloxacin, isoniazid, pyrazinamide, and ethambutol for 6 months* - **Moxifloxacin** (a fluoroquinolone) is not a first-line antitubercular drug for drug-sensitive TB but is reserved for **drug-resistant TB** or in patients who cannot tolerate **rifampicin**. - Substituting **rifampicin**, a cornerstone of first-line therapy, with moxifloxacin without a clinical indication for drug resistance is inappropriate and can compromise treatment efficacy.

Question 245: A 52-year-old man from Pakistan with newly diagnosed smear-positive pulmonary tuberculosis requires treatment. He has HIV coinfection (CD4 200 cells/mm³) and is taking tenofovir/emtricitabine/efavirenz. He also has chronic hepatitis B, hypertension (amlodipine 5mg daily), and epilepsy well-controlled on phenytoin 300mg daily. Initial ALT is 65 U/L, bilirubin 18 µmol/L. What is the most critical drug interaction requiring immediate management modification?

A. Rifampicin will reduce efavirenz levels requiring dose adjustment of antiretroviral therapy
B. Rifampicin will reduce phenytoin levels significantly increasing seizure risk (Correct Answer)
C. Isoniazid and rifampicin together create high hepatotoxicity risk with pre-existing liver disease
D. Rifampicin will reduce amlodipine levels causing inadequate blood pressure control
E. Pyrazinamide will worsen hepatitis B liver disease requiring modified TB regimen

Explanation: ***Rifampicin will reduce phenytoin levels significantly increasing seizure risk*** - **Rifampicin** is a potent **CYP450 enzyme inducer** that markedly increases the metabolism of **phenytoin**, potentially reducing its plasma levels by 50-75%. - This drug interaction presents an immediate life-threatening risk of **breakthrough seizures**, necessitating urgent dose adjustment or a switch to non-enzyme-dependent agents like **levetiracetam**. *Rifampicin will reduce efavirenz levels requiring dose adjustment of antiretroviral therapy* - While **rifampicin** does lower **efavirenz** concentrations, clinical practice (including UK guidelines) generally maintains a standard 600mg dose of efavirenz because levels often remain therapeutic. - This interaction is clinically monitored via viral load but is less immediately critical than the urgent risk of status epilepticus from sub-therapeutic phenytoin. *Isoniazid and rifampicin together create high hepatotoxicity risk with pre-existing liver disease* - Although these drugs are **hepatotoxic**, the patient's baseline **ALT (65 U/L)** is less than three times the upper limit of normal, allowing for standard therapy with close monitoring. - It is a significant long-term management consideration but does not constitute an immediate emergency compared to the loss of seizure control. *Rifampicin will reduce amlodipine levels causing inadequate blood pressure control* - **Rifampicin** induces the metabolism of **calcium channel blockers** like **amlodipine**, which may lead to suboptimal blood pressure control. - This is a manageable chronic issue and does not carry the same degree of acute morbidity as an uncontrolled seizure disorder. *Pyrazinamide will worsen hepatitis B liver disease requiring modified TB regimen* - **Pyrazinamide** is indeed the most hepatotoxic agent in the RIPE regimen, but it does not specifically worsen the viral progression of **Hepatitis B**. - Standard TB regimens are generally initiated in such patients unless there is evidence of severe **liver failure** (e.g., elevated bilirubin or prolonged PT).

Question 246: A 60-year-old man presents with progressive confusion, fever, and left-sided weakness over 3 days. MRI brain shows asymmetrical temporal lobe changes with haemorrhagic features. Lumbar puncture reveals: opening pressure 18 cmH2O, CSF red blood cells 850/mm³, white cells 245/mm³ (75% lymphocytes), protein 0.9 g/L, glucose 3.8 mmol/L (plasma glucose 5.5 mmol/L). CSF PCR for herpes simplex virus is positive. Despite intravenous aciclovir for 5 days, he remains confused with worsening seizures. What is the most appropriate next management step?

A. Continue aciclovir for full 14-day course as initial improvement takes time
B. Switch from intravenous aciclovir to oral valaciclovir for better CNS penetration
C. Add foscarnet to the treatment regimen due to possible aciclovir resistance (Correct Answer)
D. Stop aciclovir and start ganciclovir for possible CMV encephalitis
E. Increase the dose of aciclovir to 15 mg/kg three times daily

Explanation: ***Add foscarnet to the treatment regimen due to possible aciclovir resistance*** - Clinical deterioration or lack of improvement after 5 days of appropriate therapy for **HSV encephalitis** suggests **aciclovir resistance**, handled by adding **foscarnet**. - **Foscarnet** inhibits viral DNA polymerase directly without requiring activation by **viral thymidine kinase**, circumventing the most common mechanism of resistance. *Continue aciclovir for full 14-day course as initial improvement takes time* - While a standard course is 14–21 days, **worsening seizures** and persistent confusion after 5 days of therapy indicate a failure of the current regimen. - Delaying alternative treatments in the face of clinical decline increases the risk of permanent **neurological damage**. *Switch from intravenous aciclovir to oral valaciclovir for better CNS penetration* - **Intravenous aciclovir** is the gold standard for CNS infections; oral medications cannot consistently achieve the high plasma concentrations required. - **Valaciclovir** is a prodrug of aciclovir and would not address the issue if the underlying strain is already **aciclovir-resistant**. *Stop aciclovir and start ganciclovir for possible CMV encephalitis* - This patient has a **positive PCR for HSV**, making **CMV encephalitis** an unlikely primary diagnosis. - **Ganciclovir** and aciclovir share similar phosphorylation pathways (via viral kinases), meaning resistance to aciclovir often confers cross-resistance to ganciclovir. *Increase the dose of aciclovir to 15 mg/kg three times daily* - The standard dose for encephalitis is **10 mg/kg**, and failure at this dose is more likely due to **resistance** than inadequate serum levels. - Simply increasing the dose of the same drug is unlikely to overcome a resistant **thymidine kinase-deficient** viral strain.

Question 247: A 29-year-old woman completes 6 months of treatment for drug-sensitive pulmonary tuberculosis with documented sputum culture conversion at 2 months. She is now asymptomatic with a normal chest X-ray. She wishes to conceive. She asks about the risk of TB recurrence during pregnancy and the safety of becoming pregnant. What is the most appropriate counselling regarding her conception plans?

A. She should wait 12 months after treatment completion before conceiving due to high risk of relapse
B. She can conceive immediately as treatment is complete and risk of relapse is low (Correct Answer)
C. She should wait 6 months after treatment completion and undergo repeat sputum cultures before conceiving
D. She should avoid pregnancy indefinitely due to risk of reactivation during immunosuppression of pregnancy
E. She should wait 24 months after treatment completion to ensure no late relapse

Explanation: ***She can conceive immediately as treatment is complete and risk of relapse is low***- After completing a **full course** of treatment for **drug-sensitive TB** with documented **sputum culture conversion**, the risk of relapse is very low (approx. 2-3%).- Modern guidelines do not require a waiting period post-treatment, and **pregnancy** is not a significant risk factor for reactivation in patients who have been successfully cured.*She should wait 12 months after treatment completion before conceiving due to high risk of relapse*- There is no clinical evidence to support a **12-month delay**, as the majority of relapses occur shortly after treatment if they are to happen at all.- Mandating a year of waiting causes unnecessary psychological distress and is not supported by **WHO** or **UK guidelines**.*She should wait 6 months after treatment completion and undergo repeat sputum cultures before conceiving*- Routine **repeat sputum cultures** are not recommended for **asymptomatic** patients who have already achieved culture conversion and completed therapy.- A **6-month waiting period** is arbitrary and does not provide additional safety benefits for a patient who is clinically and radiologically well.*She should avoid pregnancy indefinitely due to risk of reactivation during immunosuppression of pregnancy*- Historical beliefs that **pregnancy-related immunosuppression** significantly increases TB reactivation risk have been largely refuted by current evidence.- Successful treatment effectively **eliminates the pathogen**, allowing the patient to have a safe pregnancy with no increased risk to the fetus.*She should wait 24 months after treatment completion to ensure no late relapse*- A **24-month delay** is only typically relevant in cases of **Multi-Drug Resistant (MDR-TB)**, where follow-up periods are longer due to higher failure rates.- For standard **drug-sensitive pulmonary TB**, waiting two years is disproportionate and medically unnecessary given the high success rate of the 6-month regimen.

Question 248: A 45-year-old woman with miliary tuberculosis is started on standard four-drug therapy. After 3 weeks of treatment, she develops confusion, ataxia, and ophthalmoplegia. Her serum sodium is 128 mmol/L, ALT is 45 U/L (baseline 35 U/L), and serum lactate is 4.2 mmol/L. Brain MRI shows bilateral symmetrical lesions in the mamillary bodies and thalamus. Which anti-tuberculous drug is most likely responsible for this presentation?

A. Rifampicin
B. Isoniazid (Correct Answer)
C. Pyrazinamide
D. Ethambutol
E. Streptomycin

Explanation: ***Isoniazid*** - **Isoniazid** can cause **Wernicke's encephalopathy** (confusion, ataxia, ophthalmoplegia) by interfering with **thiamine (Vitamin B1) metabolism**, particularly in malnourished individuals or those with increased metabolic demand like miliary tuberculosis. - The characteristic MRI findings of bilateral symmetrical lesions in the **mamillary bodies** and **thalamus**, along with **elevated serum lactate**, are hallmarks of severe thiamine deficiency, as thiamine is a critical cofactor in carbohydrate metabolism (e.g., pyruvate dehydrogenase). *Rifampicin* - Primarily associated with **hepatotoxicity** (though ALT elevation here is mild) and **orange discoloration of body fluids**. - It is a potent **CYP450 inducer** but does not typically cause acute neurological syndromes like Wernicke's encephalopathy or interfere with thiamine metabolism. *Pyrazinamide* - Common side effects include **hepatotoxicity** (often dose-related) and **hyperuricemia**, which can precipitate gout. - It does not cause central nervous system lesions, ophthalmoplegia, or interfere with thiamine pathways leading to lactic acidosis. *Ethambutol* - The most significant adverse effect is **optic neuritis**, leading to decreased visual acuity and **red-green color blindness**. - It does not present with confusion, ataxia, or the specific MRI findings observed in this patient's brain. *Streptomycin* - As an aminoglycoside, its primary toxicities include **ototoxicity** (vestibular and auditory damage) and **nephrotoxicity**. - It is not implicated in causing metabolic encephalopathy, thiamine deficiency, or the specific neurological symptoms and MRI findings seen in Wernicke's encephalopathy.

Question 249: A 72-year-old man develops acute bacterial meningitis and is treated with intravenous ceftriaxone and dexamethasone. Blood cultures grow Streptococcus pneumoniae with penicillin MIC of 2 mg/L. His clinical condition improves over 48 hours. CSF culture at 48 hours shows continued growth of the organism. What is the most appropriate modification to his antibiotic regimen?

A. Continue current regimen as clinical improvement suggests adequate treatment
B. Add vancomycin to the current regimen (Correct Answer)
C. Switch from ceftriaxone to high-dose benzylpenicillin
D. Add rifampicin to the current regimen
E. Stop dexamethasone and increase ceftriaxone dose

Explanation: ***Add vancomycin to the current regimen*** - The persistent growth of **Streptococcus pneumoniae** in the CSF after 48 hours, despite clinical improvement, signifies microbiological treatment failure, especially given the **penicillin MIC of 2 mg/L**. - **Vancomycin** is crucial for covering penicillin- and cephalosporin-resistant pneumococci in meningitis, and its addition ensures bactericidal activity against the persistent pathogen. *Continue current regimen as clinical improvement suggests adequate treatment* - Clinical improvement alone is insufficient when there is **persistent bacterial growth** in the CSF, which indicates ongoing infection and a high risk of relapse and neurological sequelae. - The **penicillin MIC of 2 mg/L** suggests intermediate resistance, meaning the current ceftriaxone monotherapy may not be fully effective in sterilizing the CSF. *Switch from ceftriaxone to high-dose benzylpenicillin* - A **penicillin MIC of 2 mg/L** for *S. pneumoniae* indicates intermediate resistance, making high-dose benzylpenicillin unlikely to achieve sufficient bactericidal concentrations in the CSF to eradicate the organism. - Ceftriaxone generally provides better **CSF penetration** and efficacy against *S. pneumoniae* with intermediate penicillin resistance compared to benzylpenicillin. *Add rifampicin to the current regimen* - While **rifampicin** can be used as an adjunctive agent for resistant pneumococcal meningitis, **vancomycin** is the preferred and guideline-recommended primary agent to add in this scenario of persistent growth. - Rifampicin use carries a risk of rapid development of **monotherapy resistance**, making it a secondary choice, often reserved for highly resistant strains or specific circumstances. *Stop dexamethasone and increase ceftriaxone dose* - **Dexamethasone** is vital in pneumococcal meningitis to reduce inflammation and improve neurological outcomes; stopping it prematurely is not advised. - Increasing the **ceftriaxone dose** alone is unlikely to overcome the established resistance indicated by persistent CSF growth and a significant MIC, requiring a different antibiotic with activity against resistant strains.

Question 250: A 38-year-old man with newly diagnosed HIV (CD4 count 120 cells/mm³) presents with fever, cough, and weight loss. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Three sputum samples are AFB smear-positive, and culture confirms Mycobacterium tuberculosis fully sensitive to first-line drugs. He is started on standard TB treatment. When should antiretroviral therapy (ART) be initiated?

A. Immediately, concurrent with TB treatment
B. After 2 weeks of TB treatment (Correct Answer)
C. After 2 months of TB treatment when the intensive phase is complete
D. After 6 months when TB treatment is complete
E. ART should be deferred until CD4 count falls below 100 cells/mm³

Explanation: ***After 2 weeks of TB treatment*** - For patients with HIV and TB who have a **CD4 count between 50-200 cells/mm³**, guidelines recommend initiating ART within **2 to 8 weeks** of starting anti-tuberculosis therapy. - This approach balances the need to rapidly improve immune function and reduce HIV progression with minimizing the risk of **Immune Reconstitution Inflammatory Syndrome (IRIS)** and managing potential drug toxicities. *Immediately, concurrent with TB treatment* - Starting both regimens simultaneously significantly increases the risk of developing severe **Immune Reconstitution Inflammatory Syndrome (IRIS)**, especially with a low CD4 count. - It also makes it challenging to identify the source of **drug toxicities** if adverse effects occur, as both ART and TB drugs have overlapping side effect profiles. *After 2 months of TB treatment when the intensive phase is complete* - Delaying ART until the end of the **intensive phase** (2 months) is generally recommended for patients with higher **CD4 counts (>200 cells/mm³)** or in cases of **TB meningitis**. - For this patient with a **CD4 count of 120 cells/mm³**, a 2-month delay would unnecessarily prolong severe immunodeficiency and significantly increase the risk of **HIV disease progression** and mortality. *After 6 months when TB treatment is complete* - Deferring ART until **TB treatment is complete** (6 months) is associated with substantially **higher morbidity and mortality** in HIV-infected individuals, regardless of CD4 count. - This prolonged delay leaves the underlying **immunodeficiency** unaddressed, making the patient highly susceptible to other opportunistic infections and AIDS-related complications. *ART should be deferred until CD4 count falls below 100 cells/mm³* - Current HIV treatment guidelines recommend initiating ART for **all HIV-positive individuals**, regardless of their CD4 count, to preserve immune function and prevent disease progression. - Given the patient's existing low CD4 count of **120 cells/mm³** and active tuberculosis, further deferral would place them at a critical and unnecessary risk for **clinical deterioration** and life-threatening opportunistic infections.

Question 251: A 3-month-old infant is brought to the emergency department with fever of 38.8°C, irritability, poor feeding, and a bulging fontanelle. Blood tests show: WBC 18.5 × 10⁹/L (neutrophils 15.2 × 10⁹/L), CRP 145 mg/L. Lumbar puncture reveals CSF white cells 1200/mm³ (85% neutrophils), protein 1.8 g/L, glucose 1.5 mmol/L (plasma glucose 4.8 mmol/L). Gram stain shows Gram-positive cocci in chains. What is the most appropriate antibiotic regimen?

A. Intravenous ceftriaxone alone
B. Intravenous cefotaxime and amoxicillin (Correct Answer)
C. Intravenous benzylpenicillin alone
D. Intravenous ceftriaxone and vancomycin
E. Intravenous cefotaxime and gentamicin

Explanation: ***Intravenous cefotaxime and amoxicillin*** - In infants under 3 months, **cefotaxime** is preferred over ceftriaxone because it does not displace bilirubin from albumin, avoiding the risk of **kernicterus**. - **Amoxicillin** must be added to the regimen to provide specific coverage for **Listeria monocytogenes**, an organism not covered by third-generation cephalosporins. *Intravenous ceftriaxone alone* - **Ceftriaxone** is generally avoided in neonates and very young infants due to its potential to cause **biliary sludging** and hyperbilirubinemia, leading to **kernicterus**. - This regimen lacks coverage for **Listeria monocytogenes**, which is a significant pathogen causing meningitis in infants under 3 months of age. *Intravenous benzylpenicillin alone* - While **benzylpenicillin** provides coverage for common Gram-positive cocci (like Group B Streptococcus), it lacks the necessary broad-spectrum coverage for important Gram-negative pathogens such as **E. coli**. - Given the high mortality of neonatal meningitis, **empiric therapy** must cover a wide range of common bacterial pathogens, which this single antibiotic does not achieve. *Intravenous ceftriaxone and vancomycin* - This regimen includes **ceftriaxone**, which is contraindicated in infants under 3 months due to the risk of **kernicterus**. - Although **vancomycin** covers resistant Gram-positives, this combination still does not provide adequate coverage for **Listeria monocytogenes**, a crucial pathogen in this age group. *Intravenous cefotaxime and gentamicin* - While **cefotaxime** is appropriate, **gentamicin** (an aminoglycoside) has poor penetration into the **cerebrospinal fluid (CSF)**, making it less effective for treating meningitis. - This combination also does not adequately cover **Listeria monocytogenes**, for which amoxicillin is specifically indicated in infants.

Question 252: A 42-year-old woman presents with a 4-week history of headache, low-grade fever, and personality changes. She is originally from India and moved to the UK 6 months ago. CT head shows basal meningeal enhancement and hydrocephalus. Lumbar puncture reveals: opening pressure 32 cmH2O, clear CSF, white cells 180/mm³ (80% lymphocytes), protein 2.5 g/L, glucose 1.9 mmol/L (plasma glucose 5.8 mmol/L). Ziehl-Neelsen stain is negative. What is the most appropriate initial management?

A. Start four-drug anti-tuberculous therapy immediately (Correct Answer)
B. Wait for mycobacterial culture results before starting treatment
C. Perform repeat lumbar puncture for larger CSF volume before starting treatment
D. Start empirical aciclovir for possible viral meningoencephalitis
E. Start empirical treatment for fungal meningitis with amphotericin B

Explanation: ***Start four-drug anti-tuberculous therapy immediately***- The patient's presentation with subacute headache, fever, and personality changes, combined with **basal meningeal enhancement** and **hydrocephalus** on CT, and classic CSF findings (**lymphocytic pleocytosis**, very **high protein**, very **low glucose**) in a patient from a **TB-endemic area**, is highly suggestive of **tuberculous meningitis**.- Given the high mortality and severe neurological sequelae if treatment is delayed, and the low sensitivity of **Ziehl-Neelsen stain** and slow growth of mycobacterial cultures, empirical **four-drug anti-tuberculous therapy** (RIPE) plus corticosteroids must be initiated immediately. *Wait for mycobacterial culture results before starting treatment*- **Mycobacterial cultures** can take several weeks to yield results, which is too long to delay treatment for a rapidly progressive and life-threatening condition like TB meningitis.- Delaying treatment significantly increases the risk of irreversible neurological damage, severe complications such as stroke and **hydrocephalus**, and death.*Perform repeat lumbar puncture for larger CSF volume before starting treatment*- While a larger CSF volume could potentially increase the yield for diagnostic tests, the current clinical and CSF findings are already strongly indicative of TB meningitis.- Delaying the initiation of life-saving therapy to obtain more CSF volume is not appropriate given the urgency of the situation and the clear diagnostic suspicion.*Start empirical aciclovir for possible viral meningoencephalitis*- **Viral meningoencephalitis**, particularly HSV, typically presents more acutely than the 4-week history seen here and usually has **normal CSF glucose** levels, unlike the severely low glucose in this case.- Furthermore, **basal meningeal enhancement** and **hydrocephalus** are far more characteristic of granulomatous infections like TB or fungal meningitis than typical viral etiologies.*Start empirical treatment for fungal meningitis with amphotericin B*- While fungal meningitis can present with similar CSF abnormalities (low glucose, high protein, lymphocytic pleocytosis) and imaging findings, it is less common than TB in this context and typically affects severely **immunocompromised individuals**.- The patient's background from a **TB-endemic area** and the characteristic overall picture make **tuberculous meningitis** a significantly more likely initial diagnosis, warranting immediate specific anti-TB therapy.

Question 253: A 55-year-old man with type 2 diabetes is diagnosed with pulmonary tuberculosis. He has been on metformin 1g twice daily and gliclazide 80mg twice daily for glycaemic control. After starting standard four-drug anti-tuberculous therapy, his HbA1c increases from 58 mmol/mol to 76 mmol/mol over 4 weeks. What is the most likely explanation for this deterioration in glycaemic control?

A. Isoniazid-induced pancreatitis reducing insulin secretion
B. Rifampicin-induced cytochrome P450 enzyme induction reducing gliclazide levels (Correct Answer)
C. Pyrazinamide causing insulin resistance
D. Ethambutol interfering with metformin absorption
E. Poor adherence to diabetic medications due to pill burden

Explanation: ***Rifampicin-induced cytochrome P450 enzyme induction reducing gliclazide levels*** - **Rifampicin** is a potent inducer of hepatic **cytochrome P450 enzymes** (specifically CYP2C9 and CYP3A4), which speeds up the metabolism of many drugs. - **Gliclazide**, a sulfonylurea, is metabolized by these enzymes; increased metabolism reduces its plasma concentration, leading to a significant loss of **glycaemic control**. *Isoniazid-induced pancreatitis reducing insulin secretion* - While **isoniazid** can rarely cause **pancreatitis**, this would typically present with acute abdominal pain and elevated lipase, not just an isolated rise in HbA1c. - Isoniazid is more commonly associated with **peripheral neuropathy** and **hepatotoxicity** rather than pancreatic endocrine failure. *Pyrazinamide causing insulin resistance* - **Pyrazinamide** is well known for competing with **uric acid** excretion, leading to hyperuricaemia and potentially gout, but it does not cause **insulin resistance**. - It has no documented clinical mechanism for significantly altering **blood glucose** levels or causing secondary diabetes. *Ethambutol interfering with metformin absorption* - **Ethambutol** is primarily associated with **optic neuritis** and does not impact the gastrointestinal absorption of **metformin**. - Metformin is not metabolized by the **cytochrome P450 system**, making it less susceptible to the enzyme-inducing effects of TB therapy compared to sulfonylureas. *Poor adherence to diabetic medications due to pill burden* - While **pill burden** is a factor in TB treatment, the specific pharmacological interaction between **rifampicin** and **sulfonylureas** is a classic and more likely medical cause for such rapid deterioration. - In clinical scenarios involving **rifampicin**, the metabolic induction is the primary suspected mechanism for loss of control of other oral medications.

Question 254: A 19-year-old student presents with sudden onset headache, fever, vomiting, and drowsiness. On examination, she has neck stiffness and Kernig's sign is positive. Lumbar puncture shows: opening pressure 28 cmH2O, cloudy CSF, white cells 2400/mm³ (95% neutrophils), protein 3.2 g/L, glucose 1.8 mmol/L (plasma glucose 6.5 mmol/L). Gram stain shows Gram-negative diplococci. Which organism is most likely responsible?

A. Escherichia coli
B. Streptococcus pneumoniae
C. Neisseria meningitidis (Correct Answer)
D. Haemophilus influenzae type b
E. Listeria monocytogenes

Explanation: ***Neisseria meningitidis***- The presence of **Gram-negative diplococci** on the CSF Gram stain is the classic and most definitive finding for *Neisseria meningitidis*.- The clinical presentation of sudden onset fever, headache, meningeal signs (neck stiffness, Kernig's) in a **young adult** (19-year-old student), coupled with the CSF profile (elevated opening pressure, cloudy, high protein, low glucose, and marked **neutrophilic pleocytosis**), is highly characteristic of bacterial meningitis caused by this organism.*Escherichia coli*- *Escherichia coli* are **Gram-negative bacilli (rods)**, which would appear as rod-shaped bacteria on Gram stain, not diplococci.- While a cause of bacterial meningitis, *E. coli* is predominantly seen in **neonates** or immunocompromised individuals, making it less likely in a healthy 19-year-old.*Streptococcus pneumoniae*- *Streptococcus pneumoniae* is a major cause of bacterial meningitis but is characterized by **Gram-positive diplococci**, staining purple, not Gram-negative.- This organism is more commonly associated with very young children, older adults, or individuals with specific risk factors like **splenic dysfunction**.*Haemophilus influenzae type b*- *Haemophilus influenzae type b* (Hib) appears as **Gram-negative coccobacilli**, which are smaller, more pleomorphic, and often less distinctly diplococcal than *Neisseria*.- The incidence of Hib meningitis has been significantly reduced in many populations due to widespread **childhood vaccination programs**.*Listeria monocytogenes*- *Listeria monocytogenes* are characterized as **Gram-positive rods**, directly contradicting the Gram-negative finding on the CSF Gram stain.- It typically affects specific vulnerable populations, including **neonates**, pregnant women, the **elderly**, and **immunocompromised** individuals.

Question 255: A 28-year-old healthcare worker has a positive Mantoux test (15 mm induration) during routine occupational health screening. She is asymptomatic with a normal chest X-ray. She received BCG vaccination as a teenager. Her interferon-gamma release assay (IGRA) is positive. What is the most appropriate next management step?

A. No treatment required; likely due to previous BCG vaccination
B. Offer treatment for latent tuberculosis infection with 3 months of rifampicin and isoniazid (Correct Answer)
C. Offer treatment for latent tuberculosis infection with 6 months of isoniazid
D. Repeat Mantoux test in 6 weeks to confirm result
E. Commence full anti-tuberculous therapy with four drugs for 6 months

Explanation: ***Offer treatment for latent tuberculosis infection with 3 months of rifampicin and isoniazid*** - The patient has **Latent TB Infection (LTBI)**, confirmed by a **positive IGRA (interferon-gamma release assay)**, which is highly specific and not affected by previous **BCG vaccination**. - A 3-month course of **rifampicin and isoniazid (3HR)** is a preferred regimen due to higher **completion rates** and comparable efficacy to longer monotherapy courses for LTBI. *No treatment required; likely due to previous BCG vaccination* - While the **Mantoux test** can be falsely positive due to **BCG**, a **positive IGRA** specifically identifies infection with *Mycobacterium tuberculosis*, as it uses antigens not present in BCG. - Healthcare workers with confirmed **LTBI** require management to prevent **progression to active TB**, which has a 5-10% lifetime risk. *Offer treatment for latent tuberculosis infection with 6 months of isoniazid* - While **6 months of isoniazid (6H)** is a valid alternative for LTBI, current guidelines often prefer shorter, combined regimens due to better patient adherence. - This monotherapy is associated with potentially **lower compliance** compared to the 3-month rifampicin-isoniazid course because of its longer duration. *Repeat Mantoux test in 6 weeks to confirm result* - Repeating the **tuberculin skin test (Mantoux)** is unnecessary and not indicated when an **IGRA** has already provided a more specific and reliable confirmation of infection. - Delaying treatment with repeat testing increases the window of risk for **reactivation** of latent infection to active disease. *Commence full anti-tuberculous therapy with four drugs for 6 months* - Quadruple therapy (e.g., isoniazid, rifampicin, pyrazinamide, ethambutol) is reserved for **active tuberculosis disease**, whereas this patient is **asymptomatic** with a **normal chest X-ray**, indicating latent infection. - Using four drugs for **LTBI** unnecessarily increases the risk of **drug toxicity** (such as hepatitis) and is not clinically indicated for latent disease.

Question 256: A 32-year-old man with HIV (CD4 count 85 cells/mm³) presents with headache, fever, and confusion over 5 days. CT head shows multiple ring-enhancing lesions with surrounding oedema. Lumbar puncture reveals: opening pressure 24 cmH2O, CSF protein 0.8 g/L, glucose 2.1 mmol/L (plasma glucose 5.2 mmol/L), white cells 45/mm³ (90% lymphocytes). India ink stain is positive. What is the most likely causative organism?

A. Toxoplasma gondii
B. Cryptococcus neoformans (Correct Answer)
C. Mycobacterium tuberculosis
D. JC virus
E. Listeria monocytogenes

Explanation: ***Cryptococcus neoformans*** - The positive **India ink stain** demonstrating encapsulated yeasts in the CSF is pathognomonic for **Cryptococcus neoformans** in this immunocompromised patient (CD4 count 85 cells/mm³). - The clinical picture of **meningitis** (headache, fever, confusion, elevated opening pressure, lymphocytic pleocytosis, low glucose) is characteristic, and **cryptococcomas** can explain the ring-enhancing lesions. *Toxoplasma gondii* - While **Toxoplasma gondii** is the most common cause of **multiple ring-enhancing lesions** in HIV, it would not yield a positive **India ink stain** on CSF examination. - CSF parameters in toxoplasmosis are typically non-specific, lacking the distinct **fungal meningitis** profile (low glucose, lymphocytic pleocytosis) seen here. *Mycobacterium tuberculosis* - **Tuberculous meningitis** usually presents with more profoundly **low CSF glucose** and significantly **higher CSF protein** levels than seen in this case. - Diagnosis of TB meningitis relies on **Acid-Fast Bacilli (AFB)** staining, PCR, or culture for *Mycobacterium tuberculosis*, not an India ink stain. *JC virus* - **JC virus** causes **Progressive Multifocal Leukoencephalopathy (PML)**, which is characterized by **non-enhancing white matter lesions** on CT or MRI, not ring-enhancing lesions. - PML does not typically cause the meningitic syndrome or the inflammatory CSF changes, such as elevated white cells and protein, seen in this patient. *Listeria monocytogenes* - **Listeria monocytogenes** causes bacterial meningitis, typically presenting with a **neutrophilic pleocytosis** in the CSF, unlike the lymphocytic predominance here. - Being a bacterium, it would not be detected by an **India ink stain**, and while it affects immunocompromised patients, the overall picture here points away from *Listeria*.

Question 257: A 45-year-old woman from Somalia, who moved to the UK 2 years ago, is diagnosed with active pulmonary tuberculosis. She lives in a house with her husband, two children aged 8 and 12 years, and her elderly mother. What is the most appropriate contact screening strategy for her household members?

A. Mantoux test and chest X-ray for all contacts immediately
B. Mantoux test for all contacts, with chest X-ray if positive; repeat Mantoux at 6 weeks if initially negative (Correct Answer)
C. Interferon-gamma release assay (IGRA) for all contacts immediately with chest X-ray
D. Chest X-ray for all contacts with Mantoux test only if symptomatic
E. IGRA test for adults and Mantoux test for children, both with immediate chest X-ray

Explanation: ***Mantoux test for all contacts, with chest X-ray if positive; repeat Mantoux at 6 weeks if initially negative***- Initial screening for TB contacts involves the **Mantoux test** (tuberculin skin test) to identify **latent TB infection**. A **chest X-ray** is then performed only if the Mantoux test is positive or if the contact presents with symptoms of active disease.- A crucial step is to **repeat the Mantoux test at 6 weeks** if the initial result is negative, as there is a **window period** during which the immune response to TB infection may not yet be detectable. *Mantoux test and chest X-ray for all contacts immediately*- Performing a **chest X-ray on all contacts immediately** is an unnecessary exposure to **radiation** and not cost-effective, especially for individuals without a positive screening test or symptoms.- This strategy also fails to account for the **window period** of TB infection, potentially missing recent exposures that would only become detectable after several weeks. *Interferon-gamma release assay (IGRA) for all contacts immediately with chest X-ray*- While **IGRA** is a valid test for latent TB, **Mantoux test** is often preferred or used in conjunction, especially for initial broad household screening or in children, as per national guidelines like those in the UK (e.g., NICE).- An immediate **chest X-ray for all contacts** without initial screening results or symptoms is not the standard protocol and leads to **over-investigation**. *Chest X-ray for all contacts with Mantoux test only if symptomatic*- Relying solely on a **chest X-ray** and only performing a Mantoux test if symptomatic will miss many cases of **latent TB infection**, which are often asymptomatic but require treatment to prevent active disease.- A **chest X-ray** is primarily used to detect active pulmonary disease and cannot reliably diagnose **latent TB infection** in asymptomatic individuals. *IGRA test for adults and Mantoux test for children, both with immediate chest X-ray*- While differential testing based on age (IGRA for adults, Mantoux for children) can be appropriate, an **immediate chest X-ray for all** without a positive screening test or symptoms is excessive and not guideline-compliant.- This approach also neglects the vital requirement for a **follow-up test at 6 weeks** for those initially testing negative, which is critical for detecting recent seroconversion.

Question 258: A 24-year-old university student presents to the emergency department with a 6-hour history of severe headache, photophobia, neck stiffness, and fever of 39.2°C. On examination, she has a non-blanching purpuric rash on her lower limbs. Blood pressure is 95/60 mmHg and heart rate is 115 bpm. What is the most appropriate immediate management before lumbar puncture?

A. Administer intravenous ceftriaxone immediately (Correct Answer)
B. Perform CT head scan first
C. Administer intravenous dexamethasone first
D. Obtain blood cultures before any antibiotic administration
E. Administer intravenous benzylpenicillin and await lumbar puncture results

Explanation: ***Administer intravenous ceftriaxone immediately***- In a patient with suspected **meningococcal meningitis** and **sepsis**, characterized by severe headache, neck stiffness, fever, and a **non-blanching purpuric rash**, immediate administration of empirical antibiotics is critical.- **Ceftriaxone** is a broad-spectrum third-generation cephalosporin and is the recommended first-line empirical antibiotic for suspected bacterial meningitis in adults, providing excellent coverage against *Neisseria meningitidis* and *Streptococcus pneumoniae*.*Perform CT head scan first*- A **CT head scan** before a lumbar puncture is indicated only if there are signs of raised intracranial pressure (e.g., focal neurological deficits, new-onset seizures, severe immunocompromise, papilledema, or significantly depressed level of consciousness), which are not explicitly mentioned as contraindications in this urgent scenario.- Delaying life-saving **antibiotic administration** for a CT scan in a rapidly deteriorating patient with suspected **meningococcal septicaemia** and signs of shock can lead to increased morbidity and mortality.*Administer intravenous dexamethasone first*- **Dexamethasone** is recommended to reduce neurological complications in bacterial meningitis, particularly if *Streptococcus pneumoniae* is suspected. However, it should be given **with or just before** the first dose of antibiotics.- Giving dexamethasone first, without concurrent antibiotics, would delay the most critical intervention for this life-threatening infection, especially in a patient showing signs of **septic shock**.*Obtain blood cultures before any antibiotic administration*- While obtaining **blood cultures** prior to antibiotic administration is generally good practice to identify the causative organism, in cases of suspected **meningococcal disease with sepsis** (evidenced by the purpuric rash and hemodynamic instability), antibiotics should not be delayed.- The priority is immediate treatment to prevent rapid progression and death. Cultures can be drawn quickly, but if there is any delay, antibiotics take precedence.*Administer intravenous benzylpenicillin and await lumbar puncture results*- **Benzylpenicillin** is a narrow-spectrum penicillin and is often used in the pre-hospital setting or by general practitioners if meningococcal disease is highly suspected and ceftriaxone is unavailable. However, in a hospital setting, **ceftriaxone** is preferred due to its broader spectrum of activity and superior penetration of the central nervous system.- Awaiting **lumbar puncture results** before administering antibiotics in a patient with clinical features highly suggestive of bacterial meningitis and sepsis is dangerous and can lead to rapid deterioration and death. The lumbar puncture may be delayed or contraindicated in unstable patients.

Question 259: A 68-year-old man presents with a 3-week history of productive cough, night sweats, and unintentional weight loss of 5 kg. He is a former smoker with a 40 pack-year history. Chest X-ray shows upper lobe cavitation. Sputum smear microscopy reveals acid-fast bacilli. What is the most appropriate initial treatment regimen for this patient?

A. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months (Correct Answer)
B. Rifampicin and isoniazid for 6 months
C. Rifampicin, isoniazid, and pyrazinamide for 6 months
D. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 6 months
E. Rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin for 2 months, then rifampicin and isoniazid for 10 months

Explanation: ***Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, then rifampicin and isoniazid for 4 months***- This regimen is the **standard initial treatment** for **drug-sensitive active pulmonary tuberculosis**, consisting of a 2-month **intensive phase** (RIPE) followed by a 4-month **continuation phase**.- The four-drug combination is crucial for rapidly reducing the **bacterial load**, preventing **drug resistance**, and effectively treating the cavitary disease observed in the patient. *Rifampicin and isoniazid for 6 months*- This regimen lacks the essential **intensive phase** with pyrazinamide and ethambutol, which is critical for sterilizing lesions and preventing **drug resistance** in active TB.- It is insufficient for treating active **smear-positive pulmonary TB** and would likely lead to treatment failure and increased risk of resistance. *Rifampicin, isoniazid, and pyrazinamide for 6 months*- This regimen omits **ethambutol** from the initial phase, which is important for covering potential **isoniazid resistance** until drug susceptibility results are known.- Continuing **pyrazinamide** for the full 6 months is not standard practice; it is typically used only during the initial 2-month intensive phase due to its potential for **hepatotoxicity**. *Rifampicin, isoniazid, pyrazinamide, and ethambutol for 6 months*- Administering all four drugs (RIPE) for the entire 6 months is not the standard protocol for **drug-sensitive TB** and significantly increases the risk of **adverse drug reactions** like **optic neuritis** (ethambutol) and **hyperuricemia** (pyrazinamide).- Standard protocols transition to a two-drug **continuation phase** after 2 months to minimize toxicity while maintaining efficacy. *Rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin for 2 months, then rifampicin and isoniazid for 10 months*- This regimen includes **streptomycin**, an injectable aminoglycoside, which is generally reserved for **multidrug-resistant TB (MDR-TB)** or specific forms of **extrapulmonary TB** due to its **ototoxicity** and **nephrotoxicity**.- A 12-month treatment duration is typically indicated for more complex or resistant cases, such as **TB meningitis**, and is excessively long for standard drug-sensitive pulmonary TB.

Practice by Chapter

Meningitis

Practice Questions

Tuberculosis

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Serious & Notifiable Infections — MCQs

Serious & Notifiable Infections — MCQs

On this page